{"855687e415d411e87ca50acff088a32806c8978b": [["\u0421\u0430\u043d\u043a\u0442-\u041f\u0435\u0442\u0435\u0440\u0431\u0443\u0440\u0433\u0435, \u0433\u0434\u0435 \u0441\u0430\u043c\u044b\u0439 \u0432\u044b\u0441\u043e\u043a\u0438\u0439 \u0443\u0440\u043e\u0432\u0435\u043d\u044c \u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438 \u043e\u0442 COVID-19 \u043d\u0430 100,000 \u0447\u0435\u043b\u043e\u0432\u0435\u043a \u0432 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043d\u0430 01/10/2020, \u043d\u0430 \u043e\u0434\u043d\u0443 \u0441\u043c\u0435\u0440\u0442\u044c \u043e\u0442 COVID-19 \u043f\u0440\u0438\u0445\u043e\u0434\u0438\u0442\u0441\u044f 14.6 \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u043d\u044b\u0445 \u0441\u043b\u0443\u0447\u0430\u0435\u0432 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438, \u0430 \u0432 \u0441\u0440\u0435\u0434\u043d\u0435\u043c \u043f\u043e \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u044d\u0442\u043e\u0442 \u043f\u043e\u043a\u0430\u0437\u0430\u0442\u0435\u043b\u044c \u0441\u043e\u0441\u0442\u0430\u0432\u043b\u044f\u0435\u0442 56.7 \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u043d\u044b\u0445 \u0441\u043b\u0443\u0447\u0430\u0435\u0432 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438, \u0447\u0442\u043e \u0433\u043e\u0432\u043e\u0440\u0438\u0442 \u043e\u0431 \u043e\u0433\u0440\u0430\u043d\u0438\u0447\u0435\u043d\u043d\u043e\u043c \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u0438\u0438 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u044e \u043f\u0440\u0438 \u043b\u0435\u0433\u043a\u0438\u0445 \u0438 \u0441\u0440\u0435\u0434\u043d\u0438\u0445 \u0441\u043b\u0443\u0447\u0430\u044f\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f \u0432 \u0421\u0430\u043d\u043a\u0442-\u041f\u0435\u0442\u0435\u0440\u0431\u0443\u0440\u0433\u0435.\u0410\u043d\u043d\u043e\u0442\u0430\u0446\u0438\u044f\u0426\u0435\u043b\u044c \u0440\u0430\u0431\u043e\u0442\u044b: \u041e\u0446\u0435\u043d\u043a\u0430 \u0441\u0432\u044f\u0437\u0438 \u043c\u0435\u0436\u0434\u0443 \u0432\u044b\u044f\u0432\u043b\u044f\u0435\u043c\u043e\u0441\u0442\u044c\u044e \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 (\u0442.\u0435. \u043f\u0440\u043e\u0446\u0435\u043d\u0442\u043e\u043c \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u043d\u044b\u0445 \u0441\u043b\u0443\u0447\u0430\u0435\u0432 COVID-19 \u0441\u0440\u0435\u0434\u0438 \u0432\u0441\u0435\u0445 \u0441\u043b\u0443\u0447\u0430\u0435\u0432 \u0437\u0430\u0440\u0430\u0436\u0435\u043d\u0438\u044f \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0435\u0439 \u0432 \u043d\u0430\u0441\u0435\u043b\u0435\u043d\u0438\u0438) \u0438 \u0443\u0440\u043e\u0432\u043d\u0435\u043c \u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438 \u043e\u0442 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 \u0432 \u0440\u0430\u0437\u043d\u044b\u0445 \u0441\u0443\u0431\u044a\u0435\u043a\u0442\u0430\u0445 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438.\u0414\u0430\u043d\u043d\u044b\u0435\u041c\u044b \u0438\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u043b\u0438 \u0434\u0430\u043d\u043d\u044b\u0435 \u0420\u043e\u0441\u043f\u043e\u0442\u0440\u0435\u0431\u043d\u0430\u0434\u0437\u043e\u0440\u0430 \u043e \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u0435 \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u043d\u044b\u0445 \u0441\u043b\u0443\u0447\u0430\u0435\u0432 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 \u0438 \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u0435 \u0441\u043c\u0435\u0440\u0442\u0435\u0439 \u043e\u0442 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 \u0432 \u0440\u0430\u0437\u043d\u044b\u0445 \u0441\u0443\u0431\u044a\u0435\u043a\u0442\u0430\u0445 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043d\u0430 01/10/2020 [4] .", [["COVID", "TEST", 58, 63], ["\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439", "TEST", 88, 98], ["COVID", "TEST", 142, 147]]], ["\u041c\u044b \u0442\u0430\u043a\u0436\u0435 \u0438\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u043b\u0438\u043b\u0438 \u0434\u0430\u043d\u043d\u044b\u0435 \u0420\u043e\u0441\u0441\u0442\u0430\u0442\u0430 \u043e \u0447\u0438\u0441\u043b\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u043d\u0430\u0441\u0435\u043b\u0435\u043d\u0438\u044f \u0432 \u0440\u0430\u0437\u043d\u044b\u0445 \u0441\u0443\u0431\u044a\u0435\u043a\u0442\u0430\u0445 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043d\u0430 1-\u0433\u043e \u044f\u043d\u0432\u0430\u0440\u044f, 2020 [5] \u0432 \u0446\u0435\u043b\u044f\u0445 \u043e\u0446\u0435\u043d\u043a\u0438 \u0443\u0440\u043e\u0432\u043d\u044f \u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438 \u043e\u0442 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 \u043d\u0430 100,000 \u0447\u0435\u043b\u043e\u0432\u0435\u043a \u0432 \u0440\u0430\u0437\u043d\u044b\u0445 \u0441\u0443\u0431\u044a\u0435\u043a\u0442\u0430\u0445 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438.\u0421\u0442\u0430\u0442\u0438\u0441\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u043d\u0430\u043b\u0438\u0437\u041c\u044b \u043e\u0446\u0435\u043d\u0438\u043b\u0438 \u043a\u043e\u0440\u0440\u0435\u043b\u044f\u0446\u0438\u044e \u043c\u0435\u0436\u0434\u0443 \u043a\u043e\u044d\u0444\u0444\u0438\u0446\u0438\u0435\u043d\u0442\u043e\u043c \u043b\u0435\u0442\u0430\u043b\u044c\u043d\u043e\u0441\u0442\u0438 (\u043f\u0440\u043e\u0446\u0435\u043d\u0442\u043e\u043c \u0441\u043c\u0435\u0440\u0442\u0435\u043b\u044c\u043d\u044b\u0445 \u0441\u043b\u0443\u0447\u0430\u0435\u0432 \u0441\u0440\u0435\u0434\u0438 \u0432\u0441\u0435\u0445 \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u043d\u044b\u0445 \u0441\u043b\u0443\u0447\u0430\u0435\u0432 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 \u0432 \u043d\u0430\u0441\u0435\u043b\u0435\u043d\u0438\u0438) \u0438 \u0443\u0440\u043e\u0432\u043d\u0435\u043c \u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438 \u043e\u0442 \u043d\u043e\u0432\u043e\u0439 \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 \u043d\u0430 100,000 \u0447\u0435\u043b\u043e\u0432\u0435\u043a \u0432 \u0440\u0430\u0437\u043d\u044b\u0445 \u0441\u0443\u0431\u044a\u0435\u043a\u0442\u0430\u0445 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043d\u0430 01/10/2020.", [["1-\u0433\u043e \u044f\u043d\u0432\u0430\u0440\u044f, 2020 [5] \u0432", "CHEMICAL", 107, 130], ["\u043a\u043e\u044d\u0444\u0444\u0438\u0446\u0438\u0435\u043d\u0442\u043e\u043c", "TEST", 303, 316], ["\u043b\u0435\u0442\u0430\u043b\u044c\u043d\u043e\u0441\u0442\u0438", "TEST", 317, 328], ["\u043f\u0440\u043e\u0446\u0435\u043d\u0442\u043e\u043c", "TEST", 330, 339], ["\u0441\u043c\u0435\u0440\u0442\u0435\u043b\u044c\u043d\u044b\u0445", "TEST", 340, 351], ["\u0441\u043b\u0443\u0447\u0430\u0435\u0432", "TEST", 352, 359], ["\u0441\u0440\u0435\u0434\u0438", "TEST", 360, 365], ["\u0432\u0441\u0435\u0445", "TEST", 366, 370], ["\u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439", "TEST", 396, 410], ["\u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438", "TEST", 411, 419], ["\u0432", "TEST", 420, 421], ["\u043d\u0430\u0441\u0435\u043b\u0435\u043d\u0438\u0438", "TEST", 422, 431], ["\u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438", "TEST", 443, 453], ["\u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439", "TEST", 463, 477], ["\u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438", "TEST", 478, 486], ["\u043d\u0430", "TEST", 487, 489]]]], "PMC7222974": [["IntroductionDiffuse axonal injury (DAI) is a lesion in cerebral white matter that occurs during traumatic brain injuries (TBI), most commonly caused by mechanisms involving simultaneous linear and angular acceleration and deceleration of the head, generating rupture of neuronal axons [1\u20133].", [["axonal", "ANATOMY", 20, 26], ["lesion", "ANATOMY", 45, 51], ["cerebral white matter", "ANATOMY", 55, 76], ["brain", "ANATOMY", 106, 111], ["head", "ANATOMY", 242, 246], ["neuronal axons", "ANATOMY", 270, 284], ["axonal injury", "DISEASE", 20, 33], ["DAI", "DISEASE", 35, 38], ["cerebral white matter", "DISEASE", 55, 76], ["traumatic brain injuries", "DISEASE", 96, 120], ["TBI", "DISEASE", 122, 125], ["rupture", "DISEASE", 259, 266], ["axonal", "MULTI-TISSUE_STRUCTURE", 20, 26], ["cerebral", "ORGAN", 55, 63], ["brain", "ORGAN", 106, 111], ["head", "ORGANISM_SUBDIVISION", 242, 246], ["neuronal axons", "CELLULAR_COMPONENT", 270, 284], ["IntroductionDiffuse axonal injury", "PROBLEM", 0, 33], ["a lesion in cerebral white matter", "PROBLEM", 43, 76], ["traumatic brain injuries", "PROBLEM", 96, 120], ["TBI", "PROBLEM", 122, 125], ["simultaneous linear and angular acceleration", "PROBLEM", 173, 217], ["deceleration of the head", "PROBLEM", 222, 246], ["rupture of neuronal axons", "PROBLEM", 259, 284], ["axonal injury", "OBSERVATION", 20, 33], ["lesion", "OBSERVATION", 45, 51], ["cerebral white matter", "ANATOMY", 55, 76], ["traumatic", "OBSERVATION_MODIFIER", 96, 105], ["brain", "ANATOMY", 106, 111], ["injuries", "OBSERVATION", 112, 120], ["simultaneous", "OBSERVATION_MODIFIER", 173, 185], ["linear", "OBSERVATION_MODIFIER", 186, 192], ["angular acceleration", "OBSERVATION", 197, 217], ["deceleration", "OBSERVATION_MODIFIER", 222, 234], ["head", "ANATOMY", 242, 246], ["rupture", "OBSERVATION", 259, 266]]], ["It is defined as a diffuse injury to the axons in the cerebral hemispheres, the corpus callosum, the brainstem, and, sometimes, the cerebellum, as a result of a TBI.", [["axons", "ANATOMY", 41, 46], ["cerebral hemispheres", "ANATOMY", 54, 74], ["corpus callosum", "ANATOMY", 80, 95], ["brainstem", "ANATOMY", 101, 110], ["cerebellum", "ANATOMY", 132, 142], ["TBI", "DISEASE", 161, 164], ["axons", "CELLULAR_COMPONENT", 41, 46], ["cerebral hemispheres", "MULTI-TISSUE_STRUCTURE", 54, 74], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 80, 95], ["brainstem", "ORGAN", 101, 110], ["cerebellum", "ORGAN", 132, 142], ["a diffuse injury to the axons in the cerebral hemispheres", "PROBLEM", 17, 74], ["a TBI", "PROBLEM", 159, 164], ["diffuse", "OBSERVATION_MODIFIER", 19, 26], ["injury", "OBSERVATION", 27, 33], ["axons", "ANATOMY_MODIFIER", 41, 46], ["cerebral hemispheres", "ANATOMY", 54, 74], ["corpus callosum", "ANATOMY", 80, 95], ["brainstem", "ANATOMY", 101, 110], ["cerebellum", "ANATOMY", 132, 142], ["TBI", "OBSERVATION", 161, 164]]], ["Concurrently, there is vascular injury at a capillary level, which can be seen in the early stages as isolated or multiple hemorrhages at the junction of white and gray matter [3].IntroductionAs observed by Gennarelli et al. [4], depending on its nature, a TBI can cause several degrees of lost consciousness, ranging from concussion without apparent sequelae (when the coma lasts under 15 min) to prolonged coma with bilateral decerebration and incomplete neurological recovery.", [["vascular", "ANATOMY", 23, 31], ["capillary", "ANATOMY", 44, 53], ["gray matter", "ANATOMY", 164, 175], ["neurological", "ANATOMY", 457, 469], ["hemorrhages", "DISEASE", 123, 134], ["TBI", "DISEASE", 257, 260], ["concussion", "DISEASE", 323, 333], ["coma", "DISEASE", 370, 374], ["coma", "DISEASE", 408, 412], ["vascular", "MULTI-TISSUE_STRUCTURE", 23, 31], ["capillary", "TISSUE", 44, 53], ["vascular injury", "PROBLEM", 23, 38], ["multiple hemorrhages at the junction of white and gray matter", "PROBLEM", 114, 175], ["a TBI", "PROBLEM", 255, 260], ["lost consciousness", "PROBLEM", 290, 308], ["concussion", "PROBLEM", 323, 333], ["apparent sequelae", "PROBLEM", 342, 359], ["prolonged coma", "PROBLEM", 398, 412], ["bilateral decerebration", "PROBLEM", 418, 441], ["incomplete neurological recovery", "PROBLEM", 446, 478], ["vascular", "ANATOMY", 23, 31], ["injury", "OBSERVATION", 32, 38], ["capillary level", "OBSERVATION_MODIFIER", 44, 59], ["can be seen", "UNCERTAINTY", 67, 78], ["early stages", "OBSERVATION_MODIFIER", 86, 98], ["multiple", "OBSERVATION_MODIFIER", 114, 122], ["hemorrhages", "OBSERVATION", 123, 134], ["junction", "ANATOMY_MODIFIER", 142, 150], ["bilateral", "ANATOMY_MODIFIER", 418, 427], ["decerebration", "OBSERVATION", 428, 441], ["neurological recovery", "OBSERVATION", 457, 478]]], ["The duration of coma, outcomes, and post-traumatic dysfunction observed in the primates used in Gennarelli\u2019s study also were directly linked to the direction of head movement, with coma duration, degree of post-traumatic dysfunction, and extent of DAI increasing from sagittal to oblique to lateral acceleration [4].IntroductionClinically, DAI is defined as a prolonged post-traumatic coma of at least 6 h after a TBI without demonstrable mass lesions.", [["head", "ANATOMY", 161, 165], ["mass lesions", "ANATOMY", 439, 451], ["coma", "DISEASE", 16, 20], ["post-traumatic dysfunction", "DISEASE", 36, 62], ["coma", "DISEASE", 181, 185], ["post-traumatic dysfunction", "DISEASE", 206, 232], ["DAI", "DISEASE", 248, 251], ["DAI", "DISEASE", 340, 343], ["coma", "DISEASE", 385, 389], ["TBI", "DISEASE", 414, 417], ["head", "ORGANISM_SUBDIVISION", 161, 165], ["mass lesions", "PATHOLOGICAL_FORMATION", 439, 451], ["coma", "PROBLEM", 16, 20], ["post-traumatic dysfunction", "PROBLEM", 36, 62], ["post-traumatic dysfunction", "PROBLEM", 206, 232], ["DAI", "PROBLEM", 248, 251], ["a prolonged post-traumatic coma", "PROBLEM", 358, 389], ["a TBI", "PROBLEM", 412, 417], ["demonstrable mass lesions", "PROBLEM", 426, 451], ["post-traumatic dysfunction", "OBSERVATION", 206, 232], ["without", "UNCERTAINTY", 418, 425], ["demonstrable", "OBSERVATION_MODIFIER", 426, 438], ["mass", "OBSERVATION", 439, 443]]], ["The clinical classification of DAI has three degrees: mild, moderate, and severe, as summarized in Table 1.", [["DAI", "DISEASE", 31, 34], ["DAI", "PROBLEM", 31, 34], ["mild, moderate, and severe", "PROBLEM", 54, 80], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["moderate", "OBSERVATION_MODIFIER", 60, 68], ["severe", "OBSERVATION_MODIFIER", 74, 80]]], ["In mild DAI, the coma lasts from 6 to 24 h.", [["DAI", "DISEASE", 8, 11], ["coma", "DISEASE", 17, 21], ["mild DAI", "PROBLEM", 3, 11], ["mild", "OBSERVATION_MODIFIER", 3, 7], ["DAI", "OBSERVATION", 8, 11]]], ["In moderate DAI, the coma lasts for more than 24 h, without abnormal postures.", [["DAI", "DISEASE", 12, 15], ["coma", "DISEASE", 21, 25], ["moderate DAI", "PROBLEM", 3, 15], ["abnormal postures", "PROBLEM", 60, 77], ["moderate", "OBSERVATION_MODIFIER", 3, 11], ["DAI", "OBSERVATION_MODIFIER", 12, 15]]], ["In severe DAI, the coma lasts for more than 24 h and there are signs of brainstem deficit.", [["brainstem", "ANATOMY", 72, 81], ["DAI", "DISEASE", 10, 13], ["coma", "DISEASE", 19, 23], ["brainstem deficit", "DISEASE", 72, 89], ["brainstem", "ORGAN", 72, 81], ["severe DAI", "PROBLEM", 3, 13], ["brainstem deficit", "PROBLEM", 72, 89], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["DAI", "OBSERVATION", 10, 13], ["signs of", "UNCERTAINTY", 63, 71], ["brainstem deficit", "OBSERVATION", 72, 89]]], ["Many patients classified as severe DAI will either die or never recover useful function.IntroductionClassical concussion was defined by Gennarelli et al. as a coma that lasts for less than 15 min, starting during the moment of acceleration, and accompanied by the absence of ocular opening and ability to follow visual stimuli with the eyes, the absence of a corneal reflex, and mydriasis.", [["ocular", "ANATOMY", 275, 281], ["eyes", "ANATOMY", 336, 340], ["corneal", "ANATOMY", 359, 366], ["DAI", "DISEASE", 35, 38], ["concussion", "DISEASE", 110, 120], ["coma", "DISEASE", 159, 163], ["mydriasis", "DISEASE", 379, 388], ["patients", "ORGANISM", 5, 13], ["ocular", "ORGAN", 275, 281], ["eyes", "ORGAN", 336, 340], ["corneal", "TISSUE", 359, 366], ["patients", "SPECIES", 5, 13], ["severe DAI", "PROBLEM", 28, 38], ["a coma", "PROBLEM", 157, 163], ["ocular opening", "PROBLEM", 275, 289], ["visual stimuli", "TEST", 312, 326], ["a corneal reflex", "TEST", 357, 373], ["mydriasis", "PROBLEM", 379, 388], ["eyes", "ANATOMY", 336, 340], ["corneal reflex", "ANATOMY", 359, 373], ["mydriasis", "OBSERVATION", 379, 388]]], ["The corneal areflexia lasts from 30 s to 5 min and coincides with the return of ocular opening and behavioral wakefulness.", [["corneal", "ANATOMY", 4, 11], ["ocular", "ANATOMY", 80, 86], ["corneal areflexia", "DISEASE", 4, 21], ["ocular", "ORGAN", 80, 86], ["The corneal areflexia", "PROBLEM", 0, 21], ["behavioral wakefulness", "PROBLEM", 99, 121], ["corneal", "ANATOMY", 4, 11], ["areflexia", "OBSERVATION", 12, 21], ["ocular", "ANATOMY", 80, 86], ["opening", "OBSERVATION", 87, 94]]], ["Patients go straight from the initial phase of coma to the recovery phase, and ultimately experience good neurological recovery [4, 5].IntroductionHistopathologically, DAI is divided into three degrees, of increasing severity, as seen in Table 2.", [["neurological", "ANATOMY", 106, 118], ["coma", "DISEASE", 47, 51], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["increasing severity", "PROBLEM", 206, 225], ["increasing", "OBSERVATION_MODIFIER", 206, 216], ["severity", "OBSERVATION_MODIFIER", 217, 225]]], ["With grade 1 injuries, there is histological evidence of axonal lesions in the white matter of the cerebral hemispheres.", [["axonal lesions", "ANATOMY", 57, 71], ["white matter", "ANATOMY", 79, 91], ["cerebral hemispheres", "ANATOMY", 99, 119], ["injuries", "DISEASE", 13, 21], ["axonal lesions", "PATHOLOGICAL_FORMATION", 57, 71], ["cerebral hemispheres", "MULTI-TISSUE_STRUCTURE", 99, 119], ["grade 1 injuries", "PROBLEM", 5, 21], ["axonal lesions in the white matter", "PROBLEM", 57, 91], ["grade 1", "OBSERVATION_MODIFIER", 5, 12], ["injuries", "OBSERVATION", 13, 21], ["histological evidence of", "UNCERTAINTY", 32, 56], ["axonal", "OBSERVATION_MODIFIER", 57, 63], ["lesions", "OBSERVATION", 64, 71], ["white matter", "ANATOMY_MODIFIER", 79, 91], ["cerebral hemispheres", "ANATOMY", 99, 119]]], ["With grade 2, there is also at least one focal lesion in the corpus callosum.", [["focal lesion", "ANATOMY", 41, 53], ["corpus callosum", "ANATOMY", 61, 76], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 61, 76], ["one focal lesion in the corpus callosum", "PROBLEM", 37, 76], ["grade 2", "OBSERVATION_MODIFIER", 5, 12], ["at least", "OBSERVATION_MODIFIER", 28, 36], ["one", "OBSERVATION_MODIFIER", 37, 40], ["focal", "OBSERVATION_MODIFIER", 41, 46], ["lesion", "OBSERVATION", 47, 53], ["corpus callosum", "ANATOMY", 61, 76]]], ["With grade 3, there is also a focal lesion in the dorsolateral quadrant or in the rostral quadrants of the brainstem.", [["focal lesion", "ANATOMY", 30, 42], ["dorsolateral quadrant", "ANATOMY", 50, 71], ["rostral quadrants", "ANATOMY", 82, 99], ["brainstem", "ANATOMY", 107, 116], ["dorsolateral quadrant", "CANCER", 50, 71], ["brainstem", "ORGAN", 107, 116], ["a focal lesion in the dorsolateral quadrant", "PROBLEM", 28, 71], ["grade 3", "OBSERVATION_MODIFIER", 5, 12], ["focal", "OBSERVATION_MODIFIER", 30, 35], ["lesion", "OBSERVATION", 36, 42], ["dorsolateral", "ANATOMY_MODIFIER", 50, 62], ["quadrant", "ANATOMY_MODIFIER", 63, 71], ["rostral", "ANATOMY_MODIFIER", 82, 89], ["quadrants", "ANATOMY_MODIFIER", 90, 99], ["brainstem", "ANATOMY", 107, 116]]], ["There is a close correlation between the degree of diffuse axonal injury and the severity of cranioencephalic trauma [3].", [["axonal", "ANATOMY", 59, 65], ["axonal injury", "DISEASE", 59, 72], ["trauma", "DISEASE", 110, 116], ["diffuse axonal injury", "PROBLEM", 51, 72], ["cranioencephalic trauma", "PROBLEM", 93, 116], ["diffuse", "OBSERVATION_MODIFIER", 51, 58], ["axonal injury", "OBSERVATION", 59, 72], ["severity", "OBSERVATION_MODIFIER", 81, 89], ["cranioencephalic trauma", "OBSERVATION", 93, 116]]], ["There may also be other macroscopic findings, like small amounts of blood in the subarachnoid space, and subdural or rarely frontal or temporal contusions, in addition to focal lesions in the corpus callosum or upper cerebellar peduncle in the most severe cases [4].IntroductionAbout \u00be of all patients with a TBI present with some degree of DAI.", [["blood", "ANATOMY", 68, 73], ["subarachnoid space", "ANATOMY", 81, 99], ["subdural", "ANATOMY", 105, 113], ["frontal", "ANATOMY", 124, 131], ["temporal contusions", "ANATOMY", 135, 154], ["focal lesions", "ANATOMY", 171, 184], ["corpus callosum", "ANATOMY", 192, 207], ["upper cerebellar peduncle", "ANATOMY", 211, 236], ["contusions", "DISEASE", 144, 154], ["TBI", "DISEASE", 309, 312], ["DAI", "DISEASE", 341, 344], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["subarachnoid space", "MULTI-TISSUE_STRUCTURE", 81, 99], ["focal lesions", "PATHOLOGICAL_FORMATION", 171, 184], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 192, 207], ["upper cerebellar peduncle", "MULTI-TISSUE_STRUCTURE", 211, 236], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 293, 301], ["other macroscopic findings", "PROBLEM", 18, 44], ["small amounts of blood in the subarachnoid space", "PROBLEM", 51, 99], ["subdural or rarely frontal or temporal contusions", "PROBLEM", 105, 154], ["focal lesions in the corpus callosum or upper cerebellar peduncle", "PROBLEM", 171, 236], ["a TBI", "PROBLEM", 307, 312], ["DAI", "PROBLEM", 341, 344], ["may also be", "UNCERTAINTY", 6, 17], ["macroscopic", "OBSERVATION", 24, 35], ["small", "OBSERVATION_MODIFIER", 51, 56], ["amounts", "OBSERVATION_MODIFIER", 57, 64], ["blood", "OBSERVATION", 68, 73], ["subarachnoid space", "ANATOMY", 81, 99], ["subdural", "ANATOMY", 105, 113], ["rarely", "OBSERVATION_MODIFIER", 117, 123], ["frontal", "ANATOMY_MODIFIER", 124, 131], ["temporal", "OBSERVATION_MODIFIER", 135, 143], ["contusions", "OBSERVATION", 144, 154], ["focal", "OBSERVATION_MODIFIER", 171, 176], ["lesions", "OBSERVATION", 177, 184], ["corpus callosum", "ANATOMY", 192, 207], ["upper cerebellar peduncle", "ANATOMY", 211, 236], ["most", "OBSERVATION_MODIFIER", 244, 248], ["severe", "OBSERVATION_MODIFIER", 249, 255]]], ["With severe TBI, DAI is found in almost all cases [6].", [["TBI", "DISEASE", 12, 15], ["DAI", "DISEASE", 17, 20], ["severe TBI", "PROBLEM", 5, 15], ["DAI", "PROBLEM", 17, 20], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["TBI", "OBSERVATION", 12, 15]]], ["Most patients with mild to moderate DAI have some medium to long-term recovery.", [["DAI", "DISEASE", 36, 39], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["mild to moderate DAI", "PROBLEM", 19, 39]]], ["However, in patients with severe DAI, death is the most common outcome [6, 7].", [["DAI", "DISEASE", 33, 36], ["death", "DISEASE", 38, 43], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["severe DAI", "PROBLEM", 26, 36], ["death", "PROBLEM", 38, 43]]], ["Among the group with non-fatal outcome, the prevalence of disability and dependence several months after the trauma is high, varying from 40\u201387.5% to 20\u201340%, respectively, with severe DAI the main risk factor [7].IntroductionThe clinical evaluation of DAI includes the Extended Glasgow Outcome Scale (GOSE), a global scale for assessing patients\u2019 functional outcomes, divided into eight categories: (1) dead; (2) vegetative state; (3) lower severe disability; (4) upper severe disability; (5) lower moderate disability; (6) upper moderate disability; (7) lower good recovery; (8) upper good recovery.", [["disability", "DISEASE", 58, 68], ["trauma", "DISEASE", 109, 115], ["DAI", "DISEASE", 184, 187], ["disability", "DISEASE", 448, 458], ["disability", "DISEASE", 477, 487], ["disability", "DISEASE", 508, 518], ["disability", "DISEASE", 539, 549], ["patients", "ORGANISM", 337, 345], ["patients", "SPECIES", 337, 345], ["the trauma", "PROBLEM", 105, 115], ["severe DAI", "PROBLEM", 177, 187], ["The clinical evaluation", "TEST", 225, 248], ["DAI", "PROBLEM", 252, 255], ["a global scale", "TREATMENT", 308, 322], ["lower severe disability", "PROBLEM", 435, 458], ["upper severe disability", "PROBLEM", 464, 487], ["lower moderate disability", "PROBLEM", 493, 518], ["upper moderate disability", "PROBLEM", 524, 549], ["high", "OBSERVATION_MODIFIER", 119, 123], ["severe", "OBSERVATION_MODIFIER", 177, 183], ["upper moderate", "OBSERVATION_MODIFIER", 524, 538]]], ["The recommended time to apply the scale is 3 months after trauma, as well as at 6 months and 12 months.", [["trauma", "DISEASE", 58, 64], ["trauma", "PROBLEM", 58, 64]]], ["The scale is administered via a structured interview, post-discharge.IntroductionThe highest prevalence of DAI is in young individuals, with a mean age of 28 years.", [["DAI", "DISEASE", 107, 110]]], ["The main cause of DAI is traffic accidents, followed by domestic accidents, sports accidents, assaults and accidents at work [8].IntroductionDAI is known to have cognitive, somatic and emotional sequelae, and to predispose individuals to specific psychiatric disorders and cerebral atrophy [9\u201311].", [["cerebral", "ANATOMY", 273, 281], ["DAI", "DISEASE", 18, 21], ["traffic accidents", "DISEASE", 25, 42], ["accidents", "DISEASE", 65, 74], ["accidents", "DISEASE", 83, 92], ["accidents", "DISEASE", 107, 116], ["cognitive, somatic and emotional sequelae", "DISEASE", 162, 203], ["psychiatric disorders", "DISEASE", 247, 268], ["cerebral atrophy", "DISEASE", 273, 289], ["cerebral", "ORGAN", 273, 281], ["cognitive, somatic and emotional sequelae", "PROBLEM", 162, 203], ["specific psychiatric disorders", "PROBLEM", 238, 268], ["cerebral atrophy", "PROBLEM", 273, 289], ["main", "OBSERVATION_MODIFIER", 4, 8], ["DAI", "OBSERVATION", 18, 21], ["cerebral", "ANATOMY", 273, 281], ["atrophy", "OBSERVATION", 282, 289]]], ["Approximately 50% of patients present with moderate to severe deficits related to learning and the retention of new information, while attention and executive functions are slightly altered [9].IntroductionIn the acute phase, the diagnosis of DAI is suggested by the combination of clinical symptoms and the absence of any apparent mass lesions on computed tomography (CT), or the presence of microhemorrhages at the junction of white and gray matter [8, 12].", [["mass lesions", "ANATOMY", 332, 344], ["gray matter", "ANATOMY", 439, 450], ["DAI", "DISEASE", 243, 246], ["microhemorrhages", "DISEASE", 393, 409], ["patients", "ORGANISM", 21, 29], ["lesions", "PATHOLOGICAL_FORMATION", 337, 344], ["patients", "SPECIES", 21, 29], ["moderate to severe deficits", "PROBLEM", 43, 70], ["slightly altered", "PROBLEM", 173, 189], ["DAI", "PROBLEM", 243, 246], ["clinical symptoms", "PROBLEM", 282, 299], ["any apparent mass lesions", "PROBLEM", 319, 344], ["computed tomography (CT", "TEST", 348, 371], ["microhemorrhages at the junction of white and gray matter", "PROBLEM", 393, 450], ["moderate", "OBSERVATION_MODIFIER", 43, 51], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["deficits", "OBSERVATION", 62, 70], ["acute phase", "OBSERVATION_MODIFIER", 213, 224], ["mass", "OBSERVATION", 332, 336], ["microhemorrhages", "OBSERVATION", 393, 409], ["junction", "ANATOMY_MODIFIER", 417, 425]]], ["Other neuroimaging methods\u2014like diffusional magnetic resonance imaging (MRI) and probabilistic tractography, which evaluates the connectivity of neural networks\u2014are used to follow patients after the acute phase [12].IntroductionComputed tomography (CT) is the examination of choice in the acute phase of TBI, as it is more accessible and faster than MRI and other imaging modalities.", [["neural", "ANATOMY", 145, 151], ["TBI", "DISEASE", 304, 307], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["Other neuroimaging", "TEST", 0, 18], ["diffusional magnetic resonance imaging", "TEST", 32, 70], ["MRI", "TEST", 72, 75], ["probabilistic tractography", "TEST", 81, 107], ["IntroductionComputed tomography (CT", "TEST", 216, 251], ["the examination", "TEST", 256, 271], ["TBI", "PROBLEM", 304, 307], ["MRI", "TEST", 350, 353], ["other imaging modalities", "TEST", 358, 382]]], ["The diagnosis of DAI by CT is suggested by the presence of small non-expansive hemorrhagic lesions in the areas of connection between white and gray matter, by the presence of blood in the intraventricular space and, eventually, by generalized cerebral edema [13].IntroductionHowever, MRI detects up to three times more intraparenchymal lesions than CT.", [["lesions", "ANATOMY", 91, 98], ["gray matter", "ANATOMY", 144, 155], ["blood", "ANATOMY", 176, 181], ["intraventricular space", "ANATOMY", 189, 211], ["cerebral", "ANATOMY", 244, 252], ["intraparenchymal lesions", "ANATOMY", 320, 344], ["DAI", "DISEASE", 17, 20], ["hemorrhagic", "DISEASE", 79, 90], ["cerebral edema", "DISEASE", 244, 258], ["hemorrhagic lesions", "PATHOLOGICAL_FORMATION", 79, 98], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["intraparenchymal lesions", "PATHOLOGICAL_FORMATION", 320, 344], ["DAI", "PROBLEM", 17, 20], ["CT", "TEST", 24, 26], ["small non-expansive hemorrhagic lesions", "PROBLEM", 59, 98], ["connection between white and gray matter", "PROBLEM", 115, 155], ["blood in the intraventricular space", "PROBLEM", 176, 211], ["generalized cerebral edema", "PROBLEM", 232, 258], ["MRI", "TEST", 285, 288], ["intraparenchymal lesions", "PROBLEM", 320, 344], ["CT", "TEST", 350, 352], ["small", "OBSERVATION_MODIFIER", 59, 64], ["non-expansive", "OBSERVATION_MODIFIER", 65, 78], ["hemorrhagic", "OBSERVATION_MODIFIER", 79, 90], ["lesions", "OBSERVATION", 91, 98], ["areas", "OBSERVATION_MODIFIER", 106, 111], ["gray matter", "OBSERVATION_MODIFIER", 144, 155], ["blood", "OBSERVATION", 176, 181], ["intraventricular space", "ANATOMY", 189, 211], ["generalized", "OBSERVATION_MODIFIER", 232, 243], ["cerebral", "ANATOMY", 244, 252], ["edema", "OBSERVATION", 253, 258], ["intraparenchymal", "OBSERVATION_MODIFIER", 320, 336], ["lesions", "OBSERVATION", 337, 344]]], ["Approximately 75% of patients with a clinical picture suggestive of DAI and normal CT images at an early stage have intraparenchymal abnormalities on MRI [14].", [["intraparenchymal", "ANATOMY", 116, 132], ["DAI", "DISEASE", 68, 71], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["DAI", "PROBLEM", 68, 71], ["normal CT images", "TEST", 76, 92], ["intraparenchymal abnormalities", "PROBLEM", 116, 146], ["MRI", "TEST", 150, 153], ["intraparenchymal", "OBSERVATION_MODIFIER", 116, 132], ["abnormalities", "OBSERVATION", 133, 146]]], ["However, as MRI is a time-consuming exam and cannot be done in patients with ferromagnetic devices; it is typically impossible for it to be done during the acute phase of TBI, during which patients are generally hemodynamically unstable and require monitoring devices [14].IntroductionDue to the high incidence of traffic accidents, and with DAI present in most severe TBI, this is a highly prevalent condition in Brazil, and leads to severe sequelae both for the patient and for society, as many patients become unable to work and require extended hospital and post-hospital care.", [["TBI", "DISEASE", 171, 174], ["traffic accidents", "DISEASE", 314, 331], ["DAI", "DISEASE", 342, 345], ["TBI", "DISEASE", 369, 372], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 189, 197], ["patient", "ORGANISM", 464, 471], ["patients", "ORGANISM", 497, 505], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 189, 197], ["patient", "SPECIES", 464, 471], ["patients", "SPECIES", 497, 505], ["MRI", "TEST", 12, 15], ["consuming exam", "TEST", 26, 40], ["ferromagnetic devices", "TREATMENT", 77, 98], ["TBI", "PROBLEM", 171, 174], ["generally hemodynamically unstable", "PROBLEM", 202, 236], ["monitoring devices", "TREATMENT", 249, 267], ["most severe TBI", "PROBLEM", 357, 372], ["severe sequelae", "PROBLEM", 435, 450], ["post-hospital care", "TREATMENT", 562, 580], ["severe", "OBSERVATION_MODIFIER", 435, 441], ["sequelae", "OBSERVATION", 442, 450]]], ["Furthermore, because DAI is a complicated diagnosis in its acute phase, it would be helpful to identify CT patterns that allow clinicians to predict patients\u2019 prognosis and guide therapy.MethodsThis systematic review of published studies was undertaken using the PubMed database.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["DAI", "PROBLEM", 21, 24], ["CT patterns", "TEST", 104, 115], ["guide therapy", "TREATMENT", 173, 186], ["published studies", "TEST", 220, 237]]], ["The time period for eligible studies was from January 1st, 2000, onward, and the search strategy employed the following terms: \u201cdiffuse axonal injury\u201d AND \u201ccomputed tomography.\u201dMethodsWe selected the following study inclusion criteria: (1) patients had to have had a CT exam within 24 h of their TBI; and (2) the studies had to show CT results for DAI.", [["axonal", "ANATOMY", 136, 142], ["axonal injury", "DISEASE", 136, 149], ["TBI", "DISEASE", 296, 299], ["DAI", "DISEASE", 348, 351], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["eligible studies", "TEST", 20, 36], ["diffuse axonal injury", "PROBLEM", 128, 149], ["computed tomography", "TEST", 156, 175], ["a CT exam", "TEST", 265, 274], ["their TBI", "TEST", 290, 299], ["the studies", "TEST", 309, 320], ["CT results", "TEST", 333, 343], ["DAI", "PROBLEM", 348, 351], ["diffuse", "OBSERVATION_MODIFIER", 128, 135], ["axonal injury", "OBSERVATION", 136, 149]]], ["Data were extracted from the selected papers pertaining to the following: (1) article publication (author and year); (2) study design; (3) study population (sample size, gender distribution, age, type of accident and GCS), (4) CT findings; and (5) DAI classification (Table 3).ResultsOur primary literature search on PubMed identified 97 articles.", [["GCS", "DISEASE", 217, 220], ["study population", "TEST", 139, 155], ["GCS", "TEST", 217, 220], ["CT findings", "TEST", 227, 238]]], ["After applying the date of publication and language filters, 76 articles remained.", [["publication and language filters", "TREATMENT", 27, 59]]], ["After applying the inclusion and exclusion criteria, 13 articles remained.", [["exclusion criteria", "TEST", 33, 51]]], ["Ultimately, with full-text analysis, five papers were selected for review (Fig. 1).ResultsThe total sample was of 1245 patients with TBI, of which 414 (33.25%) had DAI.ResultsSamples were divided into two large groups: DAI (+), corresponding to patients diagnosed with DAI, and DAI (\u2212), patients no diagnosed with DAI.", [["TBI", "DISEASE", 133, 136], ["DAI", "DISEASE", 164, 167], ["DAI", "DISEASE", 269, 272], ["DAI", "DISEASE", 314, 317], ["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 245, 253], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 245, 253], ["patients", "SPECIES", 287, 295], ["text analysis", "TEST", 22, 35], ["TBI", "TEST", 133, 136], ["DAI", "PROBLEM", 164, 167], ["ResultsSamples", "TEST", 168, 182], ["DAI", "PROBLEM", 269, 272], ["DAI", "PROBLEM", 314, 317]]], ["DAI grades 2 and 3 were considered severe DAI, consistent with Gennarelli et al.\u2019s classification.ResultsNote that, in Tables 3 and 4, subjects in the article by Henninger et al. [15]. are divided into two subgroups: positive hemorrhagic DAI and negative hemorrhagic DAI.ResultsIn all five articles, data were collected retrospectively.", [["DAI", "DISEASE", 42, 45], ["hemorrhagic", "DISEASE", 226, 237], ["hemorrhagic", "DISEASE", 255, 266], ["DAI grades", "TEST", 0, 10], ["severe DAI", "PROBLEM", 35, 45], ["positive hemorrhagic DAI", "PROBLEM", 217, 241], ["negative hemorrhagic DAI", "PROBLEM", 246, 270], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["DAI", "OBSERVATION", 42, 45], ["consistent with", "UNCERTAINTY", 47, 62], ["positive", "OBSERVATION_MODIFIER", 217, 225], ["hemorrhagic", "OBSERVATION_MODIFIER", 226, 237], ["DAI", "OBSERVATION", 238, 241], ["negative", "OBSERVATION_MODIFIER", 246, 254], ["hemorrhagic", "OBSERVATION_MODIFIER", 255, 266], ["DAI", "OBSERVATION_MODIFIER", 267, 270]]], ["In all five papers, patients underwent CT within the first 24 h after trauma and later underwent MRI.", [["trauma", "DISEASE", 70, 76], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["CT", "TEST", 39, 41], ["trauma", "PROBLEM", 70, 76], ["MRI", "TEST", 97, 100]]], ["The duration of time from injury to MRI varied between studies, from 24 h after trauma to several weeks.", [["trauma", "DISEASE", 80, 86], ["injury", "PROBLEM", 26, 32], ["MRI", "TEST", 36, 39], ["studies", "TEST", 55, 62], ["trauma", "PROBLEM", 80, 86]]], ["Comparisons between CT and MRI findings are summarized in Table 4.ResultsIn all the studies, there was analysis of the demographic factors of age, sex and mechanism of injury, and all had findings that were concordant with those already reported in the literature: that DAI is more common in younger patients, in males, and caused by high-energy mechanisms like traffic accidents.", [["DAI", "DISEASE", 270, 273], ["traffic accidents", "DISEASE", 362, 379], ["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 300, 308], ["CT", "TEST", 20, 22], ["MRI findings", "TEST", 27, 39], ["the studies", "TEST", 80, 91], ["injury", "PROBLEM", 168, 174], ["injury", "OBSERVATION", 168, 174], ["traffic accidents", "OBSERVATION", 362, 379]]], ["On the other hand, it is more severe in older patients.ResultsAll the studies analyzed the outcomes using the GOSE score, with the time of GOSE score application varying between the studies.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the studies", "TEST", 66, 77], ["the GOSE score", "TEST", 106, 120], ["the studies", "TEST", 178, 189], ["severe", "OBSERVATION_MODIFIER", 30, 36]]], ["All the studies generally determined that patients with severe DAI (stages II or III) exhibited a significantly lower GOSE score.ResultsOnly the Henninger et al. study exclusively selected patients with mild TBI (GCS score \u2265 12), which might explain how some of its findings were discordant with those of the other studies.", [["DAI", "DISEASE", 63, 66], ["TBI", "DISEASE", 208, 211], ["GCS", "DISEASE", 213, 216], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 189, 197], ["GOSE", "PROTEIN", 118, 122], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 189, 197], ["All the studies", "TEST", 0, 15], ["severe DAI (stages II or III)", "PROBLEM", 56, 85], ["a significantly lower GOSE score", "PROBLEM", 96, 128], ["study", "TEST", 162, 167], ["mild TBI", "PROBLEM", 203, 211], ["GCS score", "TEST", 213, 222], ["the other studies", "TEST", 305, 322], ["mild", "OBSERVATION_MODIFIER", 203, 207], ["TBI", "OBSERVATION", 208, 211]]], ["The Beretta et al. study [16] only evaluated patients with severe TBI (GCS < 9).", [["TBI", "DISEASE", 66, 69], ["GCS", "DISEASE", 71, 74], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["study", "TEST", 19, 24], ["severe TBI", "PROBLEM", 59, 69], ["GCS", "TEST", 71, 74], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["TBI", "OBSERVATION", 66, 69]]], ["Mata-Mbemba et al., in their two studies [17, 18], evaluated patients with closed TBI without subdividing the sample by condition severity.", [["TBI", "DISEASE", 82, 85], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["closed TBI", "PROBLEM", 75, 85]]], ["Likewise, Matsukawa et al. assessed patients with isolated TBI, without trauma to other organs or systems that warranted immediate intervention.ResultsOnly the Beretta study excluded patients with post-traumatic intracranial lesions that do not enter the spectrum of DAI, such as hematomas and brain contusion.", [["organs", "ANATOMY", 88, 94], ["intracranial lesions", "ANATOMY", 212, 232], ["hematomas", "ANATOMY", 280, 289], ["brain", "ANATOMY", 294, 299], ["TBI", "DISEASE", 59, 62], ["trauma", "DISEASE", 72, 78], ["post-traumatic intracranial lesions", "DISEASE", 197, 232], ["DAI", "DISEASE", 267, 270], ["hematomas", "DISEASE", 280, 289], ["brain contusion", "DISEASE", 294, 309], ["patients", "ORGANISM", 36, 44], ["organs", "ORGAN", 88, 94], ["patients", "ORGANISM", 183, 191], ["intracranial lesions", "PATHOLOGICAL_FORMATION", 212, 232], ["brain", "ORGAN", 294, 299], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 183, 191], ["isolated TBI", "PROBLEM", 50, 62], ["trauma to other organs or systems", "PROBLEM", 72, 105], ["immediate intervention", "TREATMENT", 121, 143], ["the Beretta study", "TEST", 156, 173], ["post-traumatic intracranial lesions", "PROBLEM", 197, 232], ["DAI", "PROBLEM", 267, 270], ["hematomas", "PROBLEM", 280, 289], ["brain contusion", "PROBLEM", 294, 309], ["post-traumatic", "OBSERVATION_MODIFIER", 197, 211], ["intracranial", "ANATOMY", 212, 224], ["lesions", "OBSERVATION", 225, 232], ["DAI", "OBSERVATION", 267, 270], ["hematomas", "OBSERVATION", 280, 289], ["brain", "ANATOMY", 294, 299], ["contusion", "OBSERVATION", 300, 309]]], ["The other studies did not exclude these patients, which may have biased results.ResultsIn all studies, patients were grouped according to the Adams classification: (0) negative DAI; (1) lesions suggestive of DAI in the white matter or cerebellum; (2) DAI in the corpus callosum; (3) DAI in the brainstem.", [["lesions", "ANATOMY", 186, 193], ["white matter", "ANATOMY", 219, 231], ["cerebellum", "ANATOMY", 235, 245], ["corpus callosum", "ANATOMY", 262, 277], ["brainstem", "ANATOMY", 294, 303], ["DAI", "DISEASE", 208, 211], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 103, 111], ["lesions", "PATHOLOGICAL_FORMATION", 186, 193], ["cerebellum", "ORGAN", 235, 245], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 262, 277], ["brainstem", "ORGAN", 294, 303], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 103, 111], ["The other studies", "TEST", 0, 17], ["all studies", "TEST", 90, 101], ["lesions", "PROBLEM", 186, 193], ["DAI in the white matter or cerebellum", "PROBLEM", 208, 245], ["DAI in the corpus callosum", "PROBLEM", 251, 277], ["DAI in the brainstem", "PROBLEM", 283, 303], ["lesions", "OBSERVATION", 186, 193], ["suggestive of", "UNCERTAINTY", 194, 207], ["DAI", "OBSERVATION", 208, 211], ["white matter", "ANATOMY", 219, 231], ["cerebellum", "ANATOMY", 235, 245], ["corpus callosum", "ANATOMY", 262, 277], ["brainstem", "ANATOMY", 294, 303]]], ["Henninger further subdivided patients into those with hemorrhagic DAI (hDAI), which was defined as the presence of one or more punctate hemorrhages on CT, and non-hemorrhagic DAI.", [["hemorrhagic DAI", "DISEASE", 54, 69], ["hDAI", "DISEASE", 71, 75], ["hemorrhages", "DISEASE", 136, 147], ["DAI", "DISEASE", 175, 178], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["hemorrhagic DAI", "PROBLEM", 54, 69], ["more punctate hemorrhages", "PROBLEM", 122, 147], ["CT", "TEST", 151, 153], ["non-hemorrhagic DAI", "PROBLEM", 159, 178], ["more", "OBSERVATION_MODIFIER", 122, 126], ["punctate", "OBSERVATION_MODIFIER", 127, 135], ["hemorrhages", "OBSERVATION", 136, 147], ["non-hemorrhagic", "OBSERVATION_MODIFIER", 159, 174], ["DAI", "OBSERVATION", 175, 178]]], ["Henninger divided his patients into three groups: predominant hDAI, in which there was no coexistence with mass lesions, associated hDAI, and negative hDAI.ResultsThe results of the articles were compared.", [["mass lesions", "ANATOMY", 107, 119], ["hDAI", "DISEASE", 62, 66], ["hDAI", "DISEASE", 132, 136], ["hDAI", "DISEASE", 151, 155], ["patients", "ORGANISM", 22, 30], ["hDAI", "CANCER", 62, 66], ["lesions", "PATHOLOGICAL_FORMATION", 112, 119], ["patients", "SPECIES", 22, 30], ["mass lesions", "PROBLEM", 107, 119], ["no", "UNCERTAINTY", 87, 89], ["mass", "OBSERVATION", 107, 111]]], ["There was a significant statistical difference between the DAI (+) group and the DAI (\u2212) group regarding the mechanism of trauma, with traffic accidents much more common in the DAI (+) (70%) than in the DAI (\u2212) (40%) patient group, likely due to the mechanism of trauma, which requires high energy and rotational acceleration and deceleration of the head to cause axonal rupture.", [["head", "ANATOMY", 350, 354], ["axonal", "ANATOMY", 364, 370], ["trauma", "DISEASE", 122, 128], ["traffic accidents", "DISEASE", 135, 152], ["trauma", "DISEASE", 263, 269], ["axonal rupture", "DISEASE", 364, 378], ["patient", "ORGANISM", 217, 224], ["head", "ORGANISM_SUBDIVISION", 350, 354], ["patient", "SPECIES", 217, 224], ["trauma", "PROBLEM", 122, 128], ["trauma", "PROBLEM", 263, 269], ["high energy", "PROBLEM", 286, 297], ["rotational acceleration", "PROBLEM", 302, 325], ["deceleration of the head", "PROBLEM", 330, 354], ["axonal rupture", "PROBLEM", 364, 378], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["trauma", "OBSERVATION", 122, 128], ["trauma", "OBSERVATION", 263, 269], ["head", "ANATOMY", 350, 354], ["axonal", "OBSERVATION_MODIFIER", 364, 370], ["rupture", "OBSERVATION", 371, 378]]], ["Meanwhile, in the DAI (\u2212) group, a higher proportion of patients had suffered falls (52%), which had a higher correlation with traumatic mass lesions, like hematomas and cerebral contusions (Fig. 2).ResultsThere was also a statistically significant difference in age between the groups: DAI (+) patients averaged 41 years, whereas DAI (\u2212) patients averaged 51 years old (Fig. 3).", [["traumatic mass lesions", "ANATOMY", 127, 149], ["hematomas", "ANATOMY", 156, 165], ["cerebral", "ANATOMY", 170, 178], ["traumatic mass lesions", "DISEASE", 127, 149], ["hematomas", "DISEASE", 156, 165], ["cerebral contusions", "DISEASE", 170, 189], ["patients", "ORGANISM", 56, 64], ["lesions", "PATHOLOGICAL_FORMATION", 142, 149], ["cerebral", "ORGAN", 170, 178], ["patients", "ORGANISM", 295, 303], ["patients", "ORGANISM", 339, 347], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 295, 303], ["patients", "SPECIES", 339, 347], ["falls", "PROBLEM", 78, 83], ["traumatic mass lesions", "PROBLEM", 127, 149], ["hematomas", "PROBLEM", 156, 165], ["cerebral contusions", "PROBLEM", 170, 189], ["traumatic", "OBSERVATION_MODIFIER", 127, 136], ["mass", "OBSERVATION", 137, 141], ["lesions", "OBSERVATION", 142, 149], ["hematomas", "OBSERVATION", 156, 165], ["cerebral", "ANATOMY", 170, 178], ["contusions", "OBSERVATION", 179, 189]]], ["This also relates to the mechanism of trauma, since older patients had a higher prevalence of TBI due to falls, possibly caused by postural instability.ResultsRegarding patient gender, the two patient groups were statistically similar, with males markedly outnumbering females in both groups: DAI(+) 79%; DAI (\u2212) 74% (Fig. 4).ResultsMata-Mbemba et al. (2018), assessed the relationship between both traumatic subarachnoid hemorrhage (tSAH) and intraventricular hemorrhage (IVH), jointly and alone, on the initial CT, and MRI findings.", [["subarachnoid", "ANATOMY", 409, 421], ["intraventricular", "ANATOMY", 444, 460], ["trauma", "DISEASE", 38, 44], ["TBI", "DISEASE", 94, 97], ["falls", "DISEASE", 105, 110], ["postural instability", "DISEASE", 131, 151], ["traumatic subarachnoid hemorrhage", "DISEASE", 399, 432], ["tSAH", "DISEASE", 434, 438], ["intraventricular hemorrhage", "DISEASE", 444, 471], ["IVH", "DISEASE", 473, 476], ["patients", "ORGANISM", 58, 66], ["patient", "ORGANISM", 169, 176], ["patient", "ORGANISM", 193, 200], ["patients", "SPECIES", 58, 66], ["patient", "SPECIES", 169, 176], ["patient", "SPECIES", 193, 200], ["trauma", "PROBLEM", 38, 44], ["TBI", "PROBLEM", 94, 97], ["falls", "PROBLEM", 105, 110], ["postural instability", "PROBLEM", 131, 151], ["DAI", "TEST", 305, 308], ["both traumatic subarachnoid hemorrhage (tSAH)", "PROBLEM", 394, 439], ["intraventricular hemorrhage", "PROBLEM", 444, 471], ["IVH", "PROBLEM", 473, 476], ["the initial CT", "TEST", 501, 515], ["MRI findings", "TEST", 521, 533], ["trauma", "OBSERVATION", 38, 44], ["TBI", "OBSERVATION", 94, 97], ["falls", "OBSERVATION", 105, 110], ["possibly caused", "UNCERTAINTY", 112, 127], ["postural instability", "OBSERVATION", 131, 151], ["traumatic", "OBSERVATION_MODIFIER", 399, 408], ["subarachnoid", "OBSERVATION_MODIFIER", 409, 421], ["hemorrhage", "OBSERVATION", 422, 432], ["intraventricular", "ANATOMY", 444, 460], ["hemorrhage", "OBSERVATION", 461, 471], ["IVH", "OBSERVATION", 473, 476]]], ["For tSAH, five locations were evaluated: cerebral convexities, Sylvian fissures, Sylvian vallecula, the interhemispheric fissure, and peri-mesencephalic cisterns.", [["cerebral", "ANATOMY", 41, 49], ["Sylvian fissures", "ANATOMY", 63, 79], ["Sylvian vallecula", "ANATOMY", 81, 98], ["interhemispheric fissure", "ANATOMY", 104, 128], ["peri-mesencephalic cisterns", "ANATOMY", 134, 161], ["cerebral convexities", "DISEASE", 41, 61], ["Sylvian fissures", "DISEASE", 63, 79], ["tSAH", "CANCER", 4, 8], ["cerebral", "ORGAN", 41, 49], ["tSAH", "TEST", 4, 8], ["Sylvian fissures, Sylvian vallecula, the interhemispheric fissure, and peri-mesencephalic cisterns", "PROBLEM", 63, 161], ["cerebral", "ANATOMY", 41, 49], ["convexities", "ANATOMY_MODIFIER", 50, 61], ["Sylvian fissures", "ANATOMY", 63, 79], ["Sylvian vallecula", "ANATOMY", 81, 98], ["interhemispheric fissure", "ANATOMY", 104, 128], ["peri-mesencephalic cisterns", "ANATOMY", 134, 161]]], ["A significant association between tSAH on initial CT and DAI on MRI was demonstrated, with tSAH identified on 49.4% of CTs in patients whose MRI demonstrated DAI.", [["tSAH", "CANCER", 34, 38], ["patients", "ORGANISM", 126, 134], ["tSAH", "PROTEIN", 34, 38], ["patients", "SPECIES", 126, 134], ["A significant association between tSAH", "PROBLEM", 0, 38], ["initial CT", "TEST", 42, 52], ["MRI", "TEST", 64, 67], ["tSAH", "PROBLEM", 91, 95], ["CTs", "TEST", 119, 122], ["MRI", "TEST", 141, 144], ["DAI", "PROBLEM", 158, 161], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["Of the patients with severe DAI (grades II and III), 78.4% had tSAH, and 60.8% had midline tSAH.ResultsThe composite IVH/tSAH item was independently associated with DAI.", [["DAI", "DISEASE", 28, 31], ["tSAH", "DISEASE", 63, 67], ["tSAH", "DISEASE", 91, 95], ["IVH", "DISEASE", 117, 120], ["patients", "ORGANISM", 7, 15], ["tSAH", "CANCER", 63, 67], ["patients", "SPECIES", 7, 15], ["severe DAI (grades II and III)", "PROBLEM", 21, 51], ["tSAH", "TEST", 63, 67], ["midline tSAH", "PROBLEM", 83, 95], ["The composite IVH/tSAH item", "PROBLEM", 103, 130], ["DAI", "PROBLEM", 165, 168], ["severe", "OBSERVATION_MODIFIER", 21, 27]]], ["When separated, IVH and tSAH also were associated with DAI.", [["IVH", "DISEASE", 16, 19], ["IVH", "PROBLEM", 16, 19], ["tSAH", "PROBLEM", 24, 28], ["DAI", "PROBLEM", 55, 58], ["IVH", "OBSERVATION", 16, 19]]], ["Only interhemispheric and peri-mesencephalic tSAH were independently associated with both general DAI and severe DAI.ResultsThe presence of midline tSAH on the initial CT had a sensitivity of 60.8%, a specificity of 81.7%, a positive predictive value of 43.7%, and a negative predictive value of 89.9% for predicting severe DAI.", [["interhemispheric", "ANATOMY", 5, 21], ["midline tSAH", "ANATOMY", 140, 152], ["DAI", "DISEASE", 98, 101], ["DAI", "DISEASE", 113, 116], ["DAI", "DISEASE", 324, 327], ["tSAH", "GENE_OR_GENE_PRODUCT", 45, 49], ["midline tSAH", "CANCER", 140, 152], ["interhemispheric and peri-mesencephalic tSAH", "PROBLEM", 5, 49], ["severe DAI", "PROBLEM", 106, 116], ["midline tSAH", "PROBLEM", 140, 152], ["the initial CT", "TEST", 156, 170], ["a sensitivity", "TEST", 175, 188], ["a specificity", "TEST", 199, 212], ["predicting severe DAI", "PROBLEM", 306, 327], ["interhemispheric", "ANATOMY_MODIFIER", 5, 21], ["peri-mesencephalic tSAH", "OBSERVATION", 26, 49], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["DAI", "OBSERVATION", 113, 116], ["midline", "ANATOMY_MODIFIER", 140, 147], ["severe", "OBSERVATION_MODIFIER", 317, 323], ["DAI", "OBSERVATION", 324, 327]]], ["In other words, when midline tSAH is not evident on CT, most likely the mechanism of TBI was not by shear forces, and DAI, if present, is likely not severe.ResultsIn their study, Henninger et al. found that, in their hemorrhagic DAI (hDAI) group, most of the patients were young, with more severe lesions and a higher propensity for hypotension.", [["lesions", "ANATOMY", 297, 304], ["tSAH", "DISEASE", 29, 33], ["TBI", "DISEASE", 85, 88], ["hemorrhagic", "DISEASE", 217, 228], ["hDAI", "DISEASE", 234, 238], ["hypotension", "DISEASE", 333, 344], ["patients", "ORGANISM", 259, 267], ["lesions", "PATHOLOGICAL_FORMATION", 297, 304], ["patients", "SPECIES", 259, 267], ["midline tSAH", "PROBLEM", 21, 33], ["CT", "TEST", 52, 54], ["TBI", "PROBLEM", 85, 88], ["DAI", "PROBLEM", 118, 121], ["their study", "TEST", 166, 177], ["more severe lesions", "PROBLEM", 285, 304], ["hypotension", "PROBLEM", 333, 344], ["TBI", "OBSERVATION", 85, 88], ["likely not", "UNCERTAINTY", 138, 148], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["hemorrhagic", "OBSERVATION_MODIFIER", 217, 228], ["severe", "OBSERVATION_MODIFIER", 290, 296], ["lesions", "OBSERVATION", 297, 304]]], ["Overall, 70% had grade I, 3% grade II and 27% grade III DAI.", [["DAI", "DISEASE", 56, 59], ["grade I, 3% grade II and 27% grade III DAI", "PROBLEM", 17, 59]]], ["In addition, hDAI had a higher frequency of systemic complications, like pneumonia, severe acute respiratory syndrome, sepsis and fever.", [["systemic complications", "DISEASE", 44, 66], ["pneumonia", "DISEASE", 73, 82], ["acute respiratory syndrome", "DISEASE", 91, 117], ["sepsis", "DISEASE", 119, 125], ["fever", "DISEASE", 130, 135], ["systemic complications", "PROBLEM", 44, 66], ["pneumonia", "PROBLEM", 73, 82], ["severe acute respiratory syndrome", "PROBLEM", 84, 117], ["sepsis", "PROBLEM", 119, 125], ["fever", "PROBLEM", 130, 135], ["systemic", "OBSERVATION_MODIFIER", 44, 52], ["complications", "OBSERVATION", 53, 66], ["pneumonia", "OBSERVATION", 73, 82], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome", "OBSERVATION", 97, 117], ["sepsis", "OBSERVATION", 119, 125], ["fever", "OBSERVATION", 130, 135]]], ["Likewise, cerebral edema with the need for osmotherapy was more frequent in patients with hDAI.", [["cerebral", "ANATOMY", 10, 18], ["cerebral edema", "DISEASE", 10, 24], ["hDAI", "DISEASE", 90, 94], ["cerebral edema", "PATHOLOGICAL_FORMATION", 10, 24], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["cerebral edema", "PROBLEM", 10, 24], ["osmotherapy", "TREATMENT", 43, 54], ["cerebral", "ANATOMY", 10, 18], ["edema", "OBSERVATION", 19, 24]]], ["However, hDAI had a lower risk of death at 1 year and better functional prognosis than patients without hDAI.ResultsMata-Mbemba et al. (2014) evaluated the relationship between the presence of both IVH and tSAH on the initial CT, and DAI on the subsequent MRI.", [["death", "DISEASE", 34, 39], ["hDAI", "DISEASE", 104, 108], ["IVH", "DISEASE", 198, 201], ["tSAH", "DISEASE", 206, 210], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["death", "PROBLEM", 34, 39], ["both IVH", "PROBLEM", 193, 201], ["tSAH", "PROBLEM", 206, 210], ["the initial CT", "TEST", 214, 228], ["DAI", "PROBLEM", 234, 237], ["the subsequent MRI", "TEST", 241, 259], ["both", "ANATOMY_MODIFIER", 193, 197], ["IVH", "OBSERVATION", 198, 201]]], ["Together, IVH and SAH were significantly associated with DAI in MRI; but, when separated, only IVH was a predictor of DAI.", [["IVH", "DISEASE", 10, 13], ["SAH", "DISEASE", 18, 21], ["IVH", "DISEASE", 95, 98], ["DAI", "DISEASE", 118, 121], ["IVH", "PROBLEM", 10, 13], ["SAH", "PROBLEM", 18, 21], ["DAI", "PROBLEM", 57, 60], ["MRI", "TEST", 64, 67], ["IVH", "PROBLEM", 95, 98], ["DAI", "PROBLEM", 118, 121], ["IVH", "OBSERVATION", 10, 13], ["SAH", "OBSERVATION", 18, 21], ["IVH", "OBSERVATION", 95, 98]]], ["The IVH score (using the same classification as in the other 2018 study) and DAI stage were directly correlated, with the IVH score in patients with degree II or III DAI significantly higher than in patients without DAI.", [["IVH", "DISEASE", 4, 7], ["IVH", "DISEASE", 122, 125], ["DAI", "DISEASE", 216, 219], ["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 199, 207], ["The IVH score", "PROBLEM", 0, 13], ["DAI stage", "PROBLEM", 77, 86], ["the IVH score", "PROBLEM", 118, 131], ["degree II or III DAI", "PROBLEM", 149, 169], ["DAI", "PROBLEM", 216, 219], ["IVH", "OBSERVATION", 4, 7], ["IVH", "OBSERVATION", 122, 125]]], ["Thus, IVH on the initial CT exhibited high specificity and a high negative-predictive value for the presence of DAI, of 88% and 71.7%, respectively.", [["IVH", "DISEASE", 6, 9], ["IVH", "PROBLEM", 6, 9], ["the initial CT", "TEST", 13, 27], ["DAI", "TEST", 112, 115], ["IVH", "OBSERVATION", 6, 9]]], ["This means that the absence of IVH on the initial CT means that there is probably no DAI, and especially no severe DAI (group II or III).ResultsIn their study, Matsukawa et al. [19]. evaluated the relationship between IVH at baseline and grade II DAI (corpus callosum lesion) on MRI 2 weeks post TBI.", [["corpus callosum lesion", "ANATOMY", 252, 274], ["IVH", "DISEASE", 31, 34], ["DAI", "DISEASE", 115, 118], ["IVH", "DISEASE", 218, 221], ["corpus callosum lesion", "DISEASE", 252, 274], ["TBI", "DISEASE", 296, 299], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 252, 267], ["IVH", "PROBLEM", 31, 34], ["the initial CT", "TEST", 38, 52], ["DAI", "PROBLEM", 85, 88], ["severe DAI", "PROBLEM", 108, 118], ["their study", "TEST", 147, 158], ["IVH", "PROBLEM", 218, 221], ["grade II DAI (corpus callosum lesion", "PROBLEM", 238, 274], ["MRI", "TEST", 279, 282], ["TBI", "PROBLEM", 296, 299], ["IVH", "OBSERVATION", 31, 34], ["probably no", "UNCERTAINTY", 73, 84], ["IVH", "OBSERVATION", 218, 221], ["grade II", "OBSERVATION_MODIFIER", 238, 246], ["DAI", "OBSERVATION_MODIFIER", 247, 250], ["corpus callosum", "ANATOMY", 252, 267]]], ["The number of ventricles in which blood was present predicted IVH severity.", [["ventricles", "ANATOMY", 14, 24], ["blood", "ANATOMY", 34, 39], ["IVH", "DISEASE", 62, 65], ["ventricles", "MULTI-TISSUE_STRUCTURE", 14, 24], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["IVH severity", "PROBLEM", 62, 74], ["number", "OBSERVATION_MODIFIER", 4, 10], ["ventricles", "ANATOMY", 14, 24], ["IVH", "OBSERVATION_MODIFIER", 62, 65], ["severity", "OBSERVATION_MODIFIER", 66, 74]]], ["The proportion of patients with a severe TBI (GCS < 9), abnormal pupils, and a traffic accident as the mechanism of injury were significantly higher in patients with a corpus callosum lesion (CCI).", [["corpus callosum lesion", "ANATOMY", 168, 190], ["TBI", "DISEASE", 41, 44], ["GCS", "DISEASE", 46, 49], ["abnormal pupils", "DISEASE", 56, 71], ["corpus callosum lesion", "DISEASE", 168, 190], ["CCI", "DISEASE", 192, 195], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 152, 160], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 168, 183], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 152, 160], ["a severe TBI", "PROBLEM", 32, 44], ["GCS", "TEST", 46, 49], ["abnormal pupils", "PROBLEM", 56, 71], ["injury", "PROBLEM", 116, 122], ["a corpus callosum lesion", "PROBLEM", 166, 190], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["TBI", "OBSERVATION", 41, 44], ["abnormal", "OBSERVATION_MODIFIER", 56, 64], ["pupils", "OBSERVATION", 65, 71], ["injury", "OBSERVATION", 116, 122], ["higher", "OBSERVATION_MODIFIER", 142, 148], ["corpus callosum", "ANATOMY", 168, 183], ["lesion", "OBSERVATION", 184, 190]]], ["IVH was significantly associated with CCI.", [["IVH", "DISEASE", 0, 3], ["CCI", "DISEASE", 38, 41], ["IVH", "PROBLEM", 0, 3], ["CCI", "PROBLEM", 38, 41], ["CCI", "OBSERVATION", 38, 41]]], ["The investigators also found that older age, male gender, low GCS, IVH on CT, and CCI on MRI all were associated with the future presence of disability (GOSE scale \u2264 6).", [["GCS", "DISEASE", 62, 65], ["IVH", "DISEASE", 67, 70], ["CCI", "DISEASE", 82, 85], ["disability", "DISEASE", 141, 151], ["low GCS", "PROBLEM", 58, 65], ["IVH", "PROBLEM", 67, 70], ["CT", "TEST", 74, 76], ["CCI", "TEST", 82, 85], ["MRI", "TEST", 89, 92], ["low GCS", "OBSERVATION_MODIFIER", 58, 65], ["IVH", "OBSERVATION", 67, 70]]], ["In addition, a direct correlation was identified between IVH grade and the number of CCI lesions.ResultsBeretta et al. analyzed the relationship between blood in the interpeduncular cisterns (IPC) on CT and grade III DAI (brainstem lesion) on MRI.", [["CCI lesions", "ANATOMY", 85, 96], ["blood", "ANATOMY", 153, 158], ["interpeduncular cisterns", "ANATOMY", 166, 190], ["brainstem lesion", "ANATOMY", 222, 238], ["IVH", "DISEASE", 57, 60], ["CCI", "DISEASE", 85, 88], ["CCI lesions", "CANCER", 85, 96], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["interpeduncular cisterns", "MULTI-TISSUE_STRUCTURE", 166, 190], ["brainstem lesion", "CANCER", 222, 238], ["a direct correlation", "TEST", 13, 33], ["IVH grade", "PROBLEM", 57, 66], ["CCI lesions", "PROBLEM", 85, 96], ["CT", "TEST", 200, 202], ["grade III DAI (brainstem lesion", "PROBLEM", 207, 238], ["MRI", "TEST", 243, 246], ["CCI", "OBSERVATION_MODIFIER", 85, 88], ["lesions", "OBSERVATION", 89, 96], ["blood", "ANATOMY", 153, 158], ["interpeduncular cisterns", "ANATOMY", 166, 190], ["IPC", "OBSERVATION_MODIFIER", 192, 195], ["grade III", "OBSERVATION_MODIFIER", 207, 216], ["DAI", "OBSERVATION_MODIFIER", 217, 220], ["brainstem", "ANATOMY", 222, 231], ["lesion", "OBSERVATION", 232, 238]]], ["The severity of the brain stem lesion (BSL) was defined according to the modified Firshing classification: (I) supratentorial lesions or no lesions; (II) unilateral lesions in the brainstem at any level; (III) bilateral lesions in the brainstem at any level.", [["brain stem lesion", "ANATOMY", 20, 37], ["supratentorial lesions", "ANATOMY", 111, 133], ["lesions", "ANATOMY", 140, 147], ["lesions", "ANATOMY", 165, 172], ["brainstem", "ANATOMY", 180, 189], ["lesions", "ANATOMY", 220, 227], ["brainstem", "ANATOMY", 235, 244], ["brain stem lesion", "CANCER", 20, 37], ["supratentorial lesions", "PATHOLOGICAL_FORMATION", 111, 133], ["lesions", "PATHOLOGICAL_FORMATION", 140, 147], ["lesions", "PATHOLOGICAL_FORMATION", 165, 172], ["brainstem", "ORGAN", 180, 189], ["lesions", "PATHOLOGICAL_FORMATION", 220, 227], ["brainstem", "ORGAN", 235, 244], ["the brain stem lesion", "PROBLEM", 16, 37], ["(I) supratentorial lesions", "PROBLEM", 107, 133], ["lesions", "PROBLEM", 140, 147], ["(II) unilateral lesions in the brainstem", "PROBLEM", 149, 189], ["(III) bilateral lesions in the brainstem", "PROBLEM", 204, 244], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["brain stem", "ANATOMY", 20, 30], ["lesion", "OBSERVATION", 31, 37], ["supratentorial", "ANATOMY", 111, 125], ["lesions", "OBSERVATION", 126, 133], ["no", "UNCERTAINTY", 137, 139], ["lesions", "OBSERVATION", 140, 147], ["unilateral", "OBSERVATION_MODIFIER", 154, 164], ["lesions", "OBSERVATION", 165, 172], ["brainstem", "ANATOMY", 180, 189], ["bilateral", "ANATOMY_MODIFIER", 210, 219], ["lesions", "OBSERVATION", 220, 227], ["brainstem", "ANATOMY", 235, 244]]], ["Overall, 85.3% of patients had CCI on MRI, and 75.5% had a BSL.", [["CCI", "DISEASE", 31, 34], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["CCI", "TEST", 31, 34], ["MRI", "TEST", 38, 41]]], ["Patients with blood in the IPC averaged significantly lower GCS scores than those without blood in the IPC.", [["blood", "ANATOMY", 14, 19], ["blood", "ANATOMY", 90, 95], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["Patients", "SPECIES", 0, 8], ["blood in the IPC", "PROBLEM", 14, 30], ["significantly lower GCS scores", "PROBLEM", 40, 70], ["blood in the IPC", "PROBLEM", 90, 106], ["IPC", "OBSERVATION_MODIFIER", 27, 30], ["averaged", "OBSERVATION_MODIFIER", 31, 39], ["significantly", "OBSERVATION_MODIFIER", 40, 53], ["lower GCS", "OBSERVATION_MODIFIER", 54, 63], ["IPC", "OBSERVATION", 103, 106]]], ["Patients with evidence of BSL on MRI had a significantly higher incidence of blood in their IPC on CT.", [["blood", "ANATOMY", 77, 82], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["Patients", "SPECIES", 0, 8], ["BSL", "PROBLEM", 26, 29], ["MRI", "TEST", 33, 36], ["blood in their IPC", "PROBLEM", 77, 95], ["CT", "TEST", 99, 101], ["BSL", "OBSERVATION", 26, 29], ["blood", "ANATOMY", 77, 82], ["IPC", "OBSERVATION_MODIFIER", 92, 95]]], ["The finding of blood in the IPC did not differ significantly in patients with Firshing degrees II or III DAI, though it trended towards being higher in grade III.DiscussionWorldwide, trauma causes 10% of all deaths, and trauma is the leading cause of permanent disability.", [["blood", "ANATOMY", 15, 20], ["trauma", "DISEASE", 183, 189], ["deaths", "DISEASE", 208, 214], ["trauma", "DISEASE", 220, 226], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["blood in the IPC", "PROBLEM", 15, 31], ["Firshing degrees II or III DAI", "PROBLEM", 78, 108], ["trauma", "PROBLEM", 183, 189], ["trauma", "PROBLEM", 220, 226], ["permanent disability", "PROBLEM", 251, 271], ["blood", "OBSERVATION", 15, 20], ["grade III", "OBSERVATION_MODIFIER", 152, 161]]], ["Most traumatic events occur in individuals between 5 and 44 years old [20].", [["Most traumatic events", "PROBLEM", 0, 21]]], ["According to Datasus data from 2016, in Brazil, deaths due to external causes account for approximately 12% of all deaths.", [["deaths", "DISEASE", 48, 54], ["deaths", "DISEASE", 115, 121]]], ["The age groups with the highest mortality due to external causes are those 15 to 59 years old.", [["external causes", "PROBLEM", 49, 64]]], ["Males account for 82.2% of these externally caused deaths [21].DiscussionIn Brazil, it is estimated that more than one million people live with neurological sequelae due to a TBI.", [["neurological", "ANATOMY", 144, 156], ["deaths", "DISEASE", 51, 57], ["neurological sequelae", "DISEASE", 144, 165], ["TBI", "DISEASE", 175, 178], ["people", "ORGANISM", 127, 133], ["people", "SPECIES", 127, 133], ["neurological sequelae", "PROBLEM", 144, 165], ["a TBI", "PROBLEM", 173, 178], ["TBI", "OBSERVATION", 175, 178]]], ["Males are most affected, accounting for 81.5% of the mortalities caused by TBI.", [["TBI", "DISEASE", 75, 78], ["TBI", "PROBLEM", 75, 78], ["most affected", "OBSERVATION_MODIFIER", 10, 23], ["TBI", "OBSERVATION", 75, 78]]], ["The main causes are traffic accidents, primarily involving motorcycles.", [["accidents", "DISEASE", 28, 37], ["main", "OBSERVATION_MODIFIER", 4, 8], ["traffic accidents", "OBSERVATION", 20, 37]]], ["And the mortality rate of TBI in Brazil is 12% [21].DiscussionIn our study, according to the criteria used, the incidence of DAI across all TBI patients was roughly 33%.", [["TBI", "DISEASE", 26, 29], ["DAI", "DISEASE", 125, 128], ["TBI", "DISEASE", 140, 143], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["the mortality rate", "TEST", 4, 22], ["TBI", "PROBLEM", 26, 29], ["our study", "TEST", 65, 74], ["DAI", "PROBLEM", 125, 128]]], ["According to Adams et al., the incidence of DAI in closed TBI is 29%, and that is likely to be an underestimate, since DAI may be camouflaged by other types of brain injury, like severe contusions, brain hematomas, brain injury secondary to intracranial hypertension, brain herniation leading to hemorrhage and infarction of the brainstem, and severe hypoxic injury [3].", [["brain", "ANATOMY", 160, 165], ["brain", "ANATOMY", 198, 203], ["brain", "ANATOMY", 215, 220], ["intracranial", "ANATOMY", 241, 253], ["brain", "ANATOMY", 268, 273], ["brainstem", "ANATOMY", 329, 338], ["DAI", "DISEASE", 44, 47], ["TBI", "DISEASE", 58, 61], ["DAI", "DISEASE", 119, 122], ["brain injury", "DISEASE", 160, 172], ["contusions", "DISEASE", 186, 196], ["brain hematomas", "DISEASE", 198, 213], ["brain injury", "DISEASE", 215, 227], ["intracranial hypertension", "DISEASE", 241, 266], ["brain herniation", "DISEASE", 268, 284], ["hemorrhage", "DISEASE", 296, 306], ["infarction", "DISEASE", 311, 321], ["hypoxic injury", "DISEASE", 351, 365], ["brain", "ORGAN", 160, 165], ["brain", "ORGAN", 198, 203], ["brain", "ORGAN", 215, 220], ["brain", "ORGAN", 268, 273], ["brainstem", "ORGAN", 329, 338], ["DAI", "PROBLEM", 44, 47], ["DAI", "PROBLEM", 119, 122], ["brain injury", "PROBLEM", 160, 172], ["severe contusions", "PROBLEM", 179, 196], ["brain hematomas", "PROBLEM", 198, 213], ["brain injury", "PROBLEM", 215, 227], ["intracranial hypertension", "PROBLEM", 241, 266], ["brain herniation", "PROBLEM", 268, 284], ["hemorrhage", "PROBLEM", 296, 306], ["infarction of the brainstem", "PROBLEM", 311, 338], ["severe hypoxic injury", "PROBLEM", 344, 365], ["likely to be", "UNCERTAINTY", 82, 94], ["underestimate", "OBSERVATION", 98, 111], ["brain", "ANATOMY", 160, 165], ["injury", "OBSERVATION", 166, 172], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["contusions", "OBSERVATION", 186, 196], ["brain", "ANATOMY", 198, 203], ["hematomas", "OBSERVATION", 204, 213], ["brain", "ANATOMY", 215, 220], ["injury", "OBSERVATION", 221, 227], ["intracranial", "ANATOMY", 241, 253], ["hypertension", "OBSERVATION", 254, 266], ["brain", "ANATOMY", 268, 273], ["herniation", "OBSERVATION", 274, 284], ["hemorrhage", "OBSERVATION", 296, 306], ["infarction", "OBSERVATION", 311, 321], ["brainstem", "ANATOMY", 329, 338], ["severe", "OBSERVATION_MODIFIER", 344, 350], ["hypoxic", "OBSERVATION_MODIFIER", 351, 358], ["injury", "OBSERVATION", 359, 365]]], ["In moderate to severe TBI, the prevalence of DAI is approximately 72% [6].DiscussionIn a study by Vieira et al., 89.7% of patients with DAI were male, and 43.6% between 18 and 28 years of age, with a mean age of 32 years.", [["TBI", "DISEASE", 22, 25], ["DAI", "DISEASE", 45, 48], ["DAI", "DISEASE", 136, 139], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["moderate to severe TBI", "PROBLEM", 3, 25], ["a study", "TEST", 87, 94], ["moderate", "OBSERVATION_MODIFIER", 3, 11], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["TBI", "OBSERVATION", 22, 25]]], ["The main cause of DAI in this study was traffic accidents, with motorcyclists accounting for 43.6% of these cases.", [["DAI", "DISEASE", 18, 21], ["traffic accidents", "DISEASE", 40, 57], ["DAI", "PROBLEM", 18, 21], ["main", "OBSERVATION_MODIFIER", 4, 8], ["DAI", "OBSERVATION", 18, 21]]], ["Individuals in coma (GCS \u2264 8) constituted 75.7% of the patients.", [["coma", "DISEASE", 15, 19], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["GCS", "TEST", 21, 24]]], ["In this study, no patients were classified as having mild TBI, while 19.2% had moderate and 80.8% severe TBI.", [["TBI", "DISEASE", 58, 61], ["TBI", "DISEASE", 105, 108], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["this study", "TEST", 3, 13], ["mild TBI", "PROBLEM", 53, 61], ["moderate and 80.8% severe TBI", "PROBLEM", 79, 108], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["TBI", "OBSERVATION", 58, 61], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["TBI", "OBSERVATION", 105, 108]]], ["Out of the total, 53.8% underwent surgery, and 19.2% required repeat surgeries.", [["surgery", "TREATMENT", 34, 41], ["repeat surgeries", "TREATMENT", 62, 78]]], ["In the study by Adams et al., the incidence of traffic accidents in patients with DAI was much higher than that in patients without DAI, and the incidence of DAI was much lower in patients whose TBI resulted from a fall [21].DiscussionIn this study, we found results compatible with the literature: the mean age of patients with DAI was 41 years, 79% were male, and 70% of DAI was caused by a traffic accident.", [["traffic accidents", "DISEASE", 47, 64], ["DAI", "DISEASE", 82, 85], ["DAI", "DISEASE", 132, 135], ["DAI", "DISEASE", 158, 161], ["TBI", "DISEASE", 195, 198], ["DAI", "DISEASE", 329, 332], ["DAI", "DISEASE", 373, 376], ["traffic accident", "DISEASE", 393, 409], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 315, 323], ["DAI", "PROBLEM", 82, 85], ["DAI", "PROBLEM", 132, 135], ["DAI", "PROBLEM", 158, 161], ["this study", "TEST", 238, 248], ["DAI", "PROBLEM", 373, 376], ["traffic accidents", "OBSERVATION", 47, 64]]], ["Unfortunately, GCS was not comparable between studies, as some studies did not employ this evaluation parameter.DiscussionAccording to our findings, in a patient with a closed TBI and an early CT showing no tSAH, there is probably no severe DAI; similarly, in the absence of IVH, there is also probably no severe DAI.", [["TBI", "DISEASE", 176, 179], ["tSAH", "DISEASE", 207, 211], ["DAI", "DISEASE", 241, 244], ["IVH", "DISEASE", 275, 278], ["DAI", "DISEASE", 313, 316], ["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["GCS", "TEST", 15, 18], ["some studies", "TEST", 58, 70], ["this evaluation parameter", "TEST", 86, 111], ["a closed TBI", "TEST", 167, 179], ["an early CT", "TEST", 184, 195], ["tSAH", "PROBLEM", 207, 211], ["severe DAI", "PROBLEM", 234, 244], ["IVH", "PROBLEM", 275, 278], ["severe DAI", "PROBLEM", 306, 316], ["probably", "UNCERTAINTY", 222, 230], ["no", "UNCERTAINTY", 231, 233], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["DAI", "OBSERVATION", 241, 244], ["IVH", "OBSERVATION", 275, 278], ["probably no", "UNCERTAINTY", 294, 305], ["severe", "OBSERVATION_MODIFIER", 306, 312], ["DAI", "OBSERVATION", 313, 316]]], ["If there is IVH, it is possible that the patient is more severe and has a reserved prognosis, since there is, at least, CCI.", [["IVH", "DISEASE", 12, 15], ["CCI", "DISEASE", 120, 123], ["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["IVH", "PROBLEM", 12, 15], ["CCI", "TEST", 120, 123], ["IVH", "OBSERVATION", 12, 15], ["more severe", "OBSERVATION_MODIFIER", 52, 63], ["CCI", "OBSERVATION", 120, 123]]], ["In addition, the greater the number of ventricles affected, the more serious the clinical picture is.", [["ventricles", "ANATOMY", 39, 49], ["ventricles", "MULTI-TISSUE_STRUCTURE", 39, 49], ["greater", "OBSERVATION_MODIFIER", 17, 24], ["number", "OBSERVATION_MODIFIER", 29, 35], ["ventricles", "ANATOMY", 39, 49], ["affected", "OBSERVATION", 50, 58], ["more", "OBSERVATION_MODIFIER", 64, 68], ["serious", "OBSERVATION_MODIFIER", 69, 76]]], ["The presence of blood in the IPC gives a possible diagnosis of severe DAI, either grade II or III.DiscussionThe corpus callosum and brainstem are midline structures intrinsically related to the ventricular system of the encephalon.", [["blood", "ANATOMY", 16, 21], ["corpus callosum", "ANATOMY", 112, 127], ["brainstem", "ANATOMY", 132, 141], ["midline structures", "ANATOMY", 146, 164], ["ventricular system", "ANATOMY", 194, 212], ["encephalon", "ANATOMY", 220, 230], ["DAI", "DISEASE", 70, 73], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 112, 127], ["brainstem", "ORGAN", 132, 141], ["midline structures", "TISSUE", 146, 164], ["ventricular system", "MULTI-TISSUE_STRUCTURE", 194, 212], ["encephalon", "CANCER", 220, 230], ["blood in the IPC", "PROBLEM", 16, 32], ["severe DAI", "PROBLEM", 63, 73], ["grade II or III", "PROBLEM", 82, 97], ["blood", "OBSERVATION", 16, 21], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["DAI", "OBSERVATION", 70, 73], ["corpus callosum", "ANATOMY", 112, 127], ["brainstem", "ANATOMY_MODIFIER", 132, 141], ["midline", "ANATOMY_MODIFIER", 146, 153], ["ventricular system", "ANATOMY", 194, 212], ["encephalon", "OBSERVATION", 220, 230]]], ["When the neurons of those areas suffer axonal shredding, the same shearing strain causes rupture of the midline superficial vessels.", [["neurons", "ANATOMY", 9, 16], ["axonal", "ANATOMY", 39, 45], ["midline superficial vessels", "ANATOMY", 104, 131], ["rupture", "DISEASE", 89, 96], ["neurons", "CELL", 9, 16], ["midline superficial vessels", "MULTI-TISSUE_STRUCTURE", 104, 131], ["axonal shredding", "PROBLEM", 39, 55], ["rupture of the midline superficial vessels", "PROBLEM", 89, 131], ["rupture", "OBSERVATION", 89, 96], ["midline", "ANATOMY_MODIFIER", 104, 111], ["superficial", "ANATOMY_MODIFIER", 112, 123], ["vessels", "ANATOMY", 124, 131]]], ["This mechanism produces IVH and a midline subarachnoid hemorrhage (interhemispheric and peri-mesencephalic).", [["midline subarachnoid", "ANATOMY", 34, 54], ["interhemispheric", "ANATOMY", 67, 83], ["IVH", "DISEASE", 24, 27], ["subarachnoid hemorrhage", "DISEASE", 42, 65], ["IVH", "PROBLEM", 24, 27], ["a midline subarachnoid hemorrhage", "PROBLEM", 32, 65], ["IVH", "OBSERVATION", 24, 27], ["midline", "ANATOMY_MODIFIER", 34, 41], ["subarachnoid", "ANATOMY", 42, 54], ["hemorrhage", "OBSERVATION", 55, 65], ["interhemispheric", "OBSERVATION_MODIFIER", 67, 83]]], ["Furthermore, the severity of the IVH is related to the severity of the DAI, because the greater the forces of the accident, the greater the shearing forces, both for axons and small vessels.DiscussionMoreover, the simple presence of petechial lesions on CT is not indicative of worse functional outcome (GCS < 4) in the long term, but represents a greater chance of complications in the short and medium term, such as pneumonia, SARS, sepsis, cerebral edema with the need of osmotherapy, and, consequently, the need for constant monitoring.DiscussionPatients with DAI require intensive clinical care because of the condition in which they arrive in the emergency department.", [["axons", "ANATOMY", 166, 171], ["small vessels", "ANATOMY", 176, 189], ["petechial lesions", "ANATOMY", 233, 250], ["cerebral", "ANATOMY", 443, 451], ["IVH", "DISEASE", 33, 36], ["DAI", "DISEASE", 71, 74], ["pneumonia", "DISEASE", 418, 427], ["SARS", "DISEASE", 429, 433], ["sepsis", "DISEASE", 435, 441], ["cerebral edema", "DISEASE", 443, 457], ["DAI", "DISEASE", 564, 567], ["axons", "MULTI-TISSUE_STRUCTURE", 166, 171], ["small vessels", "MULTI-TISSUE_STRUCTURE", 176, 189], ["petechial lesions", "PATHOLOGICAL_FORMATION", 233, 250], ["cerebral edema", "PATHOLOGICAL_FORMATION", 443, 457], ["the IVH", "PROBLEM", 29, 36], ["the DAI", "PROBLEM", 67, 74], ["petechial lesions", "PROBLEM", 233, 250], ["CT", "TEST", 254, 256], ["GCS", "TEST", 304, 307], ["complications", "PROBLEM", 366, 379], ["the short and medium term", "PROBLEM", 383, 408], ["pneumonia", "PROBLEM", 418, 427], ["SARS", "PROBLEM", 429, 433], ["sepsis", "PROBLEM", 435, 441], ["cerebral edema", "PROBLEM", 443, 457], ["osmotherapy", "TREATMENT", 475, 486], ["constant monitoring", "TEST", 520, 539], ["intensive clinical care", "TREATMENT", 576, 599], ["IVH", "OBSERVATION", 33, 36], ["greater", "OBSERVATION_MODIFIER", 128, 135], ["shearing forces", "OBSERVATION", 140, 155], ["small vessels", "ANATOMY", 176, 189], ["petechial", "OBSERVATION_MODIFIER", 233, 242], ["lesions", "OBSERVATION", 243, 250], ["not indicative of", "UNCERTAINTY", 260, 277], ["long term", "OBSERVATION_MODIFIER", 320, 329], ["greater", "OBSERVATION_MODIFIER", 348, 355], ["complications", "OBSERVATION", 366, 379], ["short and medium term", "OBSERVATION_MODIFIER", 387, 408], ["pneumonia", "OBSERVATION", 418, 427], ["sepsis", "OBSERVATION", 435, 441], ["cerebral", "ANATOMY", 443, 451], ["edema", "OBSERVATION", 452, 457]]], ["A reduced level of consciousness, with GCS lower with than without DAI, plus the need for orotracheal intubation for airway protection, tachypnea, hypoxia, cardiorespiratory arrest and changes in glycemia are components of the clinical picture.", [["orotracheal", "ANATOMY", 90, 101], ["airway", "ANATOMY", 117, 123], ["GCS", "DISEASE", 39, 42], ["DAI", "DISEASE", 67, 70], ["tachypnea", "DISEASE", 136, 145], ["hypoxia", "DISEASE", 147, 154], ["cardiorespiratory arrest", "DISEASE", 156, 180], ["airway", "MULTI-TISSUE_STRUCTURE", 117, 123], ["A reduced level of consciousness", "PROBLEM", 0, 32], ["GCS lower", "PROBLEM", 39, 48], ["DAI", "PROBLEM", 67, 70], ["orotracheal intubation", "TREATMENT", 90, 112], ["airway protection", "TREATMENT", 117, 134], ["tachypnea", "PROBLEM", 136, 145], ["hypoxia", "PROBLEM", 147, 154], ["cardiorespiratory arrest", "PROBLEM", 156, 180], ["changes in glycemia", "PROBLEM", 185, 204], ["the clinical picture", "PROBLEM", 223, 243], ["reduced", "OBSERVATION_MODIFIER", 2, 9], ["airway", "ANATOMY", 117, 123], ["hypoxia", "OBSERVATION", 147, 154], ["cardiorespiratory arrest", "OBSERVATION", 156, 180]]], ["Survivors of the injury often require a prolonged hospital stay, the use of sedatives and other drugs, and neurosurgical approaches, and generally experience worse outcomes than patients with TBI but without DAI.", [["TBI", "DISEASE", 192, 195], ["DAI", "DISEASE", 208, 211], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["the injury", "PROBLEM", 13, 23], ["sedatives", "TREATMENT", 76, 85], ["other drugs", "TREATMENT", 90, 101], ["neurosurgical approaches", "TREATMENT", 107, 131], ["TBI", "PROBLEM", 192, 195], ["DAI", "PROBLEM", 208, 211]]], ["In patients with severe DAI, death is the most common outcome, with the presence, at admission, of hypotension, hypoxia, hyperglycemia, and pupillary changes also predictive of increased mortality [6, 7].DiscussionThe current study has both strengths and weaknesses.", [["DAI", "DISEASE", 24, 27], ["death", "DISEASE", 29, 34], ["hypotension", "DISEASE", 99, 110], ["hypoxia", "DISEASE", 112, 119], ["hyperglycemia", "DISEASE", 121, 134], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["severe DAI", "PROBLEM", 17, 27], ["death", "PROBLEM", 29, 34], ["hypotension", "PROBLEM", 99, 110], ["hypoxia", "PROBLEM", 112, 119], ["hyperglycemia", "PROBLEM", 121, 134], ["pupillary changes", "PROBLEM", 140, 157], ["increased mortality", "PROBLEM", 177, 196], ["The current study", "TEST", 214, 231], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["DAI", "OBSERVATION", 24, 27], ["hypotension", "OBSERVATION", 99, 110], ["hypoxia", "OBSERVATION", 112, 119], ["hyperglycemia", "OBSERVATION", 121, 134], ["pupillary changes", "OBSERVATION", 140, 157], ["increased", "OBSERVATION_MODIFIER", 177, 186]]], ["Its main strengths are the large sample of patients and availability of demographic and baseline CT data.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["baseline CT data", "TEST", 88, 104], ["main", "OBSERVATION_MODIFIER", 4, 8], ["strengths", "OBSERVATION_MODIFIER", 9, 18], ["large", "OBSERVATION_MODIFIER", 27, 32]]], ["One limitation that warrants comment is that the studies used in our review failed to exclude the presence of other post-traumatic brain lesions, which could bias outcomes.", [["brain lesions", "ANATOMY", 131, 144], ["brain lesions", "PATHOLOGICAL_FORMATION", 131, 144], ["the studies", "TEST", 45, 56], ["other post-traumatic brain lesions", "PROBLEM", 110, 144], ["traumatic", "OBSERVATION_MODIFIER", 121, 130], ["brain", "ANATOMY", 131, 136], ["lesions", "OBSERVATION", 137, 144]]], ["Furthermore, the interval between the GCS and GOSE assessments and initial MRI varied between the studies.DiscussionThe implications of our study extend not just to the neurosurgical community, but to all physicians working with trauma patients.", [["trauma", "DISEASE", 229, 235], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 236, 244], ["the GCS", "TEST", 34, 41], ["GOSE assessments", "TEST", 46, 62], ["initial MRI", "TEST", 67, 78], ["the studies", "TEST", 94, 105], ["our study", "TEST", 136, 145]]], ["In the case of a patient with a closed TBI, obtaining a CT within the first 24 h can aid in both guiding therapy and predicting prognosis, in both the short and long term.", [["TBI", "DISEASE", 39, 42], ["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["a closed TBI", "PROBLEM", 30, 42], ["a CT", "TEST", 54, 58], ["both guiding therapy", "TREATMENT", 92, 112]]], ["Also, patients with DAI are more likely to have other complications, and patients with severe DAI should be kept under continuous monitoring.DiscussionThe available literature does not give an answer about the relationship between increased intracranial pressure and DAI, a relationship which clearly warrants further research, since it would have direct implications for patient management.", [["intracranial", "ANATOMY", 241, 253], ["DAI", "DISEASE", 20, 23], ["DAI", "DISEASE", 94, 97], ["DAI", "DISEASE", 267, 270], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 73, 81], ["patient", "ORGANISM", 372, 379], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 73, 81], ["patient", "SPECIES", 372, 379], ["DAI", "PROBLEM", 20, 23], ["other complications", "PROBLEM", 48, 67], ["severe DAI", "PROBLEM", 87, 97], ["continuous monitoring", "TEST", 119, 140], ["increased intracranial pressure", "PROBLEM", 231, 262], ["DAI", "PROBLEM", 267, 270], ["patient management", "TREATMENT", 372, 390], ["complications", "OBSERVATION", 54, 67], ["intracranial pressure", "ANATOMY", 241, 262]]], ["Future research also must assess DAI patients in whom the presence of other post-traumatic brain lesions has been excluded, as well as new treatment modalities for severe DAI.ConclusionsThree main conclusions can be drawn from our systemic review of the literature: (1) that there is scarce literature on a subject as prevalent as DAI; (2) that patients with a closed TBI who exhibit IVH and/or blood in the IPC on a CT performed within the first 24 h post trauma, have a worse prognosis, and the greater the number of affected ventricles, the more serious the clinical picture is; and (3) that, conversely, among patients whose early CT does not demonstrate tSAH or IVH, there is probably no severe DAI and, therefore, a better prognosis.", [["brain lesions", "ANATOMY", 91, 104], ["blood", "ANATOMY", 395, 400], ["ventricles", "ANATOMY", 528, 538], ["brain lesions", "DISEASE", 91, 104], ["DAI", "DISEASE", 171, 174], ["DAI", "DISEASE", 331, 334], ["TBI", "DISEASE", 368, 371], ["IVH", "DISEASE", 384, 387], ["trauma", "DISEASE", 457, 463], ["tSAH", "DISEASE", 659, 663], ["IVH", "DISEASE", 667, 670], ["DAI", "DISEASE", 700, 703], ["patients", "ORGANISM", 37, 45], ["brain lesions", "PATHOLOGICAL_FORMATION", 91, 104], ["patients", "ORGANISM", 345, 353], ["blood", "ORGANISM_SUBSTANCE", 395, 400], ["ventricles", "MULTI-TISSUE_STRUCTURE", 528, 538], ["patients", "ORGANISM", 614, 622], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 345, 353], ["patients", "SPECIES", 614, 622], ["other post-traumatic brain lesions", "PROBLEM", 70, 104], ["new treatment modalities", "TREATMENT", 135, 159], ["severe DAI", "PROBLEM", 164, 174], ["a closed TBI", "PROBLEM", 359, 371], ["IVH", "PROBLEM", 384, 387], ["blood in the IPC", "PROBLEM", 395, 411], ["a CT", "TEST", 415, 419], ["trauma", "PROBLEM", 457, 463], ["early CT", "TEST", 629, 637], ["tSAH", "PROBLEM", 659, 663], ["IVH", "PROBLEM", 667, 670], ["severe DAI", "PROBLEM", 693, 703], ["traumatic", "OBSERVATION_MODIFIER", 81, 90], ["brain", "ANATOMY", 91, 96], ["lesions", "OBSERVATION", 97, 104], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["DAI", "OBSERVATION", 171, 174], ["IVH", "OBSERVATION", 384, 387], ["affected ventricles", "ANATOMY", 519, 538], ["IVH", "OBSERVATION", 667, 670], ["probably", "UNCERTAINTY", 681, 689], ["no", "UNCERTAINTY", 690, 692], ["severe", "OBSERVATION_MODIFIER", 693, 699], ["DAI", "OBSERVATION", 700, 703]]]], "efbcd8252634a8399ef9266caf8582f96c445489": [["IntroductionThe ongoing coronavirus pandemic known as coronavirus disease 2019 , is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1).", [["coronavirus pandemic", "DISEASE", 24, 44], ["coronavirus disease", "DISEASE", 54, 73], ["acute respiratory syndrome coronavirus", "DISEASE", 101, 139], ["coronavirus", "ORGANISM", 24, 35], ["SARS-CoV-2", "ORGANISM", 143, 153], ["coronavirus", "SPECIES", 54, 65], ["severe acute respiratory syndrome coronavirus", "SPECIES", 94, 139], ["SARS-CoV-2", "SPECIES", 143, 153], ["The ongoing coronavirus pandemic", "PROBLEM", 12, 44], ["coronavirus disease", "PROBLEM", 54, 73], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 94, 139], ["coronavirus", "OBSERVATION", 24, 35], ["coronavirus disease", "OBSERVATION", 54, 73], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory syndrome", "OBSERVATION", 107, 127]]], ["According to Johns Hopkins dashboard, as of May 18, 2020, there are over 4.8 million confirmed cases of COVID-19 that have been reported in 188 countries and territories and claimed more than 318,000 lives.", [["COVID", "TEST", 104, 109]]], ["More than 1.5 million cases were confirmed in the U.S.IntroductionCoronaviruses are a group of viruses that cause a significant percentage of all common colds in human adults and children.", [["Coronaviruses", "DISEASE", 66, 79], ["colds", "DISEASE", 153, 158], ["Coronaviruses", "CANCER", 66, 79], ["human", "ORGANISM", 162, 167], ["children", "ORGANISM", 179, 187], ["human", "SPECIES", 162, 167], ["children", "SPECIES", 179, 187], ["human", "SPECIES", 162, 167], ["significant", "OBSERVATION_MODIFIER", 116, 127], ["percentage", "OBSERVATION_MODIFIER", 128, 138], ["common", "OBSERVATION_MODIFIER", 146, 152], ["colds", "OBSERVATION", 153, 158]]], ["Four human coronavirus including 229E, OC43, NL63, and HKU1 are prevalent and typically cause common cold symptoms in immunocompetent individuals (3) .IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus to cross species to infect human populations (probably transmitted from bats or another host), causing pandemics over the past two decades (4, 5, 6) .", [["acute respiratory syndrome coronavirus", "DISEASE", 170, 208], ["human", "ORGANISM", 5, 10], ["coronavirus", "ORGANISM", 11, 22], ["229E", "GENE_OR_GENE_PRODUCT", 33, 37], ["OC43", "GENE_OR_GENE_PRODUCT", 39, 43], ["NL63", "GENE_OR_GENE_PRODUCT", 45, 49], ["HKU1", "GENE_OR_GENE_PRODUCT", 55, 59], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 151, 210], ["SARS-CoV-2", "ORGANISM", 212, 222], ["human", "ORGANISM", 276, 281], ["human", "SPECIES", 5, 10], ["coronavirus", "SPECIES", 11, 22], ["human", "SPECIES", 276, 281], ["human coronavirus", "SPECIES", 5, 22], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 151, 208], ["SARS-CoV-2", "SPECIES", 212, 222], ["human", "SPECIES", 276, 281], ["Four human coronavirus", "TEST", 0, 22], ["OC43", "TEST", 39, 43], ["NL63", "TEST", 45, 49], ["HKU1", "TEST", 55, 59], ["common cold symptoms in immunocompetent individuals", "PROBLEM", 94, 145], ["acute respiratory syndrome coronavirus", "PROBLEM", 170, 208], ["SARS-CoV", "TEST", 212, 220], ["the third coronavirus", "PROBLEM", 227, 248], ["infect human populations", "PROBLEM", 269, 293], ["pandemics", "PROBLEM", 352, 361], ["coronavirus", "OBSERVATION", 11, 22], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory syndrome", "OBSERVATION", 176, 196]]], ["The previous two were the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in 2002 and the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in 2012 (7, 8) .", [["acute respiratory syndrome coronavirus", "DISEASE", 33, 71], ["SARS-CoV) outbreak", "DISEASE", 73, 91], ["respiratory syndrome coronavirus", "DISEASE", 120, 152], ["MERS-CoV) outbreak", "DISEASE", 154, 172], ["SARS-CoV", "ORGANISM", 73, 81], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 108, 152], ["MERS-CoV", "ORGANISM", 154, 162], ["severe acute respiratory syndrome coronavirus", "SPECIES", 26, 71], ["SARS-CoV", "SPECIES", 73, 81], ["Middle East respiratory syndrome coronavirus", "SPECIES", 108, 152], ["MERS-CoV", "SPECIES", 154, 162], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 22, 71], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 104, 152], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory syndrome coronavirus", "OBSERVATION", 39, 71], ["Middle", "ANATOMY_MODIFIER", 108, 114], ["respiratory syndrome coronavirus", "OBSERVATION", 120, 152]]], ["SARS-Cov-2 has a unique pathogenesis because it causes both upper and lower respiratory tract infections (9) .", [["lower respiratory tract", "ANATOMY", 70, 93], ["SARS", "DISEASE", 0, 4], ["respiratory tract infections", "DISEASE", 76, 104], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["upper", "ORGANISM_SUBDIVISION", 60, 65], ["lower", "ORGANISM_SUBDIVISION", 70, 75], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["a unique pathogenesis", "PROBLEM", 15, 36], ["both upper and lower respiratory tract infections", "PROBLEM", 55, 104], ["both", "ANATOMY_MODIFIER", 55, 59], ["upper", "ANATOMY_MODIFIER", 60, 65], ["lower", "ANATOMY_MODIFIER", 70, 75], ["respiratory tract", "ANATOMY", 76, 93], ["infections", "OBSERVATION", 94, 104]]], ["SARS-CoV-2 is classified as a novel betacoronavirus belonging to the sarbecovirus subgenus of Coronaviridae family.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["betacoronavirus", "CANCER", 36, 51], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 94, 107], ["Coronaviridae family", "PROTEIN", 94, 114], ["SARS-CoV", "SPECIES", 0, 8], ["a novel betacoronavirus", "PROBLEM", 28, 51]]], ["The genome sequence of SARS-CoV-2 is about 89% identical to bat SARS-like-CoVZXC21 and 82% identical to human SARS-CoV.", [["SARS", "DISEASE", 110, 114], ["SARS-CoV-2", "ORGANISM", 23, 33], ["bat SARS-like-CoVZXC21", "ORGANISM", 60, 82], ["human", "ORGANISM", 104, 109], ["SARS-CoV", "ORGANISM", 110, 118], ["CoVZXC21", "DNA", 74, 82], ["human", "SPECIES", 104, 109], ["SARS-CoV-2", "SPECIES", 23, 33], ["human SARS-CoV", "SPECIES", 104, 118], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["bat SARS", "TEST", 60, 68]]], ["It has been reported that SARS-CoV-2 uses the same cell entry receptor, ACE2, to infect humans as SARS-CoV, so clinical similarity between the two viruses is expected, particularly in severe cases (10) .IntroductionThe virus is typically spread by close physical contact and via respiratory droplets when people cough or sneeze (11, 12, 13) .", [["cell", "ANATOMY", 51, 55], ["respiratory droplets", "ANATOMY", 279, 299], ["SARS", "DISEASE", 98, 102], ["cough", "DISEASE", 312, 317], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["cell", "CELL", 51, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["humans", "ORGANISM", 88, 94], ["SARS-CoV", "ORGANISM", 98, 106], ["people", "ORGANISM", 305, 311], ["cell entry receptor", "PROTEIN", 51, 70], ["ACE2", "PROTEIN", 72, 76], ["humans", "SPECIES", 88, 94], ["people", "SPECIES", 305, 311], ["humans", "SPECIES", 88, 94], ["SARS-CoV", "SPECIES", 98, 106], ["SARS", "PROBLEM", 26, 30], ["ACE2", "TREATMENT", 72, 76], ["The virus", "PROBLEM", 215, 224], ["cough", "PROBLEM", 312, 317], ["viruses", "OBSERVATION", 147, 154], ["virus", "OBSERVATION", 219, 224]]], ["People may also catch COVID-19 by touching their eyes, nose, or mouth immediately after touching a contaminated surface (12, 13) .", [["eyes", "ANATOMY", 49, 53], ["nose", "ANATOMY", 55, 59], ["mouth", "ANATOMY", 64, 69], ["surface", "ANATOMY", 112, 119], ["People", "ORGANISM", 0, 6], ["eyes", "ORGAN", 49, 53], ["nose", "ORGANISM_SUBDIVISION", 55, 59], ["mouth", "ORGANISM_SUBDIVISION", 64, 69], ["People", "SPECIES", 0, 6], ["catch COVID", "TEST", 16, 27], ["eyes", "ANATOMY", 49, 53], ["nose", "ANATOMY", 55, 59], ["mouth", "ANATOMY", 64, 69]]], ["It is most contagious when people are symptomatic, however, it may also spread when a person is asymptomatic (13).", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["person", "SPECIES", 86, 92], ["symptomatic", "PROBLEM", 38, 49], ["most", "UNCERTAINTY", 6, 10], ["contagious", "OBSERVATION_MODIFIER", 11, 21], ["symptomatic", "OBSERVATION_MODIFIER", 38, 49]]], ["Nasal cells are identified as the key entry point for SARS-CoV-2 (14) .", [["Nasal cells", "ANATOMY", 0, 11], ["Nasal cells", "CELL", 0, 11], ["Nasal cells", "CELL_TYPE", 0, 11], ["SARS-CoV", "SPECIES", 54, 62], ["Nasal cells", "TREATMENT", 0, 11], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["cells", "OBSERVATION", 6, 11]]], ["Goblet and ciliated cells in the nose have high levels of the entry proteins ACE-2 and TMPRSS2 that SARS-CoV-2 uses to get into human cells.", [["Goblet", "ANATOMY", 0, 6], ["ciliated cells", "ANATOMY", 11, 25], ["nose", "ANATOMY", 33, 37], ["cells", "ANATOMY", 134, 139], ["Goblet", "CELL", 0, 6], ["ciliated cells", "CELL", 11, 25], ["nose", "ORGAN", 33, 37], ["ACE-2", "GENE_OR_GENE_PRODUCT", 77, 82], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 87, 94], ["SARS-CoV-2", "ORGANISM", 100, 110], ["human", "ORGANISM", 128, 133], ["cells", "CELL", 134, 139], ["Goblet and ciliated cells", "CELL_TYPE", 0, 25], ["entry proteins", "PROTEIN", 62, 76], ["ACE", "PROTEIN", 77, 80], ["TMPRSS2", "PROTEIN", 87, 94], ["human cells", "CELL_TYPE", 128, 139], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["Goblet and ciliated cells in the nose", "PROBLEM", 0, 37], ["ACE", "TEST", 77, 80], ["TMPRSS2", "TEST", 87, 94], ["CoV", "TEST", 105, 108], ["ciliated cells", "OBSERVATION", 11, 25], ["nose", "ANATOMY", 33, 37], ["high levels", "OBSERVATION_MODIFIER", 43, 54]]], ["The virus exploits existing secretory pathways in nasal goblet cells sustained at a pre-symptomatic stage.", [["nasal goblet cells", "ANATOMY", 50, 68], ["nasal goblet cells", "CELL", 50, 68], ["nasal goblet cells", "CELL_TYPE", 50, 68], ["The virus", "PROBLEM", 0, 9], ["nasal goblet cells", "PROBLEM", 50, 68], ["virus", "OBSERVATION", 4, 9], ["nasal", "ANATOMY", 50, 55], ["goblet cells", "OBSERVATION", 56, 68]]], ["Nasal carriage is likely to be a key feature of transmission, therefore drugs administered intranasally could be highly effective in limiting spread.", [["Nasal", "ANATOMY", 0, 5], ["Nasal", "ORGAN", 0, 5], ["drugs", "TREATMENT", 72, 77]]], ["The two key entry proteins ACE2 and TMPRSS2 were also found in cells in the cornea of the eye, ocular as another route of infection (14, 15) .", [["cells", "ANATOMY", 63, 68], ["cornea", "ANATOMY", 76, 82], ["eye", "ANATOMY", 90, 93], ["ocular", "ANATOMY", 95, 101], ["infection", "DISEASE", 122, 131], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 36, 43], ["cells", "CELL", 63, 68], ["cornea", "ORGAN", 76, 82], ["eye", "ORGAN", 90, 93], ["ocular", "ORGAN", 95, 101], ["entry proteins", "PROTEIN", 12, 26], ["ACE2", "PROTEIN", 27, 31], ["TMPRSS2", "PROTEIN", 36, 43], ["TMPRSS2", "TEST", 36, 43], ["infection", "PROBLEM", 122, 131], ["cornea", "ANATOMY", 76, 82], ["eye", "ANATOMY", 90, 93], ["ocular", "ANATOMY", 95, 101], ["infection", "OBSERVATION", 122, 131]]], ["With SARS-CoV-2 detected in human tears, ocular secretions might be a potential for human to human spread (16) .", [["tears", "ANATOMY", 34, 39], ["ocular secretions", "ANATOMY", 41, 58], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 5, 15], ["human", "ORGANISM", 28, 33], ["ocular secretions", "ORGAN", 41, 58], ["human", "ORGANISM", 84, 89], ["human", "ORGANISM", 93, 98], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 93, 98], ["SARS", "PROBLEM", 5, 9], ["CoV", "TEST", 10, 13], ["human tears", "PROBLEM", 28, 39], ["ocular secretions", "PROBLEM", 41, 58], ["SARS", "OBSERVATION", 5, 9], ["ocular", "ANATOMY", 41, 47], ["secretions", "OBSERVATION", 48, 58]]], ["There is controversy on whether the eye could be a transmission route for COVID-19, however, even if COVID 19 positive patients have no virus shedding through tears, the eye remains a potential portal of entry for ocular and systemic disease from the virus (16) .", [["eye", "ANATOMY", 36, 39], ["eye", "ANATOMY", 170, 173], ["ocular", "ANATOMY", 214, 220], ["ocular and systemic disease", "DISEASE", 214, 241], ["eye", "ORGAN", 36, 39], ["patients", "ORGANISM", 119, 127], ["eye", "ORGAN", 170, 173], ["ocular", "ORGAN", 214, 220], ["patients", "SPECIES", 119, 127], ["COVID", "TEST", 74, 79], ["COVID", "TEST", 101, 106], ["virus shedding through tears", "PROBLEM", 136, 164], ["ocular and systemic disease", "PROBLEM", 214, 241], ["the virus", "PROBLEM", 247, 256], ["eye", "ANATOMY", 36, 39], ["no", "UNCERTAINTY", 133, 135], ["virus", "OBSERVATION", 136, 141], ["eye", "ANATOMY", 170, 173], ["systemic disease", "OBSERVATION", 225, 241]]], ["Therefore, developing nasal and ocular treatment to reduce and prevent transmission of the debilitating virus is a viable while potentially highly effective strategy.IntroductionThere is no known vaccine or specific antiviral treatment for COVID-19, but development efforts are underway, including testing of existing medications (12) .", [["nasal", "ANATOMY", 22, 27], ["ocular", "ANATOMY", 32, 38], ["nasal", "ORGAN", 22, 27], ["nasal and ocular treatment", "TREATMENT", 22, 48], ["the debilitating virus", "PROBLEM", 87, 109], ["known vaccine", "TREATMENT", 190, 203], ["specific antiviral treatment", "TREATMENT", 207, 235], ["COVID", "TEST", 240, 245], ["existing medications", "TREATMENT", 309, 329], ["nasal", "ANATOMY", 22, 27], ["ocular", "ANATOMY", 32, 38], ["treatment", "OBSERVATION", 39, 48], ["debilitating", "OBSERVATION_MODIFIER", 91, 103], ["virus", "OBSERVATION", 104, 109], ["no known", "UNCERTAINTY", 187, 195]]], ["Current primary treatment is limited to supportive treatment of symptoms.", [["Current primary treatment", "TREATMENT", 0, 25], ["supportive treatment", "TREATMENT", 40, 60], ["symptoms", "PROBLEM", 64, 72]]], ["Recommended preventive measures include hand washing, covering the mouth when coughing, maintaining distance from other people, and monitoring and self-isolation for people suspected for being infected (12) .", [["hand", "ANATOMY", 40, 44], ["mouth", "ANATOMY", 67, 72], ["hand", "ORGANISM_SUBDIVISION", 40, 44], ["mouth", "ORGANISM_SUBDIVISION", 67, 72], ["people", "ORGANISM", 120, 126], ["people", "ORGANISM", 166, 172], ["people", "SPECIES", 120, 126], ["people", "SPECIES", 166, 172], ["preventive measures", "TREATMENT", 12, 31], ["hand washing", "TREATMENT", 40, 52], ["coughing", "PROBLEM", 78, 86], ["self-isolation", "TREATMENT", 147, 161], ["mouth", "ANATOMY", 67, 72]]], ["The COVID-19 case fatality rate has not yet peaked and it is anticipated that many more deaths will occur despite the efforts from many countries.", [["deaths", "DISEASE", 88, 94], ["The COVID", "TEST", 0, 9]]], ["There is, therefore, an urgent need to find effective ways to prevent and treat this virus.IntroductionPovidone-iodine (PVP-I) is a complex of polyvinylpyrrolidone and iodine.", [["IntroductionPovidone-iodine", "CHEMICAL", 91, 118], ["PVP-I", "CHEMICAL", 120, 125], ["polyvinylpyrrolidone", "CHEMICAL", 143, 163], ["iodine", "CHEMICAL", 168, 174], ["IntroductionPovidone-iodine", "CHEMICAL", 91, 118], ["PVP-I", "CHEMICAL", 120, 125], ["polyvinylpyrrolidone", "CHEMICAL", 143, 163], ["iodine", "CHEMICAL", 168, 174], ["IntroductionPovidone-iodine", "SIMPLE_CHEMICAL", 91, 118], ["PVP-I", "SIMPLE_CHEMICAL", 120, 125], ["polyvinylpyrrolidone", "SIMPLE_CHEMICAL", 143, 163], ["iodine", "SIMPLE_CHEMICAL", 168, 174], ["this virus", "PROBLEM", 80, 90], ["IntroductionPovidone", "TREATMENT", 91, 111], ["iodine (PVP-I", "TREATMENT", 112, 125], ["polyvinylpyrrolidone", "TREATMENT", 143, 163], ["iodine", "TREATMENT", 168, 174]]], ["It is also called iodophor and contains 9-12% iodine.", [["iodine", "CHEMICAL", 46, 52], ["iodine", "CHEMICAL", 46, 52], ["iodophor", "SIMPLE_CHEMICAL", 18, 26], ["iodine", "SIMPLE_CHEMICAL", 46, 52], ["iodine", "TREATMENT", 46, 52]]], ["It is a powerful disinfectant with broad-spectrum application and is effective against viruses, bacteria, fungi, and mold spores.", [["spores", "ANATOMY", 122, 128], ["broad-spectrum application", "TREATMENT", 35, 61], ["viruses", "PROBLEM", 87, 94], ["bacteria", "PROBLEM", 96, 104], ["fungi", "PROBLEM", 106, 111], ["mold spores", "PROBLEM", 117, 128], ["mold spores", "OBSERVATION", 117, 128]]], ["PVP-I products have been used as disinfectant for the inactivation of various bacteria and viruses for years because of their strong bactericidal and antiviral activities.", [["PVP-I", "CHEMICAL", 0, 5], ["PVP", "CHEMICAL", 0, 3], ["PVP-I products", "TREATMENT", 0, 14], ["various bacteria", "PROBLEM", 70, 86], ["viruses", "PROBLEM", 91, 98], ["antiviral activities", "TREATMENT", 150, 170], ["antiviral activities", "OBSERVATION", 150, 170]]], ["Povidone-iodine (PVP-I) is routinely used in ophthalmology and general surgery.", [["Povidone-iodine", "CHEMICAL", 0, 15], ["PVP-I", "CHEMICAL", 17, 22], ["Povidone-iodine", "CHEMICAL", 0, 15], ["PVP-I", "CHEMICAL", 17, 22], ["Povidone-iodine", "SIMPLE_CHEMICAL", 0, 15], ["PVP-I", "SIMPLE_CHEMICAL", 17, 22], ["Povidone", "TREATMENT", 0, 8], ["iodine (PVP-I)", "TREATMENT", 9, 23], ["general surgery", "TREATMENT", 63, 78]]], ["PVP-I has been used in acute and chronic treatment of a variety of human indications.", [["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["acute and chronic treatment", "TREATMENT", 23, 50], ["a variety of human indications", "TREATMENT", 54, 84], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["chronic", "OBSERVATION_MODIFIER", 33, 40]]], ["There have been numerous clinical studies demonstrating the safety of PVP-I in a variety of topical applications in ophthalmology, otology, rhinology and dermatology (18, 19, 20, 21, 22, 23, 24) .", [["PVP-I", "CHEMICAL", 70, 75], ["PVP-I", "CHEMICAL", 70, 75], ["PVP-I", "SIMPLE_CHEMICAL", 70, 75], ["numerous clinical studies", "TEST", 16, 41]]], ["PVP-I in nasal usage was also well documented, including both single use (24, 25) and multiple applications.", [["nasal", "ANATOMY", 9, 14], ["PVP-I", "CHEMICAL", 0, 5], ["PVP", "CHEMICAL", 0, 3], ["PVP-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["nasal", "ORGAN", 9, 14], ["multiple applications", "TREATMENT", 86, 107]]], ["3M Company introduced PVP-I based skin and nasal antiseptic (Povidone Iodine Solution 5% w/w [0.5% available iodine] USP).", [["skin", "ANATOMY", 34, 38], ["nasal", "ANATOMY", 43, 48], ["PVP-I", "CHEMICAL", 22, 27], ["Povidone Iodine", "CHEMICAL", 61, 76], ["iodine", "CHEMICAL", 109, 115], ["PVP", "CHEMICAL", 22, 25], ["iodine", "CHEMICAL", 109, 115], ["skin", "ORGAN", 34, 38], ["iodine] USP", "SIMPLE_CHEMICAL", 109, 120], ["Company introduced PVP-I based skin and nasal antiseptic (Povidone Iodine Solution", "TREATMENT", 3, 85], ["skin", "ANATOMY", 34, 38], ["nasal", "ANATOMY", 43, 48]]], ["It has rapid, broad-spectrum antimicrobial activity, which reduces nasal bacteria, including S. aureus, by 99.5% in just one hour and maintains this reduction for at least 12 hours (26, 27) .", [["nasal bacteria", "ANATOMY", 67, 81], ["S. aureus", "ORGANISM", 93, 102], ["S. aureus", "SPECIES", 93, 102], ["S. aureus", "SPECIES", 93, 102], ["nasal bacteria", "PROBLEM", 67, 81], ["S. aureus", "PROBLEM", 93, 102], ["this reduction", "TREATMENT", 144, 158], ["rapid", "OBSERVATION_MODIFIER", 7, 12], ["broad", "OBSERVATION_MODIFIER", 14, 19], ["antimicrobial activity", "OBSERVATION", 29, 51], ["nasal", "ANATOMY", 67, 72], ["bacteria", "OBSERVATION", 73, 81], ["aureus", "OBSERVATION", 96, 102]]], ["In the clinical setting, rhinologists and oral surgeons commonly use higher concentrations of PVP-I for various antimicrobial therapies as it offers an affordable, potent, well-tolerated and widely available antiseptic option with little to no cross-resistance.", [["oral", "ANATOMY", 42, 46], ["PVP-I", "CHEMICAL", 94, 99], ["PVP-I", "CHEMICAL", 94, 99], ["rhinologists", "ORGANISM", 25, 37], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["PVP-I", "SIMPLE_CHEMICAL", 94, 99], ["oral surgeons", "TREATMENT", 42, 55], ["PVP", "TREATMENT", 94, 97], ["various antimicrobial therapies", "TREATMENT", 104, 135], ["antiseptic option", "TREATMENT", 208, 225]]], ["Gluck and colleagues reported a phase I study (n=35) assessing tolerability and local effect of a PVP-I spray (PVP-I 2.2 or 4.4%) in single and repeated (3 times a day for 3 days).", [["PVP-I", "CHEMICAL", 98, 103], ["PVP-I", "CHEMICAL", 111, 116], ["PVP", "CHEMICAL", 98, 101], ["PVP-I", "CHEMICAL", 111, 116], ["PVP-I", "SIMPLE_CHEMICAL", 98, 103], ["a phase I study", "TEST", 30, 45], ["a PVP-I spray (PVP-I", "TREATMENT", 96, 116]]], ["No safety-relevant finding or serious adverse events were reported, no evidence for cyto-nor genotoxicity obtained (28) .IntroductionIt was reported that PVP-I formulations are effective against both enveloped and non-enveloped viruses (29, 30, 31) .", [["PVP-I", "CHEMICAL", 154, 159], ["PVP-I", "CHEMICAL", 154, 159], ["PVP-I", "SIMPLE_CHEMICAL", 154, 159], ["serious adverse events", "PROBLEM", 30, 52], ["cyto-nor genotoxicity", "PROBLEM", 84, 105], ["PVP-I formulations", "TREATMENT", 154, 172], ["non-enveloped viruses", "PROBLEM", 214, 235], ["no evidence for", "UNCERTAINTY", 68, 83], ["non-enveloped", "OBSERVATION_MODIFIER", 214, 227], ["viruses", "OBSERVATION", 228, 235]]], ["The virucidal activity is mainly due to the free iodine released from PVP-I (32) .", [["iodine", "CHEMICAL", 49, 55], ["PVP-I", "CHEMICAL", 70, 75], ["iodine", "CHEMICAL", 49, 55], ["PVP-I", "CHEMICAL", 70, 75], ["iodine", "SIMPLE_CHEMICAL", 49, 55], ["PVP-I", "SIMPLE_CHEMICAL", 70, 75], ["the free iodine", "TREATMENT", 40, 55], ["virucidal activity", "OBSERVATION", 4, 22]]], ["In one study, PVP-I was effective in inhibiting SARS-CoV infectivity (33) (34, 36, 37) .", [["PVP-I", "CHEMICAL", 14, 19], ["PVP-I", "CHEMICAL", 14, 19], ["PVP-I", "SIMPLE_CHEMICAL", 14, 19], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 48, 56], ["SARS-CoV", "SPECIES", 48, 56], ["one study", "TEST", 3, 12], ["PVP", "TEST", 14, 17], ["CoV infectivity", "TEST", 53, 68]]], ["PVP-I has also shown efficacy in preventing the infection and limiting the spread of Ebola virus disease (EBV) (38) .", [["PVP-I", "CHEMICAL", 0, 5], ["infection", "DISEASE", 48, 57], ["Ebola virus disease", "DISEASE", 85, 104], ["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["Ebola virus", "ORGANISM", 85, 96], ["EBV", "ORGANISM", 106, 109], ["Ebola virus", "SPECIES", 85, 96], ["Ebola virus", "SPECIES", 85, 96], ["EBV", "SPECIES", 106, 109], ["the infection", "PROBLEM", 44, 57], ["Ebola virus disease", "PROBLEM", 85, 104], ["infection", "OBSERVATION", 48, 57], ["spread", "OBSERVATION_MODIFIER", 75, 81], ["Ebola virus", "OBSERVATION", 85, 96]]], ["Additionally, it is reported that PVP-I is virucidal against non-enveloped viruses e.g. polyomavirus, adenovirus, and poliovirus type 1 (31) .", [["PVP-I", "CHEMICAL", 34, 39], ["PVP-I", "CHEMICAL", 34, 39], ["PVP-I", "GENE_OR_GENE_PRODUCT", 34, 39], ["non-enveloped viruses", "ORGANISM", 61, 82], ["polyomavirus", "ORGANISM", 88, 100], ["adenovirus", "ORGANISM", 102, 112], ["poliovirus type 1", "ORGANISM", 118, 135], ["poliovirus type 1", "SPECIES", 118, 135], ["PVP", "TEST", 34, 37], ["non-enveloped viruses", "PROBLEM", 61, 82], ["polyomavirus", "PROBLEM", 88, 100], ["adenovirus", "PROBLEM", 102, 112], ["poliovirus type", "TEST", 118, 133]]], ["Due to the similarities among enveloped viruses, PVP-I is expected to show virucidal efficacy against SARS-CoV-2.", [["PVP-I", "CHEMICAL", 49, 54], ["SARS", "DISEASE", 102, 106], ["PVP-I", "CHEMICAL", 49, 54], ["PVP-I", "GENE_OR_GENE_PRODUCT", 49, 54], ["SARS-CoV-2", "ORGANISM", 102, 112], ["SARS-CoV", "SPECIES", 102, 110], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["viruses", "OBSERVATION", 40, 47]]], ["However, there is no published data on the use of iodine for the treatment or prevention of COVID-19.", [["iodine", "CHEMICAL", 50, 56], ["iodine", "CHEMICAL", 50, 56], ["COVID-19", "CHEMICAL", 92, 100], ["iodine", "SIMPLE_CHEMICAL", 50, 56], ["iodine", "TREATMENT", 50, 56], ["the treatment", "TREATMENT", 61, 74], ["COVID", "TEST", 92, 97], ["no", "UNCERTAINTY", 18, 20]]], ["Currently no PVP-I product has been approved as a potential protection and prevention for the spread of this new debilitating virus. as an adjunct to currently recommended PPE (39).IntroductionIt's well known that nasal solutions are cleared off rapidly from the nasal cavity, while the conventional liquid ocular formulation is eliminated from the precorneal area immediately upon instillation because of lacrimation and effective nasolacrimal drainage (40) .", [["nasal", "ANATOMY", 214, 219], ["nasal cavity", "ANATOMY", 263, 275], ["ocular", "ANATOMY", 307, 313], ["precorneal area", "ANATOMY", 349, 364], ["nasolacrimal", "ANATOMY", 432, 444], ["PVP-I", "CHEMICAL", 13, 18], ["PVP-I", "CHEMICAL", 13, 18], ["PVP-I", "GENE_OR_GENE_PRODUCT", 13, 18], ["nasal cavity", "ORGANISM_SUBDIVISION", 263, 275], ["nasolacrimal", "PATHOLOGICAL_FORMATION", 432, 444], ["PVP", "TREATMENT", 13, 16], ["prevention", "TREATMENT", 75, 85], ["this new debilitating virus", "PROBLEM", 104, 131], ["nasal solutions", "TREATMENT", 214, 229], ["the conventional liquid ocular formulation", "TREATMENT", 283, 325], ["instillation", "TREATMENT", 382, 394], ["lacrimation", "PROBLEM", 406, 417], ["effective nasolacrimal drainage", "TREATMENT", 422, 453], ["no", "UNCERTAINTY", 10, 12], ["PVP", "OBSERVATION", 13, 16], ["debilitating", "OBSERVATION_MODIFIER", 113, 125], ["virus", "OBSERVATION", 126, 131], ["nasal", "ANATOMY", 214, 219], ["nasal cavity", "ANATOMY", 263, 275], ["precorneal area", "ANATOMY", 349, 364], ["drainage", "OBSERVATION", 445, 453]]], ["The short contact time of water-soluble povidone-iodine on nasal mucosa or in the eye is undesirable and would necessitate frequent and multiple administration to maintain the virucidal efficacy, thereby limiting practicality and increasing medical burden for the patient.", [["nasal mucosa", "ANATOMY", 59, 71], ["eye", "ANATOMY", 82, 85], ["povidone-iodine", "CHEMICAL", 40, 55], ["povidone-iodine", "CHEMICAL", 40, 55], ["povidone-iodine", "SIMPLE_CHEMICAL", 40, 55], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 59, 71], ["eye", "ORGAN", 82, 85], ["patient", "ORGANISM", 264, 271], ["patient", "SPECIES", 264, 271], ["water-soluble povidone", "TREATMENT", 26, 48], ["iodine", "TREATMENT", 49, 55], ["nasal mucosa", "PROBLEM", 59, 71], ["frequent and multiple administration", "TREATMENT", 123, 159], ["the virucidal efficacy", "TREATMENT", 172, 194], ["short", "OBSERVATION_MODIFIER", 4, 9], ["nasal mucosa", "ANATOMY", 59, 71], ["eye", "ANATOMY", 82, 85]]], ["In addition, frequent dosing can lead to irritation and potential toxicity.", [["irritation", "DISEASE", 41, 51], ["toxicity", "DISEASE", 66, 74], ["frequent dosing", "TREATMENT", 13, 28], ["irritation", "PROBLEM", 41, 51], ["potential toxicity", "PROBLEM", 56, 74]]], ["Therefore, developing a safe, non-toxic and longacting PVP-I nasal spray or ophthalmic eye drop is an urgent medical need to protect people from SARS-CoV-2 infection, as well as to block the transmission through the nasal cavity or through the eye.IntroductionIn the current study, we investigated the in-vitro virucidal efficacy of PVP-I in-situ gel forming formulations against SARS-CoV-2 virus along with their safety assessment in animal toxicology studies.", [["nasal", "ANATOMY", 61, 66], ["eye", "ANATOMY", 87, 90], ["nasal cavity", "ANATOMY", 216, 228], ["eye", "ANATOMY", 244, 247], ["PVP-I", "CHEMICAL", 55, 60], ["SARS", "DISEASE", 145, 149], ["infection", "DISEASE", 156, 165], ["PVP-I", "CHEMICAL", 333, 338], ["PVP", "CHEMICAL", 55, 58], ["PVP-I", "CHEMICAL", 333, 338], ["eye", "ORGAN", 87, 90], ["people", "ORGANISM", 133, 139], ["SARS-CoV-2", "ORGANISM", 145, 155], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 216, 228], ["eye", "ORGAN", 244, 247], ["PVP-I", "SIMPLE_CHEMICAL", 333, 338], ["SARS-CoV-2 virus", "ORGANISM", 380, 396], ["people", "SPECIES", 133, 139], ["CoV-2 virus", "SPECIES", 385, 396], ["SARS-CoV-2", "SPECIES", 145, 155], ["SARS-CoV-2 virus", "SPECIES", 380, 396], ["non-toxic and longacting PVP", "TREATMENT", 30, 58], ["I nasal spray", "TREATMENT", 59, 72], ["ophthalmic eye drop", "TREATMENT", 76, 95], ["an urgent medical", "TREATMENT", 99, 116], ["SARS", "PROBLEM", 145, 149], ["CoV-2 infection", "PROBLEM", 150, 165], ["the current study", "TEST", 263, 280], ["PVP-I in-situ gel", "TREATMENT", 333, 350], ["SARS", "PROBLEM", 380, 384], ["CoV-2 virus", "PROBLEM", 385, 396], ["their safety assessment", "TEST", 408, 431], ["animal toxicology studies", "TEST", 435, 460], ["eye", "ANATOMY", 87, 90], ["infection", "OBSERVATION", 156, 165], ["nasal cavity", "ANATOMY", 216, 228], ["eye", "ANATOMY", 244, 247]]], ["The results suggest that both IVIEW-1201 and IVIEW-1503, reduced SARS-CoV-2 viral titers to near or below the level of detection after 2 minutes of exposure.", [["IVIEW-1201", "CHEMICAL", 30, 40], ["IVIEW-1503", "CHEMICAL", 45, 55], ["IVIEW-1201", "CHEMICAL", 30, 40], ["IVIEW-1503", "CHEMICAL", 45, 55], ["IVIEW-1201", "SIMPLE_CHEMICAL", 30, 40], ["IVIEW-1503", "SIMPLE_CHEMICAL", 45, 55], ["SARS-CoV-2", "ORGANISM", 65, 75], ["IVIEW", "TEST", 30, 35], ["IVIEW", "TEST", 45, 50], ["reduced SARS", "PROBLEM", 57, 69], ["CoV", "TEST", 70, 73], ["viral titers", "TEST", 76, 88]]], ["Therefore, these preparations could potentially be used as a disinfectant for the virus in the nasal cavity or in the eye, respectively.", [["nasal cavity", "ANATOMY", 95, 107], ["eye", "ANATOMY", 118, 121], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 95, 107], ["eye", "ORGAN", 118, 121], ["these preparations", "TREATMENT", 11, 29], ["a disinfectant", "TREATMENT", 59, 73], ["the virus in the nasal cavity", "PROBLEM", 78, 107], ["nasal cavity", "ANATOMY", 95, 107], ["eye", "ANATOMY", 118, 121]]], ["By employing either the sustained release nasal spray or ophthalmic eye drop delivery technologies, we expect to reduce, treat, and eliminate SARS-CoV-2 in the nasal, sinus cavity, and in the eye.", [["nasal", "ANATOMY", 42, 47], ["eye", "ANATOMY", 68, 71], ["nasal", "ANATOMY", 160, 165], ["sinus cavity", "ANATOMY", 167, 179], ["eye", "ANATOMY", 192, 195], ["SARS", "DISEASE", 142, 146], ["eye", "ORGAN", 68, 71], ["nasal", "ORGAN", 160, 165], ["sinus cavity", "MULTI-TISSUE_STRUCTURE", 167, 179], ["eye", "ORGAN", 192, 195], ["SARS-CoV", "SPECIES", 142, 150], ["the sustained release nasal spray", "TREATMENT", 20, 53], ["ophthalmic eye drop delivery technologies", "TREATMENT", 57, 98], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150], ["nasal", "ANATOMY", 160, 165], ["sinus cavity", "ANATOMY", 167, 179], ["eye", "ANATOMY", 192, 195]]], ["Additionally, the long-acting nasal spray can potentially be utilized as a prophylaxis for protecting against SARS-CoV-2 infection.Toxicological Studies of Dilute PVP-I Formulations Ocular Toxicity StudyWe have conducted a 7-Day Repeat Topical Ocular Dose Toxicity Study in rabbits to determine the potential ocular toxicity of PVP-I gel forming formulations at two concentrations, and a PVP-I /dexamethasone (dex) formulation (PVP-I 0.6%/dex 0.1%, this formulation was advanced by Shire Llc. for phase III clinical trials against adenoviral conjunctivitis in 2017 as SHP640) comparing each to the vehicle when administered by repeat topical ocular doses over a 7-day period to New Zealand white rabbits.", [["nasal", "ANATOMY", 30, 35], ["ocular", "ANATOMY", 309, 315], ["ocular", "ANATOMY", 642, 648], ["SARS-CoV-2 infection", "DISEASE", 110, 130], ["Ocular Toxicity", "DISEASE", 182, 197], ["Toxicity", "DISEASE", 256, 264], ["ocular toxicity", "DISEASE", 309, 324], ["PVP-I gel", "CHEMICAL", 328, 337], ["PVP-I", "CHEMICAL", 388, 393], ["dexamethasone", "CHEMICAL", 395, 408], ["dex", "CHEMICAL", 410, 413], ["PVP-I", "CHEMICAL", 428, 433], ["adenoviral conjunctivitis", "DISEASE", 531, 556], ["SHP640", "CHEMICAL", 568, 574], ["PVP", "CHEMICAL", 163, 166], ["PVP", "CHEMICAL", 328, 331], ["PVP-I", "CHEMICAL", 388, 393], ["dexamethasone", "CHEMICAL", 395, 408], ["PVP-I", "CHEMICAL", 428, 433], ["SARS-CoV-2", "ORGANISM", 110, 120], ["rabbits", "ORGANISM", 274, 281], ["PVP-I", "SIMPLE_CHEMICAL", 328, 333], ["PVP-I", "SIMPLE_CHEMICAL", 388, 393], ["dexamethasone", "SIMPLE_CHEMICAL", 395, 408], ["dex", "SIMPLE_CHEMICAL", 410, 413], ["PVP-I", "SIMPLE_CHEMICAL", 428, 433], ["adenoviral", "ORGANISM", 531, 541], ["rabbits", "ORGANISM", 696, 703], ["rabbits", "SPECIES", 274, 281], ["rabbits", "SPECIES", 696, 703], ["SARS-CoV-2", "SPECIES", 110, 120], ["rabbits", "SPECIES", 274, 281], ["the long-acting nasal spray", "TREATMENT", 14, 41], ["a prophylaxis", "TREATMENT", 73, 86], ["SARS", "PROBLEM", 110, 114], ["CoV", "PROBLEM", 115, 118], ["2 infection", "PROBLEM", 119, 130], ["Toxicological Studies", "TEST", 131, 152], ["Dilute PVP", "TREATMENT", 156, 166], ["Ocular Toxicity Study", "TEST", 182, 203], ["Repeat Topical Ocular Dose Toxicity", "TREATMENT", 229, 264], ["ocular toxicity", "PROBLEM", 309, 324], ["PVP-I gel forming formulations", "TREATMENT", 328, 358], ["a PVP-I /dexamethasone (dex) formulation", "TREATMENT", 386, 426], ["PVP-I", "TREATMENT", 428, 433], ["dex", "TREATMENT", 439, 442], ["phase III clinical trials", "TREATMENT", 497, 522], ["adenoviral conjunctivitis", "PROBLEM", 531, 556], ["repeat topical ocular doses", "TREATMENT", 627, 654], ["New Zealand white rabbits", "TREATMENT", 678, 703], ["infection", "OBSERVATION", 121, 130]]], ["Only rabbits with clinical normal eyes were used in this study.", [["eyes", "ANATOMY", 34, 38], ["rabbits", "ORGANISM", 5, 12], ["eyes", "ORGAN", 34, 38], ["rabbits", "SPECIES", 5, 12], ["this study", "TEST", 52, 62], ["eyes", "ANATOMY", 34, 38]]], ["12 female rabbits were equally divided into four groups with three (3) rabbits per group.Toxicological Studies of Dilute PVP-I Formulations Ocular Toxicity StudyGroup one is vehicle, Group 2 is test group using 0.6% (6 mg/mL) PVP-I gel forming solution.Toxicological Studies of Dilute PVP-I Formulations Ocular Toxicity StudyGroup 3 is a test group using 1.0% (10 mg/mL) PVP-I gel forming solution, and Group 4 is a test group using PVP-I 0.6% (6 mg/mL)/ dex 0.1% (1 mg/mL) suspension.", [["PVP-I", "CHEMICAL", 121, 126], ["Ocular Toxicity", "DISEASE", 140, 155], ["PVP-I gel", "CHEMICAL", 226, 235], ["PVP", "CHEMICAL", 285, 288], ["Ocular Toxicity", "DISEASE", 304, 319], ["PVP-I gel", "CHEMICAL", 371, 380], ["PVP-I", "CHEMICAL", 433, 438], ["PVP", "CHEMICAL", 121, 124], ["PVP", "CHEMICAL", 226, 229], ["PVP", "CHEMICAL", 285, 288], ["PVP", "CHEMICAL", 371, 374], ["PVP", "CHEMICAL", 433, 436], ["rabbits", "ORGANISM", 10, 17], ["rabbits", "ORGANISM", 71, 78], ["PVP-I gel", "SIMPLE_CHEMICAL", 226, 235], ["PVP-I", "SIMPLE_CHEMICAL", 371, 376], ["PVP-I", "SIMPLE_CHEMICAL", 433, 438], ["rabbits", "SPECIES", 10, 17], ["rabbits", "SPECIES", 71, 78], ["rabbits", "SPECIES", 10, 17], ["Toxicological Studies", "TEST", 89, 110], ["Dilute PVP", "TREATMENT", 114, 124], ["Ocular Toxicity", "PROBLEM", 140, 155], ["PVP-I gel forming solution", "TREATMENT", 226, 252], ["Toxicological Studies", "TEST", 253, 274], ["Dilute PVP", "TREATMENT", 278, 288], ["a test group", "TREATMENT", 336, 348], ["PVP-I gel forming solution", "TREATMENT", 371, 397], ["a test group using PVP-I", "TREATMENT", 414, 438], ["dex", "TREATMENT", 455, 458]]], ["Each eye was dosed 35 \u00b5L/eye/dose for twice a day.", [["eye", "ANATOMY", 5, 8], ["eye", "ANATOMY", 25, 28], ["eye", "ORGAN", 5, 8], ["eye", "ORGAN", 25, 28]]], ["The fluorescein and rose Bengal scores were assessed by calculating a global score for each eye at each time point as well as score incidence.Intranasal Administration Toxicity StudyWe have conducted a 28-day toxicity study using Sprague Dawley CD\u00ae IGS rats to determine the potential subchronic toxicity of a PVP-I formulation (0.8% PVP-I/0.064% Budesonide gel forming nasal spray formulation).", [["eye", "ANATOMY", 92, 95], ["nasal", "ANATOMY", 370, 375], ["fluorescein", "CHEMICAL", 4, 15], ["Toxicity", "DISEASE", 168, 176], ["toxicity", "DISEASE", 209, 217], ["toxicity", "DISEASE", 296, 304], ["PVP-I", "CHEMICAL", 310, 315], ["PVP-I", "CHEMICAL", 334, 339], ["Budesonide", "CHEMICAL", 347, 357], ["fluorescein", "CHEMICAL", 4, 15], ["PVP-I", "CHEMICAL", 310, 315], ["PVP", "CHEMICAL", 334, 337], ["Budesonide", "CHEMICAL", 347, 357], ["fluorescein", "SIMPLE_CHEMICAL", 4, 15], ["eye", "ORGAN", 92, 95], ["Sprague Dawley CD\u00ae", "ORGANISM", 230, 248], ["rats", "ORGANISM", 253, 257], ["PVP-I", "SIMPLE_CHEMICAL", 310, 315], ["Budesonide", "SIMPLE_CHEMICAL", 347, 357], ["nasal", "ORGANISM_SUBDIVISION", 370, 375], ["rats", "SPECIES", 253, 257], ["Sprague Dawley CD\u00ae", "SPECIES", 230, 248], ["The fluorescein", "TEST", 0, 15], ["rose Bengal scores", "TEST", 20, 38], ["IGS rats", "TEST", 249, 257], ["a PVP-I formulation", "TREATMENT", 308, 327], ["PVP", "TREATMENT", 334, 337], ["Budesonide gel forming nasal spray formulation", "TREATMENT", 347, 393]]], ["Sixty healthy rats (60) were selected for the test and equally distributed into four test groups and two recovery groups (control and high dose).", [["rats", "ORGANISM", 14, 18], ["rats", "SPECIES", 14, 18], ["the test", "TEST", 42, 50]]], ["Intranasal administration of the formulation at dose levels of 25, 50 and 75 \u00b5l and saline control at dose levels of 75 \u00b5l were evaluated.", [["saline", "SIMPLE_CHEMICAL", 84, 90], ["the formulation at dose levels", "TEST", 29, 59], ["saline control", "TREATMENT", 84, 98], ["dose levels", "TEST", 102, 113]]], ["The saline control or the test substance was administered into the right nostril via a 200 \u00b5l pipette twice daily (approximately 12 hours apart).", [["right nostril", "ANATOMY", 67, 80], ["saline", "SIMPLE_CHEMICAL", 4, 10], ["nostril", "ORGAN", 73, 80], ["The saline control", "TREATMENT", 0, 18], ["the test substance", "TREATMENT", 22, 40], ["a 200 \u00b5l pipette", "TREATMENT", 85, 101], ["right", "ANATOMY_MODIFIER", 67, 72], ["nostril", "ANATOMY", 73, 80]]], ["The animals were observed at least once daily for viability, signs of gross toxicity, and behavioral changes, and weekly for a battery of detailed observations.", [["toxicity", "DISEASE", 76, 84], ["animals", "ORGANISM", 4, 11], ["viability", "PROBLEM", 50, 59], ["gross toxicity", "PROBLEM", 70, 84], ["behavioral changes", "PROBLEM", 90, 108], ["gross", "OBSERVATION_MODIFIER", 70, 75], ["toxicity", "OBSERVATION", 76, 84]]], ["All main study animals were subjected to a necropsy of the upper respiratory tract and related sinuses at study termination (Day 29).Intranasal Administration Toxicity StudyThyroids and lungs were collected and weighed.", [["upper respiratory tract", "ANATOMY", 59, 82], ["sinuses", "ANATOMY", 95, 102], ["lungs", "ANATOMY", 186, 191], ["Toxicity", "DISEASE", 159, 167], ["animals", "ORGANISM", 15, 22], ["upper respiratory", "ORGANISM_SUBDIVISION", 59, 76], ["tract", "ORGANISM_SUBDIVISION", 77, 82], ["sinuses", "ORGAN", 95, 102], ["lungs", "ORGAN", 186, 191], ["All main study", "TEST", 0, 14], ["a necropsy of the upper respiratory tract", "PROBLEM", 41, 82], ["Intranasal Administration", "TREATMENT", 133, 158], ["upper", "ANATOMY_MODIFIER", 59, 64], ["respiratory tract", "ANATOMY", 65, 82], ["sinuses", "ANATOMY", 95, 102], ["lungs", "ANATOMY", 186, 191]]], ["This formulation has higher PVP-I concentration compared to IVIEW-1503 formulation (0.6%).Intranasal Administration Toxicity StudySince the intranasal usage of high concentration of PVP-I had no safety issues in the subchronic toxicity study, IVIEW-1503 as a nasal spray formulation should also have minimal to no safety concern.Virucidal AssayThe IVIEW-1201 (1.0% PVP-I) and IVIEW-1503 (0.6% PVP-I) formulations were tested for virucidal activity at the following concentrations: full strength (90% sample and 10% virus solution), 1/1.8, 1/3.2, and 1/10 diluted in simulated tears or simulated nasal fluid, respectively.", [["nasal", "ANATOMY", 259, 264], ["sample", "ANATOMY", 500, 506], ["nasal fluid", "ANATOMY", 595, 606], ["PVP-I", "CHEMICAL", 28, 33], ["IVIEW-1503", "CHEMICAL", 60, 70], ["Toxicity", "DISEASE", 116, 124], ["PVP-I", "CHEMICAL", 182, 187], ["toxicity", "DISEASE", 227, 235], ["IVIEW-1503", "CHEMICAL", 243, 253], ["IVIEW-1201", "CHEMICAL", 348, 358], ["PVP-I", "CHEMICAL", 365, 370], ["IVIEW-1503", "CHEMICAL", 376, 386], ["PVP-I", "CHEMICAL", 393, 398], ["PVP-I", "CHEMICAL", 28, 33], ["IVIEW-1503", "CHEMICAL", 60, 70], ["PVP-I", "CHEMICAL", 182, 187], ["IVIEW-1503", "CHEMICAL", 243, 253], ["IVIEW-1201", "CHEMICAL", 348, 358], ["PVP", "CHEMICAL", 365, 368], ["IVIEW-1503", "CHEMICAL", 376, 386], ["PVP", "CHEMICAL", 393, 396], ["PVP-I", "SIMPLE_CHEMICAL", 28, 33], ["IVIEW-1503", "SIMPLE_CHEMICAL", 60, 70], ["IVIEW-1503", "SIMPLE_CHEMICAL", 243, 253], ["IVIEW-1201", "SIMPLE_CHEMICAL", 348, 358], ["IVIEW-1503", "SIMPLE_CHEMICAL", 376, 386], ["PVP-I", "SIMPLE_CHEMICAL", 393, 398], ["nasal fluid", "MULTI-TISSUE_STRUCTURE", 595, 606], ["This formulation", "TREATMENT", 0, 16], ["higher PVP", "TREATMENT", 21, 31], ["IVIEW", "TEST", 60, 65], ["Intranasal Administration", "TREATMENT", 90, 115], ["high concentration of PVP", "TREATMENT", 160, 185], ["safety issues", "PROBLEM", 195, 208], ["the subchronic toxicity study", "TEST", 212, 241], ["IVIEW", "TEST", 243, 248], ["a nasal spray formulation", "TREATMENT", 257, 282], ["Virucidal Assay", "TEST", 329, 344], ["The IVIEW", "TEST", 344, 353], ["IVIEW", "TEST", 376, 381], ["formulations", "TREATMENT", 400, 412], ["virucidal activity", "TREATMENT", 429, 447], ["nasal", "ANATOMY", 595, 600], ["fluid", "OBSERVATION", 601, 606]]], ["Solution and virus were incubated at 37\u02daC for three contact times of 30 seconds, 2 minutes, and 10 minutes.", [["virus", "TREATMENT", 13, 18]]], ["Following the contact period, the solutions were neutralized by a 1/10 dilution in test media containing 10% FBS and 0.5% sodium thiosulfate.Virus QuantificationNeutralized samples were serially diluted using eight half-log dilutions in the test medium.", [["FBS", "ANATOMY", 109, 112], ["samples", "ANATOMY", 173, 180], ["FBS", "CHEMICAL", 109, 112], ["sodium thiosulfate", "CHEMICAL", 122, 140], ["sodium thiosulfate", "CHEMICAL", 122, 140], ["FBS", "ORGANISM_SUBSTANCE", 109, 112], ["sodium thiosulfate", "SIMPLE_CHEMICAL", 122, 140], ["Virus", "ORGANISM", 141, 146], ["the solutions", "TREATMENT", 30, 43], ["a 1/10 dilution in test media", "TREATMENT", 64, 93], ["10% FBS", "TREATMENT", 105, 112], ["0.5% sodium thiosulfate", "TREATMENT", 117, 140], ["Virus QuantificationNeutralized samples", "TREATMENT", 141, 180]]], ["Each dilution was added to 4 wells of a 96-well plate with 80-100% confluent VERO 76 cells.", [["VERO 76 cells", "ANATOMY", 77, 90], ["VERO 76 cells", "CELL", 77, 90], ["VERO 76 cells", "CELL_LINE", 77, 90], ["Each dilution", "TREATMENT", 0, 13]]], ["The toxicity controls were added to an additional 4 wells and 2 of these wells were infected with virus to serve as neutralization controls, ensuring that the neutralized samples did not continue to inhibit growth and detection of surviving virus.", [["samples", "ANATOMY", 171, 178], ["toxicity", "DISEASE", 4, 12], ["The toxicity controls", "TREATMENT", 0, 21], ["an additional 4 wells", "TREATMENT", 36, 57], ["these wells", "TREATMENT", 67, 78], ["virus", "TREATMENT", 98, 103], ["neutralization controls", "TREATMENT", 116, 139], ["the neutralized samples", "TEST", 155, 178], ["surviving virus", "PROBLEM", 231, 246]]], ["All plates were incubated at 37\u00b0C, 5% CO 2 .Virus QuantificationOn day 6, the post-infection plates were scored for presence or absence of viral cytopathic effect (CPE).", [["All plates", "TEST", 0, 10], ["the post-infection plates", "TEST", 74, 99], ["viral cytopathic effect", "PROBLEM", 139, 162], ["viral cytopathic effect", "OBSERVATION", 139, 162]]], ["The Reed-Muench method was used to determine end-point titers (50% cell culture infectious dose, CCID50) of the samples, and the log reduction value (LRV) of the compound compared to the negative (water) control was calculated.ControlsThe reduction of virus in formulation-treated test wells compared to virus controls was calculated as the log reduction value (LRV).", [["cell", "ANATOMY", 67, 71], ["samples", "ANATOMY", 112, 119], ["cell", "CELL", 67, 71], ["The Reed-Muench method", "TREATMENT", 0, 22], ["the samples", "TEST", 108, 119], ["the log reduction value", "TEST", 125, 148], ["the compound", "PROBLEM", 158, 170], ["virus in formulation", "TREATMENT", 252, 272], ["test wells", "TEST", 281, 291], ["virus controls", "TREATMENT", 304, 318], ["reduction", "OBSERVATION_MODIFIER", 239, 248], ["virus", "OBSERVATION", 252, 257]]], ["Toxicity controls were tested with media not containing virus to see if the samples were toxic to cells.", [["samples", "ANATOMY", 76, 83], ["cells", "ANATOMY", 98, 103], ["Toxicity", "DISEASE", 0, 8], ["cells", "CELL", 98, 103], ["Toxicity controls", "PROBLEM", 0, 17], ["media", "TREATMENT", 35, 40], ["virus", "PROBLEM", 56, 61], ["the samples", "TEST", 72, 83], ["toxic to cells", "PROBLEM", 89, 103]]], ["Neutralization controls were tested to ensure that virus inactivation did not continue after the specified contact time, and that residual sample in the titer assay plates did not inhibit growth and detection of surviving virus.", [["sample", "ANATOMY", 139, 145], ["Neutralization controls", "TREATMENT", 0, 23], ["virus inactivation", "PROBLEM", 51, 69], ["residual sample", "PROBLEM", 130, 145], ["the titer assay plates", "TEST", 149, 171], ["surviving virus", "PROBLEM", 212, 227]]], ["This was done by adding toxicity samples to titer test plates then spiking each well with a low amount of virus (~60 CCID50) that would produce an observable amount of CPE during the incubation period.Ocular Toxicity Study ResultsNo meaningful signs of ocular irritation or corneal staining were observed in the vehicle groupIntranasal Administration Toxicity Study ResultsThere were no mortalities during the course of the study and no test substance-related changes in body weight, body weight gain, food consumption, thyroid weights and lung weights for the duration of the study.", [["Ocular", "ANATOMY", 201, 207], ["ocular", "ANATOMY", 253, 259], ["corneal", "ANATOMY", 274, 281], ["body", "ANATOMY", 471, 475], ["body", "ANATOMY", 484, 488], ["thyroid", "ANATOMY", 520, 527], ["lung", "ANATOMY", 540, 544], ["toxicity", "DISEASE", 24, 32], ["CPE", "CHEMICAL", 168, 171], ["Toxicity", "DISEASE", 208, 216], ["ocular irritation", "DISEASE", 253, 270], ["Toxicity", "DISEASE", 351, 359], ["weight gain", "DISEASE", 489, 500], ["ocular", "ORGAN", 253, 259], ["corneal", "TISSUE", 274, 281], ["body", "ORGANISM_SUBDIVISION", 471, 475], ["body", "ORGANISM_SUBDIVISION", 484, 488], ["thyroid", "ORGAN", 520, 527], ["lung", "ORGAN", 540, 544], ["toxicity samples", "TEST", 24, 40], ["titer test plates", "TEST", 44, 61], ["a low amount of virus", "PROBLEM", 90, 111], ["CPE", "PROBLEM", 168, 171], ["Ocular Toxicity Study", "TEST", 201, 222], ["ocular irritation", "PROBLEM", 253, 270], ["corneal staining", "PROBLEM", 274, 290], ["mortalities", "PROBLEM", 387, 398], ["the study", "TEST", 420, 429], ["test substance", "TEST", 437, 451], ["body weight gain", "PROBLEM", 484, 500], ["thyroid weights", "TEST", 520, 535], ["lung weights", "TEST", 540, 552], ["the study", "TEST", 573, 582], ["observable", "OBSERVATION_MODIFIER", 147, 157], ["amount", "OBSERVATION_MODIFIER", 158, 164], ["CPE", "OBSERVATION", 168, 171], ["meaningful", "OBSERVATION_MODIFIER", 233, 243], ["signs", "OBSERVATION_MODIFIER", 244, 249], ["ocular", "ANATOMY", 253, 259], ["irritation", "OBSERVATION", 260, 270], ["corneal", "ANATOMY", 274, 281], ["staining", "OBSERVATION", 282, 290], ["no", "UNCERTAINTY", 384, 386], ["mortalities", "OBSERVATION", 387, 398], ["thyroid", "ANATOMY", 520, 527], ["lung", "ANATOMY", 540, 544]]], ["There were no macroscopic observations at terminal sacrifice considered attributable to the administration of the formulation intranasally.", [["intranasally", "ANATOMY", 126, 138], ["macroscopic observations at terminal sacrifice", "PROBLEM", 14, 60], ["the formulation intranasally", "TREATMENT", 110, 138], ["no", "UNCERTAINTY", 11, 13]]], ["Following a gross necropsy of the upper respiratory tract and related sinuses, there were no signs of irritation and no abnormalities were detected.", [["upper respiratory tract", "ANATOMY", 34, 57], ["sinuses", "ANATOMY", 70, 77], ["upper respiratory", "ORGANISM_SUBDIVISION", 34, 51], ["tract", "ORGANISM_SUBDIVISION", 52, 57], ["sinuses", "ORGAN", 70, 77], ["a gross necropsy of the upper respiratory tract", "PROBLEM", 10, 57], ["irritation", "PROBLEM", 102, 112], ["abnormalities", "PROBLEM", 120, 133], ["gross", "OBSERVATION_MODIFIER", 12, 17], ["necropsy", "OBSERVATION", 18, 26], ["upper", "ANATOMY_MODIFIER", 34, 39], ["respiratory tract", "ANATOMY", 40, 57], ["sinuses", "ANATOMY", 70, 77], ["no signs of", "UNCERTAINTY", 90, 101], ["irritation", "OBSERVATION", 102, 112], ["no", "UNCERTAINTY", 117, 119], ["abnormalities", "OBSERVATION", 120, 133]]], ["Therefore, it has demonstrated the subchronic intranasal use of PVP-I is expected to have no toxicity concerns.Virucidal Assay ResultsVirus LRV (log reduction value) for IVIEW-1201 and IVIEW-1503 against SARS-CoV-2 virus are shown in Table 1 .", [["PVP-I", "CHEMICAL", 64, 69], ["toxicity", "DISEASE", 93, 101], ["IVIEW-1201", "CHEMICAL", 170, 180], ["IVIEW-1503", "CHEMICAL", 185, 195], ["PVP-I", "CHEMICAL", 64, 69], ["IVIEW-1201", "CHEMICAL", 170, 180], ["PVP-I", "SIMPLE_CHEMICAL", 64, 69], ["ResultsVirus LRV", "ORGANISM", 127, 143], ["IVIEW-1201", "SIMPLE_CHEMICAL", 170, 180], ["IVIEW-1503", "ORGANISM", 185, 195], ["SARS-CoV-2 virus", "ORGANISM", 204, 220], ["SARS-CoV-2 virus", "SPECIES", 204, 220], ["IVIEW-1201", "SPECIES", 170, 180], ["IVIEW-1503", "SPECIES", 185, 195], ["SARS-CoV-2 virus", "SPECIES", 204, 220], ["PVP", "TREATMENT", 64, 67], ["toxicity concerns", "PROBLEM", 93, 110], ["Virucidal Assay", "TEST", 111, 126], ["LRV", "TEST", 140, 143], ["IVIEW", "TEST", 170, 175], ["IVIEW", "TEST", 185, 190], ["SARS", "PROBLEM", 204, 208], ["CoV", "TEST", 209, 212], ["subchronic", "OBSERVATION_MODIFIER", 35, 45]]], ["PVP-I formulation toxicity was not observed at any concentration.", [["PVP-I", "CHEMICAL", 0, 5], ["toxicity", "DISEASE", 18, 26], ["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "SIMPLE_CHEMICAL", 0, 5], ["PVP", "TEST", 0, 3], ["I formulation toxicity", "PROBLEM", 4, 26]]], ["Ethanol (45%) had some observable toxicity at the 30-second and 2-minute time points.", [["Ethanol", "CHEMICAL", 0, 7], ["toxicity", "DISEASE", 34, 42], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["Ethanol", "TREATMENT", 0, 7], ["some observable toxicity", "PROBLEM", 18, 42]]], ["As a result of this toxicity, the presence of virus could not be ruled out in those wells therefore the limit of detection was 1.7 log 10 CCID 50 of virus per 0.1 mL. patients (44, 45, 46, 47, 48) .", [["toxicity", "DISEASE", 20, 28], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["this toxicity", "PROBLEM", 15, 28], ["virus", "PROBLEM", 46, 51], ["virus", "TREATMENT", 149, 154], ["virus", "OBSERVATION", 46, 51]]], ["One of the major limitations of the drugs mentioned above is that there is no data available on the adverse reactions of the high dosages of the antiviral drugs whenVirucidal Assay Resultsgiven for long durations.", [["the drugs", "TREATMENT", 32, 41], ["the adverse reactions", "PROBLEM", 96, 117], ["the antiviral drugs", "TREATMENT", 141, 160], ["major", "OBSERVATION_MODIFIER", 11, 16]]], ["The duration of medication needed is also currently unknown (48) .Virucidal Assay ResultsStudies have shown that the SARS-CoV-2 virus uses angiotensin-converting enzyme 2 (ACE2)Virucidal Assay Resultsin the lungs as a receptor and relies on an enzyme known as transmembrane protease serine 2 (TMPRSS2) to enter and fuse with host cells in order to replicate (49) .", [["lungs", "ANATOMY", 207, 212], ["cells", "ANATOMY", 330, 335], ["angiotensin", "CHEMICAL", 139, 150], ["serine", "CHEMICAL", 283, 289], ["SARS-CoV-2 virus", "ORGANISM", 117, 133], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 139, 170], ["ACE2", "GENE_OR_GENE_PRODUCT", 172, 176], ["lungs", "ORGAN", 207, 212], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 260, 291], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 293, 300], ["host cells", "CELL", 325, 335], ["angiotensin-converting enzyme 2", "PROTEIN", 139, 170], ["ACE2", "PROTEIN", 172, 176], ["transmembrane protease serine 2", "PROTEIN", 260, 291], ["TMPRSS2", "PROTEIN", 293, 300], ["host cells", "CELL_TYPE", 325, 335], ["CoV-2 virus", "SPECIES", 122, 133], ["SARS-CoV-2 virus", "SPECIES", 117, 133], ["medication", "TREATMENT", 16, 26], ["Virucidal Assay", "TEST", 66, 81], ["the SARS", "TEST", 113, 121], ["CoV", "TEST", 122, 125], ["angiotensin", "TREATMENT", 139, 150], ["enzyme", "TEST", 162, 168], ["Virucidal Assay", "TEST", 177, 192], ["an enzyme", "TEST", 241, 250], ["transmembrane protease serine", "TREATMENT", 260, 289], ["lungs", "ANATOMY", 207, 212]]], ["This has led medical professionals to test existing antivirals that are known to interfere with viral membrane fusion and disrupt RNA polymerase in order to prevent further viral production in hosts.Virucidal Assay ResultsHydroxychloroquine, an antimalarial and derivative of chloroquine, is one such therapy that is believed to be one of the potential therapies in treating COVID-19.", [["membrane", "ANATOMY", 102, 110], ["Hydroxychloroquine", "CHEMICAL", 222, 240], ["chloroquine", "CHEMICAL", 276, 287], ["Hydroxychloroquine", "CHEMICAL", 222, 240], ["chloroquine", "CHEMICAL", 276, 287], ["COVID-19", "CHEMICAL", 375, 383], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 222, 240], ["chloroquine", "SIMPLE_CHEMICAL", 276, 287], ["RNA polymerase", "PROTEIN", 130, 144], ["antivirals", "TREATMENT", 52, 62], ["viral membrane fusion", "TREATMENT", 96, 117], ["disrupt RNA polymerase", "TREATMENT", 122, 144], ["further viral production in hosts", "PROBLEM", 165, 198], ["Virucidal Assay", "TREATMENT", 199, 214], ["Hydroxychloroquine", "TREATMENT", 222, 240], ["an antimalarial", "TREATMENT", 242, 257], ["chloroquine", "TREATMENT", 276, 287], ["one such therapy", "TREATMENT", 292, 308], ["COVID", "TEST", 375, 380], ["viral production", "OBSERVATION", 173, 189]]], ["Its mechanism has been used to prevent the transport of virions to the replication site by altering pH and block viral endocytosis to hosts (49) .", [["virions", "TREATMENT", 56, 63], ["altering pH", "PROBLEM", 91, 102], ["block viral endocytosis", "PROBLEM", 107, 130]]], ["However, in a recent COVID-19 trial consisting of 36 patients, 14 patients treated with hydroxychloroquine have continued to show symptoms of upper or lower respiratory tract infections (50) .", [["lower respiratory tract", "ANATOMY", 151, 174], ["hydroxychloroquine", "CHEMICAL", 88, 106], ["respiratory tract infections", "DISEASE", 157, 185], ["hydroxychloroquine", "CHEMICAL", 88, 106], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 66, 74], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 88, 106], ["upper", "ORGANISM_SUBDIVISION", 142, 147], ["lower", "ORGANISM_SUBDIVISION", 151, 156], ["respiratory tract", "ORGANISM_SUBDIVISION", 157, 174], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 66, 74], ["hydroxychloroquine", "TREATMENT", 88, 106], ["symptoms", "PROBLEM", 130, 138], ["upper or lower respiratory tract infections", "PROBLEM", 142, 185], ["upper", "ANATOMY_MODIFIER", 142, 147], ["lower", "ANATOMY_MODIFIER", 151, 156], ["respiratory tract", "ANATOMY", 157, 174], ["infections", "OBSERVATION", 175, 185]]], ["Although hydroxychloroquine has increased potency and tolerable safety profile compared to chloroquine, potential adverse effects such as electrolyte imbalance and fatal dysrhythmias could take place (50) .", [["hydroxychloroquine", "CHEMICAL", 9, 27], ["chloroquine", "CHEMICAL", 91, 102], ["dysrhythmias", "DISEASE", 170, 182], ["hydroxychloroquine", "CHEMICAL", 9, 27], ["chloroquine", "CHEMICAL", 91, 102], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 9, 27], ["chloroquine", "SIMPLE_CHEMICAL", 91, 102], ["hydroxychloroquine", "TREATMENT", 9, 27], ["chloroquine", "TREATMENT", 91, 102], ["potential adverse effects", "PROBLEM", 104, 129], ["electrolyte imbalance", "PROBLEM", 138, 159], ["fatal dysrhythmias", "PROBLEM", 164, 182]]], ["Another possible therapy, Remdesivir \u00ae , a nucleotide analogue, inhibits viral RNA polymerase and was developed as a substance to combat ebolaviruses, SARS-CoV, and MERS-CoV (49, 52, 53) .", [["Remdesivir \u00ae", "CHEMICAL", 26, 38], ["nucleotide", "CHEMICAL", 43, 53], ["ebolaviruses", "DISEASE", 137, 149], ["SARS-CoV", "DISEASE", 151, 159], ["Remdesivir", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 43, 53], ["Remdesivir \u00ae", "SIMPLE_CHEMICAL", 26, 38], ["SARS-CoV", "ORGANISM", 151, 159], ["MERS-CoV", "ORGANISM", 165, 173], ["viral RNA polymerase", "PROTEIN", 73, 93], ["SARS-CoV", "SPECIES", 151, 159], ["MERS-CoV", "SPECIES", 165, 173], ["therapy", "TREATMENT", 17, 24], ["Remdesivir", "TREATMENT", 26, 36], ["a nucleotide analogue", "TREATMENT", 41, 62], ["viral RNA polymerase", "PROBLEM", 73, 93], ["SARS", "PROBLEM", 151, 155], ["CoV", "TEST", 170, 173], ["possible", "UNCERTAINTY", 8, 16]]], ["With significant results in in vitro testing against SARS-CoV-2, the therapy appears to be another potential prophylaxis.", [["SARS-CoV-2", "ORGANISM", 53, 63], ["SARS-CoV", "SPECIES", 53, 61], ["vitro testing", "TEST", 31, 44], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61], ["the therapy", "TREATMENT", 65, 76], ["another potential prophylaxis", "TREATMENT", 91, 120]]], ["PVP-I is a low-cost topical medication which could significantly reduce the burden on the existing health care system if it is proven to be effective in reducing viral load.", [["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "CHEMICAL", 0, 5], ["PVP-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["a low-cost topical medication", "TREATMENT", 9, 38], ["reducing viral load", "PROBLEM", 153, 172], ["viral load", "OBSERVATION", 162, 172]]], ["Presently, the estimated cost of managing a patient with proven positivity for COVID 19 but without any complications is $9,673.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["COVID", "TEST", 79, 84], ["any complications", "PROBLEM", 100, 117]]], ["For a patient with complications or co-morbidity it is $13,767 and for a patient with major complications or co-morbidity it increases to $20,292 (54) .", [["patient", "ORGANISM", 6, 13], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 6, 13], ["patient", "SPECIES", 73, 80], ["complications", "PROBLEM", 19, 32], ["co-morbidity", "PROBLEM", 36, 48], ["major complications", "PROBLEM", 86, 105], ["co-morbidity", "PROBLEM", 109, 121]]], ["If we only assess the deceased patients (281,399 by May 10, 2020) and presume that they were hospitalized without complications prior to their death, the amount globally spent to treat this condition would be over 2.72 billion USD.", [["death", "DISEASE", 143, 148], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["complications", "PROBLEM", 114, 127], ["this condition", "PROBLEM", 185, 199]]], ["This still does not include testing costs or healthcare costs for those patients with mild to moderate complications.Virucidal Assay ResultsThe next phase is to determine if topical PVP-I nasal sprays and irrigations will result in a reduction in the SARS-CoV-2 viral load, and to show whether there is a significant reduction in hospitalization or need for advanced life support in these patients.", [["nasal", "ANATOMY", 188, 193], ["PVP-I", "CHEMICAL", 182, 187], ["SARS", "DISEASE", 251, 255], ["PVP", "CHEMICAL", 182, 185], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 389, 397], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 389, 397], ["mild to moderate complications", "PROBLEM", 86, 116], ["Virucidal Assay", "TEST", 117, 132], ["topical PVP-I nasal sprays", "TREATMENT", 174, 200], ["irrigations", "TREATMENT", 205, 216], ["a reduction", "PROBLEM", 232, 243], ["the SARS", "TEST", 247, 255], ["CoV-2 viral load", "TEST", 256, 272], ["advanced life support", "TREATMENT", 358, 379], ["moderate", "OBSERVATION_MODIFIER", 94, 102], ["complications", "OBSERVATION", 103, 116], ["significant", "OBSERVATION_MODIFIER", 305, 316], ["reduction", "OBSERVATION_MODIFIER", 317, 326]]], ["Based on a clinical study in", [["a clinical study", "TEST", 9, 25]]]], "PMC7297419": [["Authors' contributionBoth authors have equal contribution and approve for final submission.Financial support and sponsorshipNil.Conflicts of interestThere are no conflicts of interest.", [["Financial support", "TREATMENT", 91, 108], ["sponsorshipNil", "TREATMENT", 113, 127], ["no", "UNCERTAINTY", 159, 161], ["conflicts", "OBSERVATION", 162, 171]]]], "PMC7424127": [["Characteristics of Low-Income Latino ChildrenAs of 2018, about 1 in 4 of all US children are Latino and economic security is precarious for many (Child Trends, 2018; Federal Interagency Forum on Child and Family Statistics, 2014).", [["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["Low", "OBSERVATION_MODIFIER", 19, 22]]], ["Roughly 1/3 of Latino children experience poverty, which amounts to about 5.7 million children, and is the highest rate of poverty for any US racial/ethnic minority group (DeNavas-Walt & Proctor, 2015; Lopez & Valasco, 2011).", [["poverty", "DISEASE", 42, 49], ["children", "ORGANISM", 22, 30], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 22, 30], ["children", "SPECIES", 86, 94]]], ["The vast majority (over 90%) of Latino children in this country are US born (Murphey, Guzman & Torres, 2014), meaning that they are eligible for means-tested assistance programs that are for citizen children.", [["children", "ORGANISM", 39, 47], ["children", "ORGANISM", 199, 207], ["children", "SPECIES", 39, 47], ["children", "SPECIES", 199, 207], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17]]], ["However, Latino households have some of the lowest utilization rates of these government assistance programs compared with other low-income groups (Alvira-Hammond & Gennetian, 2015), which means that these available benefits are failing to reach these vulnerable children.", [["children", "ORGANISM", 263, 271], ["children", "SPECIES", 263, 271], ["these government assistance programs", "TREATMENT", 72, 108]]], ["Lastly, many Latino children are growing up in households with immigrant parents and/or grandparents.", [["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28]]], ["Immigrant children and adults experience risk due to challenges or trauma experienced prior to, during and post-migration to the USA (Thibeault, Mendez, Nelson-Gray, & Stein, 2017; Van Hook & Glick, 2020).", [["trauma", "DISEASE", 67, 73], ["children", "ORGANISM", 10, 18], ["adults", "ORGANISM", 23, 29], ["children", "SPECIES", 10, 18], ["trauma", "PROBLEM", 67, 73]]], ["Estimates based on the US Census data show 1 in 4 Latino children has a parent who lacks authorization to reside permanently in the USA (Clarke, Turner & Guzman, 2017).", [["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["the US Census data", "TEST", 19, 37]]], ["When immigrants feel unsafe in their communities, this further isolates children from resources, such as other adult and peer relationships as well as searching for and participating in ECE programs (Vesely, Goodman, Ewaida, & Kearney, 2015; Yoshikawa, Kholoptseva, & Suarez-Orozco, 2013).Characteristics of Low-Income Latino ChildrenThere are a multitude of other characteristics that define Latino children in the USA such as their country of birth, parental countries of birth, US citizenship status, time in the USA, language spoken at home, English speaking proficiency, literacy, highest educational level attained outside of the USA, to name a few (U.S. Department of Health and Human Services, 2014).", [["children", "ORGANISM", 72, 80], ["Children", "ORGANISM", 326, 334], ["children", "ORGANISM", 400, 408], ["Human", "ORGANISM", 686, 691], ["children", "SPECIES", 72, 80], ["Children", "SPECIES", 326, 334], ["children", "SPECIES", 400, 408], ["Human", "SPECIES", 686, 691], ["Low", "OBSERVATION_MODIFIER", 308, 311]]], ["The Southeastern region of the USA, along with the Pacific Northwest and central US states, has experienced rapid, substantial growth in Latino households, making them new destination or emerging Latino communities (Helms, Hengstebeck, Rodriguez, Mendez, & Crosby, 2015; Lichter, Sanders, & Johnson, 2015).", [["substantial", "OBSERVATION_MODIFIER", 115, 126], ["growth", "OBSERVATION_MODIFIER", 127, 133]]], ["Other states have historically been home to large numbers of Latino children for some time now, often referred to as established gateway communities (Lichter et al., 2015; Singer, 2008).", [["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76]]], ["A study with immigrant mothers, many with origins in Central America, found that ethnic enclaves were a place where information was shared via social networks (Vesely et al., 2015).", [["A study", "TEST", 0, 7], ["Central", "ANATOMY_MODIFIER", 53, 60]]], ["Taken together, the diversity of background of Latino children, as well as their tendency to experience high rates of poverty and/or trauma, must be considered in any examination of their participation in early care and education.Overview of the PaperThis paper synthesizes the research on how participation in early care and education programs might serve as a critical protective factor for Latino children\u2019s development and mitigate their exposure to adverse childhood experiences (ACEs).", [["poverty", "DISEASE", 118, 125], ["trauma", "DISEASE", 133, 139], ["children", "ORGANISM", 54, 62], ["children", "ORGANISM", 400, 408], ["children", "SPECIES", 54, 62], ["children", "SPECIES", 400, 408], ["trauma", "PROBLEM", 133, 139], ["any examination", "TEST", 163, 178], ["education programs", "TREATMENT", 326, 344]]], ["Latino populations have been shown to have some of the highest rates of exposure to ACEs (Andrews, Haws, Acosta, Acosta Canchila, Carlo, et al., 2019; Ellis & Dietz, 2017; Slopen, Shonkoff, Albert, Yoshikawa, Jacobs, Stoltz, et al., 2016).", [["ACEs", "DISEASE", 84, 88]]], ["To guide the synthesis, a theoretical perspective is described which incorporates the sociocultural and transactional context that must be considered in examining ACEs among Latino children, their families, and ECE programs or providers.", [["children", "ORGANISM", 181, 189], ["children", "SPECIES", 181, 189]]], ["Next, this paper discusses the developmental and protective benefits that early care and education provides, focusing especially on the impacts that center-based early childhood education programs like Early Head Start and Head Start have had on reducing the impact of ACEs.", [["ACEs", "DISEASE", 269, 273], ["Head", "ANATOMY", 208, 212], ["Head", "ANATOMY", 223, 227]]], ["Finally, this paper explores how well ECE programs and providers are serving Latino families by reviewing literature on the barriers and facilitators of ECE access and utilization for Latino households.", [["ECE access", "TREATMENT", 153, 163]]], ["The paper concludes with several recommendations intended to offset these obstacles in order to enhance the participation and reach of ECE as protective experiences for Latino children.Sociocultural Theory and Transactional FrameworkAs a backdrop for the review, existing sociocultural theory and ecological-transactional developmental frameworks illustrate how ECE can play a role in the development of Latino children (Bronfenbrenner & Morris, 2006; Garc\u0131a Coll, Lamberty, Jenkins, McAdoo, Crnic, Wasik, et al., 1996; Masten & Barnes, 2018; Mendez & Westerberg, 2012).", [["children", "ORGANISM", 176, 184], ["ECE", "GENE_OR_GENE_PRODUCT", 362, 365], ["children", "ORGANISM", 411, 419], ["ECE", "PROTEIN", 362, 365], ["children", "SPECIES", 176, 184], ["children", "SPECIES", 411, 419]]], ["To best examine child development within a broader context, parental decisions about child care and use of government assistance must also be situated within a broader historical and contemporary socioecological context.", [["government assistance", "TREATMENT", 107, 128]]], ["In Garcia Coll and colleagues\u2019 (1996) Integrated Model for the Study of Developmental Competencies in Children of Color, a seminal framework for understanding minority child development in context, social stratification within society impacts the environments in which children and families live, attend school, and work.", [["children", "ORGANISM", 269, 277], ["Children", "SPECIES", 102, 110], ["children", "SPECIES", 269, 277], ["the Study", "TEST", 59, 68], ["seminal", "ANATOMY", 123, 130]]], ["Furthermore, this model articulates that environments can either promote or inhibit children\u2019s development and will eventually influence how families socialize and share their cultural beliefs and practices to contribute to child outcomes.", [["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92]]], ["According to the theory, and supported by research, in promotive community environments, ECE programs can provide secure and enriching settings for Latino children, as well as support parent\u2019s need for work, and provide a social support network for immigrant families (Vesely et al., 2013).", [["children", "ORGANISM", 155, 163], ["children", "SPECIES", 155, 163], ["ECE programs", "TREATMENT", 89, 101]]], ["In contrast, neighborhoods and communities that feel unsafe or discriminatory may lead families to keep children at home as a proactive safety strategy (Bartlett & Ramos-Olazagasti, 2018; Matthews et al., 2018) due to mistrust, and parents may limit their involvement in employment, use of programs, or other enrichment opportunities for the family (Brabeck, Sibley, Taubin, & Murcia, 2016).", [["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112]]], ["Thus, the perceived unsafe environment serves as an inhibiting influence by limiting the reach of ECE and other services to Latino children.Sociocultural Theory and Transactional FrameworkAlthough significant numbers of Latino children use ECE, research continues to reveal the negative, and far-reaching, impacts of the present-day climate around immigration policy for Latino children and families (Van Hook & Glick, 2020).", [["children", "ORGANISM", 131, 139], ["children", "ORGANISM", 227, 235], ["children", "ORGANISM", 378, 386], ["children", "SPECIES", 131, 139], ["children", "SPECIES", 227, 235], ["children", "SPECIES", 378, 386], ["significant", "OBSERVATION_MODIFIER", 197, 208], ["numbers", "OBSERVATION_MODIFIER", 209, 216], ["negative", "OBSERVATION", 278, 286]]], ["Uncertainty stemming from changes to the federal definition of a public charge are reducing the likelihood of family participation in government assistance programs and impacting the decision-making process for families applying for benefits (Bernstein, Gonzalez, Karpman, & Zuckerman, 2019).", [["Uncertainty stemming", "PROBLEM", 0, 20], ["a public charge", "TREATMENT", 63, 78]]], ["ECE providers are reporting negative impacts on enrollments and attendance as immigrant and Latino families report being less willing to separate from their children (Matthews et al., 2018).", [["children", "ORGANISM", 157, 165], ["children", "SPECIES", 157, 165]]], ["This same study reported that ECE providers felt less equipped to support the needs of immigrant families, and they were struggling to connect the families to other community resources (Matthews et al., 2018).", [["This same study", "TEST", 0, 15]]], ["For these reasons, community-based organizations (CBOs) play a key role within communities to assist immigrants within communities to locate the resources they need, and to form connections with community groups that will help the family respond to pressures (Yoshikawa et al., 2013).Sociocultural Theory and Transactional FrameworkFigure 1 captures the range of influences on young Latino children and families.", [["children", "ORGANISM", 390, 398], ["children", "SPECIES", 390, 398]]], ["This model illustrates how the transactional relationships between and among families, ECE providers and programs, and community-based organizations weave together a stronger promotive environment that can serve as a deeper set of protective experiences for low-income Latino children.", [["children", "ORGANISM", 276, 284], ["children", "SPECIES", 276, 284]]], ["Specifically, the bidirectional arrows signify the number of reciprocal interactions between members of the children\u2019s microsystem and exosystem contexts (Bronfenbrenner & Morris, 2006).", [["children", "ORGANISM", 108, 116], ["children", "SPECIES", 108, 116], ["number", "OBSERVATION_MODIFIER", 51, 57]]], ["Opportunities to mitigate the impact of ACEs during childhood occur within and across the other systems, such as home/family, ECE, and neighborhood/community.", [["ACEs", "DISEASE", 40, 44]]], ["Developing mutual connections that support children across the microsystems will serve to buffer the impact of ACEs on children.Overview of Adversity and Resilience in Latino ChildrenAn analysis of adversity and resilience requires examining how children\u2019s resilience emerges within a particular developmental context, as specific child characteristics transact with environmental influences to promote adaptation or recovery in the face of extreme adversity (Ellis & Dietz, 2017; Hays-Grudo & Morris, 2020; Luthar, Cicchetti, & Becker, 2000; Masten & Barnes, 2018).", [["ACEs", "DISEASE", 111, 115], ["children", "ORGANISM", 43, 51], ["ACEs", "GENE_OR_GENE_PRODUCT", 111, 115], ["children", "ORGANISM", 119, 127], ["children", "ORGANISM", 246, 254], ["children", "SPECIES", 43, 51], ["children", "SPECIES", 119, 127], ["children", "SPECIES", 246, 254]]], ["In this section, we provide a review of some of the common and unique adverse childhood experiences encountered by Latino children in the USA.", [["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130]]], ["Although just 5% of the sample in the seminal research study on ACEs included Latino adults, they were represented in the highest prevalence of risk (11.2% endorsed four or more categories of ACEs; Felitti, Anda, Nordenberg, Williamson, Spitz, Edwards, et al., 1998).", [["the seminal research study", "TEST", 34, 60]]], ["Continued research on Latinos has documented the number of risks facing children, especially when they are born into high levels of poverty (Lichter, et al., 2015).", [["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80]]], ["Today, about 1/3 of all Latino children are living in poverty, which dramatically increases the likelihood of exposure to ACES and often decreases the likelihood of reliable, easy access to mental health and other supportive services for children and their families.", [["ACES", "DISEASE", 122, 126], ["children", "ORGANISM", 31, 39], ["children", "ORGANISM", 238, 246], ["children", "SPECIES", 31, 39], ["children", "SPECIES", 238, 246]]], ["Particularly concerning are the highest rates of suicidality among Latina adolescents relative to other ethnic/racial groups (Zayes & Pilat, 2008), which could be reduced by changing the negative trajectory from Latino ACEs to later mental health difficulties.Overview of Adversity and Resilience in Latino ChildrenIn addition to rates of poverty, work has shown the high rates of exposure to traumatic events and acculturative stress among recently arriving immigrant children (Thibeault et al., 2017).", [["suicidality", "DISEASE", 49, 60], ["ACEs", "DISEASE", 219, 223], ["children", "ORGANISM", 469, 477], ["adolescents", "SPECIES", 74, 85], ["children", "SPECIES", 469, 477], ["suicidality", "PROBLEM", 49, 60], ["traumatic events", "PROBLEM", 393, 409], ["acculturative stress", "PROBLEM", 414, 434]]], ["Other unpredictable stressors facing Latinos include economic uncertainty (Vesely, et al., 2015), immigration policy and harmful impacts on families (Yoshikawa, et al., 2013), and uncertainty regarding eligibility for services (Alvira-Hammond & Gennetian, 2015).", [["unpredictable", "OBSERVATION_MODIFIER", 6, 19], ["stressors", "OBSERVATION", 20, 29]]], ["Finally, the practice of family separation occurring at the southern US border has caused major organizations that support child development to declare the traumatic separation of young children from their primary caregivers as a major assault on the attachment and security of developing Latino children (Bousa, Camacho-Thompson, Carlo, Franco, Garcia Coll, Halgunseth et al., 2018).Overview of Adversity and Resilience in Latino ChildrenLatino rates of engagement in high-stress work situations also creates pressures on the family, which can have spillover effects onto the quality of the family-child experiences (Helms, Hengstebeck, Rodriguez, Mendez, & Crosby, 2015; Sandstrom & Huerta, 2013).", [["children", "ORGANISM", 186, 194], ["children", "ORGANISM", 296, 304], ["children", "SPECIES", 186, 194], ["children", "SPECIES", 296, 304], ["pressures", "OBSERVATION_MODIFIER", 510, 519]]], ["Instability in the family is also created by Latinos employed in job sectors that include high rates of nonstandard work schedules (outside of M-F 9\u20135) where child care is less available, and workers receive little advance notice of their hours (Crosby & Mendez, 2017).", [["Instability", "PROBLEM", 0, 11]]], ["In a study of Latino migrant farmworkers, ACEs were related to higher exposure to harsh working conditions, and to larger effects of these harsh working conditions on depression and anxiety symptoms (Andrews et al., 2019).", [["depression", "DISEASE", 167, 177], ["anxiety", "DISEASE", 182, 189], ["ACEs", "PROBLEM", 42, 46], ["harsh working conditions", "PROBLEM", 82, 106], ["depression", "PROBLEM", 167, 177], ["anxiety symptoms", "PROBLEM", 182, 198]]], ["Taken together, all these factors create stress and uncertainty, which is a risk to the stability of the family unit and parent\u2019s mental health, which can compromise parents\u2019 ability to buffer their own children from ACEs.Benefits of ECE for Latino Children Exposed to ACEsFor children who have directly experienced trauma early in life, ECE environments can provide safety and stability (Bartlett, Smith, & Bringewatt, 2017; Paschall & Mastergeorge, 2016).", [["ACEs", "DISEASE", 217, 221], ["trauma", "DISEASE", 316, 322], ["children", "ORGANISM", 203, 211], ["Children", "ORGANISM", 249, 257], ["children", "ORGANISM", 277, 285], ["children", "SPECIES", 203, 211], ["Children", "SPECIES", 249, 257], ["children", "SPECIES", 277, 285], ["trauma", "PROBLEM", 316, 322]]], ["Traumas that young children face could have severe and early impacts on child development, due to the intense fear experienced or threat posed to the child\u2019s well-being (Lieberman, Chu, Van Horn, & Harris, 2011).", [["Traumas", "DISEASE", 0, 7], ["children", "ORGANISM", 19, 27], ["children", "SPECIES", 19, 27], ["Traumas", "PROBLEM", 0, 7], ["severe", "OBSERVATION_MODIFIER", 44, 50]]], ["Therefore, ECE programs and providers are in a unique position to offer benefits to children experiencing trauma through (a) screening and detecting, (b) offering nurturing environments to offset or buffer from instability or ancillary effect due to the trauma, such as loss of a caregiver or witnessing domestic violence, and (c) supporting the family of the child who has experienced a trauma (Bartlett, et al., 2017), especially by connecting families to health or mental health resources.", [["trauma", "DISEASE", 106, 112], ["trauma", "DISEASE", 254, 260], ["domestic violence", "DISEASE", 304, 321], ["trauma", "DISEASE", 388, 394], ["children", "ORGANISM", 84, 92], ["child", "ORGANISM", 360, 365], ["children", "SPECIES", 84, 92], ["trauma", "PROBLEM", 106, 112], ["a) screening", "TEST", 122, 134], ["nurturing environments", "TREATMENT", 163, 185], ["instability", "PROBLEM", 211, 222], ["ancillary effect", "PROBLEM", 226, 242], ["the trauma", "PROBLEM", 250, 260], ["a trauma", "PROBLEM", 386, 394]]], ["Because childhood adversities also co-occur (Hays-Grudo, 2020; Shonkoff et al., 2012), attending to the prevalence of traumatic exposure for children across different settings, particularly within Latino and immigrant communities facing high levels of discrimination (Ramos-Olazagasti et al., 2017), is paramount.", [["traumatic", "DISEASE", 118, 127], ["children", "ORGANISM", 141, 149], ["children", "SPECIES", 141, 149]]], ["The field is increasingly calling for a unified approach to reducing the exposure to ACEs among children and coordinated responses of systems, including ECE, child welfare, health care, education, and others, have been proposed as a way to mitigate the impact of toxic stress on the developing brain and disrupt pathways from early childhood trauma to future negative health and educational outcomes, particularly among minority populations (Hays-Grudo, 2020; Lieberman et al., 2011; Shonkoff, et al., 2012).Benefits of ECE for Latino Children Exposed to ACEsTo promote an understanding of how ECE contributes to resilience, let us turn to the evidence that ECE programs have a positive impact on low-income children who face adversity, including Latino children (Berlin, Martoccio, & Jones Harden, 2018; Bitler, Hoynes, & Domina, 2014; Crosnoe, 2007; Magnuson, Lahaie & Waldfogel, 2006; Mendez, Crosby & Siskind, 2018; Merritt & Klein, 2015).", [["brain", "ANATOMY", 294, 299], ["ACEs", "DISEASE", 85, 89], ["trauma", "DISEASE", 342, 348], ["children", "ORGANISM", 96, 104], ["brain", "ORGAN", 294, 299], ["children", "ORGANISM", 708, 716], ["children", "ORGANISM", 754, 762], ["children", "SPECIES", 96, 104], ["Children", "SPECIES", 535, 543], ["children", "SPECIES", 708, 716], ["children", "SPECIES", 754, 762], ["toxic stress", "PROBLEM", 263, 275], ["brain", "ANATOMY", 294, 299]]], ["For example, Early Head Start, a federal funded ECE program serving families of children under three, uses a range of delivery models across diverse communities including home-based services, center-based experiences, or a combination of settings to enhance parenting and child wellbeing.", [["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["Head", "ANATOMY", 19, 23]]], ["Early Head Start (EHS) has produced positive effects for children with adverse childhood experiences including maltreatment, homelessness, and families with mental health difficulties (Kane, Bailey, Wheat, & Halle, 2020).", [["maltreatment", "DISEASE", 111, 123], ["homelessness", "DISEASE", 125, 137], ["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["mental health difficulties", "PROBLEM", 157, 183], ["Head", "ANATOMY", 6, 10]]], ["Children participating in Early Head Start were less likely over time to be involved with the child welfare system, and the effects are in part driven by positive impacts of EHS on parenting including improved parent warmth with their child, lower parenting stress, and less conflict in the family (Green, Ayoub, Bartlett, Furrer, Chazen Cohen, Buttita et al., 2018).", [["EHS", "DISEASE", 174, 177], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["In a sample of low-income children (33% Latino) involved with child welfare services who had a supervisory neglect status, language development was greater for children who experienced ECE settings as compared with those who did not (Merritt & Klein, 2015).", [["children", "ORGANISM", 26, 34], ["children", "ORGANISM", 160, 168], ["children", "SPECIES", 26, 34], ["children", "SPECIES", 160, 168]]], ["More generally, a significant benefit of home visitation programs are the repeated opportunities for screening children\u2019s ongoing exposure to ACEs, which permits more targeted supports and interventions to be offered to families (McKelvey, Conners Edge, Fitzgerald, Kraleti, & Whiteside-Mansell, 2017).Benefits of ECE for Latino Children Exposed to ACEsIn the first evaluation of an enhanced Early Head Start program model with a predominantly Latino sample (87%), researchers compared two conditions: one intervention group receiving an EHS home-based program combined with the Attachment Biobehavioral Checkup (ABC; Dozier & Bernard, 2017) which is an evidenced-based, parent-child attachment intervention, and the control group receiving an EHS home-based program combined with parents receiving a weekly book intervention.", [["ACEs", "DISEASE", 142, 146], ["children", "ORGANISM", 111, 119], ["children", "SPECIES", 111, 119], ["Children", "SPECIES", 329, 337], ["home visitation programs", "TREATMENT", 41, 65], ["interventions", "TREATMENT", 189, 202], ["child attachment intervention", "TREATMENT", 678, 707], ["a weekly book intervention", "TREATMENT", 799, 825]]], ["Parents who participated in the ABC intervention group plus EHS were rated by observers as significantly more sensitive/responsive, less intrusive, and higher on positive regard and overall sensitivity toward their infants than the Book-of-the-Week plus EHS control group (Berlin et al., 2018).", [["infants", "ORGANISM", 215, 222], ["infants", "SPECIES", 215, 222]]], ["The effect size for intrusiveness was large (d = .77) which is a considerable positive step toward increasing the likelihood of a secure attachment (Berlin et al., 2018), as intrusive behavior among parents is alarming for infants and traumatic experiences for children often co-occur with traumatized parents (Lieberman, Chu, Van Horn, & Harris, 2011).", [["intrusive behavior", "DISEASE", 174, 192], ["traumatic", "DISEASE", 235, 244], ["infants", "ORGANISM", 223, 230], ["children", "ORGANISM", 261, 269], ["infants", "SPECIES", 223, 230], ["children", "SPECIES", 261, 269], ["intrusiveness", "PROBLEM", 20, 33], ["a considerable positive step", "PROBLEM", 63, 91], ["effect", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["The ABC intervention was delivered by bilingual and trained parent coaches in the language of choice for parents, an adaptation that accounted for the linguistic diversity of the families.", [["ABC", "GENE_OR_GENE_PRODUCT", 4, 7], ["The ABC intervention", "TREATMENT", 0, 20]]], ["This research showed the value added of attachment-based interventions, which is important as the original evaluation of the EHS impact did not find an effect on maternal supportiveness of children for Latino mothers (Raikes, Vogel, & Love, 2013).Benefits of ECE for Latino Children Exposed to ACEsMore generally, the literature also documents broad developmental benefits of ECE for Latino children, as well as other immigrant origin children (Votruba-Drzal, Coley, Collins, & Miller, 2015).", [["children", "ORGANISM", 189, 197], ["children", "ORGANISM", 391, 399], ["children", "ORGANISM", 435, 443], ["children", "SPECIES", 189, 197], ["Children", "SPECIES", 274, 282], ["children", "SPECIES", 391, 399], ["children", "SPECIES", 435, 443], ["the original evaluation", "TEST", 94, 117]]], ["Specifically, ECE is a critical context for supporting the language, cognitive and social development, and growth for children who are dual language learners (DLLs; children who are learning two languages; McNamara, 2016).", [["children", "ORGANISM", 118, 126], ["children", "ORGANISM", 165, 173], ["ECE", "PROTEIN", 14, 17], ["children", "SPECIES", 118, 126], ["children", "SPECIES", 165, 173]]], ["Evidence shows that when DLL students receive culturally relevant, high-quality instruction in English and Spanish and appropriate assessment of their emerging language abilities in both languages, early learning outcomes are optimized, and children can reap the benefits of being multi-lingual (Espinosa & Garcia, 2012; Goldenberg, Nemeth, Hicks, Zepeda & Cardona, 2013; National Academies of Science, Engineering & Medicine, 2017).", [["children", "ORGANISM", 241, 249], ["children", "SPECIES", 241, 249]]], ["For other developmental outcomes, evaluations of ECE center-based programs such as Head Start show greater than expected, positive impacts, from Latino and Spanish-speaking children\u2019s participation in ECE (Bitler et al., 2014; Crosnoe, 2007; Magnuson, Lahaie & Waldfogel, 2006).", [["children", "ORGANISM", 173, 181], ["children", "SPECIES", 173, 181], ["evaluations", "TEST", 34, 45], ["ECE center", "TEST", 49, 59], ["Head", "ANATOMY", 83, 87]]], ["A longitudinal study of children birth to five enrolled in Educare programs found that dual language learner children showed greater gains in receptive vocabulary relative to English speakers, and that effects for children entering the program at earlier ages were stronger, although children entering for only a year or two made rapid gains, suggesting that early entry in ECE has benefits for dual language learners (Yazejiana, Bryant, Freel, Burchinal, and the Educare Learning Network (ELN) Investigative Team, 2015).", [["children", "ORGANISM", 24, 32], ["children", "ORGANISM", 109, 117], ["children", "ORGANISM", 214, 222], ["children", "ORGANISM", 284, 292], ["children", "SPECIES", 24, 32], ["children", "SPECIES", 109, 117], ["children", "SPECIES", 214, 222], ["children", "SPECIES", 284, 292], ["A longitudinal study", "TEST", 0, 20]]], ["In terms of school readiness skills for immigrant children, research found use of subsidized center-based care was linked to children\u2019s early reading skills, possibly due to exposure to print materials and language stimulation in classrooms (Johnson, Ruhm, Wen-Jui, & Waldfogel, 2014).", [["children", "ORGANISM", 50, 58], ["children", "ORGANISM", 125, 133], ["children", "SPECIES", 50, 58], ["children", "SPECIES", 125, 133]]], ["Lastly, research found long-term associations showing Latino children enrolled in public school pre-K scored higher on standardized tests of math and literacy during third grade than children in subsidized center-based care (although Head Start centers were excluded from this research), after controlling for baseline characteristics and preschool entry skills (Ansari, L\u03ccpez, Manfra, Bleiker, Dinehart, Hartman et al., 2017).Benefits of ECE for Latino Children Exposed to ACEsFinally, we have examples of improvement in culturally congruent service delivery across ECE programs serving young Latino children and their families.", [["children", "ORGANISM", 61, 69], ["children", "ORGANISM", 183, 191], ["children", "ORGANISM", 601, 609], ["children", "SPECIES", 61, 69], ["children", "SPECIES", 183, 191], ["Children", "SPECIES", 454, 462], ["children", "SPECIES", 601, 609], ["long-term", "OBSERVATION_MODIFIER", 23, 32]]], ["Research has shown that when cultural adaptations are made to existing preventive interventions for Latino families, outcomes are generally positive (Beasley, Silovsky, Espeleta, Robinson, Hartwig, Morris et al., 2017; Griner & Smith, 2006; Mendez & Westerberg, 2012).", [["preventive interventions", "TREATMENT", 71, 95]]], ["For example, a study of the Legacy for Children\u2122 parenting program, which previously showed evidence of effectiveness with English-speaking Latino families, also found that Spanish-speaking parents were able to participate after translation of intervention content and cultural adaptations (e.g., adding recordings of traditional, familiar songs, using Spanish-speaking, Latino recruiters) were made (Beasley et al., 2017).", [["parents", "ORGANISM", 190, 197], ["a study", "TEST", 13, 20], ["intervention content", "TREATMENT", 244, 264]]], ["In an embedded parenting intervention within Head Start programs, cultural adaptations to The Companion Curriculum, including providing bilingual facilitators, Spanish-translations, opportunities for practicing English conversation skills, and holding sessions multiple nights a week, was effective in facilitating participation by Spanish-speaking parents with low levels of acculturation to the USA (Mendez & Westerberg, 2012).", [["an embedded parenting intervention", "TREATMENT", 3, 37]]], ["These studies show the continued importance of incorporating culture and language adaptations into ECE programs that work with parents, especially to maximize the impact of their interventions.Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesGiven the benefits of ECE as a protective experience, what do we know about Latino children and how their participation in ECE is changing over time?", [["children", "ORGANISM", 363, 371], ["Children", "SPECIES", 259, 267], ["children", "SPECIES", 363, 371], ["These studies", "TEST", 0, 13], ["incorporating culture", "TEST", 47, 68], ["their interventions", "TREATMENT", 173, 192]]], ["Throughout this review, and across the field, we are using the term ECE to encompass a wide array of non-parental child care options and programs, which may occur across different settings (home or center) as well as for variable number of hours, often while parents work (Crosnoe, 2007; Gennetian, Datta, Goerge, Zanoni, Brandon, Witte, & Krishnamurty, 2019).", [["non-parental child care options", "TREATMENT", 101, 132]]], ["For Latino children, long-held beliefs that their families were not interested in using non-parental care for their children are likely less true today, as alternative explanations in the data are coming to light (Ackert, Ressler, Ansari, & Crosnoe, 2018; Mendez et al., 2018).", [["children", "ORGANISM", 11, 19], ["children", "ORGANISM", 116, 124], ["children", "SPECIES", 11, 19], ["children", "SPECIES", 116, 124]]], ["With the inclusion of larger numbers of low-income Latino children in nationally representative data sets (e.g., National Study for Early Care and Education; NSECE, 2012), we are now able to look at within group variation in families\u2019 use of ECE and how it serves to support children\u2019s overall development.", [["children", "ORGANISM", 58, 66], ["children", "ORGANISM", 275, 283], ["children", "SPECIES", 58, 66], ["children", "SPECIES", 275, 283], ["larger", "OBSERVATION_MODIFIER", 22, 28], ["numbers", "OBSERVATION_MODIFIER", 29, 36], ["low", "OBSERVATION_MODIFIER", 40, 43]]], ["The findings suggest that gaps in ECE participation by Latino families are closing relative to White and Black peers (Crosby, Mendez, Guzman, & Lopez, 2016) with about 53% of Latino families using non-parental care for their preschool child.", [["child", "ORGANISM", 235, 240], ["child", "SPECIES", 235, 240], ["gaps", "OBSERVATION_MODIFIER", 26, 30]]], ["In 2016\u20132017, 38% of children enrolled in Head Start were Latino, with 35% percent of children enrolled in Early Head Start from a Latino background (Child Trends Databank, 2018).Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesFamilies in the USA endorse their top reason for using non-parental child care is to support their desire to work (Gennetian et al., 2019), and this is also true for low-income Latino households.", [["children", "ORGANISM", 21, 29], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 21, 29], ["children", "SPECIES", 86, 94], ["Children", "SPECIES", 245, 253], ["Head", "ANATOMY", 42, 46], ["Head", "ANATOMY", 113, 117]]], ["Examining the search process revealed another layer in inequity for low-income Latino households.", [["the search process", "TEST", 10, 28], ["layer", "OBSERVATION_MODIFIER", 46, 51]]], ["Using these same NSECE (2012) data, researchers found that low-income Latino parents reported conducting significantly fewer numbers of searches during the prior 24 months and considered fewer providers (Mendez & Crosby, 2018).Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesUnfortunately, studies continue to document a lack of equity for Latinos across diverse ECE programs (Harding & Paulsell, 2018).", [["Children", "SPECIES", 293, 301]]], ["While Latino children are 35% of the CCDF-eligible population, just 20% of those receiving CCDF benefits are Latino (U.S. GAO, 2016).", [["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21]]], ["In an analysis of Head Start participation, Latino children fare slightly better and with 38% participation rate compared with 54% of African American children and 43% of all eligible low-income children (Schmit & Walker, 2016).", [["children", "ORGANISM", 51, 59], ["children", "ORGANISM", 151, 159], ["children", "ORGANISM", 195, 203], ["children", "SPECIES", 51, 59], ["children", "SPECIES", 151, 159], ["children", "SPECIES", 195, 203], ["Head", "ANATOMY", 18, 22]]], ["This same report conducted a state level analysis and showed that 6 of the 10 states (SC, GA, NC, TN, FL, AL) with the lowest success in serving Latino children in Head Start were in the Southern USA (Schmit & Walker, 2016).", [["children", "ORGANISM", 152, 160], ["children", "SPECIES", 152, 160], ["a state level analysis", "TEST", 27, 49], ["GA", "TEST", 90, 92], ["NC", "TEST", 94, 96], ["Head", "ANATOMY", 164, 168]]], ["In a study of the 13 states serving the highest numbers of low-income Latino children, researchers found a number of administrative burden requirements, such as required documentation or English-only applications, that likely served as barriers to applying for and becoming eligible for CCDF subsidies for child care (Hill, Gennetian, & Mendez, 2019).Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesEven accounting for all possible ECE arrangements, including family, friend and neighbor care, and center care arrangements, disparities for Latinos persist.", [["children", "ORGANISM", 77, 85], ["children", "SPECIES", 77, 85], ["Children", "SPECIES", 417, 425], ["a study", "TEST", 3, 10], ["administrative burden requirements", "TREATMENT", 117, 151]]], ["In a national study using 2012 data from the NSECE (2012), comparisons showed that gaps between utilization rates for low-income white (56%) and Latino preschool age children (53%) are narrowing (Crosby et al., 2016).", [["children", "ORGANISM", 166, 174], ["children", "SPECIES", 166, 174], ["a national study", "TEST", 3, 19], ["utilization rates", "TEST", 96, 113], ["narrowing", "PROBLEM", 185, 194], ["narrowing", "OBSERVATION", 185, 194]]], ["However, there remain wide gaps in enrollment for infants and toddlers by race/ethnicity.", [["infants", "ORGANISM", 50, 57], ["infants", "SPECIES", 50, 57], ["wide gaps", "PROBLEM", 22, 31], ["wide", "OBSERVATION_MODIFIER", 22, 26], ["gaps", "OBSERVATION", 27, 31]]], ["Use of ECE centers is around 15\u201318% for low-income Latino and white infants and toddlers, compared with 26% for low-income African American infants and toddlers (Crosby et al., 2016).", [["infants", "ORGANISM", 68, 75], ["infants", "ORGANISM", 140, 147], ["infants", "SPECIES", 68, 75], ["infants", "SPECIES", 140, 147], ["ECE centers", "TEST", 7, 18]]], ["This gap is critically important to better examine, as center-based care tends to be of a higher quality and more impactful for developmental and learning outcomes for low-income children than other care (Zaslow, Crosby & Smith, 2013).", [["children", "ORGANISM", 179, 187], ["children", "SPECIES", 179, 187]]], ["More research is also needed regarding the impact of home and neighbor care, given that these arrangements are used with greater frequency for infants and toddlers (Crosby et al., 2016).Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesThe child care accommodation model offers an explanation (Hill et al., 2019; Weber, 2011) of how parental access to care requires a series of decisions and tradeoffs for the family to consider in locating and using a child care arrangement.", [["infants", "ORGANISM", 143, 150], ["infants", "SPECIES", 143, 150], ["Children", "SPECIES", 252, 260], ["a child care arrangement", "TREATMENT", 488, 512]]], ["For example, even though 90% of children under 10 are US born (Murphey et al., 2014), the climate surrounding families who are immigrants to this country may have a negative impact on families seeking resources from government sources of assistance (Bernstein, et al., 2019; Vesely, Ewaida, & Kearney, 2013).Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesCharacteristics of low-income Latino households and work reveal how child care may not be meeting the needs of families.", [["children", "ORGANISM", 32, 40], ["children", "SPECIES", 32, 40], ["Children", "SPECIES", 374, 382]]], ["This means that although children have access to multiple caregivers, juggling work schedules and child care arrangements can be challenging.", [["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33], ["juggling work schedules", "TREATMENT", 70, 93], ["child care arrangements", "TREATMENT", 98, 121]]], ["In addition, Latino employment tends to occur during non-standard working house (outside of M-F 9\u20135) at higher rates than other low-income populations (Crosby & Mendez, 2017), with a national study finding that over 3/4 of low-income Latino children with a working parent have a least one parent working non-standard hours (Crosby & Mendez, 2017).", [["children", "ORGANISM", 241, 249], ["children", "SPECIES", 241, 249], ["a national study", "TEST", 181, 197]]], ["Lastly, somewhat counter to prior observations about who cares for young children, Latino families report lower availability of a relative to provide care for a child than their White and African American peers (Guzman, Hickman, Turner, & Gennetian, 2016).", [["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["Hickman", "ANATOMY", 220, 227]]], ["A barrier for entry into ECE programs or obtaining quality child care is that families who need care may be unsuccessfully searching for providers or programs that also accommodate non-standard work schedules.Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesFinally, instability and stress associated with work among low-income families, including Latino families, provide a stressor on the family and complicates locating child care that is available and affordable.", [["Children", "SPECIES", 275, 283], ["A barrier for entry into ECE programs", "TREATMENT", 0, 37]]], ["One study found that roughly half of low-income Latino working parents receive short advance notice of work hours (i.e., 1 week or less), with higher rates reported by immigrant households (Crosby & Mendez, 2017).", [["One study", "TEST", 0, 9]]], ["This type of scheduling likely makes planning for and maintaining care arrangements difficult, especially with providers that offer less flexible care and payment options.", [["less flexible care", "TREATMENT", 132, 150], ["payment options", "TREATMENT", 155, 170]]], ["Work-related risk also creates challenges to provide nurturing environments, when adults who were exposed to ACEs now struggle with their own wellbeing (Andrews et al., 2019).Barriers and Facilitators of ECE Utilization by Low-Income Latino Children and FamiliesIn sum, barriers for low-income Latino families to access care include lack of awareness, lack of affordable options, or inability of providers/programs to support work schedules of Latino families.", [["Children", "SPECIES", 241, 249]]], ["Given the high prevalence of non-standard work hours, and instability in work schedules, these factors will complicate parents securing arrangements for their children.", [["children", "ORGANISM", 159, 167], ["children", "SPECIES", 159, 167], ["instability in work schedules", "PROBLEM", 58, 87]]], ["Currently, low percentages of infants and toddlers are enrolled in center-based care, which would provide low-income Latino children with greater access to screenings and services that are effective in promoting positive parenting and child well-being (Berlin et al., 2018).Family and Parenting Assets to Offset Risk ::: Looking Forward: Including Latino Family and Community Assets Within ECE SettingsAttitudes about education and importance of respect and deference to educators have been examined as assets within Latino families.", [["infants", "ORGANISM", 30, 37], ["children", "ORGANISM", 124, 132], ["infants", "SPECIES", 30, 37], ["children", "SPECIES", 124, 132], ["low", "OBSERVATION_MODIFIER", 11, 14], ["percentages", "OBSERVATION_MODIFIER", 15, 26]]], ["For example, Fuller and Garcia Coll (2010) review cultural values for Latino families that have been included in empirical studies such as bien educado (Reese, Balzano, Gallimore, & Goldberg, 1995), the idea of raising a child with good manners, and respeto, which emphasizes obedience and children should not argue with adults (Calzada, Fernandez, & Cortes, 2010).", [["children", "ORGANISM", 290, 298], ["children", "SPECIES", 290, 298], ["cultural values", "TEST", 50, 65]]], ["Their paper argues that Latino parental control derives from attributions made about the importance of instructing the child in appropriate and inappropriate ways of interacting with other children and adults, in support of cultural values such as familism and respeto (Halgunseth, Ispa, & Rudy, 2006).Family and Parenting Assets to Offset Risk ::: Looking Forward: Including Latino Family and Community Assets Within ECE SettingsOther examples of parental knowledge and intentional behavior include simultaneous language development of bilingual children (Hammer et al., 2007), high levels of children\u2019s social competence at kindergarten entry (Galindo & Fuller, 2010), and unique, child-focused sociocultural patterns of family engagement during early childhood (McWayne, Melzi, Limlingan, & Schick, 2016).", [["children", "ORGANISM", 189, 197], ["children", "ORGANISM", 547, 555], ["children", "ORGANISM", 594, 602], ["children", "SPECIES", 189, 197], ["children", "SPECIES", 547, 555], ["children", "SPECIES", 594, 602], ["cultural values", "TEST", 224, 239]]], ["Consistent with the beliefs about the value of education among Latinos, a study using the ECLS-K by Crosnoe & Kalil (2010) found that Mexican immigrant mothers who were involved in their own schooling showed increased engagement with their children over a 4-year period, suggesting that changes in educational attainment, regardless of degree attainment, impact child development.", [["mothers", "ORGANISM", 152, 159], ["children", "ORGANISM", 240, 248], ["children", "SPECIES", 240, 248], ["a study", "TEST", 72, 79], ["the ECLS", "TEST", 86, 94]]], ["This work is consistent with researchers who have concluded the value of two-generation (e.g., child and family) early intervention model for working with Latino families, due to the interconnected nature of family members and the need for increased education and learning opportunities for both parents and children (Crosnoe & Kalil, 2010; Mendez & Westerberg, 2012).Community Level Factors that Impact Latino Parenting ::: Looking Forward: Including Latino Family and Community Assets Within ECE SettingsThe economic choices facing a family create both assets or reduced risk, as for example, work showing that low-income Latinos reside in higher income neighborhoods, perhaps as a strategy for reducing ACEs associated with residing in poor neighborhoods (Fuller & Garcia Coll, 2010).", [["ACEs", "DISEASE", 706, 710], ["children", "ORGANISM", 308, 316], ["children", "SPECIES", 308, 316], ["consistent with", "UNCERTAINTY", 13, 28]]], ["In contrast, negative community experiences and attitudes toward immigrants may lead parents to become more isolated and less trusting toward systems seeking to offer resources for Latino children, including government assistance (Vesely et al., 2013).", [["children", "ORGANISM", 188, 196], ["children", "SPECIES", 188, 196]]], ["This also increases pressure on ECE providers to reach the most vulnerable families within communities (Matthews, Ulrich, & Cervantes, 2018).", [["ECE providers", "TREATMENT", 32, 45], ["increases", "OBSERVATION_MODIFIER", 10, 19], ["pressure", "OBSERVATION_MODIFIER", 20, 28]]], ["Studies of interventions designed to reach immigrant Latino families found that increasing communication between ECE providers in Head Start centers and parents led to higher parental involvement and home, school, and in parent-teacher conferences (Mendez, Westerberg & Thibeault, 2013); however, efforts to encourage parents to enroll in language classes at a local community college failed due to lack of trust of outsiders (Mendez & Westerberg, 2012).", [["interventions", "TREATMENT", 11, 24]]], ["Examining community density of child care center and Latinos, researchers found that as the density of both supply in a county increased, so did enrollment, and that increased Latino density mattered after controlling for supply, suggesting that social networks in ethnic enclaves for Latinos is an important strategy for building connections to programs (Ackert, et al., 2018).Community Level Factors that Impact Latino Parenting ::: Looking Forward: Including Latino Family and Community Assets Within ECE SettingsIn sum, while research has been accelerating toward a deeper understanding of ECE environments as protective experiences for Latino children, more work remains.", [["children", "ORGANISM", 648, 656], ["children", "SPECIES", 648, 656], ["increased Latino density", "PROBLEM", 166, 190], ["increased", "OBSERVATION_MODIFIER", 166, 175], ["Latino", "OBSERVATION_MODIFIER", 176, 182], ["density", "OBSERVATION", 183, 190]]], ["For researchers, it is a now a question of intentional inclusion of promoting influences or protective factors in studies, so we can better understand constructs like social ties among Latino communities (Ackert et al., 2018), parenting strengths including attitudes and practices (Calzada et al., 2010; Crosnoe & Khalil, 2010), and relationships between families and ECE providers (Mendez & Westerberg, 2012) that offer important assets to children as they enter ECE programs.", [["children", "ORGANISM", 441, 449], ["children", "SPECIES", 441, 449]]], ["The design of our longitudinal and national data collection efforts must better reflect the diverse characteristics of this heterogeneous population of children and their families (Guzman, Ramos-Olazagasti, Miller, Padilla, Ryberg, & Vega, 2018).", [["children", "ORGANISM", 152, 160], ["children", "SPECIES", 152, 160], ["our longitudinal and national data collection efforts", "PROBLEM", 14, 67], ["heterogeneous", "OBSERVATION_MODIFIER", 124, 137]]], ["For those studying trauma and ACEs among low-income children, increasing familiarity with the Latino community and factors driving ECE utilization, economic uncertainty, and family instability will be important areas for integration within research studies.", [["trauma", "DISEASE", 19, 25], ["ACEs", "DISEASE", 30, 34], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["trauma", "PROBLEM", 19, 25], ["research studies", "TEST", 240, 256]]], ["Finally, preventative interventions and treatments that can be offered through ECE settings (Berlin et al., 2018) or through partnerships with health care delivery systems should be investigated, as Latinos continue to experience incidents of trauma, ongoing discrimination, and other poverty-associated risks (Andrews et al. 2019; Ramos-Olazagasti et al., 2017).Implications for Enhancing Early Childhood Practice and Policy for Latino ChildrenThis paper concludes with a set of priorities for the field to consider for enhancing early childhood practice and policy for Latino children.", [["trauma", "DISEASE", 243, 249], ["children", "ORGANISM", 578, 586], ["children", "SPECIES", 578, 586], ["preventative interventions", "TREATMENT", 9, 35], ["treatments", "TREATMENT", 40, 50], ["health care delivery systems", "TREATMENT", 143, 171], ["trauma", "PROBLEM", 243, 249]]], ["These are particularly timely to consider, given that the USA is experiencing an unprecedented threat to the child care sector associated with tremendous job loss and closures of programs during the Covid-19 pandemic (Zero to Three, 2020).", [["tremendous job loss", "PROBLEM", 143, 162], ["closures of programs", "TREATMENT", 167, 187], ["the Covid", "TEST", 195, 204], ["tremendous", "OBSERVATION_MODIFIER", 143, 153], ["job loss", "OBSERVATION", 154, 162]]], ["There is also emerging evidence that Latino families are currently experiencing significant unsafe work risks (Genettian & Johnson, 2020), making the future engagement with ECE programs even more critical to buffer children from the poverty-associated stressors in their homes and neighborhoods, as well as to detect ACEs and offer services for parents.", [["children", "ORGANISM", 215, 223], ["children", "SPECIES", 215, 223], ["ECE programs", "TREATMENT", 173, 185]]], ["The ECE workforce must be prepared to work more effectively with diverse groups of families, particularly Latino immigrants with high levels of ACEs exposure.", [["ACEs", "CHEMICAL", 144, 148], ["ACEs", "GENE_OR_GENE_PRODUCT", 144, 148], ["ACEs exposure", "TREATMENT", 144, 157]]], ["Improving the quality of ECE for young children can occur, for example, through implementation of evidence-based parenting programs, home visitation, and the provision of access to specialists who assist families with children\u2019s health, educational, and developmental needs.", [["children", "ORGANISM", 39, 47], ["children", "ORGANISM", 218, 226], ["children", "SPECIES", 39, 47], ["children", "SPECIES", 218, 226]]], ["Training in approaches for culturally relevant teaching methods for working with dual language learners and their families (McNamara, 2016) will increase children\u2019s\u2019 ability to community and express their feelings.", [["children", "ORGANISM", 154, 162], ["children", "SPECIES", 154, 162]]], ["Also, expanding access to information and trainings on ACEs, better recognition of the stressors associated with living in an immigrant community, and use of principles of trauma-informed care will help with teacher preparation and readiness to serve vulnerable families well.", [["trauma", "DISEASE", 172, 178], ["ACEs", "TREATMENT", 55, 59], ["trauma", "PROBLEM", 172, 178]]], ["This should occur at the teacher preparation level and as on-going professional development for teachers and within the quality improvement process for ECE programs.Routinely Identify ACEs within ECE Settings to Inform Service Delivery.", [["ECE programs", "TREATMENT", 152, 164], ["Delivery", "TREATMENT", 227, 235]]], ["Through ECE developmental screenings, community partnerships with mental health providers, and mechanisms for building safety and trust networks, particularly in communities with recently arriving immigrants in new destination communities, ECE is poised to make an impact on reducing the impact of ACEs and other stressors for Latino children and families.", [["ACEs", "DISEASE", 298, 302], ["children", "ORGANISM", 334, 342], ["children", "SPECIES", 334, 342]]], ["The timing of these interventions matter (Masten & Barnes, 2018), as early identification and intervention can offset future, and worsening, outcomes (Morris et al., 2018; Shonkoff et al., 2012).", [["intervention", "TREATMENT", 94, 106], ["worsening", "OBSERVATION_MODIFIER", 130, 139]]], ["Training for providers in trauma-informed approaches to care, including recognition of emotional and behavioral signs of distress among Latino children, is needed (Bartlett & Ramos-Olazagasti, 2018; Bartlett, Smith, Bringewatt, 2017).", [["trauma", "DISEASE", 26, 32], ["children", "ORGANISM", 143, 151], ["children", "SPECIES", 143, 151], ["distress", "PROBLEM", 121, 129]]], ["Inclusion of evidence-based attachment interventions in ECE settings serving Latino families is supported to improve maternal supportiveness and increase children\u2019s secure attachments with caregivers (Berlin et al., 2018).", [["children", "ORGANISM", 154, 162], ["children", "SPECIES", 154, 162], ["based attachment interventions", "TREATMENT", 22, 52], ["attachment", "OBSERVATION_MODIFIER", 28, 38]]], ["We need greater attention to these issues among our researchers studying ACEs among Latino samples, particularly those with ongoing longitudinal studies, as well as national data to inform rates of ACEs and association poverty-related traumatic events.", [["ACEs", "DISEASE", 198, 202], ["Latino samples", "TEST", 84, 98], ["ongoing longitudinal studies", "TEST", 124, 152], ["traumatic events", "PROBLEM", 235, 251]]], ["This will allow a more complete picture of the needs and assets to emerge, in order to understand what is working to offset the risk of ACEs and other trauma experienced in early childhood.Build Community and Provider Networks to Better Serve Latino Families.", [["ACEs", "DISEASE", 136, 140], ["trauma", "DISEASE", 151, 157], ["other trauma", "PROBLEM", 145, 157]]], ["ECE providers/agencies are in a good position to provide outreach and support for low-income Latino family members and/or children are experiencing stress or trauma, with appropriate training (Matthews, et al., 2018).", [["trauma", "DISEASE", 158, 164], ["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["trauma", "PROBLEM", 158, 164]]], ["The density of Latinos in a community has been associated with greater use of ECE, after controlling for supply, and so building social ties among members of a Latino community may increase utilization (Ackert et al., 2018).", [["density", "OBSERVATION_MODIFIER", 4, 11]]], ["However, Latino parents may need greater assistance in locating ECE programs and understanding benefits they may provide to children, given the lower rates of searches by Latino households relative to other low-income groups (Mendez & Crosby, 2018).", [["children", "ORGANISM", 124, 132], ["children", "SPECIES", 124, 132]]], ["Lieberman et al. (2011) note that most traumatized children are not found in mental health clinics; rather, they are more routinely seen in child care and health care settings.", [["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59]]], ["Thus, community partnerships that connect ECE with other sectors serving vulnerable children, including housing, pediatrics, child welfare, and non-profits addressing domestic violence and homelessness, are also needed to create community resilience and offset the toxic stress that comes from high exposure to ACEs (Ellis & Dietz, 2017).Increase Access to Affordable and Available ECE for Latino parents.", [["domestic violence", "DISEASE", 167, 184], ["homelessness", "DISEASE", 189, 201], ["ACEs", "DISEASE", 311, 315], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["the toxic stress", "PROBLEM", 261, 277], ["toxic stress", "OBSERVATION_MODIFIER", 265, 277]]], ["Significant gaps exist in the ability of ECE, particularly center-based programs, to reach and meet the need for ECE among Latino families (Mendez, 2018).", [["Significant gaps", "PROBLEM", 0, 16], ["gaps", "OBSERVATION", 12, 16]]], ["No-cost federal programs for low-income children including Head Start and Early Head Start do not have the capacity to serve all eligible Latino children.", [["children", "ORGANISM", 40, 48], ["children", "ORGANISM", 145, 153], ["children", "SPECIES", 40, 48], ["children", "SPECIES", 145, 153], ["Head", "ANATOMY", 59, 63]]], ["Enrollments of Latino children are 38% participation rate compared with 54% of African American children and 43% of all eligible low-income children, and enrollment in the South is low relative to the increases of the population in this region (Schmit & Walker, 2016).", [["children", "ORGANISM", 22, 30], ["children", "ORGANISM", 96, 104], ["children", "ORGANISM", 140, 148], ["children", "SPECIES", 22, 30], ["children", "SPECIES", 96, 104], ["children", "SPECIES", 140, 148], ["increases", "OBSERVATION_MODIFIER", 201, 210]]], ["The cost of child care is a top concern among this population, as well as other low-income groups, with a recent analysis showing 4 out of 10 low-income Latinos reporting child care costs that exceed government-recommended guidelines of 7% of the total household budget (Crosby, Mendez & Barnes, 2019).", [["a recent analysis", "TEST", 104, 121]]], ["Continued public investments in ECE that increase supply and lower the cost of care for low-income Latino families are also needed.ConclusionThis paper offers a roadmap for future work investigating the assets and risk facing low-income Latino children in the USA.", [["children", "ORGANISM", 244, 252], ["children", "SPECIES", 244, 252]]], ["As we face a new economic downturn associated with the onset of the Covid-19 pandemic, our most vulnerable families will require sustained and careful monitoring to ensure that children are protected.", [["children", "ORGANISM", 177, 185], ["children", "SPECIES", 177, 185], ["the Covid", "TEST", 64, 73], ["careful monitoring", "TEST", 143, 161], ["new", "OBSERVATION_MODIFIER", 13, 16]]], ["Also, without a resurgence of investment in child care, workers will be unable to secure positions that allow them to provide economic support for their families.", [["economic support", "TREATMENT", 126, 142]]], ["High levels of stress and exposure to violence, as well as continued bias and discrimination against Latino populations and other immigrant groups, will constitute some of the most formidable adverse childhood experiences for our young and vulnerable children.", [["violence", "DISEASE", 38, 46], ["children", "ORGANISM", 251, 259], ["children", "SPECIES", 251, 259]]], ["Providing robust, affordable, and inclusive early care and education opportunities, with the additional supports and services for addressing trauma, are essential investments we can and must take as we look toward building resilience.", [["trauma", "DISEASE", 141, 147], ["trauma", "PROBLEM", 141, 147]]]], "8f6b7f7481a2416fb09f1b0f6a4fec9206d9a90b": [["2019-nCoV makes use of a densely glycosylated, homotrimeric class I fusion spike (S) 23protein to gain entry into host cells.", [["cells", "ANATOMY", 119, 124], ["homotrimeric class I fusion spike (S) 23protein", "GENE_OR_GENE_PRODUCT", 47, 94], ["cells", "CELL", 119, 124], ["nCoV", "DNA", 5, 9], ["homotrimeric class I fusion spike (S) 23protein", "PROTEIN", 47, 94], ["host cells", "CELL_TYPE", 114, 124], ["a densely glycosylated", "TREATMENT", 23, 45], ["host cells", "OBSERVATION", 114, 124]]], ["The S protein exists in a metastable prefusion conformation 24 that undergoes a dramatic structural rearrangement to fuse the viral membrane with the host cell 25 membrane (7, 8) .", [["membrane", "ANATOMY", 132, 140], ["cell 25 membrane", "ANATOMY", 155, 171], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["cell 25 membrane", "CELLULAR_COMPONENT", 155, 171], ["S protein", "PROTEIN", 4, 13], ["metastable prefusion conformation 24", "PROTEIN", 26, 62], ["The S protein", "TEST", 0, 13], ["a metastable prefusion conformation", "PROBLEM", 24, 59], ["a dramatic structural rearrangement", "PROBLEM", 78, 113], ["metastable", "OBSERVATION_MODIFIER", 26, 36], ["prefusion conformation", "OBSERVATION", 37, 59], ["dramatic", "OBSERVATION_MODIFIER", 80, 88], ["structural rearrangement", "OBSERVATION", 89, 113], ["viral membrane", "OBSERVATION", 126, 140], ["host cell", "OBSERVATION", 150, 159], ["25 membrane", "OBSERVATION_MODIFIER", 160, 171]]], ["This process is triggered by binding of the S1 subunit to a host-cell receptor, 26 which destabilizes the prefusion trimer, resulting in shedding of the S1 subunit and transition of 27 the S2 subunit to a highly stable postfusion conformation (9) .", [["cell", "ANATOMY", 65, 69], ["S1 subunit", "PROTEIN", 44, 54], ["host-cell receptor", "PROTEIN", 60, 78], ["prefusion trimer", "PROTEIN", 106, 122], ["S1 subunit", "PROTEIN", 153, 163], ["S2 subunit", "PROTEIN", 189, 199], ["the prefusion trimer", "PROBLEM", 102, 122], ["prefusion trimer", "OBSERVATION", 106, 122], ["S1", "ANATOMY", 153, 155], ["highly", "OBSERVATION_MODIFIER", 205, 211], ["stable", "OBSERVATION_MODIFIER", 212, 218], ["postfusion", "OBSERVATION", 219, 229]]], ["In order to engage a host-cell 28 receptor, the receptor-binding domain (RBD) of S1 undergoes hinge-like conformational 29 movements that transiently hide or expose the determinants of receptor binding.", [["host-cell 28 receptor", "PROTEIN", 21, 42], ["receptor-binding domain", "PROTEIN", 48, 71], ["RBD", "PROTEIN", 73, 76], ["S1", "PROTEIN", 81, 83], ["hinge", "PROTEIN", 94, 99], ["receptor binding", "PROBLEM", 185, 201]]], ["These two states 30 are referred to as the \"down\" conformation and the \"up\" conformation, where \"down\" 31 corresponds to the receptor-inaccessible state and \"up\" corresponds to the receptor-accessible 32 state, which is thought to be less stable (10) (11) (12) (13) .", [["receptor-inaccessible state", "PROTEIN", 125, 152], ["receptor-accessible 32 state", "PROTEIN", 181, 209], ["thought to be", "UNCERTAINTY", 220, 233], ["less", "OBSERVATION_MODIFIER", 234, 238], ["stable", "OBSERVATION_MODIFIER", 239, 245]]], ["Due to the indispensable function of the S 33 protein it represents a vulnerable target for antibody-mediated neutralization, and 34 characterization of the prefusion S structure would provide atomic-level information to guide 35 vaccine design and development.", [["S 33", "GENE_OR_GENE_PRODUCT", 41, 45], ["S 33 protein", "PROTEIN", 41, 53], ["antibody-mediated neutralization", "TREATMENT", 92, 124], ["the prefusion S structure", "TREATMENT", 153, 178]]], ["36 receptor-binding to exposed RBDs leads to an unstable 3 RBD-up conformation that results in 59 shedding of S1 and refolding of S2 (11, 12) .", [["RBDs", "PATHOLOGICAL_FORMATION", 31, 35], ["RBDs", "PROTEIN", 31, 35], ["RBD", "PROTEIN", 59, 62], ["S1", "PROTEIN", 110, 112], ["S2", "PROTEIN", 130, 132], ["an unstable 3 RBD", "PROBLEM", 45, 62], ["unstable", "OBSERVATION", 48, 56], ["S2", "ANATOMY", 130, 132]]], ["602019-nCoV makes use of a densely glycosylated, homotrimeric class I fusion spike (S) 23Because the S2 subunit appeared to be a symmetric trimer, we performed a 3D 61 refinement imposing C3 symmetry, resulting in a 3.", [["602019-nCoV", "CHEMICAL", 0, 11], ["homotrimeric class I fusion spike (S) 23Because", "PROTEIN", 49, 96], ["S2 subunit", "PROTEIN", 101, 111], ["C3", "PROTEIN", 188, 190], ["a densely glycosylated", "TREATMENT", 25, 47], ["a 3D 61 refinement imposing C3 symmetry", "TREATMENT", 160, 199]]], ["682019-nCoV makes use of a densely glycosylated, homotrimeric class I fusion spike (S) 23The overall structure of 2019-nCoV S resembles that of SARS-CoV S, with a root mean 69 square deviation (RMSD) of 3.8 \u00c5 over 959 C\u03b1 atoms.", [["682019-nCoV", "CHEMICAL", 0, 11], ["SARS", "DISEASE", 144, 148], ["C\u03b1", "CHEMICAL", 218, 220], ["homotrimeric class I fusion spike (S) 23", "PROTEIN", 49, 89], ["2019", "PROTEIN", 114, 118], ["nCoV S", "PROTEIN", 119, 125], ["SARS-CoV", "SPECIES", 144, 152], ["a densely glycosylated", "TREATMENT", 25, 47], ["The overall structure", "TEST", 89, 110], ["SARS", "PROBLEM", 144, 148], ["CoV S", "TEST", 149, 154], ["a root mean", "TEST", 161, 172], ["RMSD", "TEST", 194, 198]]], ["The largest discrepancy between these 70 two structures is a conformational difference between the positions of the RBDs in their 71 respective \"down\" conformations ( Figure 2A) .", [["RBDs", "PROTEIN", 116, 120], ["a conformational difference", "PROBLEM", 59, 86], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["discrepancy", "OBSERVATION_MODIFIER", 12, 23], ["conformational difference", "OBSERVATION", 61, 86]]], ["Whereas the SARS-CoV RBD in the \"down\" 72 conformation packs tightly against the N-terminal domain (NTD) of the neighboring protomer, 73 the 2019-nCoV RBD in the \"down\" conformation is angled closer to the central cavity of the 74 homotrimer.", [["SARS", "DISEASE", 12, 16], ["N-", "CHEMICAL", 81, 83], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 12, 20], ["SARS-CoV RBD", "PROTEIN", 12, 24], ["N-terminal domain", "PROTEIN", 81, 98], ["NTD", "PROTEIN", 100, 103], ["2019-nCoV RBD", "PROTEIN", 141, 154], ["74 homotrimer", "PROTEIN", 228, 241], ["SARS-CoV", "SPECIES", 12, 20], ["the SARS", "PROBLEM", 8, 16], ["CoV RBD", "PROBLEM", 17, 24], ["conformation packs", "TREATMENT", 42, 60], ["the N-terminal domain", "PROBLEM", 77, 98], ["nCoV RBD", "PROBLEM", 146, 154], ["CoV RBD", "OBSERVATION", 17, 24], ["central cavity", "ANATOMY", 206, 220]]], ["Despite this observed conformational difference, when the individual structural 75 domains of 2019-nCoV S are aligned to their counterparts from SARS-CoV S, they reflect the 76 high degree of structural homology between the two proteins, with the NTDs, RBDs, 77 subdomains 1 and 2 (SD1 and SD2) and S2 subunits yielding RMSD values of 2.6 \u00c5, 3.0 \u00c5, 2.7 78 \u00c5 and 2.0 \u00c5, respectively ( Figure 2B) .", [["structural 75 domains", "PROTEIN", 69, 90], ["2019", "PROTEIN", 94, 98], ["nCoV S", "PROTEIN", 99, 105], ["NTDs", "PROTEIN", 247, 251], ["RBDs", "PROTEIN", 253, 257], ["77 subdomains 1 and 2", "PROTEIN", 259, 280], ["SD1", "PROTEIN", 282, 285], ["SD2", "PROTEIN", 290, 293], ["S2 subunits", "PROTEIN", 299, 310], ["RMSD", "PROTEIN", 320, 324], ["SARS-CoV S", "TEST", 145, 155], ["the NTDs", "TEST", 243, 251], ["RBDs", "TEST", 253, 257], ["SD1", "TEST", 282, 285], ["SD2", "TEST", 290, 293], ["S2 subunits", "TEST", 299, 310], ["RMSD values", "TEST", 320, 331]]], ["79 2019-nCoV S shares roughly 96% sequence identity with the S protein from the bat 80 coronavirus RaTG13, with the most notable variation arising from an insertion in the S1/S2 81 protease cleavage site that results in an \"RRAR\" furin recognition site in 2019-nCoV, rather than 82 the single arginine in SARS-CoV (Supplementary Figure 5 ) (19) (20) (21) (22) .", [["arginine", "CHEMICAL", 293, 301], ["arginine", "CHEMICAL", 293, 301], ["bat 80 coronavirus", "ORGANISM", 80, 98], ["RaTG13", "GENE_OR_GENE_PRODUCT", 99, 105], ["furin", "GENE_OR_GENE_PRODUCT", 230, 235], ["arginine", "AMINO_ACID", 293, 301], ["S protein", "PROTEIN", 61, 70], ["coronavirus RaTG13", "PROTEIN", 87, 105], ["S1/S2 81 protease cleavage site", "DNA", 172, 203], ["RRAR", "PROTEIN", 224, 228], ["furin recognition site", "PROTEIN", 230, 252], ["coronavirus", "SPECIES", 87, 98], ["bat 80 coronavirus", "SPECIES", 80, 98], ["SARS-CoV", "SPECIES", 305, 313], ["the S protein", "TEST", 57, 70], ["an insertion", "TREATMENT", 152, 164], ["protease cleavage site", "PROBLEM", 181, 203], ["an \"RRAR\" furin recognition site", "PROBLEM", 220, 252], ["CoV (Supplementary Figure", "TEST", 310, 335], ["S1", "ANATOMY", 172, 174]]], ["A similar phenomenon 83 has been observed for influenza viruses, where amino acid insertions that create a polybasic furin 84 site in a related position in influenza hemagglutinin proteins are often found in highly virulent 85 avian and human influenza viruses (23) .", [["influenza viruses", "DISEASE", 46, 63], ["amino acid", "CHEMICAL", 71, 81], ["influenza viruses", "DISEASE", 243, 260], ["amino acid", "CHEMICAL", 71, 81], ["influenza viruses", "ORGANISM", 46, 63], ["amino acid", "AMINO_ACID", 71, 81], ["furin", "GENE_OR_GENE_PRODUCT", 117, 122], ["influenza hemagglutinin", "ORGANISM", 156, 179], ["85 avian", "ORGANISM", 224, 232], ["human influenza viruses", "ORGANISM", 237, 260], ["polybasic furin 84 site", "PROTEIN", 107, 130], ["influenza hemagglutinin proteins", "PROTEIN", 156, 188], ["avian", "SPECIES", 227, 232], ["human", "SPECIES", 237, 242], ["influenza viruses", "SPECIES", 243, 260], ["human influenza viruses", "SPECIES", 237, 260], ["A similar phenomenon", "PROBLEM", 0, 20], ["influenza viruses", "PROBLEM", 46, 63], ["amino acid insertions", "TREATMENT", 71, 92], ["a polybasic furin 84 site", "PROBLEM", 105, 130], ["influenza hemagglutinin proteins", "PROBLEM", 156, 188], ["human influenza viruses", "PROBLEM", 237, 260], ["influenza viruses", "OBSERVATION", 243, 260]]], ["In addition to this insertion of residues in the S1/S2 86 junction, 29 variant residues exist between 2019-nCoV S and RaTG13 S, with 17 of these 87 positions mapping to the RBD (Supplementary Figures 5 and 6) .", [["RBD", "DISEASE", 173, 176], ["S1", "PROTEIN", 49, 51], ["RBD", "PROTEIN", 173, 176], ["this insertion of residues in the S1/S2 86 junction", "TREATMENT", 15, 66], ["29 variant residues", "PROBLEM", 68, 87], ["residues", "OBSERVATION", 33, 41], ["S1", "ANATOMY", 49, 51], ["S2", "ANATOMY_MODIFIER", 52, 54], ["86 junction", "ANATOMY", 55, 66], ["RBD", "ANATOMY", 173, 176]]], ["We also formed a complex of ACE2 bound to the 2019-nCoV S 98 ectodomain and observed it by negative-stain EM, where it strongly resembled the complex 99 formed between SARS-CoV S and ACE2, which has been observed at high-resolution by cryo-100 EM ( Figure 3B ) (14, 27) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 168, 178], ["ACE2", "GENE_OR_GENE_PRODUCT", 183, 187], ["ACE2", "PROTEIN", 28, 32], ["2019-nCoV S 98 ectodomain", "PROTEIN", 46, 71], ["complex 99", "PROTEIN", 142, 152], ["SARS-CoV S", "PROTEIN", 168, 178], ["ACE2", "PROTEIN", 183, 187], ["SARS-CoV", "SPECIES", 168, 176], ["ACE2 bound", "PROBLEM", 28, 38], ["SARS", "PROBLEM", 168, 172], ["CoV S", "TEST", 173, 178], ["ACE2", "TEST", 183, 187], ["complex", "OBSERVATION_MODIFIER", 17, 24]]], ["The high affinity of 2019-nCoV S for human ACE2 may contribute to 101 the apparent ease with which 2019-nCoV can spread from human-to-human(1), however 102 additional studies are needed to investigate this possibility.", [["human", "ORGANISM", 37, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["nCoV", "GENE_OR_GENE_PRODUCT", 104, 108], ["human", "ORGANISM", 125, 130], ["human", "ORGANISM", 134, 139], ["nCoV S", "PROTEIN", 26, 32], ["human ACE2", "PROTEIN", 37, 47], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 134, 139], ["human ACE2", "TREATMENT", 37, 47], ["additional studies", "TEST", 156, 174]]], ["1032019-nCoV makes use of a densely glycosylated, homotrimeric class I fusion spike (S) 23The overall structural homology and shared receptor usage between SARS-CoV S and 1042019-nCoV S prompted us to test published SARS-CoV RBD-directed monoclonal antibodies 105(mAbs) for cross-reactivity to the 2019-nCoV RBD ( Figure 4A) .", [["1032019-nCoV", "CHEMICAL", 0, 12], ["CoV", "ORGANISM", 221, 224], ["nCoV", "DNA", 8, 12], ["homotrimeric class I fusion spike (S) 23", "PROTEIN", 50, 90], ["SARS-CoV RBD-directed monoclonal antibodies 105", "PROTEIN", 216, 263], ["mAbs", "PROTEIN", 264, 268], ["RBD", "PROTEIN", 308, 311], ["SARS-CoV", "SPECIES", 156, 164], ["SARS-CoV", "SPECIES", 216, 224], ["a densely glycosylated", "TREATMENT", 26, 48], ["CoV S", "TEST", 161, 166], ["SARS", "TEST", 216, 220], ["CoV RBD", "TEST", 221, 228], ["monoclonal antibodies", "TEST", 238, 259], ["cross-reactivity", "TEST", 274, 290]]], ["A 2019-nCoV RBD-SD1 106 fragment (S residues 319-591) was recombinantly expressed, and appropriate folding of this 107 construct was validated by measuring ACE2 binding using biolayer interferometry (BLI) 108 ( Figure 4B ).", [["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["2019-nCoV RBD-SD1 106 fragment", "DNA", 2, 32], ["ACE2", "PROTEIN", 156, 160], ["SD1 106 fragment", "PROBLEM", 16, 32], ["S residues", "TEST", 34, 44], ["biolayer interferometry", "TEST", 175, 198], ["BLI", "TEST", 200, 203], ["fragment", "OBSERVATION_MODIFIER", 24, 32]]], ["Cross-reactivity of the SARS-CoV RBD-directed mAbs S230, m396 and 80R was 109 then evaluated by BLI (12, (28) (29) (30) .", [["SARS", "DISEASE", 24, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 24, 32], ["SARS-CoV RBD-directed mAbs S230", "PROTEIN", 24, 55], ["m396", "PROTEIN", 57, 61], ["80R", "PROTEIN", 66, 69], ["SARS-CoV", "SPECIES", 24, 32], ["the SARS", "TEST", 20, 28], ["CoV RBD", "TEST", 29, 36], ["BLI", "TEST", 96, 99]]], ["Despite the relatively high degree of structural homology suggests that SARS-directed mAbs will not necessarily be cross-reactive and that future antibody 115 isolation and therapeutic design efforts will benefit from using 2019-nCoV S proteins as probes.", [["SARS", "DISEASE", 72, 76], ["SARS-directed mAbs", "PROTEIN", 72, 90], ["2019-nCoV S proteins", "PROTEIN", 224, 244], ["SARS-directed mAbs", "PROBLEM", 72, 90], ["future antibody", "TEST", 139, 154], ["therapeutic design efforts", "TREATMENT", 173, 199], ["2019-nCoV S proteins", "TREATMENT", 224, 244]]], ["1162019-nCoV S prompted us to test published SARS-CoV RBD-directed monoclonal antibodies 105The rapid global spread of 2019-nCoV, prompting the PHEIC declaration by WHO 117 signals the urgent need for coronavirus vaccines and therapeutics.", [["1162019-nCoV", "CHEMICAL", 0, 12], ["CoV", "ORGANISM", 50, 53], ["coronavirus", "ORGANISM", 201, 212], ["SARS-CoV RBD-directed monoclonal antibodies 105", "PROTEIN", 45, 92], ["1162019-nCoV", "SPECIES", 0, 12], ["SARS-CoV", "SPECIES", 45, 53], ["coronavirus", "SPECIES", 201, 212], ["SARS", "TEST", 45, 49], ["CoV RBD", "TEST", 50, 57], ["monoclonal antibodies", "TEST", 67, 88], ["coronavirus vaccines", "TREATMENT", 201, 221], ["therapeutics", "TREATMENT", 226, 238]]], ["Knowing the atomic-level 118 structure of the spike will support precision vaccine design and discovery of antivirals, 119 facilitating medical countermeasure development.", [["the spike", "PROBLEM", 42, 51], ["precision vaccine", "TREATMENT", 65, 82], ["antivirals", "TREATMENT", 107, 117]]], ["120Protein expression and purification 122To express the prefusion S ectodomain, a gene encoding residues 1\u22121208 of 2019-nCoV S 123 Table 1 .", [["prefusion S ectodomain", "GENE_OR_GENE_PRODUCT", 57, 79], ["purification 122To", "PROTEIN", 26, 44], ["prefusion S ectodomain", "PROTEIN", 57, 79], ["Protein expression", "TEST", 3, 21], ["purification", "TEST", 26, 38]]], ["156Cryo-EM data processing 157Motion correction, CTF-estimation and non-templated particle picking were performed in Warp 158 (32) .", [["CTF", "PROTEIN", 49, 52], ["CTF-estimation", "TEST", 49, 63], ["non-templated particle picking", "PROBLEM", 68, 98]]], ["Extracted particles were imported into cryoSPARC v2.12.4 (15) for 2D classification, 3D 159 classification and non-uniform 3D refinement.", [["cryoSPARC", "TEST", 39, 48], ["2D classification", "TEST", 66, 83], ["non-uniform 3D refinement", "TREATMENT", 111, 136], ["particles", "OBSERVATION_MODIFIER", 10, 19]]], ["The C1 RBD \"up\" reconstruction was sharpened 160 in cryoSPARC, and the 3D reconstruction with C3 symmetry was subjected to local B-factor 161 sharpening using LocalDeBlur (33) .", [["C1 RBD", "PROTEIN", 4, 10], ["C3", "PROTEIN", 94, 96], ["reconstruction", "TREATMENT", 16, 30], ["cryoSPARC", "TEST", 52, 61], ["the 3D reconstruction with C3 symmetry", "TREATMENT", 67, 105], ["C1", "ANATOMY", 4, 6], ["RBD", "OBSERVATION", 7, 10]]], ["Some of the data processing and refinement software was 163 curated by SBGrid (37) .", [["refinement software", "TEST", 32, 51]]], ["166Surface plasmon resonance 167His-tagged 2019-nCoV S was immobilized to an NiNTA sensorchip (GE Healthcare) to a level 168 of ~800 response units (RUs) using a Biacore X100 (GE Healthcare) and a running buffer 169 composed of 10 mM HEPES pH 8.0, 150 mM NaCl and 0.05% Tween 20.", [["NaCl", "CHEMICAL", 255, 259], ["NaCl", "CHEMICAL", 255, 259], ["Tween 20", "CHEMICAL", 270, 278], ["nCoV S", "CELL_LINE", 48, 54], ["plasmon resonance", "TEST", 11, 28], ["a Biacore X100 (GE Healthcare", "TREATMENT", 160, 189], ["a running buffer", "TREATMENT", 195, 211], ["HEPES pH", "TEST", 234, 242], ["150 mM NaCl", "TREATMENT", 248, 259]]], ["Serial dilutions of 170 purified and untagged ACE2 were injected ranging in concentration from 250 to 15.6 nM.", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["untagged ACE2", "PROTEIN", 37, 50], ["Serial dilutions", "TEST", 0, 16], ["untagged ACE2", "PROBLEM", 37, 50], ["15.6 nM", "OBSERVATION_MODIFIER", 102, 109]]], ["The 171 resulting data were fit to a 1:1 binding model using Biacore Evaluation Software (GE 172Surface plasmon resonance 167Healthcare).", [["Biacore Evaluation", "TEST", 61, 79]]], ["His-tagged SARS-CoV RBD-SD1 was immobilized to an NiNTA sensorchip to a 173 level of ~350 RUs using a Biacore X100 and the same running buffer listed above.", [["His", "CHEMICAL", 0, 3], ["SARS-CoV", "ORGANISM", 11, 19], ["SARS-CoV RBD", "PROTEIN", 11, 23], ["SD1", "PROTEIN", 24, 27], ["SARS-CoV", "SPECIES", 11, 19], ["tagged SARS", "TEST", 4, 15], ["CoV RBD", "TEST", 16, 23], ["a Biacore", "TEST", 100, 109]]], ["Serial 174 dilutions of purified and untagged ACE2 were injected ranging in concentration from 500 to 31.3 175 nM.", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["untagged ACE2", "PROTEIN", 37, 50], ["Serial 174 dilutions", "TEST", 0, 20], ["untagged ACE2", "PROBLEM", 37, 50]]], ["The resulting data were fit to a 1:1 binding model using Biacore Evaluation Software.", [["Biacore Evaluation", "TEST", 57, 75]]], ["176Negative stain EM 177Purified 2019-nCoV S was diluted to a concentration of 0.032 mg/mL in 2 mM Tris pH 8.0, 200 178 mM NaCl and 0.02% NaN3.", [["EM 177Purified 2019-nCoV S", "CHEMICAL", 18, 44], ["NaCl", "CHEMICAL", 123, 127], ["NaN3", "CHEMICAL", 138, 142], ["NaCl", "CHEMICAL", 123, 127], ["NaN3", "CHEMICAL", 138, 142], ["NaN3", "SIMPLE_CHEMICAL", 138, 142], ["Tris pH", "TEST", 99, 106], ["NaCl", "TEST", 123, 127]]], ["Diluted S protein was mixed with a 1.5-fold molar excess of ACE2 179 and the mixture was incubated on ice for 1 minute before 4.8 uL of the protein mixture was 180 deposited on a CF400-Cu grid (Electron Microscopy Sciences) before being stained with 181 methylamine tungstate (Nanoprobes).", [["ACE2 179", "CHEMICAL", 60, 68], ["CF400-Cu", "CHEMICAL", 179, 187], ["methylamine tungstate", "CHEMICAL", 254, 275], ["Cu", "CHEMICAL", 185, 187], ["methylamine tungstate", "CHEMICAL", 254, 275], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["181 methylamine tungstate", "SIMPLE_CHEMICAL", 250, 275], ["Nanoprobes", "SIMPLE_CHEMICAL", 277, 287], ["Diluted S protein", "PROTEIN", 0, 17], ["Diluted S protein", "TEST", 0, 17], ["a 1.5-fold molar excess of ACE2", "TREATMENT", 33, 64], ["the protein mixture", "TEST", 136, 155], ["181 methylamine tungstate (Nanoprobes", "TREATMENT", 250, 287]]], ["Micrographs were collected manually using TIA 183 v4.14 software at a magnification of x92,000, corresponding to a pixel size of 1.63 \u00c5/pixel.", [["Micrographs", "TEST", 0, 11], ["TIA", "TEST", 42, 45], ["a pixel size", "TEST", 113, 125], ["size", "OBSERVATION_MODIFIER", 121, 125]]], ["CTF 184 estimation, particle picking and 2D class averaging were performed in cisTEM (38) .", [["CTF", "TEST", 0, 3]]], ["185Biolayer interferometry 186Fc-tagged 2019-nCoV RBD-SD1 was immobilized to an anti-human capture (AHC) sensortip 187 (Fort\u00e9Bio) using an Octet RED96e (Fort\u00e9Bio).", [["2019", "PROTEIN", 40, 44], ["RBD", "PROTEIN", 50, 53], ["SD1", "PROTEIN", 54, 57], ["Biolayer interferometry", "TEST", 3, 26], ["an anti-human capture", "TEST", 77, 98], ["sensortip", "TEST", 105, 114]]], ["The sensortip was then dipped into 100 nM 188 ACE2 to measure association before being dipped into a well containing only running buffer 189", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["ACE2", "PROTEIN", 46, 50], ["The sensortip", "TEST", 0, 13], ["ACE2", "TEST", 46, 50]]]], "fe79337d6a31d53ac2c4b9f03e8107c0a08ec159": [["INTRODUCTIONIn early 2020, coronavirus disease 2019 (COVID- 19) , which arises from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has been the world's largest health crisis (1, 2) .", [["coronavirus disease", "DISEASE", 27, 46], ["COVID- 19", "CHEMICAL", 53, 62], ["acute respiratory syndrome coronavirus", "DISEASE", 91, 129], ["SARS-CoV-2) infection", "DISEASE", 133, 154], ["coronavirus", "ORGANISM", 27, 38], ["COVID- 19", "ORGANISM", 53, 62], ["SARS-CoV-2", "ORGANISM", 133, 143], ["CoV-2", "SPECIES", 138, 143], ["coronavirus disease 2019 (COVID- 19", "SPECIES", 27, 62], ["severe acute respiratory syndrome coronavirus", "SPECIES", 84, 129], ["SARS-CoV-2", "SPECIES", 133, 143], ["coronavirus disease", "PROBLEM", 27, 46], ["COVID", "TEST", 53, 58], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 84, 129], ["SARS", "PROBLEM", 133, 137], ["infection", "PROBLEM", 145, 154], ["coronavirus disease", "OBSERVATION", 27, 46], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome", "OBSERVATION", 97, 117], ["infection", "OBSERVATION", 145, 154]]], ["SARS-CoV-2 is rapidly spreading around the world and infected more than 4000,000 people worldwide as of May 16th 2020 (1, 3, 4) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["SARS-CoV", "SPECIES", 0, 8], ["rapidly", "OBSERVATION_MODIFIER", 14, 21], ["spreading", "OBSERVATION_MODIFIER", 22, 31]]], ["According to the coronavirus guidelines, the disease is generally classified into 4 types: mild, moderate, severe, and critical (5) .", [["the disease", "PROBLEM", 41, 52], ["mild, moderate, severe", "PROBLEM", 91, 113], ["disease", "OBSERVATION", 45, 52], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["moderate", "OBSERVATION_MODIFIER", 97, 105], ["severe", "OBSERVATION_MODIFIER", 107, 113]]], ["Zhang reported that mild or moderate patients accounted for more than 80% of patients with COVID-19 (6) .", [["COVID-19", "CHEMICAL", 91, 99], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 91, 96], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["moderate", "OBSERVATION_MODIFIER", 28, 36]]], ["The severe and critical patients usually require more attention due to the poor outcomes, according to previous reports (7) .", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["severe", "OBSERVATION_MODIFIER", 4, 10]]], ["However, the clinical characteristics and prognostic factors of mild-moderate patients have rarely been reported.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["mild-moderate patients", "PROBLEM", 64, 86], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["moderate", "OBSERVATION_MODIFIER", 69, 77]]], ["In addition, these mild or moderate patients should be admitted to the hospital to prevent progression of the disease and should be isolated from susceptible populations to prevent further transmission.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["the disease", "PROBLEM", 106, 117], ["susceptible populations", "PROBLEM", 146, 169], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["moderate", "OBSERVATION_MODIFIER", 27, 35], ["disease", "OBSERVATION", 110, 117]]], ["However, the limited capacity of designated hospitals for infectious disease patients makes the prevention and treatment of COVID-19 challenging.INTRODUCTIONMobile cabin hospitals, generally composed of medical treatment units, ward units, technical support units, and others, are a type of modular health equipment with emergency treatment, surgical treatment, clinical testing, and other functions and are widely used in a variety of emergency treatment scenarios, the military field, and other fields (8) .", [["infectious disease", "DISEASE", 58, 76], ["COVID-19", "CHEMICAL", 124, 132], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["infectious disease", "PROBLEM", 58, 76], ["COVID", "TEST", 124, 129], ["medical treatment units", "TREATMENT", 203, 226], ["technical support units", "TREATMENT", 240, 263], ["emergency treatment", "TREATMENT", 321, 340], ["surgical treatment", "TREATMENT", 342, 360], ["clinical testing", "TEST", 362, 378], ["emergency treatment scenarios", "TREATMENT", 436, 465]]], ["During the past infectious disease epidemics or natural disasters, mobile cabin hospitals have been put in place to cope with the shortage of medical sources (9, 10) .", [["infectious disease", "DISEASE", 16, 34], ["mobile cabin hospitals", "TREATMENT", 67, 89]]], ["In Wuhan, several novel mobile cabin hospitals were transformed from large public facilities such as sports stadium and exhibition center in a very short time, providing thousands of beds to admit and treat mild-to-moderate COVID-19 patients.", [["COVID", "DISEASE", 224, 229], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 233, 241]]], ["If condition worsening occurred, patients were transferred to a nearby designated hospital for critical patients.INTRODUCTIONIn this study, we aimed to describe the clinical characteristics and outcomes of 869 hospitalized mild-moderate patients from Wuchang Mobile Cabin Hospital and compared the clinical findings of patients with COVID-19 stratified according to sex, age, comorbidity, and time of diseases onset.Study Design and ParticipantsThis was a retrospective study.", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 237, 245], ["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 319, 327], ["Participants", "SPECIES", 433, 445], ["condition worsening", "PROBLEM", 3, 22], ["this study", "TEST", 128, 138], ["COVID", "TEST", 333, 338], ["comorbidity", "PROBLEM", 376, 387], ["diseases onset", "PROBLEM", 401, 415], ["a retrospective study", "TEST", 454, 475], ["moderate", "OBSERVATION_MODIFIER", 228, 236]]], ["The study involving human participants was reviewed and approved by the Institutional Ethics Board of Renmin Hospital of Wuhan University.", [["human", "ORGANISM", 20, 25], ["human", "SPECIES", 20, 25], ["participants", "SPECIES", 26, 38], ["human", "SPECIES", 20, 25], ["The study", "TEST", 0, 9]]], ["Written informed consent from the participants' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.", [["participants", "SPECIES", 34, 46], ["this study", "TEST", 110, 120]]], ["During the period of February 6th, 2020 to February 20th, 2020, 869 confirmed hospitalized cases of SARS-CoV2 admitted to Wuchang Mobile Cabin Hospital were enrolled in this study.", [["SARS-CoV2", "DISEASE", 100, 109], ["SARS", "PROBLEM", 100, 104], ["this study", "TEST", 169, 179]]], ["The diagnosis of COVID-19 was made according to the Diagnosis and Treatment of Pneumonia Infected by Novel Coronavirus (5th trial edition) published by the General Office of the National Health Commission and the General Office of the National Administration of Traditional Chinese Medicine (11) .Study Design and ParticipantsAccording to the Diagnosis and Treatment of Pneumonia Infected by Novel Coronavirus (5th trial edition), all of the recruited patients were classified as mild-moderate on admission.", [["Pneumonia", "DISEASE", 79, 88], ["Pneumonia", "DISEASE", 370, 379], ["patients", "ORGANISM", 452, 460], ["patients", "SPECIES", 452, 460], ["COVID", "TEST", 17, 22], ["Pneumonia", "PROBLEM", 79, 88], ["Traditional Chinese Medicine", "TREATMENT", 262, 290], ["Pneumonia", "PROBLEM", 370, 379], ["Novel Coronavirus (5th trial edition", "TREATMENT", 392, 428], ["Pneumonia", "OBSERVATION", 79, 88], ["Pneumonia", "OBSERVATION", 370, 379], ["mild", "OBSERVATION_MODIFIER", 480, 484], ["moderate", "OBSERVATION_MODIFIER", 485, 493]]], ["The detail criterion (11) for clinical classification: Mild: mild signs or symptoms, imaging shows no signs of pneumonia; Moderate: fever, respiratory tract symptoms, imaging shows pneumonia; Severe: satisfy any of the following: (1) respiratory distress, respiratory rate \u226530 beats per minute; (2) SpO 2 \u2264 93% at resting; (3) arterial PaO 2 /FiO 2 \u2264 300 mmHg; Critical: satisfy any of the following: (1) respiratory failure, need mechanical ventilation; (2) shock; (3) combined with other organ failure, requiring intensive care.", [["respiratory tract", "ANATOMY", 139, 156], ["respiratory", "ANATOMY", 234, 245], ["respiratory", "ANATOMY", 256, 267], ["arterial", "ANATOMY", 327, 335], ["respiratory", "ANATOMY", 405, 416], ["organ", "ANATOMY", 490, 495], ["pneumonia", "DISEASE", 111, 120], ["fever", "DISEASE", 132, 137], ["respiratory tract symptoms", "DISEASE", 139, 165], ["pneumonia", "DISEASE", 181, 190], ["respiratory distress", "DISEASE", 234, 254], ["respiratory failure", "DISEASE", 405, 424], ["shock", "DISEASE", 459, 464], ["organ failure", "DISEASE", 490, 503], ["PaO 2", "CHEMICAL", 336, 341], ["tract", "ORGANISM_SUBDIVISION", 151, 156], ["organ", "ORGAN", 490, 495], ["mild signs or symptoms", "PROBLEM", 61, 83], ["imaging", "TEST", 85, 92], ["pneumonia", "PROBLEM", 111, 120], ["fever", "PROBLEM", 132, 137], ["respiratory tract symptoms", "PROBLEM", 139, 165], ["imaging", "TEST", 167, 174], ["pneumonia", "PROBLEM", 181, 190], ["respiratory distress", "PROBLEM", 234, 254], ["respiratory rate", "TEST", 256, 272], ["SpO", "TEST", 299, 302], ["arterial PaO", "TEST", 327, 339], ["FiO", "TEST", 343, 346], ["respiratory failure", "PROBLEM", 405, 424], ["mechanical ventilation", "TREATMENT", 431, 453], ["shock", "PROBLEM", 459, 464], ["other organ failure", "PROBLEM", 484, 503], ["intensive care", "TREATMENT", 515, 529], ["Mild", "OBSERVATION_MODIFIER", 55, 59], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["no signs of", "UNCERTAINTY", 99, 110], ["pneumonia", "OBSERVATION", 111, 120], ["Moderate", "OBSERVATION_MODIFIER", 122, 130], ["fever", "OBSERVATION", 132, 137], ["respiratory tract", "ANATOMY", 139, 156], ["pneumonia", "OBSERVATION", 181, 190], ["respiratory", "ANATOMY", 234, 245], ["distress", "OBSERVATION", 246, 254], ["respiratory", "ANATOMY", 405, 416], ["failure", "OBSERVATION", 417, 424], ["mechanical ventilation", "OBSERVATION", 431, 453], ["organ", "ANATOMY", 490, 495], ["failure", "OBSERVATION", 496, 503]]], ["The onset of disease was defined as the time of the first occurrence of related symptoms.Study Design and ParticipantsThe outcome information of these patients was collected until March 6th, 2020, including remaining in the mobile cabin hospital, discharged, and transferred to the designated hospital for critical patients due to worsening of the patient's condition.", [["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 315, 323], ["patient", "ORGANISM", 348, 355], ["Participants", "SPECIES", 106, 118], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 315, 323], ["patient", "SPECIES", 348, 355], ["disease", "PROBLEM", 13, 20], ["related symptoms", "PROBLEM", 72, 88], ["worsening of the patient's condition", "PROBLEM", 331, 367], ["disease", "OBSERVATION", 13, 20]]], ["The worsening of the condition of patients may have been due to COVID-19 or basic diseases.", [["patients", "ORGANISM", 34, 42], ["COVID-19", "GENE_OR_GENE_PRODUCT", 64, 72], ["patients", "SPECIES", 34, 42], ["COVID", "TEST", 64, 69], ["basic diseases", "PROBLEM", 76, 90], ["worsening", "OBSERVATION_MODIFIER", 4, 13], ["diseases", "OBSERVATION", 82, 90]]], ["To be specific, if patients met any of the following criteria (12), they were quickly transferred to the designated higher-level hospitals: (1) met the criterion of severe or critical; (2) lung imaging showing a greater than 50% progression of lesions within 24-48 h; (3) development of basic disease, such as hypertension, diabetes, coronary artery disease, etc. To compare the outcomes of patients by stratification according to the onset time of diseases, we analyzed information within 15 days of admission.Data CollectionThe clinical data (including basic information, clinical symptoms and signs, history, comorbidities, treatment and outcomes) were obtained by experienced clinicians based on the medical records system of the hospital.", [["lung", "ANATOMY", 189, 193], ["lesions", "ANATOMY", 244, 251], ["coronary artery", "ANATOMY", 334, 349], ["hypertension", "DISEASE", 310, 322], ["diabetes", "DISEASE", 324, 332], ["coronary artery disease", "DISEASE", 334, 357], ["patients", "ORGANISM", 19, 27], ["lung", "ORGAN", 189, 193], ["lesions", "PATHOLOGICAL_FORMATION", 244, 251], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 334, 349], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 391, 399], ["lung imaging", "TEST", 189, 201], ["a greater than 50% progression of lesions", "PROBLEM", 210, 251], ["basic disease", "PROBLEM", 287, 300], ["hypertension", "PROBLEM", 310, 322], ["diabetes", "PROBLEM", 324, 332], ["coronary artery disease", "PROBLEM", 334, 357], ["diseases", "PROBLEM", 449, 457], ["Data Collection", "TEST", 511, 526], ["The clinical data", "TEST", 526, 543], ["clinical symptoms", "PROBLEM", 574, 591], ["comorbidities", "PROBLEM", 612, 625], ["lung", "ANATOMY", 189, 193], ["greater", "OBSERVATION_MODIFIER", 212, 219], ["lesions", "OBSERVATION", 244, 251], ["basic disease", "OBSERVATION", 287, 300], ["hypertension", "OBSERVATION", 310, 322], ["diabetes", "OBSERVATION", 324, 332], ["coronary artery", "ANATOMY", 334, 349], ["disease", "OBSERVATION", 350, 357]]], ["Manifestations on computed tomography (CT) were summarized by integrating the documentation or description in medical charts.Grouping According to Different FactorsSex was classified as male or female.", [["computed tomography (CT", "TEST", 18, 41]]], ["Since 99.7% of patients were less than 70 years, age was classified into three groups according to the population distribution: <45, 45-60, and >60 years.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["Comorbidities were determined based on the patient's selfreport on admission and were initially treated as a categorical variable (yes vs. no).", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["Comorbidities", "PROBLEM", 0, 13]]], ["Patients with unclear onset information were excluded from the onset time cohorts.Statistical AnalysisStatistical analyses were conducted with SPSS software version 22.0 (Chicago, USA) and EmpowerStats software.Statistical AnalysisThe continuous variables are expressed as the median and interquartile range (IQR), and the differences between any two groups were determined by the Mann-Whitney test.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Statistical AnalysisStatistical analyses", "TEST", 82, 122], ["SPSS software version", "TEST", 143, 164], ["Statistical Analysis", "TEST", 211, 231]]], ["The categorical variables are presented as counts (percentages) and were compared with chi-square tests, although Fisher's exact test was used when the data were limited.", [["chi-square tests", "TEST", 87, 103], ["Fisher's exact test", "TEST", 114, 133], ["the data", "TEST", 148, 156]]], ["The Kaplan-Meier test was used to compare the cumulative risk rate.", [["Meier test", "TEST", 11, 21]]], ["Cox proportional hazard regression models and landmark analysis were applied to identify the potential risk factors associated with the endpoint as appropriate, with the hazard ratio (HR) and 95% confidence interval (95% CI) being reported.Clinical Characteristics According to ComorbidityOf the 869 cases, 121 patients (121/869; 13.9%) were reported to have at least one comorbidity.", [["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 311, 319], ["Cox proportional hazard regression models", "PROBLEM", 0, 41], ["landmark analysis", "TEST", 46, 63], ["the hazard ratio", "TEST", 166, 182], ["HR", "TEST", 184, 186]]], ["The most common comorbidities included hypertension (91/869; 10.5%), diabetes (21/869; 2.4%) and COPD/asthma (11/869; 1.6%) ( Table 1) .", [["hypertension", "DISEASE", 39, 51], ["diabetes", "DISEASE", 69, 77], ["COPD", "DISEASE", 97, 101], ["asthma", "DISEASE", 102, 108], ["The most common comorbidities", "PROBLEM", 0, 29], ["hypertension", "PROBLEM", 39, 51], ["diabetes", "PROBLEM", 69, 77], ["COPD", "PROBLEM", 97, 101], ["asthma", "PROBLEM", 102, 108], ["hypertension", "OBSERVATION", 39, 51], ["COPD", "OBSERVATION", 97, 101], ["asthma", "OBSERVATION", 102, 108]]], ["Patients with at least one comorbidity were older (median: 59 vs. 51 years, p < 0.001).Clinical Characteristics According to ComorbidityOf the patients who were transferred to the designated hospital for further treatment, there were more patients with at least one comorbidity than without (23/121, 19% vs. 72/748, 9.6%, p = 0.002).", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 143, 151], ["patients", "ORGANISM", 239, 247], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 239, 247], ["further treatment", "TREATMENT", 204, 221], ["p", "TEST", 322, 323]]], ["No significant differences were observed in the discharged patients between the two groups (Table 3) .Clinical Characteristics According to Onset Time of COVID-19The onset time cohorts were classified into four groups: Period 1, January 16th to January 25th, 2020 (n = 226); Period 2, January 26th to January 31st, 2020 (n = 235); Period 3, February 1st to February 6th, 2020 (n = 184); and Period 4, February 7th to February 14th, 2020 (n = 106).", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["COVID", "TEST", 154, 159], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26]]], ["Figures 1A,B) .", [["B", "GENE_OR_GENE_PRODUCT", 11, 12]]], ["The analyses of lung CT found that the period 4 group had fewer patients with pneumonia.", [["lung", "ANATOMY", 16, 20], ["pneumonia", "DISEASE", 78, 87], ["lung", "ORGAN", 16, 20], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["lung CT", "TEST", 16, 23], ["pneumonia", "PROBLEM", 78, 87], ["lung", "ANATOMY", 16, 20], ["pneumonia", "OBSERVATION", 78, 87]]], ["The severity of CT manifestations was also decreasing, which was illustrated by the following items: rate of unilateral lung (Prognostic AnalysesWe defined transfer to a designated hospital as the endpoint.", [["lung", "ANATOMY", 120, 124], ["lung", "ORGAN", 120, 124], ["CT manifestations", "PROBLEM", 16, 33], ["rate of unilateral lung", "PROBLEM", 101, 124], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["decreasing", "OBSERVATION_MODIFIER", 43, 53], ["unilateral", "ANATOMY_MODIFIER", 109, 119], ["lung", "ANATOMY", 120, 124]]], ["Patients aged 45 or older had significantly higher risks of reaching the endpoint than those younger than 45 years old (p < 0.05) (Figure 2A) .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Patients with at least one comorbidity also had significantly higher risks of reaching the endpoint than those without comorbidities (p < 0.05) (Figure 2B) .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["comorbidities", "PROBLEM", 119, 132]]], ["After adjusting for comorbidities and sex, patients aged 45 or older were more likely to reach the endpoint than those younger than 45 years old (HR, 1.892, 95% CI, 1.154-3.102, p = 0.011) (Figure 2C) .", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["comorbidities", "PROBLEM", 20, 33], ["HR", "TEST", 146, 148], ["CI", "TEST", 161, 163], ["p", "TEST", 178, 179]]], ["After adjusting for age and sex, patients with comorbidities were more likely to reach the endpoint than those without comorbidities (HR, 2.733, 95% CI, 1.496-4.994, p = 0.001) (Figure 2C ) when staying in the mobile cabin hospital for more than 10 days.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["comorbidities", "PROBLEM", 47, 60], ["comorbidities", "PROBLEM", 119, 132], ["HR", "TEST", 134, 136], ["CI", "TEST", 149, 151]]], ["However, there were no significant differences between patients with or without comorbidities within 10 days of hospitalization ( Figure 2C) .", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["comorbidities", "PROBLEM", 80, 93], ["no", "UNCERTAINTY", 20, 22], ["significant", "OBSERVATION_MODIFIER", 23, 34]]], ["Since a total of 466 patients were available in lung CT reports.", [["lung", "ANATOMY", 48, 52], ["patients", "ORGANISM", 21, 29], ["lung", "ORGAN", 48, 52], ["patients", "SPECIES", 21, 29], ["lung CT", "TEST", 48, 55], ["lung", "ANATOMY", 48, 52]]], ["Therefore, we recruited these 466 patients in a new model to analyze the CT findings of prognostic value.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["the CT", "TEST", 69, 75], ["prognostic value", "PROBLEM", 88, 104]]], ["The univariate proportion COX regress analysis found that several lung CT features (ground-glass opacity, reticular/linear, air bronchogram, and consolidation shadow) were associated with prognosis.", [["lung", "ANATOMY", 66, 70], ["reticular", "ANATOMY", 106, 115], ["air bronchogram", "ANATOMY", 124, 139], ["COX", "GENE_OR_GENE_PRODUCT", 26, 29], ["lung", "ORGAN", 66, 70], ["COX", "PROTEIN", 26, 29], ["The univariate proportion COX", "TREATMENT", 0, 29], ["several lung CT features", "TEST", 58, 82], ["ground-glass opacity", "PROBLEM", 84, 104], ["reticular/linear, air bronchogram", "PROBLEM", 106, 139], ["consolidation shadow", "PROBLEM", 145, 165], ["several", "OBSERVATION_MODIFIER", 58, 65], ["lung", "ANATOMY", 66, 70], ["ground", "OBSERVATION_MODIFIER", 84, 90], ["glass opacity", "OBSERVATION", 91, 104], ["reticular", "OBSERVATION_MODIFIER", 106, 115], ["linear", "OBSERVATION_MODIFIER", 116, 122], ["air bronchogram", "OBSERVATION", 124, 139], ["consolidation", "OBSERVATION_MODIFIER", 145, 158], ["shadow", "OBSERVATION_MODIFIER", 159, 165]]], ["The multivariate COX regression analysis indicated that ground-glass opacity (HR, 2.096, 95% CI, 1.102-3.985, p = 0.024), reticular/linear (HR, 2.07, 95% CI, 1.275-3.362, p = 0.003), air bronchogram (HR, 4.741, 95% CI, 1.869-12.029, p = 0.001), and consolidation shadow (HR, 8.994, 95% CI, 4.953-16.331, p < 0.001) were associated with the poor outcome (transfer to the designated high-level hospitals due to condition worsen) for mild-moderate COVID-19 patients.", [["reticular", "ANATOMY", 122, 131], ["COVID", "DISEASE", 445, 450], ["patients", "ORGANISM", 454, 462], ["patients", "SPECIES", 454, 462], ["The multivariate COX regression analysis", "TEST", 0, 40], ["ground-glass opacity", "PROBLEM", 56, 76], ["HR", "TEST", 78, 80], ["CI", "TEST", 93, 95], ["p", "TEST", 110, 111], ["reticular/linear", "PROBLEM", 122, 138], ["HR", "TEST", 140, 142], ["CI", "TEST", 154, 156], ["p", "TEST", 171, 172], ["air bronchogram", "TEST", 183, 198], ["HR", "TEST", 200, 202], ["CI", "TEST", 215, 217], ["p", "TEST", 233, 234], ["consolidation shadow", "PROBLEM", 249, 269], ["HR", "TEST", 271, 273], ["CI", "TEST", 286, 288], ["mild-moderate COVID", "PROBLEM", 431, 450], ["ground", "OBSERVATION_MODIFIER", 56, 62], ["glass opacity", "OBSERVATION", 63, 76], ["reticular", "ANATOMY_MODIFIER", 122, 131], ["linear", "OBSERVATION_MODIFIER", 132, 138], ["air bronchogram", "OBSERVATION", 183, 198], ["consolidation", "OBSERVATION_MODIFIER", 249, 262], ["shadow", "OBSERVATION_MODIFIER", 263, 269], ["moderate", "OBSERVATION_MODIFIER", 436, 444]]], ["The multivariate COX regression model has adjusted age, sex, and comorbidity ( Table 5 ).DISCUSSIONOur study was designed to analyze the clinical findings and outcomes of mild-moderate patients in one novel mobile cabin hospital in Wuhan, China.", [["COX", "GENE_OR_GENE_PRODUCT", 17, 20], ["patients", "ORGANISM", 185, 193], ["COX", "PROTEIN", 17, 20], ["patients", "SPECIES", 185, 193], ["The multivariate COX regression model", "PROBLEM", 0, 37], ["DISCUSSIONOur study", "TEST", 89, 108], ["mild", "OBSERVATION_MODIFIER", 171, 175], ["moderate", "OBSERVATION_MODIFIER", 176, 184]]], ["Our study found that older age, comorbidities, several lung CT features (e.g., groundglass opacity, reticular/linear, air bronchogram, or consolidation shadow) were associated with aggravation of patients' conditions, which indicated that patients with these characteristics should receive additional attention in mobile cabin hospitals.", [["lung", "ANATOMY", 55, 59], ["reticular", "ANATOMY", 100, 109], ["lung", "ORGAN", 55, 59], ["patients", "ORGANISM", 196, 204], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 239, 247], ["Our study", "TEST", 0, 9], ["comorbidities", "PROBLEM", 32, 45], ["several lung CT features", "TEST", 47, 71], ["groundglass opacity", "PROBLEM", 79, 98], ["reticular/linear, air bronchogram", "PROBLEM", 100, 133], ["consolidation shadow", "PROBLEM", 138, 158], ["aggravation of patients' conditions", "PROBLEM", 181, 216], ["several", "OBSERVATION_MODIFIER", 47, 54], ["lung", "ANATOMY", 55, 59], ["opacity", "OBSERVATION", 91, 98], ["reticular", "OBSERVATION_MODIFIER", 100, 109], ["linear", "OBSERVATION_MODIFIER", 110, 116], ["air bronchogram", "OBSERVATION", 118, 133], ["consolidation", "OBSERVATION_MODIFIER", 138, 151], ["shadow", "OBSERVATION_MODIFIER", 152, 158]]], ["In addition, typical clinical symptoms showed a decreasing trend with time, which suggested that the initial symptoms of mildmoderate patients with COVID-19 may become insidious.", [["mildmoderate", "DISEASE", 121, 133], ["COVID-19", "CHEMICAL", 148, 156], ["COVID-19", "CHEMICAL", 148, 156], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["typical clinical symptoms", "PROBLEM", 13, 38], ["the initial symptoms", "PROBLEM", 97, 117], ["COVID", "TEST", 148, 153], ["insidious", "PROBLEM", 168, 177], ["decreasing", "OBSERVATION_MODIFIER", 48, 58]]], ["Several articles related to COVID-19 have revealed that most of the patients infected with SARS-CoV-2 had mild or moderate infections (2, 6, 13) .", [["SARS", "DISEASE", 91, 95], ["infections", "DISEASE", 123, 133], ["patients", "ORGANISM", 68, 76], ["SARS-CoV-2", "ORGANISM", 91, 101], ["COVID-19", "DNA", 28, 36], ["patients", "SPECIES", 68, 76], ["SARS-CoV", "SPECIES", 91, 99], ["COVID", "TEST", 28, 33], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99], ["mild or moderate infections", "PROBLEM", 106, 133], ["infected", "OBSERVATION", 77, 85], ["mild", "OBSERVATION_MODIFIER", 106, 110], ["moderate", "OBSERVATION_MODIFIER", 114, 122], ["infections", "OBSERVATION", 123, 133]]], ["These patients with mild-moderate disease could recover with general treatment, although a few patients require intensive care due to the worsening of their condition (9) .", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 95, 103], ["mild-moderate disease", "PROBLEM", 20, 41], ["general treatment", "TREATMENT", 61, 78], ["intensive care", "TREATMENT", 112, 126], ["the worsening of their condition", "PROBLEM", 134, 166], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["moderate", "OBSERVATION_MODIFIER", 25, 33], ["disease", "OBSERVATION", 34, 41], ["worsening", "OBSERVATION_MODIFIER", 138, 147]]], ["However, these patients were not effectively treated or isolated due to limited medical resources in the early stages.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["The activities of these mild-moderate patients further aggravated the spread of the disease in the community.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["moderate", "OBSERVATION_MODIFIER", 29, 37], ["disease", "OBSERVATION", 84, 91]]], ["From February 6th 2020 to February 20th, 869 mild-moderate patients were admitted to one of these hospitals, Wuchang Fangcang Hospital that was built within 3 days and could offer 800 beds for patients.", [["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 193, 201], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["moderate", "OBSERVATION_MODIFIER", 50, 58]]], ["Of the 869 patients, 70.9% recovered in the hospital, and 10.9% were transferred to the high-level designated hospital due to patients' condition aggravation in a timely manner for further treatment.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 126, 134], ["patients' condition aggravation", "PROBLEM", 126, 157], ["further treatment", "TREATMENT", 181, 198]]], ["Literature has demonstrated that cabin hospitals played a critical role in the management of previous infectious disease and disasters (9, 10) .", [["infectious disease", "DISEASE", 102, 120], ["previous infectious disease", "PROBLEM", 93, 120], ["infectious", "OBSERVATION", 102, 112]]], ["Compared to the traditional mobile hospitals, these novel cabin hospitals had three key characteristics (rapid construction, massive scale, and low cost) and five essential functions (isolation, triage, basic medical care, frequent monitoring and rapid referral, and essential living and social engagement) (14) .", [["basic medical care", "TREATMENT", 203, 221], ["frequent monitoring", "TEST", 223, 242]]], ["The earlier implementation of social distancing could obviously limit the epidemic and even reduce death (15) .", [["death", "DISEASE", 99, 104]]], ["Interestingly, 12 days after the first fangcang hospitals started admitting patients, the number of confirmed cases in Wuhan steadily declined from Feb 18th, 2020 (16).", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84]]], ["Another study also suggested that these novel mobile cabin hospitals were characterized by flexibility and played an important role in the control of epidemic (17) .", [["Another study", "TEST", 0, 13]]], ["Therefore, fangcang hospitals may provide inspires for other countries in COVID-19 epidemic.", [["COVID", "TEST", 74, 79]]], ["Sex differences among patients infected with SARS-CoV-2 have been described (18) .", [["SARS", "DISEASE", 45, 49], ["patients", "ORGANISM", 22, 30], ["SARS-CoV-2", "ORGANISM", 45, 55], ["patients", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 45, 49], ["infected", "OBSERVATION", 31, 39]]], ["In our study, sex differences existed in the symptoms of COVID-19.", [["COVID", "DISEASE", 57, 62], ["COVID-19", "CHEMICAL", 57, 65], ["our study", "TEST", 3, 12], ["the symptoms", "PROBLEM", 41, 53], ["COVID", "TEST", 57, 62]]], ["Females had more chest tightness, dyspnea and diarrhea, and male patients had a higher rate of fatigue, muscle aches, and anorexia.", [["chest", "ANATOMY", 17, 22], ["muscle", "ANATOMY", 104, 110], ["chest tightness", "DISEASE", 17, 32], ["dyspnea", "DISEASE", 34, 41], ["diarrhea", "DISEASE", 46, 54], ["fatigue", "DISEASE", 95, 102], ["muscle aches", "DISEASE", 104, 116], ["anorexia", "DISEASE", 122, 130], ["chest", "ORGANISM_SUBDIVISION", 17, 22], ["patients", "ORGANISM", 65, 73], ["muscle", "ORGAN", 104, 110], ["patients", "SPECIES", 65, 73], ["more chest tightness", "PROBLEM", 12, 32], ["dyspnea", "PROBLEM", 34, 41], ["diarrhea", "PROBLEM", 46, 54], ["fatigue", "PROBLEM", 95, 102], ["muscle aches", "PROBLEM", 104, 116], ["anorexia", "PROBLEM", 122, 130], ["chest", "ANATOMY", 17, 22], ["tightness", "OBSERVATION", 23, 32], ["dyspnea", "OBSERVATION", 34, 41], ["diarrhea", "OBSERVATION", 46, 54], ["muscle", "ANATOMY", 104, 110], ["aches", "OBSERVATION", 111, 116], ["anorexia", "OBSERVATION", 122, 130]]], ["However, the prognosis was not influenced by sex, although a previous study suggested that males were associated with more severe cases.", [["a previous study", "TEST", 59, 75], ["more severe cases", "PROBLEM", 118, 135]]], ["This may be because patients in the hospital had mild disease on admission.DISCUSSIONSeveral studies have suggested that older age and comorbidities are significantly associated with composite endpoints or death (2, 19, 20) .", [["death", "DISEASE", 206, 211], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["mild disease", "PROBLEM", 49, 61], ["DISCUSSIONSeveral studies", "TEST", 75, 100], ["comorbidities", "PROBLEM", 135, 148], ["death", "PROBLEM", 206, 211], ["may be", "UNCERTAINTY", 5, 11], ["mild", "OBSERVATION_MODIFIER", 49, 53], ["disease", "OBSERVATION", 54, 61]]], ["Chest CT plays a critical role in the diagnosis and evaluation of COVID-19.", [["COVID-19", "CHEMICAL", 66, 74], ["Chest CT", "TEST", 0, 8], ["evaluation", "TEST", 52, 62], ["COVID", "TEST", 66, 71]]], ["The incidences of consolidation, linear opacities, crazy-paving pattern, and bronchial wall thickening in severe/critical patients were significantly higher than those of the ordinary patients (21) .", [["bronchial wall", "ANATOMY", 77, 91], ["opacities", "DISEASE", 40, 49], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 77, 91], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 184, 192], ["consolidation", "PROBLEM", 18, 31], ["linear opacities", "PROBLEM", 33, 49], ["crazy-paving pattern", "PROBLEM", 51, 71], ["bronchial wall thickening", "PROBLEM", 77, 102], ["consolidation", "OBSERVATION", 18, 31], ["linear", "OBSERVATION_MODIFIER", 33, 39], ["opacities", "OBSERVATION", 40, 49], ["crazy", "OBSERVATION_MODIFIER", 51, 56], ["paving", "OBSERVATION_MODIFIER", 57, 63], ["pattern", "OBSERVATION_MODIFIER", 64, 71], ["bronchial", "ANATOMY", 77, 86], ["wall", "ANATOMY_MODIFIER", 87, 91], ["thickening", "OBSERVATION", 92, 102], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["critical", "OBSERVATION_MODIFIER", 113, 121], ["significantly", "OBSERVATION_MODIFIER", 136, 149], ["higher", "OBSERVATION_MODIFIER", 150, 156]]], ["Our study found that relatively severe CT manifestations existed in older age patients or patients with at least one comorbidity.", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 90, 98], ["Our study", "TEST", 0, 9], ["relatively severe CT manifestations", "PROBLEM", 21, 56], ["relatively", "OBSERVATION_MODIFIER", 21, 31], ["severe", "OBSERVATION_MODIFIER", 32, 38]]], ["More patients aged 45 years or older reached the endpoint, and older age was a potential risk factor for the endpoint.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["However, the patients over 60 years did not have more cumulative risk than the 45-60 years group, which was not consistent with the literature reports (22, 23) .", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["not consistent with", "UNCERTAINTY", 108, 127]]], ["This may be due to the age limitation of the mobile hospital that required advanced age patients, especially those with comorbidities, to be directly admitted to designated hospitals.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["may be due to", "UNCERTAINTY", 5, 18]]], ["Similarly, comorbidities may be another risk factor for the development of endpoints.", [["comorbidities", "PROBLEM", 11, 24]]], ["In the other proportion COX regression model, results showed that several chest CT features (e.g., ground-glass opacity, reticular/linear, air bronchogram, or consolidation shadow) were associated with the poor outcome for mild-moderate COVID-19 patients.", [["chest", "ANATOMY", 74, 79], ["reticular", "ANATOMY", 121, 130], ["air bronchogram", "ANATOMY", 139, 154], ["COVID", "DISEASE", 237, 242], ["COX", "GENE_OR_GENE_PRODUCT", 24, 27], ["patients", "ORGANISM", 246, 254], ["COX", "PROTEIN", 24, 27], ["patients", "SPECIES", 246, 254], ["several chest CT features", "TEST", 66, 91], ["ground-glass opacity", "PROBLEM", 99, 119], ["reticular/linear, air bronchogram", "PROBLEM", 121, 154], ["consolidation shadow", "PROBLEM", 159, 179], ["mild-moderate COVID", "PROBLEM", 223, 242], ["several", "OBSERVATION_MODIFIER", 66, 73], ["chest", "ANATOMY", 74, 79], ["ground", "OBSERVATION_MODIFIER", 99, 105], ["glass opacity", "OBSERVATION", 106, 119], ["reticular", "OBSERVATION_MODIFIER", 121, 130], ["linear", "OBSERVATION_MODIFIER", 131, 137], ["air bronchogram", "OBSERVATION", 139, 154], ["consolidation", "OBSERVATION_MODIFIER", 159, 172], ["shadow", "OBSERVATION_MODIFIER", 173, 179], ["mild", "OBSERVATION_MODIFIER", 223, 227], ["moderate", "OBSERVATION_MODIFIER", 228, 236]]], ["These results reminded us that patients with these risk factors should receive more attention to prevent patients' condition aggravation.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 105, 113], ["these risk factors", "PROBLEM", 45, 63], ["patients' condition aggravation", "PROBLEM", 105, 136]]], ["Or, the doctors should identify these patients early and transfer them to the high-level designated hospitals.DISCUSSIONThe characteristics of generational transmission may be diverse due to virus mutations.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["generational transmission", "PROBLEM", 143, 168], ["virus mutations", "PROBLEM", 191, 206]]], ["The initial symptoms of infected patients may have changed with time.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["The initial symptoms", "PROBLEM", 0, 20], ["infected", "OBSERVATION", 24, 32]]], ["One study suggested that a novel SARS-CoV-2 mutation (ORF3a) had been found in Europe and may appear to be spreading worldwide (24) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["ORF3a", "GENE_OR_GENE_PRODUCT", 54, 59], ["SARS-CoV-2 mutation", "DNA", 33, 52], ["ORF3a", "DNA", 54, 59], ["SARS-CoV", "SPECIES", 33, 41], ["One study", "TEST", 0, 9], ["a novel SARS", "TEST", 25, 37]]], ["Therefore, we explored the clinical dynamics in mildmoderate patients from Wuchang Mobile Cabin Hospital.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69]]], ["Our results revealed that the typical symptoms of COVID-19, including fever, cough, fatigue, muscle aches, and anorexia, showed a decreasing trend with time.", [["muscle", "ANATOMY", 93, 99], ["COVID", "DISEASE", 50, 55], ["fever", "DISEASE", 70, 75], ["cough", "DISEASE", 77, 82], ["fatigue", "DISEASE", 84, 91], ["muscle aches", "DISEASE", 93, 105], ["anorexia", "DISEASE", 111, 119], ["muscle", "ORGAN", 93, 99], ["the typical symptoms", "PROBLEM", 26, 46], ["COVID", "TEST", 50, 55], ["fever", "PROBLEM", 70, 75], ["cough", "PROBLEM", 77, 82], ["fatigue", "PROBLEM", 84, 91], ["muscle aches", "PROBLEM", 93, 105], ["anorexia", "PROBLEM", 111, 119], ["muscle", "ANATOMY", 93, 99], ["decreasing", "OBSERVATION_MODIFIER", 130, 140]]], ["In addition, catarrhal symptoms showed an increasing trend, although the difference was not significant.", [["catarrhal", "DISEASE", 13, 22], ["catarrhal", "PATHOLOGICAL_FORMATION", 13, 22], ["catarrhal symptoms", "PROBLEM", 13, 31], ["an increasing trend", "PROBLEM", 39, 58], ["catarrhal", "OBSERVATION_MODIFIER", 13, 22], ["increasing", "OBSERVATION_MODIFIER", 42, 52], ["trend", "OBSERVATION_MODIFIER", 53, 58]]], ["The results suggested that the typical symptoms of mild-moderate patients may become insidious, especially in the later stage of epidemic.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["the typical symptoms", "PROBLEM", 27, 47], ["mild-moderate patients", "PROBLEM", 51, 73], ["insidious", "PROBLEM", 85, 94], ["epidemic", "PROBLEM", 129, 137], ["mild", "OBSERVATION_MODIFIER", 51, 55], ["moderate", "OBSERVATION_MODIFIER", 56, 64], ["insidious", "OBSERVATION_MODIFIER", 85, 94]]], ["First, as previously described, virus mutation may be responsible for the phenomenon, although the evidence is limited.", [["virus mutation", "PROBLEM", 32, 46], ["the phenomenon", "PROBLEM", 70, 84], ["may be responsible for", "UNCERTAINTY", 47, 69]]], ["Secondly, the detection capability of SARS-CoV-2 for contacts were furtherly enhanced, which lead to the recognition of COVID-19 patients before the symptoms appeared (15) .", [["SARS", "DISEASE", 38, 42], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["SARS-CoV", "SPECIES", 38, 46], ["the detection capability", "TEST", 10, 34], ["SARS", "TEST", 38, 42], ["CoV", "TEST", 43, 46], ["COVID", "TEST", 120, 125], ["the symptoms", "PROBLEM", 145, 157]]], ["Besides, the number of new cases was gradually reduced after Feb 2nd, 2020 and the medical assistance measures were gradually boosted during this period, which gave hospitals extra capacity to deal with patients with mild symptoms or single symptoms (14, 15) .", [["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["the medical assistance measures", "TREATMENT", 79, 110], ["mild symptoms", "PROBLEM", 217, 230], ["single symptoms", "PROBLEM", 234, 249], ["new", "OBSERVATION_MODIFIER", 23, 26]]], ["In brief, while some factors may affect the registration of patient's symptoms, it may be hard for health workers to identify COVID-19 according to the symptoms.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["patient's symptoms", "PROBLEM", 60, 78], ["COVID", "TEST", 126, 131], ["the symptoms", "PROBLEM", 148, 160]]], ["In addition, the conditions on lung CT showed an improving trend, although the outcomes of patients within 15 days of admission were not different among the groups.DISCUSSIONSome limitations existed in our study.", [["lung", "ANATOMY", 31, 35], ["lung", "ORGAN", 31, 35], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["lung CT", "TEST", 31, 38], ["our study", "TEST", 202, 211], ["lung", "ANATOMY", 31, 35], ["improving", "OBSERVATION_MODIFIER", 49, 58], ["trend", "OBSERVATION_MODIFIER", 59, 64]]], ["Laboratory tests of most patients were unavailable due to the limitations of converted hospitals.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["Laboratory tests", "TEST", 0, 16]]], ["Another limitation of our study was the self-report of comorbidities on admission.", [["our study", "TEST", 22, 31], ["comorbidities", "PROBLEM", 55, 68]]], ["In addition, only 869 patients from one mobile cabin hospital were analyzed.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["A larger sample size may further increase the reliability of the conclusion.CONCLUSIONOlder age, comorbidities and some chest CT features (e.g., ground-glass opacity, reticular/linear, air bronchogram, or consolidation shadow) were associated with poor outcomes for these mild-moderate patients.", [["chest", "ANATOMY", 120, 125], ["reticular", "ANATOMY", 167, 176], ["air bronchogram", "ANATOMY", 185, 200], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 286, 294], ["A larger sample size", "PROBLEM", 0, 20], ["comorbidities", "PROBLEM", 97, 110], ["some chest CT features", "TEST", 115, 137], ["ground-glass opacity", "PROBLEM", 145, 165], ["reticular/linear, air bronchogram", "PROBLEM", 167, 200], ["consolidation shadow", "PROBLEM", 205, 225], ["these mild-moderate patients", "PROBLEM", 266, 294], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["size", "OBSERVATION_MODIFIER", 16, 20], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["chest", "ANATOMY", 120, 125], ["ground", "OBSERVATION_MODIFIER", 145, 151], ["glass opacity", "OBSERVATION", 152, 165], ["reticular", "OBSERVATION_MODIFIER", 167, 176], ["linear", "OBSERVATION_MODIFIER", 177, 183], ["air bronchogram", "OBSERVATION", 185, 200], ["consolidation", "OBSERVATION_MODIFIER", 205, 218], ["shadow", "OBSERVATION_MODIFIER", 219, 225], ["mild", "OBSERVATION_MODIFIER", 272, 276], ["moderate", "OBSERVATION_MODIFIER", 277, 285]]], ["The initial symptoms of mildmoderate patients with COVID-19 may became insidious and deserve our attention.DATA AVAILABILITY STATEMENTThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.ETHICS STATEMENTThe studies involving human participants were reviewed and approved by the Institutional Ethics Board of Renmin Hospital of Wuhan University.", [["mildmoderate", "DISEASE", 24, 36], ["COVID-19", "CHEMICAL", 51, 59], ["COVID-19", "CHEMICAL", 51, 59], ["patients", "ORGANISM", 37, 45], ["human", "ORGANISM", 293, 298], ["patients", "SPECIES", 37, 45], ["human", "SPECIES", 293, 298], ["participants", "SPECIES", 299, 311], ["human", "SPECIES", 293, 298], ["The initial symptoms", "PROBLEM", 0, 20], ["COVID", "TEST", 51, 56], ["insidious", "PROBLEM", 71, 80]]], ["Written informed consent from the participants' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.AUTHOR CONTRIBUTIONSMW and SG had full access to all of the data in the study.", [["participants", "SPECIES", 34, 46], ["this study", "TEST", 110, 120], ["the study", "TEST", 268, 277]]], ["JZ, MW, and MZ designed the study and analysis the data.", [["MZ", "CHEMICAL", 12, 14], ["the study", "TEST", 24, 33], ["analysis the data", "TEST", 38, 55]]], ["JZ, MW, MZ, and SG contributed equally to the study.", [["MZ", "CHEMICAL", 8, 10], ["SG", "TREATMENT", 16, 18], ["the study", "TEST", 42, 51]]], ["JY, DY, ZW, WD, DL, ML, JL, WP, ZL, YX, and MZ critical revision of the manuscript for important intellectual content.", [["MZ", "CHEMICAL", 44, 46], ["MZ critical revision", "TREATMENT", 44, 64], ["important intellectual content", "PROBLEM", 87, 117], ["DL", "ANATOMY", 16, 18], ["JL", "ANATOMY", 24, 26], ["ZL", "ANATOMY", 32, 34], ["revision", "OBSERVATION", 56, 64]]], ["MW and JW study supervision.FUNDINGThis study was supported by the emergency technical project for COVID-19 from the Wuhan Science and Technology Bureau, No. 20200202010016.", [["FUNDINGThis study", "TEST", 28, 45]]]], "15cb8cdb5ff19ca2dc34036339aad3b8bdfadbee": [["IntroductionDangerous viruses have been appearing from time to time attacking the human body and causing several health problems, deaths and socio-economic damage worldwide.", [["body", "ANATOMY", 88, 92], ["deaths", "DISEASE", 130, 136], ["human", "ORGANISM", 82, 87], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["Dangerous viruses", "PROBLEM", 12, 29], ["socio-economic damage worldwide", "PROBLEM", 141, 172], ["human body", "ANATOMY", 82, 92]]], ["For instance, a novel coronavirus (nCoV) was identified on January 7, 2020 responsible for the initial cases of pneumonia occurred in Wuhan, China.", [["pneumonia", "DISEASE", 112, 121], ["coronavirus", "ORGANISM", 22, 33], ["nCoV", "CANCER", 35, 39], ["a novel coronavirus (nCoV)", "TREATMENT", 14, 40], ["pneumonia", "PROBLEM", 112, 121], ["pneumonia", "OBSERVATION", 112, 121]]], ["This virus has recently been reported as extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses [7] .", [["acute respiratory syndrome coronavirus", "DISEASE", 49, 87], ["acute respiratory syndrome coronavirus 2", "ORGANISM", 49, 89], ["SARS-CoV-2", "ORGANISM", 91, 101], ["SARS-CoV-2", "SPECIES", 91, 101], ["This virus", "PROBLEM", 0, 10], ["extreme acute respiratory syndrome coronavirus", "PROBLEM", 41, 87], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["the Coronavirus Study", "TEST", 106, 127], ["extreme", "OBSERVATION_MODIFIER", 41, 48], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["respiratory syndrome", "OBSERVATION", 55, 75]]], ["Because its genetic sequence is very similar to that of severe acute respiratory syndrome (SARS), another coronavirus that appeared for first time in 2002 and caused a pandemic with more than 80 0 0 infected people and 800 deaths.", [["acute respiratory syndrome", "DISEASE", 63, 89], ["SARS", "DISEASE", 91, 95], ["deaths", "DISEASE", 223, 229], ["coronavirus", "ORGANISM", 106, 117], ["people", "ORGANISM", 208, 214], ["people", "SPECIES", 208, 214], ["severe acute respiratory syndrome", "PROBLEM", 56, 89], ["SARS", "PROBLEM", 91, 95], ["another coronavirus", "PROBLEM", 98, 117], ["a pandemic", "PROBLEM", 166, 176], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory syndrome", "OBSERVATION", 69, 89]]], ["Another coronavirus that causes severe disease in humans is middle east respiratory syndrome (MERS), identified for the first time in 2012 in the Middle East having connection with camels.", [["coronavirus", "DISEASE", 8, 19], ["middle east respiratory syndrome", "DISEASE", 60, 92], ["MERS", "DISEASE", 94, 98], ["coronavirus", "ORGANISM", 8, 19], ["humans", "ORGANISM", 50, 56], ["coronavirus", "SPECIES", 8, 19], ["humans", "SPECIES", 50, 56], ["humans", "SPECIES", 50, 56], ["Another coronavirus", "PROBLEM", 0, 19], ["severe disease in humans", "PROBLEM", 32, 56], ["middle east respiratory syndrome", "PROBLEM", 60, 92], ["coronavirus", "OBSERVATION", 8, 19], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["disease", "OBSERVATION", 39, 46], ["middle", "OBSERVATION_MODIFIER", 60, 66], ["east", "OBSERVATION_MODIFIER", 67, 71], ["respiratory syndrome", "OBSERVATION", 72, 92]]], ["As of 24 March 2020, more than 372,757 cases of SARS-CoV-2 have been confirmed in 196 countries and territories, including 195,511 cases in European region, and the number of deaths from the virus has reached 16,231 globally, according to the World Health Organization (WHO) [27] .", [["SARS", "DISEASE", 48, 52], ["deaths", "DISEASE", 175, 181], ["SARS-CoV-2", "ORGANISM", 48, 58], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["the virus", "PROBLEM", 187, 196]]], ["Also, already existing viruses like hepatitis B virus (HBV) and hu- * Corresponding author.IntroductionE-mail addresses: k.hattaf@yahoo.fr (K. Hattaf), hemen_dutta08@rediffmail.com (H. Dutta). man immunodeficiency virus (HIV) are still causing large numbers of deaths worldwide.", [["hepatitis B", "DISEASE", 36, 47], ["man immunodeficiency virus (HIV)", "DISEASE", 193, 225], ["deaths", "DISEASE", 261, 267], ["hepatitis B virus", "ORGANISM", 36, 53], ["HBV", "ORGANISM", 55, 58], ["man immunodeficiency virus", "ORGANISM", 193, 219], ["HIV", "ORGANISM", 221, 224], ["hepatitis B virus", "SPECIES", 36, 53], ["man immunodeficiency virus", "SPECIES", 193, 219], ["HIV", "SPECIES", 221, 224], ["hepatitis B virus", "SPECIES", 36, 53], ["HBV", "SPECIES", 55, 58], ["man immunodeficiency virus", "SPECIES", 193, 219], ["HIV", "SPECIES", 221, 224], ["hepatitis B virus", "PROBLEM", 36, 53], ["man immunodeficiency virus", "PROBLEM", 193, 219], ["HIV", "PROBLEM", 221, 224], ["viruses", "OBSERVATION", 23, 30], ["hepatitis", "OBSERVATION", 36, 45], ["immunodeficiency virus", "OBSERVATION", 197, 219], ["large", "OBSERVATION_MODIFIER", 244, 249], ["numbers", "OBSERVATION_MODIFIER", 250, 257]]], ["As per an estimation in 2015, 257 million people were living with chronic hepatitis B infection (defined as hepatitis B surface antigen positive), and death of 887,0 0 0 people, mostly due to cirrhosis and hepatocellular carcinoma (i.e. primary liver cancer) [28] .", [["hepatocellular carcinoma", "ANATOMY", 206, 230], ["primary liver cancer", "ANATOMY", 237, 257], ["chronic hepatitis B infection", "DISEASE", 66, 95], ["hepatitis B surface antigen", "CHEMICAL", 108, 135], ["death", "DISEASE", 151, 156], ["cirrhosis", "DISEASE", 192, 201], ["hepatocellular carcinoma", "DISEASE", 206, 230], ["primary liver cancer", "DISEASE", 237, 257], ["people", "ORGANISM", 42, 48], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 108, 135], ["people", "ORGANISM", 170, 176], ["hepatocellular carcinoma", "CANCER", 206, 230], ["liver cancer", "CANCER", 245, 257], ["people", "SPECIES", 42, 48], ["people", "SPECIES", 170, 176], ["hepatitis B", "SPECIES", 74, 85], ["chronic hepatitis B infection", "PROBLEM", 66, 95], ["hepatitis B surface antigen", "TEST", 108, 135], ["death", "PROBLEM", 151, 156], ["cirrhosis", "PROBLEM", 192, 201], ["hepatocellular carcinoma", "PROBLEM", 206, 230], ["primary liver cancer", "PROBLEM", 237, 257], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["hepatitis", "OBSERVATION", 74, 83], ["infection", "OBSERVATION", 86, 95], ["cirrhosis", "OBSERVATION", 192, 201], ["hepatocellular", "ANATOMY", 206, 220], ["carcinoma", "OBSERVATION", 221, 230], ["liver", "ANATOMY", 245, 250], ["cancer", "OBSERVATION", 251, 257]]], ["Also, 770,0 0 0 people died from HIV-related causes and 1.7 million people were newly infected in 2018 [29] .IntroductionThe rapid spread of viruses has been attracting the attention of researchers to carry out new researches to understand various associated aspects.", [["people", "ORGANISM", 16, 22], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 16, 22], ["HIV", "SPECIES", 33, 36], ["people", "SPECIES", 68, 74], ["HIV", "SPECIES", 33, 36], ["HIV", "PROBLEM", 33, 36], ["viruses", "PROBLEM", 141, 148], ["rapid", "OBSERVATION_MODIFIER", 125, 130], ["spread", "OBSERVATION_MODIFIER", 131, 137], ["viruses", "OBSERVATION", 141, 148]]], ["It has been shown biologically that viruses can spread by both modes, viz., virus-to-cell mode via the extracellular environment and through cell-to-cell transmission mode by direct cell-cell contact [13, 14, 23] .", [["cell", "ANATOMY", 85, 89], ["extracellular", "ANATOMY", 103, 116], ["cell", "ANATOMY", 141, 145], ["cell", "ANATOMY", 149, 153], ["cell", "ANATOMY", 182, 186], ["cell", "ANATOMY", 187, 191], ["cell", "CELL", 85, 89], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["cell", "CELL", 141, 145], ["cell", "CELL", 149, 153], ["cell", "CELL", 182, 186], ["cell", "CELL", 187, 191], ["viruses", "PROBLEM", 36, 43], ["virus", "TEST", 76, 81], ["the extracellular environment", "TEST", 99, 128], ["viruses", "OBSERVATION", 36, 43]]], ["During cell-to-cell transmission, it is possible for several viral particles to be transferred from infected to uninfected cells via structures called infectious or virological synapses [13] .", [["cell", "ANATOMY", 7, 11], ["cell", "ANATOMY", 15, 19], ["cells", "ANATOMY", 123, 128], ["cell", "CELL", 7, 11], ["cell", "CELL", 15, 19], ["cells", "CELL", 123, 128], ["uninfected cells", "CELL_TYPE", 112, 128], ["several viral particles", "PROBLEM", 53, 76], ["virological synapses", "PROBLEM", 165, 185], ["possible for", "UNCERTAINTY", 40, 52], ["infectious", "OBSERVATION_MODIFIER", 151, 161]]], ["In the case of HIV infection, cell-to-cell transmission may be 10-10 0 0 times more effective than the passive dissemination of virons via the extracellular environment [2, 4, 5] .", [["cell", "ANATOMY", 30, 34], ["cell", "ANATOMY", 38, 42], ["extracellular", "ANATOMY", 143, 156], ["HIV infection", "DISEASE", 15, 28], ["HIV", "ORGANISM", 15, 18], ["cell", "CELL", 30, 34], ["cell", "CELL", 38, 42], ["virons", "SIMPLE_CHEMICAL", 128, 134], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 143, 156], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 15, 18], ["HIV infection", "PROBLEM", 15, 28], ["cell", "TEST", 30, 34], ["cell transmission", "TEST", 38, 55], ["HIV", "OBSERVATION_MODIFIER", 15, 18], ["infection", "OBSERVATION", 19, 28]]], ["In [30] , HIV is used as a model virus in understanding the processes that consequence in viral spread via virus-to-cell or cell contact dependent mode.", [["cell", "ANATOMY", 116, 120], ["cell", "ANATOMY", 124, 128], ["HIV", "ORGANISM", 10, 13], ["cell", "CELL", 116, 120], ["cell", "CELL", 124, 128], ["HIV", "SPECIES", 10, 13], ["HIV", "PROBLEM", 10, 13], ["a model virus", "TREATMENT", 25, 38], ["viral spread via virus", "PROBLEM", 90, 112]]], ["In the same work, it is demonstrated that HIV can spread by virus-to-cell mode if all steps of the viral replication cycle are efficient.", [["cell", "ANATOMY", 69, 73], ["HIV", "ORGANISM", 42, 45], ["cell", "CELL", 69, 73], ["HIV", "SPECIES", 42, 45], ["HIV", "PROBLEM", 42, 45], ["virus", "PROBLEM", 60, 65], ["the viral replication cycle", "TREATMENT", 95, 122], ["viral replication", "OBSERVATION", 99, 116]]], ["If any of these steps is impaired, then co-cultures of HIV donor cells with specific target cells allow effective viral spreading.IntroductionLatently infected cells are those cells which include the viruses but do not producing them due to time lag between both the moment of infection and the moment when the infected cell becomes active to create new infectious viruses.", [["cells", "ANATOMY", 65, 70], ["cells", "ANATOMY", 92, 97], ["cells", "ANATOMY", 160, 165], ["cells", "ANATOMY", 176, 181], ["cell", "ANATOMY", 320, 324], ["infection", "DISEASE", 277, 286], ["HIV", "ORGANISM", 55, 58], ["cells", "CELL", 65, 70], ["cells", "CELL", 92, 97], ["cells", "CELL", 160, 165], ["cells", "CELL", 176, 181], ["cell", "CELL", 320, 324], ["HIV donor cells", "CELL_TYPE", 55, 70], ["target cells", "CELL_TYPE", 85, 97], ["HIV", "SPECIES", 55, 58], ["HIV donor cells", "PROBLEM", 55, 70], ["specific target cells", "PROBLEM", 76, 97], ["effective viral spreading", "PROBLEM", 104, 129], ["IntroductionLatently infected cells", "PROBLEM", 130, 165], ["those cells", "PROBLEM", 170, 181], ["the viruses", "PROBLEM", 196, 207], ["infection", "PROBLEM", 277, 286], ["the infected cell", "PROBLEM", 307, 324], ["new infectious viruses", "PROBLEM", 350, 372], ["infected cells", "OBSERVATION", 151, 165], ["viruses", "OBSERVATION", 200, 207], ["infection", "OBSERVATION", 277, 286], ["infected cell", "OBSERVATION", 311, 324], ["new", "OBSERVATION_MODIFIER", 350, 353], ["infectious", "OBSERVATION", 354, 364]]], ["For some viruses like herpesvirus, latency is an essential mechanism for immune evasion and viral persistence [16, 17] .", [["herpesvirus", "ORGANISM", 22, 33], ["some viruses", "PROBLEM", 4, 16], ["herpesvirus", "PROBLEM", 22, 33], ["immune evasion", "PROBLEM", 73, 87], ["viral persistence", "PROBLEM", 92, 109], ["viruses", "OBSERVATION", 9, 16], ["herpesvirus", "OBSERVATION", 22, 33]]], ["One of the major hurdles in eliminating HIV infection completely is the presence of a small reservoir of latently infected cells that can survive through long-term suppression of viral replication by extremely active anti-retroviral therapy (HAART) [6, 21, 22] .", [["cells", "ANATOMY", 123, 128], ["HIV infection", "DISEASE", 40, 53], ["latently infected", "DISEASE", 105, 122], ["HIV", "ORGANISM", 40, 43], ["cells", "CELL", 123, 128], ["latently infected cells", "CELL_TYPE", 105, 128], ["HIV", "SPECIES", 40, 43], ["HIV", "SPECIES", 40, 43], ["HIV infection", "PROBLEM", 40, 53], ["a small reservoir of latently infected cells", "PROBLEM", 84, 128], ["long-term suppression", "TREATMENT", 154, 175], ["viral replication", "TREATMENT", 179, 196], ["extremely active anti-retroviral therapy (HAART", "TREATMENT", 200, 247], ["major", "OBSERVATION_MODIFIER", 11, 16], ["hurdles", "OBSERVATION", 17, 24], ["HIV", "OBSERVATION_MODIFIER", 40, 43], ["infection", "OBSERVATION", 44, 53], ["small", "OBSERVATION_MODIFIER", 86, 91], ["reservoir", "OBSERVATION_MODIFIER", 92, 101], ["latently", "OBSERVATION_MODIFIER", 105, 113], ["infected cells", "OBSERVATION", 114, 128], ["long-term suppression", "OBSERVATION_MODIFIER", 154, 175], ["viral replication", "OBSERVATION", 179, 196], ["active", "OBSERVATION_MODIFIER", 210, 216], ["anti-retroviral therapy", "OBSERVATION", 217, 240]]], ["A recent study found that cell-to-cell transmission contributes to the production of latently infected cells [1] .", [["cell", "ANATOMY", 26, 30], ["cell", "ANATOMY", 34, 38], ["cells", "ANATOMY", 103, 108], ["latently infected", "DISEASE", 85, 102], ["cell", "CELL", 26, 30], ["cell", "CELL", 34, 38], ["cells", "CELL", 103, 108], ["latently infected cells", "CELL_TYPE", 85, 108], ["A recent study", "TEST", 0, 14], ["latently infected cells", "PROBLEM", 85, 108], ["latently", "OBSERVATION_MODIFIER", 85, 93], ["infected cells", "OBSERVATION", 94, 108]]], ["This mode of viral transmission is found to contribute to both the spread and pathogenesis of the virus in vivo and to the production and maintenance of latent reservoirs that represent a serious barrier to the curing of the infection [19] .IntroductionThe above biological studies inspire to propose the following model:Introductionwhere S ( t ), L ( t ), A ( t ) and V ( t ) respectively indicate the concentration of susceptible cells, latently infected cells, actively infected cells and free virus particles at time t .", [["cells", "ANATOMY", 432, 437], ["cells", "ANATOMY", 457, 462], ["cells", "ANATOMY", 482, 487], ["infection", "DISEASE", 225, 234], ["cells", "CELL", 432, 437], ["cells", "CELL", 457, 462], ["cells", "CELL", 482, 487], ["susceptible cells", "CELL_TYPE", 420, 437], ["latently infected cells", "CELL_TYPE", 439, 462], ["actively infected cells", "CELL_TYPE", 464, 487], ["viral transmission", "PROBLEM", 13, 31], ["the virus", "PROBLEM", 94, 103], ["latent reservoirs", "PROBLEM", 153, 170], ["the infection", "PROBLEM", 221, 234], ["susceptible cells", "PROBLEM", 420, 437], ["latently infected cells", "PROBLEM", 439, 462], ["actively infected cells", "PROBLEM", 464, 487], ["free virus particles", "PROBLEM", 492, 512], ["viral", "OBSERVATION", 13, 18], ["latent", "OBSERVATION_MODIFIER", 153, 159], ["reservoirs", "OBSERVATION", 160, 170], ["serious", "OBSERVATION_MODIFIER", 188, 195], ["infection", "OBSERVATION", 225, 234], ["susceptible cells", "OBSERVATION", 420, 437], ["latently", "OBSERVATION_MODIFIER", 439, 447], ["infected cells", "OBSERVATION", 448, 462], ["infected cells", "OBSERVATION", 473, 487], ["free virus", "OBSERVATION", 492, 502]]], ["It is also considered that susceptible cells are generated at a constant rate of \u03bb, die at a rate of dS and become infected either through free virus at a rate of p ( S, V ) V , or through direct contact with actively infected cells at a rate of q ( S, A ) A , or by direct contact with latently infected cells at a rate of h ( S, L ) L .", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 227, 232], ["cells", "ANATOMY", 305, 310], ["cells", "CELL", 39, 44], ["V ) V", "GENE_OR_GENE_PRODUCT", 170, 175], ["cells", "CELL", 227, 232], ["cells", "CELL", 305, 310], ["susceptible cells", "CELL_TYPE", 27, 44], ["actively infected cells", "CELL_TYPE", 209, 232], ["latently infected cells", "CELL_TYPE", 287, 310], ["susceptible cells", "PROBLEM", 27, 44], ["infected", "PROBLEM", 115, 123], ["free virus", "PROBLEM", 139, 149], ["actively infected cells", "PROBLEM", 209, 232], ["latently infected cells", "PROBLEM", 287, 310], ["susceptible cells", "OBSERVATION", 27, 44], ["infected", "OBSERVATION", 115, 123]]], ["The term p(S, V ) V + q (S, A ) A + h (S, L ) L then describes the total infection rate of susceptible cells.", [["cells", "ANATOMY", 103, 108], ["infection", "DISEASE", 73, 82], ["cells", "CELL", 103, 108], ["susceptible cells", "CELL_TYPE", 91, 108], ["The term p(S, V ) V", "TEST", 0, 19], ["the total infection rate of susceptible cells", "PROBLEM", 63, 108], ["infection", "OBSERVATION", 73, 82], ["susceptible cells", "OBSERVATION", 91, 108]]], ["It is assumed a fraction \u03b7 of infected cells to be latently infected cells and the remaining (1 \u2212 \u03b7) becomes actively infected cells, where 0 < \u03b7 \u2264 1.IntroductionWe take e and a as the parameters for the death rates of latently and actively infected cells.", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 69, 74], ["cells", "ANATOMY", 127, 132], ["cells", "ANATOMY", 250, 255], ["death", "DISEASE", 204, 209], ["latently and actively infected", "DISEASE", 219, 249], ["cells", "CELL", 39, 44], ["cells", "CELL", 69, 74], ["cells", "CELL", 127, 132], ["cells", "CELL", 250, 255], ["infected cells", "CELL_TYPE", 30, 44], ["latently infected cells", "CELL_TYPE", 51, 74], ["actively infected cells", "CELL_TYPE", 109, 132], ["latently and actively infected cells", "CELL_TYPE", 219, 255], ["infected cells", "PROBLEM", 30, 44], ["latently infected cells", "PROBLEM", 51, 74], ["actively infected cells", "PROBLEM", 109, 132], ["the death rates of latently", "PROBLEM", 200, 227], ["actively infected cells", "PROBLEM", 232, 255], ["infected cells", "OBSERVATION", 30, 44], ["latently", "OBSERVATION_MODIFIER", 51, 59], ["infected cells", "OBSERVATION", 60, 74], ["infected cells", "OBSERVATION", 118, 132], ["infected cells", "OBSERVATION", 241, 255]]], ["Also, r, k and \u03bc are the parameters respectively for the production rate of virus from actively infected cells, the rate at which the latently infected cells are transmitted to actively infected cells, and the clearance rate of virus.", [["cells", "ANATOMY", 105, 110], ["cells", "ANATOMY", 152, 157], ["cells", "ANATOMY", 195, 200], ["cells", "CELL", 105, 110], ["cells", "CELL", 152, 157], ["cells", "CELL", 195, 200], ["actively infected cells", "CELL_TYPE", 87, 110], ["latently infected cells", "CELL_TYPE", 134, 157], ["actively infected cells", "CELL_TYPE", 177, 200], ["k", "TEST", 9, 10], ["the production rate of virus", "PROBLEM", 53, 81], ["actively infected cells", "PROBLEM", 87, 110], ["the rate", "TEST", 112, 120], ["the latently infected cells", "PROBLEM", 130, 157], ["actively infected cells", "PROBLEM", 177, 200], ["the clearance rate of virus", "PROBLEM", 206, 233], ["infected cells", "OBSERVATION", 96, 110], ["latently", "OBSERVATION_MODIFIER", 134, 142], ["infected cells", "OBSERVATION", 143, 157], ["infected cells", "OBSERVATION", 186, 200]]], ["Fig. 1 is an illustration of the schematic diagram of model (1) .IntroductionAs in Hattaf and Yousfi [10] , 11 ], the general incidences p ( S, V ), q ( S, A ) and h ( S, L ) are assumed to be continuously differentiable in the interior of IR 2 + and also satisfy the following hypotheses:IntroductionIt should be noted that model (1) extends as well as generalizes many special cases available in the literature.", [["Introduction", "TREATMENT", 289, 301]]], ["As example, one can get the latent infection model of Pankavich [18] with p(S, V ) = \u03b2 1 S, q (S, A ) = 0 , h (S, L ) = 0 and \u03c1 = 0 , where \u03b2 1 is the virus-to-cell infection rate.", [["cell", "ANATOMY", 160, 164], ["infection", "DISEASE", 35, 44], ["infection", "DISEASE", 165, 174], ["\u03b2 1", "GENE_OR_GENE_PRODUCT", 140, 143], ["cell", "CELL", 160, 164], ["\u03b2 1", "PROTEIN", 140, 143], ["Pankavich", "TEST", 54, 63], ["S", "TEST", 95, 96], ["S", "TEST", 111, 112], ["\u03c1", "TEST", 126, 127], ["the virus", "TEST", 147, 156], ["cell infection rate", "PROBLEM", 160, 179], ["infection", "OBSERVATION", 35, 44], ["cell", "ANATOMY", 160, 164], ["infection", "OBSERVATION", 165, 174]]], ["Furthermore, the model (1) includes the class of HIV infection models for different rates of infection and latently infected cells as investigated in Wang et al. [26] .IntroductionThe model (1) reduces toIntroductionwhen all of infected cells become latently infected cells (i.e. \u03b7 = 1 ).IntroductionThis system includes the following viral models:Introduction\u2022 Model of Rong et al. [20] with p(S, The paper has been organized as follows: In Section 2 , the existence of equilibria and the well-posedness of the model including nonnegativity and boundedness of the solutions have been established.", [["cells", "ANATOMY", 125, 130], ["cells", "ANATOMY", 237, 242], ["cells", "ANATOMY", 268, 273], ["HIV infection", "DISEASE", 49, 62], ["infection", "DISEASE", 93, 102], ["latently infected", "DISEASE", 107, 124], ["HIV", "ORGANISM", 49, 52], ["cells", "CELL", 125, 130], ["cells", "CELL", 237, 242], ["cells", "CELL", 268, 273], ["latently infected cells", "CELL_TYPE", 107, 130], ["infected cells", "CELL_TYPE", 228, 242], ["latently infected cells", "CELL_TYPE", 250, 273], ["HIV", "SPECIES", 49, 52], ["HIV infection models", "PROBLEM", 49, 69], ["infection", "PROBLEM", 93, 102], ["latently infected cells", "PROBLEM", 107, 130], ["The model (1) reduces toIntroductionwhen", "TREATMENT", 180, 220], ["infected cells", "PROBLEM", 228, 242], ["latently infected cells", "PROBLEM", 250, 273], ["the solutions", "TREATMENT", 561, 574], ["HIV", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 53, 62], ["infection", "OBSERVATION", 93, 102], ["latently", "OBSERVATION_MODIFIER", 107, 115], ["infected cells", "OBSERVATION", 116, 130], ["latently", "OBSERVATION_MODIFIER", 250, 258], ["infected cells", "OBSERVATION", 259, 273]]], ["The stability analysis of the equilibria has been presented in Section 3 .", [["stability", "OBSERVATION_MODIFIER", 4, 13], ["equilibria", "OBSERVATION_MODIFIER", 30, 40]]], ["An application and illustrative numerical simulations have been given in Section 4 .", [["An application", "TREATMENT", 0, 14], ["illustrative numerical simulations", "TREATMENT", 19, 53]]], ["The Section 5 is for conclusion in terms of both mathematical and biological perspectives of the findings.Well-posedness and equilibriaThis section first establishes the well-posedness of our model (1) by proving the nonnegativity and boundedness of solutions.", [["equilibriaThis section", "TREATMENT", 125, 147]]], ["Then we derive the threshold parameter for the existence of equilibria.Theorem 2.1.", [["the threshold parameter", "TREATMENT", 15, 38], ["Theorem", "TEST", 71, 78], ["equilibria", "OBSERVATION", 60, 70]]], ["DenoteTheorem 2.1.", [["DenoteTheorem", "TEST", 0, 13]]], ["All solutions of model (1) with nonnegative initial conditions remain nonnegative and boundedIt is obvious that model (1) has always one infection-free equilibriumTheorem 2.1.", [["infection", "DISEASE", 137, 146], ["one infection", "PROBLEM", 133, 146], ["free equilibriumTheorem", "TEST", 147, 170], ["infection", "OBSERVATION", 137, 146]]], ["All solutions of model (1) with nonnegative initial conditions remain nonnegative and boundedThen we define the basic reproduction number of (1) as follows:Theorem 2.1.", [["Theorem", "TEST", 156, 163]]], ["This number can be rewritten as followsTheorem 2.1.", [["Theorem", "TEST", 39, 46]]], ["All solutions of model (1) with nonnegative initial conditions remain nonnegative and boundedThe other equilibrium of model (1) satisfies the following systemTheorem 2.1.", [["systemTheorem", "TEST", 152, 165]]], ["All solutions of model (1) with nonnegative initial conditions remain nonnegative and boundedkA \u2212 \u03bcV = 0 .Theorem 2.1.", [["Theorem", "TEST", 106, 113]]], ["All solutions of model (1) with nonnegative initial conditions remain nonnegative and bounded.Stability analysisThis section deals with the stability analysis of two equilibria E p and E * .", [["Stability analysis", "TEST", 94, 112], ["the stability analysis", "TEST", 136, 158]]], ["However, the global stability is established by using two techniques, the first is based on the definition which consists to prove that the solution of the model converges to the equilibrium point independently of the initial conditions.", [["global", "OBSERVATION_MODIFIER", 13, 19], ["stability", "OBSERVATION", 20, 29]]], ["The second technique is based on the direct Lyapunov method which aims to construct an appropriate Lyapunov functional.Stability analysiswhereStability analysisIt is obvious that \u03be = \u2212d is a negative root of Eq.", [["root", "ANATOMY", 200, 204], ["\u03be = \u2212d", "SIMPLE_CHEMICAL", 179, 185], ["The second technique", "TREATMENT", 0, 20], ["the direct Lyapunov method", "TREATMENT", 33, 59], ["Stability analysiswhereStability analysis", "TEST", 119, 160]]], ["The other roots are determined by the following equation:Stability analysisIf R 0 < 1 , then a 1 > 0, a 2 > 0, a 3 > 0 andStability analysisBy the Routh-Hurwitz Theorem [8] , we know that all roots of (9) have negative real parts.", [["roots", "ANATOMY", 10, 15], ["roots", "ANATOMY", 192, 197], ["roots", "ORGAN", 10, 15], ["roots", "ANATOMY", 10, 15]]], ["Thus, the infection-free equilibrium E p is locally asymptotically stable if R 0 < 1 .", [["infection", "DISEASE", 10, 19], ["the infection", "PROBLEM", 6, 19], ["infection", "OBSERVATION", 10, 19]]], ["(9) has at least one positive root.", [["root", "ANATOMY", 30, 34], ["root", "ORGAN", 30, 34], ["positive root", "OBSERVATION", 21, 34]]], ["This implies that the infection-free equilibrium E p becomes unstable when R 0 > 1 .Stability analysisThe following theorem characterizes the global stability of the infection-free equilibrium E p when R 0 < 1 .Theorem 3.2.", [["infection", "DISEASE", 22, 31], ["infection", "DISEASE", 166, 175], ["the infection", "PROBLEM", 18, 31], ["Stability analysis", "TEST", 84, 102], ["the infection", "PROBLEM", 162, 175], ["Theorem", "TEST", 211, 218], ["infection", "OBSERVATION", 22, 31], ["global", "OBSERVATION_MODIFIER", 142, 148], ["stability", "OBSERVATION_MODIFIER", 149, 158], ["infection", "OBSERVATION", 166, 175]]], ["The infection-free equilibrium E p is globally asymptotically stable whenProof.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["We have the following inequality from the first equation of (1)Theorem 3.2.", [["Theorem", "TEST", 63, 70]]], ["The infection-free equilibrium E p is globally asymptotically stable whenThen for arbitrary > 0, there exist a t 1 > 0 such thatTheorem 3.2.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["arbitrary", "TEST", 82, 91], ["Theorem", "TEST", 128, 135], ["infection", "OBSERVATION", 4, 13]]], ["The infection-free equilibrium E p is globally asymptotically stable whenFrom the last three equations of (1) , for t \u2265 t 1 , we haveTheorem 3.2.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["Theorem", "TEST", 133, 140], ["infection", "OBSERVATION", 4, 13], ["free", "OBSERVATION_MODIFIER", 14, 18], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["The infection-free equilibrium E p is globally asymptotically stable whenConsider the following comparison systemTheorem 3.2.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["comparison systemTheorem", "TEST", 96, 120], ["infection", "OBSERVATION", 4, 13]]], ["The infection-free equilibrium E p is globally asymptotically stable whenThis system can be rewritten as follows The eigenvalues of the matrix M satisfy the following equation:Theorem 3.2.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["Theorem", "TEST", 176, 183], ["infection", "OBSERVATION", 4, 13]]], ["The infection-free equilibrium E p is globally asymptotically stable whenIt follows from the Routh-Hurwitz Theorem that all eigenvalues of M have negative real parts.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["free", "OBSERVATION_MODIFIER", 14, 18]]], ["Therefore,Theorem 3.2.", [["Theorem", "TEST", 10, 17]]], ["The infection-free equilibrium E p is globally asymptotically stable whenFrom the first equation of (1) , for t \u2265 t 1 , we can getTheorem 3.2.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["Theorem", "TEST", 130, 137], ["infection", "OBSERVATION", 4, 13], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["The infection-free equilibrium E p is globally asymptotically stable whenThis completes the proof of Theorem 3.2 .Theorem 3.2.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["Theorem", "TEST", 101, 108], ["Theorem", "TEST", 114, 121], ["infection", "OBSERVATION", 4, 13]]], ["The infection-free equilibrium E p is globally asymptotically stable whenNext, we investigate the global asymptotic stability of the chronic infection equilibrium E * ( S * , L * , A * , V * ) by assuming that R 0 > 1 and the incidence functions p, q and h satisfy, \u2200 S, L, A, V > 0, the following further hypothesis:Theorem 3.2.", [["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 141, 150], ["The infection", "PROBLEM", 0, 13], ["the chronic infection", "PROBLEM", 129, 150], ["the incidence functions", "TEST", 222, 245], ["q", "TEST", 249, 250], ["satisfy", "TEST", 257, 264], ["S", "TEST", 268, 269], ["L", "TEST", 271, 272], ["A", "TEST", 274, 275], ["V", "TEST", 277, 278], ["Theorem", "TEST", 317, 324], ["infection", "OBSERVATION", 4, 13], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["infection", "OBSERVATION", 141, 150]]], ["The infection-free equilibrium E p is globally asymptotically stable whenSince the incidence function p ( S, V ) is strictly monotonically increasing with respect to S , we deduce thatTheorem 3.2.", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["Theorem", "TEST", 184, 191], ["infection", "OBSERVATION", 4, 13], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["The infection-free equilibrium E p is globally asymptotically stable whenSince ( x ) \u2265 0, we have dW dt \u2264 0 with equality if and only if S = S * , L = L * , A = A * and V = V * .", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["From LaSalle's invariance principle [12] , we conclude that the chronic infection equilibrium E * is globally asymptotically stable when R 0 > 1 .Application and numerical simulationsIn this section, we first apply our main results to the following HIV infection model:Application and numerical simulationsThen the assumption ( H 4 ) is also satisfied.", [["infection", "DISEASE", 72, 81], ["HIV infection", "DISEASE", 249, 262], ["HIV", "SPECIES", 249, 252], ["the chronic infection equilibrium E", "PROBLEM", 60, 95], ["numerical simulations", "TEST", 162, 183], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["infection", "OBSERVATION", 72, 81], ["stable", "OBSERVATION_MODIFIER", 125, 131]]], ["In this special case, the basic reproduction number has the following form:Application and numerical simulationsAccording to Theorems 3.2 and 3.3 , we deduce the following result.Application and numerical simulationsCorollary 4.1.", [["numerical simulations", "TEST", 195, 216]]], ["Let R 0 defined by (11) .Application and numerical simulations(i) If R 0 < 1 , then the infection-free equilibrium E p of model (10) is globally asymptotically stable.Application and numerical simulations(ii) If R 0 > 1 , then the infection-free equilibrium E p becomes unstable and the chronic infection equilibrium E * of model (10) is globally asymptotically stable for \u03c1 = 0 and \u03b7 = 1 .Application and numerical simulationsNow, we carry out numerical simulations to confirm the above analytical results concerning the dynamics of model with the parameter values given in Table 1 .Application and numerical simulationsFirstly, we choose \u03b2 1 = 5 .", [["infection", "DISEASE", 88, 97], ["infection", "DISEASE", 231, 240], ["infection", "DISEASE", 295, 304], ["Let R 0", "GENE_OR_GENE_PRODUCT", 0, 7], ["Let R 0", "DNA", 0, 7], ["the infection", "PROBLEM", 84, 97], ["numerical simulations(ii)", "TREATMENT", 183, 208], ["the infection", "PROBLEM", 227, 240], ["unstable", "PROBLEM", 270, 278], ["the chronic infection equilibrium", "PROBLEM", 283, 316], ["numerical simulations", "TEST", 406, 427], ["numerical simulations", "TEST", 445, 466], ["the parameter values", "TEST", 545, 565], ["numerical simulations", "TEST", 600, 621], ["infection", "OBSERVATION", 88, 97], ["stable", "OBSERVATION_MODIFIER", 160, 166], ["infection", "OBSERVATION", 231, 240], ["chronic", "OBSERVATION_MODIFIER", 287, 294], ["infection", "OBSERVATION", 295, 304], ["stable", "OBSERVATION", 362, 368]]], ["Hence, model (10) has an infection-free equilibrium E p (719.4245, 0, 0, 0).", [["infection", "DISEASE", 25, 34], ["an infection", "PROBLEM", 22, 34], ["infection", "OBSERVATION", 25, 34]]], ["Fig. 4 shows that E * (618.5765, 5.4708, 3.5012, 58.3445) is globally asymptotically stable despite \u03c1 = 0 and \u03b7 = 1.", [["\u03c1", "TEST", 100, 101], ["stable", "OBSERVATION_MODIFIER", 85, 91]]], ["Thus, the conditions \u03c1 = 0 and \u03b7 = 1 are not necessary for the global asymptotic stability of the chronic infection equilibrium E * .", [["infection", "DISEASE", 106, 115], ["the conditions \u03c1", "TEST", 6, 22], ["the chronic infection equilibrium", "PROBLEM", 94, 127], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["infection", "OBSERVATION", 106, 115]]], ["We will prove analytically this open problem in future work.ConclusionsThe work developed a model by using tools and techniques of mathematics for infection by viruses with latently infected cells and cell-to-cell transmission.", [["cells", "ANATOMY", 191, 196], ["cell", "ANATOMY", 201, 205], ["cell", "ANATOMY", 209, 213], ["infection", "DISEASE", 147, 156], ["latently infected", "DISEASE", 173, 190], ["cells", "CELL", 191, 196], ["cell", "CELL", 201, 205], ["cell", "CELL", 209, 213], ["latently infected cells", "CELL_TYPE", 173, 196], ["infection", "PROBLEM", 147, 156], ["viruses", "PROBLEM", 160, 167], ["latently infected cells", "PROBLEM", 173, 196], ["cell", "TEST", 201, 205], ["infection", "OBSERVATION", 147, 156], ["infected cells", "OBSERVATION", 182, 196]]], ["It also identified two equilibria, viz. an infection-free equilibrium E p and chronic infection equilibrium E * .", [["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 86, 95], ["an infection", "PROBLEM", 40, 52], ["chronic infection equilibrium", "PROBLEM", 78, 107], ["two", "OBSERVATION_MODIFIER", 19, 22], ["equilibria", "OBSERVATION", 23, 33], ["infection", "OBSERVATION", 43, 52], ["free", "OBSERVATION_MODIFIER", 53, 57], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["infection", "OBSERVATION", 86, 95]]], ["It is proved that E p is globally asymptotically stable if the basic reproduction number is less than one, which implies that the virus is eradicable and the infection is curable.", [["infection", "DISEASE", 158, 167], ["E p", "GENE_OR_GENE_PRODUCT", 18, 21], ["the virus", "PROBLEM", 126, 135], ["the infection", "PROBLEM", 154, 167], ["stable", "OBSERVATION_MODIFIER", 49, 55], ["virus", "OBSERVATION", 130, 135], ["infection", "OBSERVATION", 158, 167]]], ["And, when the basic reproduction number is greater than one, E p becomes unstable and E * is globally asymptotically stable for \u03c1 = 0 and \u03b7 = 1 .", [["stable", "OBSERVATION", 117, 123]]], ["In this case, the virus persists in the host.", [["the virus", "PROBLEM", 14, 23], ["virus", "OBSERVATION", 18, 23]]], ["On the other hand, the models and results presented in Callaway and Perelson [3] , Hu et al. [9] , Maziane et al. [15] , Pankavich [18] , Rong et al. [20] , Sun et al. [24] , Wang et al. [25] , 26 ] are improved and generalized.ConclusionsIt is observed from the explicit formula of the basic reproduction number R 0 given in (3) that R 0 is as sum of the basic reproduction numbers for the classical virus-to-cell infection mode R 01 , cell-to-cell transmission mode via actively infected cells R 02 and cell-to-cell transmission mode via latently infected cells R 03 .", [["cell", "ANATOMY", 410, 414], ["cell", "ANATOMY", 437, 441], ["cell", "ANATOMY", 445, 449], ["cells", "ANATOMY", 490, 495], ["cell", "ANATOMY", 505, 509], ["cell", "ANATOMY", 513, 517], ["cells", "ANATOMY", 558, 563], ["infection", "DISEASE", 415, 424], ["cell", "CELL", 410, 414], ["cell", "CELL", 437, 441], ["cell", "CELL", 445, 449], ["cells", "CELL", 490, 495], ["R 02", "CELL", 496, 500], ["cell", "CELL", 505, 509], ["cell", "CELL", 513, 517], ["cells", "CELL", 558, 563], ["R 02", "CELL_LINE", 496, 500], ["R 03", "CELL_LINE", 564, 568], ["Pankavich", "TREATMENT", 121, 130], ["the classical virus", "PROBLEM", 387, 406], ["cell", "TEST", 437, 441], ["actively infected cells", "PROBLEM", 472, 495], ["R 02", "TEST", 496, 500], ["cell", "TEST", 505, 509], ["latently infected cells", "PROBLEM", 540, 563], ["generalized", "OBSERVATION_MODIFIER", 216, 227], ["infected cells", "OBSERVATION", 481, 495], ["latently", "OBSERVATION_MODIFIER", 540, 548], ["infected cells", "OBSERVATION", 549, 563]]], ["Hence, ignoring the cell-to-cell transmission in viral infections dynamics will underestimate R 0 .", [["cell", "ANATOMY", 20, 24], ["cell", "ANATOMY", 28, 32], ["infections", "DISEASE", 55, 65], ["cell", "CELL", 20, 24], ["cell", "CELL", 28, 32], ["ignoring the cell", "TEST", 7, 24], ["viral infections dynamics", "PROBLEM", 49, 74], ["viral infections", "OBSERVATION", 49, 65]]], ["Further, the study of this paper can be of help for the biologists to develop effective treatments against viral infections in order to reduce the patients' basic reproduction number to less than one and eliminate the latent reservoirs which represent the main obstacle to the eradication of virus from the human body.Credit statementAuthor 1 discussed the research problem with Author 2 first.", [["body", "ANATOMY", 313, 317], ["viral infections", "DISEASE", 107, 123], ["patients", "ORGANISM", 147, 155], ["human", "ORGANISM", 307, 312], ["body", "ORGANISM_SUBDIVISION", 313, 317], ["patients", "SPECIES", 147, 155], ["human", "SPECIES", 307, 312], ["human", "SPECIES", 307, 312], ["the study", "TEST", 9, 18], ["effective treatments", "TREATMENT", 78, 98], ["viral infections", "PROBLEM", 107, 123], ["the latent reservoirs", "PROBLEM", 214, 235], ["latent", "OBSERVATION_MODIFIER", 218, 224], ["reservoirs", "OBSERVATION", 225, 235], ["main", "OBSERVATION_MODIFIER", 256, 260], ["eradication", "OBSERVATION", 277, 288], ["virus", "OBSERVATION", 292, 297], ["human body", "ANATOMY_MODIFIER", 307, 317]]]], "8006e0c5ae130001f8b63257a3a85e3e1ee1661c": [["Mathematics Subject Classification (2010) MSC 34D23 \u00b7 MSC 92D30 \u00b7 MSC 92D25IntroductionIn the classical compartmental models of epidemiology, the key parameters such as the transmission and vaccination rates are assumed to remain the same during an epidemic.", [["MSC 34D23 \u00b7 MSC 92D30 \u00b7 MSC", "ANATOMY", 42, 69], ["MSC 34D23 \u00b7 MSC 92D30 \u00b7 MSC 92D25", "CELL", 42, 75], ["MSC 92D30", "CELL_LINE", 54, 63], ["MSC 92D25", "CELL_LINE", 66, 75], ["vaccination rates", "TEST", 190, 207]]], ["As an example, consider a SIR model with vaccination of the form\u1e60 = \u2212 \u03b2SI N \u2212 vS \u2212 \u00b5S + \u00b5N,Introductionwhere S, I and R are densities of the populations of susceptible, infected and recovered individuals, respectively; N = S + I + R is the total population density; \u03b2 is the transmission rate, which can be expressed as the product of the average number of daily contacts a susceptible individual has with other individuals and the probability of transmission during each contact; v is the vaccination rate; \u03b3 is the recovery rate; and, \u00b5 is the birth/mortality rate (or immigration/emigration rate; for childhood infections, individuals leave the group at a certain age).", [["infections", "DISEASE", 614, 624], ["I + R", "GENE_OR_GENE_PRODUCT", 227, 232], ["a SIR model with vaccination", "TREATMENT", 24, 52], ["the form\u1e60", "TEST", 56, 65], ["SI", "TEST", 71, 73], ["S", "TEST", 84, 85], ["N", "PROBLEM", 89, 90], ["Introductionwhere S", "TEST", 91, 110], ["the total population density", "PROBLEM", 236, 264], ["the transmission rate", "TEST", 271, 292], ["immigration/emigration rate", "TREATMENT", 571, 598], ["childhood infections", "PROBLEM", 604, 624], ["densities", "OBSERVATION", 124, 133], ["susceptible", "OBSERVATION_MODIFIER", 156, 167], ["infected", "OBSERVATION_MODIFIER", 169, 177], ["total", "OBSERVATION_MODIFIER", 240, 245], ["population", "OBSERVATION_MODIFIER", 246, 256], ["density", "OBSERVATION", 257, 264]]], ["The recovered individuals are assumed to be immune to the disease.", [["individuals", "ORGANISM", 14, 25], ["the disease", "PROBLEM", 54, 65], ["disease", "OBSERVATION", 58, 65]]], ["In this particular model setup, the equality of the birth and mortality rates ensures the conservation of the total population density, i.e. N is constant.IntroductionThe key parameter is the so-called basic reproduction number R 0 .", [["the total population density", "PROBLEM", 106, 134], ["total", "OBSERVATION_MODIFIER", 110, 115], ["population", "OBSERVATION_MODIFIER", 116, 126], ["density", "OBSERVATION", 127, 134], ["constant", "OBSERVATION_MODIFIER", 146, 154]]], ["If R 0 < 1, the infection dies out in the long run; if R 0 > 1, the infection spreads in the population (Korobeinikov et al. 2002; Korobeinikov et al. 2004; Ullah et al. 2013 ) Due to their simplicity, the standard SIR model and its variants, including (1), assume that the hosts are unable to respond in any way to the advent of an epidemic and disregard the ability of the community to adapt its behavior to the danger.", [["infection", "DISEASE", 16, 25], ["infection", "DISEASE", 68, 77], ["the infection dies", "PROBLEM", 12, 30], ["the infection", "PROBLEM", 64, 77], ["infection", "OBSERVATION", 16, 25], ["infection", "OBSERVATION", 68, 77]]], ["Humans, however, are able to intelligently respond to a threat as they receive and perceive information regarding the epidemic from the \"outside\" world, the government and health authorities, and can adjust their behavior to avoid or to reduce the risk of being infected.", [["Humans", "ORGANISM", 0, 6], ["infected", "PROBLEM", 262, 270], ["infected", "OBSERVATION", 262, 270]]], ["Typical aspects of this adaptability may include simple precautionary measures, such as refraining from potentially dangerous contacts, increasing hygiene, using hand sanitizer and disinfectants, wearing face mask in public places, adjusting a general life style, taking an extra portion of vitamin C in a case of a common cold, or using vaccination in a case of influenza.", [["hand", "ANATOMY", 162, 166], ["vitamin C", "CHEMICAL", 291, 300], ["influenza", "DISEASE", 363, 372], ["vitamin C", "CHEMICAL", 291, 300], ["hand", "ORGANISM_SUBDIVISION", 162, 166], ["vitamin C", "SIMPLE_CHEMICAL", 291, 300], ["simple precautionary measures", "TREATMENT", 49, 78], ["hand sanitizer", "TREATMENT", 162, 176], ["disinfectants", "TREATMENT", 181, 194], ["face mask", "TREATMENT", 204, 213], ["a general life style", "TREATMENT", 242, 262], ["an extra portion of vitamin C", "TREATMENT", 271, 300], ["vaccination", "TREATMENT", 338, 349], ["influenza", "PROBLEM", 363, 372]]], ["At the threat of epidemics, the government and health authorities can intervene by promoting immunizations, if available, raising awareness in the population about the current severity of the epidemic, providing access to effective and affordable medicines and tests, working with school authorities, using media and/or administrative pressure, etc. During the covid-19 epidemics we have seen such interventions imposed by the authorities on an unprecedented scale including massive quarantine and social distancing measures, business restrictions, gathering limitations, stay-at-home and shelter-in-place orders and closing the state borders.IntroductionIn order to account for the adaptability of the population, the assumptions of the standard SIR models, which postulate constant transmission and vaccination rates during the whole time period in question, was revisited in several different ways.", [["epidemics", "PROBLEM", 17, 26], ["promoting immunizations", "TREATMENT", 83, 106], ["affordable medicines", "TREATMENT", 236, 256], ["tests", "TEST", 261, 266], ["media", "TREATMENT", 307, 312], ["administrative pressure", "TREATMENT", 320, 343], ["the covid", "TEST", 357, 366], ["such interventions", "TREATMENT", 393, 411], ["an unprecedented scale", "TREATMENT", 442, 464], ["massive quarantine", "TREATMENT", 475, 493], ["social distancing measures", "TREATMENT", 498, 524], ["vaccination rates", "TREATMENT", 801, 818], ["epidemics", "OBSERVATION", 17, 26]]], ["The incidence rate of the modified form \u03b2SI/(1 + aI) or \u03b2SI/(1 + aS) was used to account for the saturation effect with saturation rate a.", [["SI", "PROTEIN", 57, 59], ["aI", "PROBLEM", 49, 51], ["the saturation effect", "PROBLEM", 93, 114], ["saturation rate", "TEST", 120, 135]]], ["The first form is based on the assumption that an increase in the number of infective individuals leads to a reduction of the incidence rate; the second form is associated with protective measures taken by susceptible individuals against the infection.", [["infection", "DISEASE", 242, 251], ["infective individuals", "PROBLEM", 76, 97], ["the incidence rate", "PROBLEM", 122, 140], ["protective measures", "TREATMENT", 177, 196], ["the infection", "PROBLEM", 238, 251], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["infective", "OBSERVATION", 76, 85], ["infection", "OBSERVATION", 242, 251]]], ["Their extensions of these models include non-pharmaceutical intervention factors such as quarantine and isolation of patients (Hou et Immunization is a proven and probably the most effective tool for controlling and eliminating infectious diseases.", [["infectious diseases", "DISEASE", 228, 247], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["non-pharmaceutical intervention factors", "TREATMENT", 41, 80], ["isolation of patients (Hou et Immunization", "TREATMENT", 104, 146], ["infectious diseases", "PROBLEM", 228, 247]]], ["It was hypothesized that a vaccination effort can be more efficient when it is pulsed in time rather than uniform.", [["a vaccination effort", "TREATMENT", 25, 45]]], ["The effect of pulsed vaccination policy has been studied quite extensively (Agur et al. 1993; Lu et al. 2002) where a detailed comparison of models with constant and pulsed vaccination rate is provided.", [["pulsed vaccination policy", "TREATMENT", 14, 39], ["constant and pulsed vaccination rate", "TREATMENT", 153, 189]]], ["Piecewise smooth epidemiological models of switched vaccination, implemented once the number of people exposed to a virus reaches a critical level, were studied in Wang et al. (2014) .", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["switched vaccination", "TREATMENT", 43, 63], ["a virus", "PROBLEM", 114, 121]]], ["In yet another class of epidemiological models with adaptive switching behavior, a stochastic switching model was combined with an economic optimal stopping problem to determine the optimal timings for public health interventions (Sims et al. 2016) .", [["adaptive switching behavior", "TREATMENT", 52, 79], ["a stochastic switching model", "TREATMENT", 81, 109], ["public health interventions", "TREATMENT", 202, 229]]], ["Models studied in Chladn\u00e1 et al. (2020) assume that intervention measures are implemented when the number of infected individuals exceeds a critical level, and the intervention stops when this number drops below a different (lower) threshold.", [["intervention measures", "TREATMENT", 52, 73], ["infected individuals", "PROBLEM", 109, 129], ["the intervention", "TREATMENT", 160, 176], ["infected", "OBSERVATION", 109, 117]]], ["Implications of such two-threshold intervention strategies for dynamics of an SIR model were considered both in the case of switched vaccination rate (see Section 2.1) and switched transmission rate.IntroductionMultiple factors can influence the willingness of an individual to receive immunization depending on the perceived risk of contracting the disease, risk of possible complications, personal beliefs, etc. These risks vary with age, health conditions, lifestyle and profession.", [["such two-threshold intervention strategies", "TREATMENT", 16, 58], ["an SIR model", "TEST", 75, 87], ["switched vaccination rate", "TREATMENT", 124, 149], ["immunization", "TREATMENT", 286, 298], ["the disease", "PROBLEM", 346, 357], ["complications", "PROBLEM", 376, 389]]], ["Further, interventions of the health authorities and administrative measures at the level of a county or state can vary in scale depending on the availability of resources, the local economic situation and other factors.", [["administrative measures", "TREATMENT", 53, 76]]], ["All these variations lead to the heterogeneity of the response of the population to the advent of an epidemic.IntroductionIn this paper, we propose a variant of the SIR model with a heterogeneous response and analyze how the heterogeneity affects the dynamics.", [["epidemic", "OBSERVATION", 101, 109]]], ["We focus on the scenario when interventions of the health authorities affect the vaccination rate (assuming vaccines are available) while the transmission rate remains constant; the case of variable transmission rate will be considered elsewhere.", [["the vaccination rate", "TREATMENT", 77, 97], ["vaccines", "TREATMENT", 108, 116], ["the transmission rate", "TEST", 138, 159], ["variable transmission rate", "TREATMENT", 190, 216]]], ["As a starting point, we adopt the approach of Chladn\u00e1 et al. (2020) to modeling the homogeneous switched response of a subpopulation to the varying number of infected individuals by a two-threshold two-state relay operator (as described in Section 2.1).", [["varying", "OBSERVATION_MODIFIER", 140, 147], ["infected", "OBSERVATION", 158, 166]]], ["To reflect the heterogeneity, multiple subpopulations are considered, each characterized by a different pair of switching thresholds.", [["the heterogeneity", "PROBLEM", 11, 28], ["heterogeneity", "OBSERVATION", 15, 28], ["multiple", "OBSERVATION_MODIFIER", 30, 38], ["subpopulations", "OBSERVATION", 39, 53]]], ["The main simplification is that perfect mixing of the population is assumed.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This leads to a differential model with just two variables, S and I, but with a complex operator relationship between the vaccination rate v and the density of the infected individuals I. As such, this operator relationship, known as the Preisach operator, accounts for the heterogeneity of the response.", [["density", "OBSERVATION_MODIFIER", 149, 156], ["infected", "OBSERVATION", 164, 172]]], ["Heterogeneity of intervention policies can be modeled in a similar fashion (see Section 2.2).IntroductionWe show that the system with the Preisach operator is amenable to analysis when interpreted as a switched system (Bernardo et al. 2008 ) associated with a one-parameter family of nonlinear planar vector fields \u03a6 u = \u03a6 u (I, S) (where u \u2208 R is a parameter).", [["Preisach operator", "DNA", 138, 155], ["intervention policies", "TREATMENT", 17, 38]]], ["The Preisach operator imposes non-trivial rules for switching from one vector field to another.", [["Preisach operator", "DNA", 4, 21]]], ["Some intuition can be drawn from dynamics of systems with dry friction such as models of presliding friction behavior (Al-Bender et al. 2004; Ruderman 2011), and population models with theresholds (Meza et al. 2009 ).IntroductionUsing the switched systems approach, we show that if R 0 \u2264 1, then the infection-free equilibrium is globally stable.", [["infection", "DISEASE", 300, 309], ["dry friction", "PROBLEM", 58, 70], ["presliding friction behavior", "PROBLEM", 89, 117], ["the infection", "PROBLEM", 296, 309], ["infection", "OBSERVATION", 300, 309], ["globally", "OBSERVATION_MODIFIER", 330, 338], ["stable", "OBSERVATION_MODIFIER", 339, 345]]], ["Namely, the system has a connected set of endemic equilibrium states characterized by different proportion of infected and immune individuals 1 .", [["infected and immune individuals", "PROBLEM", 110, 141], ["endemic equilibrium", "OBSERVATION", 42, 61], ["infected", "OBSERVATION", 110, 118]]], ["In this case, we show that every trajectory converges either to one of the endemic equilibrium states or to a periodic orbit corresponding to the recurrence of the disease.", [["orbit", "ANATOMY", 119, 124], ["orbit", "ORGAN", 119, 124], ["a periodic orbit", "PROBLEM", 108, 124], ["the disease", "PROBLEM", 160, 171], ["orbit", "ANATOMY", 119, 124], ["disease", "OBSERVATION", 164, 171]]], ["Under additional natural assumptions, we prove the global stability of the set of endemic equilibrium states by adapting the method of Lyapunov functions.", [["global", "OBSERVATION_MODIFIER", 51, 57], ["stability", "OBSERVATION_MODIFIER", 58, 67], ["endemic equilibrium", "OBSERVATION", 82, 101], ["Lyapunov functions", "OBSERVATION", 135, 153]]], ["We establish the global stability of the switched system by controlling the increment V u (I 1 , S 1 ) \u2212 V u (I 2 , S 2 ) of the Lyapunov function along a trajectory between the switching points, and the difference V u1 (I, S) \u2212 V u2 (I, S) of the Lyapunov functions at those points.", [["Lyapunov", "PROTEIN", 129, 137], ["V u1", "PROTEIN", 215, 219], ["Lyapunov", "PROTEIN", 248, 256], ["V u (I", "TEST", 105, 111], ["the Lyapunov function", "PROBLEM", 125, 146], ["the Lyapunov functions", "PROBLEM", 244, 266], ["global", "OBSERVATION_MODIFIER", 17, 23], ["stability", "OBSERVATION", 24, 33], ["Lyapunov function", "OBSERVATION", 129, 146], ["Lyapunov functions", "OBSERVATION", 248, 266]]], ["Numerical analysis of SIR models with the Preisach operator was previously performed in (Pimenov et al. 2010 , Pimenov et al. 2012 The paper is organized as follows.", [["Preisach operator", "DNA", 42, 59], ["the Preisach operator", "TREATMENT", 38, 59]]], ["In Section 3 some preliminary properties of the Preisach operator and the model are discussed, including hysteresis loops, equilibrium states and the global stability of the infection-free equilibrium in the case R 0 \u2264 1.", [["infection", "DISEASE", 174, 183], ["Preisach operator", "DNA", 48, 65], ["the Preisach operator", "TREATMENT", 44, 65], ["hysteresis loops, equilibrium states", "PROBLEM", 105, 141], ["the infection", "PROBLEM", 170, 183], ["global", "OBSERVATION_MODIFIER", 150, 156], ["stability", "OBSERVATION_MODIFIER", 157, 166], ["infection", "OBSERVATION", 174, 183]]], ["Sections 4 and 5 present the main results on dynamics in the case R 0 > 1 and their proofs.ModelWe consider the following SIR modelModelwith an additional feedback loop, which relates the variable vaccination rate v = v(t) to the concurrent and past values of the density I = I(t) of the infected population.", [["Sections", "TEST", 0, 8], ["an additional feedback loop", "TREATMENT", 141, 168], ["the infected population", "PROBLEM", 284, 307], ["density", "OBSERVATION", 264, 271], ["infected", "OBSERVATION_MODIFIER", 288, 296], ["population", "OBSERVATION", 297, 307]]], ["In the main part of the paper, it is assumed that the function I : R + \u2192 R is mapped to the function v : R + \u2192 R by the so-called continuous Preisach operator, which is described in the following sections.", [["sections", "ANATOMY", 196, 204], ["R + \u2192 R", "GENE_OR_GENE_PRODUCT", 67, 74], ["R + \u2192 R", "GENE_OR_GENE_PRODUCT", 105, 112], ["I : R + \u2192 R", "PROTEIN", 63, 74]]], ["Regardless of the specific form of the feedback, one can see that the sum I + S + R is conserved by system (2) , and the last equation is redundant.", [["S + R", "GENE_OR_GENE_PRODUCT", 78, 83], ["I", "PROTEIN", 74, 75], ["redundant", "OBSERVATION", 138, 147]]], ["Without loss of generality, we can interpret S, I, R as relative densities assuming that I + S + R = 1 at all times.", [["loss of generality", "PROBLEM", 8, 26], ["densities", "OBSERVATION", 65, 74]]], ["We denote \u03b4 = \u00b5 + \u03b3 and rewrite the system as\u0130ModelNote that the domainModelis flow-invariant for this system.", [["\u03b4 = \u00b5 + \u03b3", "SIMPLE_CHEMICAL", 10, 19]]], ["Indeed, in this region,\u0130 \u2264 (\u03b2 \u2212 \u03b4)I an\u1e0bModel(where we use \u03b4 > \u00b5), which implies the statement.", [["\u03b4", "PROTEIN", 58, 59]]], ["We will consider trajectories from the domain D only.Switched model with one non-ideal relay operatorIn Chladn\u00e1 et al. 2020 , the relationship between the density of the infected population, I = I(t), and the vaccination rate was modeled by the simplest hysteretic operator called the non-ideal relay, which is also known as a rectangular hysteresis loop or a lazy switch (Visintin 1994) .", [["domain D", "PROTEIN", 39, 47], ["the vaccination rate", "TEST", 205, 225], ["a rectangular hysteresis loop", "TREATMENT", 325, 354], ["a lazy switch", "TREATMENT", 358, 371], ["density", "OBSERVATION_MODIFIER", 155, 162], ["infected", "OBSERVATION_MODIFIER", 170, 178], ["population", "OBSERVATION", 179, 189], ["rectangular hysteresis", "OBSERVATION", 327, 349]]], ["The relay operator is characterized by two scalar parameters \u03b1 1 and \u03b1 2 , the threshold values, with \u03b1 1 < \u03b1 2 .", [["two scalar parameters", "TEST", 39, 60], ["the threshold values", "TEST", 75, 95]]], ["The input of the relay is an arbitrary continuous function of time, I : R + \u2192 R. The state \u03bd \u03b1 (\u00b7) equals either 0 or 1 at any moment t \u2208 R + .", [["\u03b1", "PROTEIN", 93, 94], ["\u00b7", "PROTEIN", 96, 97]]], ["If the input value at some instant is below the lower threshold value \u03b1 1 , then the state at this instant is 0 and it remains equal to 0 as long as the input is below the upper threshold value \u03b1 2 .", [["the input value", "TEST", 3, 18], ["upper threshold", "OBSERVATION_MODIFIER", 172, 187]]], ["Given any continuous input I : R + \u2192 R and an initial value of the state, \u03bd \u03b1 (0) = \u03bd 0 \u03b1 , satisfying the constraintsSwitched model with one non-ideal relay operatorthe state of the relay at the future moments t > 0 is defined bySwitched model with one non-ideal relay operatorThis time series of the state, which depends both on the input I(t) (t \u2265 0) and the initial state \u03bd \u03b1 (0) = \u03bd 0 \u03b1 of the relay, will be denoted bySwitched model with one non-ideal relay operatorBy definition, the state satisfies the constraints \u03bd \u03b1 (t) = 1 whenever I(t) \u2265 \u03b1 2 ; \u03bd \u03b1 (t) = 0 whenever I(t) \u2264 \u03b1 1 (9) at all times.", [["R + \u2192 R", "GENE_OR_GENE_PRODUCT", 31, 38], ["the constraints", "TEST", 507, 522], ["\u03b1", "TEST", 585, 586]]], ["If the input oscillates between two values I 1 , I 2 , such that I 1 < \u03b1 1 < \u03b1 2 < I 2 , then the point (I(t), \u03bd \u03b1 (t)) moves counterclockwise along the rectangular hysteresis loop shown in Figure 1 .Switched model with one non-ideal relay operatorIn Chladn\u00e1 et al. (2020) , it was assumed that interventions of the health authority change the vaccination rate according to the following rules.", [["I 2", "PROTEIN", 83, 86], ["the input oscillates", "TEST", 3, 23], ["two values I", "TEST", 32, 44], ["the rectangular hysteresis loop", "TREATMENT", 149, 180], ["the vaccination rate", "TREATMENT", 340, 360], ["rectangular hysteresis", "OBSERVATION", 153, 175]]], ["The vaccination rate is switched from a lower rate v nat to a higher rate v int := v nat + q 0 , Fig. 1 The non-ideal relay operator defined by (7) q 0 > 0, when the density of the infected population reaches a threshold value \u03b1 2 .", [["The vaccination rate", "TREATMENT", 0, 20], ["a lower rate v nat", "TREATMENT", 38, 56], ["the infected population", "PROBLEM", 177, 200], ["infected", "OBSERVATION_MODIFIER", 181, 189], ["population", "OBSERVATION_MODIFIER", 190, 200]]], ["The intervention stops when the number of infected individuals drops below a lower threshold value \u03b1 1 , at which point the vaccination rate returns to its lower value v nat .", [["The intervention", "TREATMENT", 0, 16], ["infected individuals", "PROBLEM", 42, 62], ["the vaccination rate", "TEST", 120, 140], ["infected", "OBSERVATION", 42, 50]]], ["Using the definition (7) of the non-ideal relay operator (8) , this leads to the formulaSwitched model with one non-ideal relay operatorCoupling of this operator equation with dynamic equations (3) results in a switched system.", [["a switched system", "TREATMENT", 209, 226]]], ["As shown in Chladn\u00e1 et al. (2020), switched system (3), (10) exhibits different dynamic scenarios depending on its parameters.", [["different dynamic scenarios", "PROBLEM", 70, 97]]], ["In particular, it can have a globally stable endemic equilibrium.", [["globally", "OBSERVATION_MODIFIER", 29, 37], ["stable", "OBSERVATION_MODIFIER", 38, 44], ["endemic", "OBSERVATION_MODIFIER", 45, 52], ["equilibrium", "OBSERVATION", 53, 64]]], ["Alternatively, a locally stable endemic equilibrium coexists with a stable periodic orbit.", [["orbit", "ORGAN", 84, 89], ["a locally stable endemic equilibrium coexists", "PROBLEM", 15, 60], ["a stable periodic orbit", "PROBLEM", 66, 89], ["locally", "OBSERVATION_MODIFIER", 17, 24], ["stable", "OBSERVATION_MODIFIER", 25, 31], ["endemic", "OBSERVATION_MODIFIER", 32, 39], ["equilibrium coexists", "OBSERVATION", 40, 60], ["stable", "OBSERVATION_MODIFIER", 68, 74], ["periodic", "OBSERVATION_MODIFIER", 75, 83], ["orbit", "ANATOMY", 84, 89]]], ["Along this orbit, the vaccination rate (10) switches between the values v nat and v nat + q 0 twice per period.Model with heterogeneous vaccination rateNow, we consider a model, in which several vaccination laws of the form (10), with different thresholds \u03b1, are combined either because the health authority employs multiple intervention strategies or because different individuals respond differently to the advent of an epidemic.Model with heterogeneous vaccination rateAssume that the health authority has multiple intervention policies (numbered n = 1, . . . , N ) in place, each increasing the vaccination rate by a certain amount q n while the intervention is implemented, in order to provide a response, which is adequate to the severity of the epidemic.", [["orbit", "ANATOMY", 11, 16], ["orbit", "ORGAN", 11, 16], ["the vaccination rate", "TEST", 18, 38], ["multiple intervention strategies", "TREATMENT", 316, 348], ["multiple intervention policies", "TREATMENT", 509, 539], ["the vaccination rate", "TREATMENT", 595, 615], ["the intervention", "TREATMENT", 646, 662], ["orbit", "ANATOMY", 11, 16], ["heterogeneous", "OBSERVATION_MODIFIER", 122, 135], ["vaccination", "OBSERVATION", 136, 147], ["heterogeneous", "OBSERVATION_MODIFIER", 442, 455], ["vaccination", "OBSERVATION", 456, 467], ["epidemic", "OBSERVATION", 752, 760]]], ["Further, assume that each intervention policy is guided by the two-threshold start/stop rule, such as in (10), associated with a particular pair of thresholds \u03b1 n = (\u03b1 n 1 , \u03b1 n 2 ).", [["a particular pair of thresholds", "PROBLEM", 127, 158]]], ["Under these assumptions, the vaccination rate in system (3) is given byModel with heterogeneous vaccination rateThis formula defines a mapping from the space of continuous inputs I : R + \u2192 R to the space of piecewise constant outputs v : R + \u2192 R, which is known as the discrete Preisach operator ( Krasnosel'skii et al. 1983), see Figure 2 .Model with heterogeneous vaccination rateIn particular, the vaccination rate (11) is set to change at multiple thresholds \u03b1 n 1 , \u03b1 n 2 .", [["R + \u2192 R", "GENE_OR_GENE_PRODUCT", 183, 190], ["R + \u2192 R", "GENE_OR_GENE_PRODUCT", 238, 245], ["the vaccination rate", "TEST", 25, 45], ["heterogeneous vaccination rate", "TREATMENT", 82, 112], ["a mapping", "TEST", 133, 142], ["heterogeneous vaccination rateIn", "TREATMENT", 352, 384], ["the vaccination rate", "TEST", 397, 417], ["heterogeneous", "OBSERVATION_MODIFIER", 352, 365], ["vaccination", "OBSERVATION", 366, 377]]], ["In particular, the willingness to receive vaccination can vary significantly from individual to individual for the same level of threat of contracting the disease.", [["vaccination", "TREATMENT", 42, 53], ["the disease", "PROBLEM", 151, 162], ["disease", "OBSERVATION", 155, 162]]], ["In order to account for the heterogeneity of the individual response, let us divide the susceptible population into non-intersecting subpopulations parametrized by points \u03b1 of a subset \u03a0 \u2282 {\u03b1 = (\u03b1 1 , \u03b1 2 ) : \u03b1 1 < \u03b1 2 } of the \u03b1-plane.", [["a subset", "TEST", 176, 184]]], ["Assuming that the vaccination rate for a subpopulation labeled \u03b1 is given by (10) with q = q(\u03b1), the total vaccination rate equalsModel with heterogeneous vaccination ratewhere the probability measure F describes the distribution of the susceptible population over the index set \u03a0 (the set of threshold pairs).", [["the vaccination rate", "TEST", 14, 34], ["the total vaccination rate", "TEST", 97, 123], ["the susceptible population", "PROBLEM", 233, 259], ["susceptible", "OBSERVATION_MODIFIER", 237, 248], ["population", "OBSERVATION", 249, 259]]], ["Then, the mapping of the space of continuous inputs I : R + \u2192 R to the space of outputs v : R + \u2192 R defined by (12) is known as the general Preisach operator, which includes the discrete Preisach operator (11) and a continuous Preisach model (corresponding to an absolutely continuous measure F ) as particular cases.", [["R + \u2192 R", "GENE_OR_GENE_PRODUCT", 56, 63], ["a continuous Preisach model", "TREATMENT", 214, 241]]], ["In either case, the Preisach operator is referred to as a superposition (or parallel connection) of weighted non-ideal relays.Continuous Preisach modelLet us consider a rigorous definition of the Preisach operator (12) with an absolutely continuous measure F (Krasnosel'skii et al., 1989).", [["Preisach operator", "DNA", 20, 37], ["the Preisach operator", "TREATMENT", 192, 213]]], ["It involves a collection of non-ideal relays R \u03b1 , which respond to the same continuous input I = I(t) independently.", [["R \u03b1", "GENE_OR_GENE_PRODUCT", 45, 48], ["R \u03b1", "PROTEIN", 45, 48]]], ["The relays contributing to the system have different pairs of thresholds \u03b1 = (\u03b1 1 , \u03b1 2 ) \u2208 \u03a0, where we assume that \u03a0 is measurable and bounded; the \u03b1-plane is called the Preisach plane.", [["\u03a0", "PROTEIN", 116, 117]]], ["The output of the continuous Preisach model is the scalar-valued functionContinuous Preisach modelwhere q : \u03a0 \u2192 R is a positive bounded measurable function (measure density) representing the weights of the relays; and, \u03bd 0 \u03b1 is the initial state of the relay R \u03b1 for any given \u03b1 \u2208 \u03a0.", [["\u03a0 \u2192 R", "GENE_OR_GENE_PRODUCT", 108, 113], ["\u03bd 0 \u03b1", "GENE_OR_GENE_PRODUCT", 219, 224], ["R \u03b1", "GENE_OR_GENE_PRODUCT", 259, 262], ["\u03bd 0 \u03b1", "PROTEIN", 219, 224], ["R \u03b1", "PROTEIN", 259, 262], ["\u03b1", "PROTEIN", 277, 278], ["The output", "TEST", 0, 10], ["a positive bounded measurable function", "PROBLEM", 117, 155], ["output", "OBSERVATION_MODIFIER", 4, 10], ["positive", "OBSERVATION", 119, 127]]], ["The function \u03bd 0 = \u03bd 0 \u03b1 : \u03a0 \u2192 {0, 1} of the variable \u03b1 = (\u03b1 1 , \u03b1 2 ) is referred to as the initial state of the Preisach operator.", [["Preisach operator", "PROTEIN", 114, 131], ["The function", "TEST", 0, 12]]], ["It is assumed to be measurable and satisfy the constraints (5), (6) , in which case the initial state-input pair is called compatible.", [["assumed to be", "UNCERTAINTY", 6, 19], ["measurable", "OBSERVATION_MODIFIER", 20, 30]]], ["These requirements ensure that the integral in (13) is well-defined for each t \u2265 0 and, furthermore, the output v(\u00b7) of the Preisach model is continuous.", [["the output v", "TEST", 101, 113], ["the Preisach model", "TEST", 120, 138]]], ["The input-output operator of the Preisach model defined by (13) will be denoted byContinuous Preisach modelwhere both the input I : R + \u2192 R and the initial state \u03bd 0 = \u03bd 0 \u03b1 (which is compatible with the input) are the arguments; the value of this operator is the output v :Continuous Preisach modelIn what follows we consider system (3) with the vaccination rate defined by equation (13).PreliminariesWe begin by discussing some of the properties of the Preisach operator and system (3), (13).Global Lipschitz continuity.The Preisach operator (14)Global Lipschitz continuity.for any \u03c4 \u2265 0 withGlobal Lipschitz continuity.Let us denote by U the set of all triplets (I 0 , S 0 , \u03bd 0 ), where (I 0 , S 0 ) \u2208 D (see (4)) and the initial state \u03bd 0 of the Preisach operator is compatible with I 0 .", [["R + \u2192 R", "GENE_OR_GENE_PRODUCT", 132, 139], ["I : R", "PROTEIN", 128, 133], ["I 0", "PROTEIN", 788, 791], ["Continuous Preisach modelIn", "TREATMENT", 274, 301], ["the vaccination rate", "TREATMENT", 343, 363], ["Global Lipschitz continuity", "PROBLEM", 494, 521], ["The Preisach operator", "TREATMENT", 522, 543], ["Global Lipschitz continuity", "TREATMENT", 548, 575], ["any \u03c4 \u2265 0 withGlobal Lipschitz continuity", "PROBLEM", 580, 621], ["Lipschitz continuity", "OBSERVATION", 501, 521]]], ["The global Lipschitz estimate (15) ensures (for example, using the Picard-Lindel\u00f6f type of argument) that for given (I 0 , S 0 , \u03bd 0 ) \u2208 U, system (3) with the Preisach operator (14) has a unique local solution with the initial data I(0) = I 0 , S(0) = S 0 and the initial state \u03bd 0 (see, for example, the survey in Leonov et al. 2017 ).", [["the Picard", "TREATMENT", 63, 73], ["a unique local solution", "TREATMENT", 187, 210], ["global", "OBSERVATION_MODIFIER", 4, 10], ["Lipschitz", "OBSERVATION", 11, 20]]], ["These solutions induce a semi-flow in the set U, which is considered to be the phase space of system (3) and is endowed with a metric by the natural embedding into the space R 2 \u00d7L 1 (\u03a0; R).", [["These solutions", "TREATMENT", 0, 15]]], ["This leads to the standard definition of local and global stability including stability of equilibrium states and periodic solutions.", [["periodic solutions", "TREATMENT", 114, 132], ["local", "OBSERVATION_MODIFIER", 41, 46], ["global", "OBSERVATION_MODIFIER", 51, 57], ["stability", "OBSERVATION_MODIFIER", 58, 67], ["stability", "OBSERVATION_MODIFIER", 78, 87], ["equilibrium states", "OBSERVATION", 91, 109]]], ["In particular, an equilibrium is a triplet (I 0 , S 0 , \u03bd 0 ) \u2208 U and a periodic solution is a periodic function (I(\u00b7), S(\u00b7), \u03bd(\u00b7)) : R + \u2192 U where the last component viewed as a function \u03bd : R + \u00d7 \u03a0 \u2192 {0, 1} of two variables t \u2208 R + and \u03b1 \u2208 \u03a0 is given by (8) .Global Lipschitz continuity.The vaccination rate (13) at an equilibrium is constant, while for a periodic solution the vaccination rate is also periodic with the period of I and S.Hysteresis loops.We call a periodic input I = I(t) simple if each local minimum of this input is its global minimum and each local maximum is its global maximum.", [["\u03b1 \u2208 \u03a0", "SIMPLE_CHEMICAL", 238, 243], ["R", "PROTEIN", 134, 135], ["\u03bd", "PROTEIN", 188, 189], ["\u03b1", "PROTEIN", 238, 239], ["a periodic solution", "TREATMENT", 70, 89], ["a periodic function", "TEST", 93, 112], ["R", "TEST", 192, 193], ["variables", "TEST", 216, 225], ["Global Lipschitz continuity", "PROBLEM", 261, 288], ["The vaccination rate", "TEST", 289, 309], ["a periodic solution the vaccination rate", "TREATMENT", 356, 396], ["Lipschitz continuity", "OBSERVATION", 268, 288]]], ["That is, the input increases from its global minimum value to its global maximum value and then decreases back to its global minimum value over one period.", [["global", "OBSERVATION_MODIFIER", 66, 72], ["maximum", "OBSERVATION_MODIFIER", 73, 80]]], ["Let us consider inputs I : R + \u2192 [0, 1].Hysteresis loops.The following property of the Preisach operator is called monocyclicity: for any T -periodic input I(t), t \u2265 0, and any admissible initial state of the Preisach operator, the corresponding output v(t) = (P[\u03bd 0 ]I)(t) satisfies v(t + T ) = v(t) for all t \u2265 T .", [["Preisach operator", "DNA", 87, 104], ["I(t)", "PROTEIN", 156, 160], ["Preisach operator", "PROTEIN", 209, 226], ["Hysteresis loops", "PROBLEM", 40, 56], ["the corresponding output v", "TEST", 228, 254], ["satisfies v", "TEST", 274, 285]]], ["Further, for a simple periodic input, the output is defined byHysteresis loops.for t \u2265 T , where the Lipschitz continuous functionsv(\u00b7),v(\u00b7) increase and satisfyv (I) 0, which in turn depend on the initial states \u03bd 0 \u03b1 of the relays at the moment t = 0 and the value of the input I on the interval [0, t 0 ] (cf. (8)).", [["byHysteresis loops", "PROTEIN", 60, 78], ["a simple periodic input", "TREATMENT", 13, 36], ["the output", "TEST", 38, 48], ["byHysteresis loops", "OBSERVATION", 60, 78]]], ["As such, on any interval of monotonicity of the input, the input-output pair (I, v) follows one of infinitely many possible branches of the Preisach operator, and a particular branch followed by the input-output pair is uniquely defined by the prior history of the input variations and the initial states of the relays.Equilibrium points.We will assume thatEquilibrium points.Due to this assumption and the compatibility constraint (9), the inclusion \u03b1 \u2208 \u03a0 implies that all the relays are in state \u03bd \u03b1 = 0 when I = 0.", [["Preisach operator", "PROTEIN", 140, 157], ["branches", "ANATOMY_MODIFIER", 124, 132], ["branch", "OBSERVATION_MODIFIER", 176, 182]]], ["Therefore, system (3), (13) has a unique infection-free equilibriumEquilibrium points.in which the state \u03bd 0 = \u03bd 0 \u03b1 : \u03a0 \u2192 {0, 1} of the Preisach operator is the identical zero.", [["infection", "DISEASE", 41, 50], ["a unique infection", "PROBLEM", 32, 50], ["the Preisach operator", "TEST", 133, 154], ["infection", "OBSERVATION", 41, 50], ["free equilibriumEquilibrium", "OBSERVATION", 51, 78]]], ["According to (13) , the vaccination rate at this equilibrium is minimal and equals v nat .Equilibrium points.In addition, ifEquilibrium points.then system (3), (13) also has a family of endemic equilibrium statesEquilibrium points.with (I * , S * ) \u2208 D, where the vaccination rate v 0 is related to the state \u03bd 0 = \u03bd 0 \u03b1 : \u03a0 \u2192 {0, 1} of the Preisach operator byEquilibrium points.These equilibria form a connected set in U. Further, the set (27) includes equilibrium states with different vaccination rates v 0 and different proportions of the infected and recovered populations, while the fraction of the susceptible individuals is the same at all these states.Remark 1If \u03a0 is different from (24) and includes points (\u03b1 1 , \u03b1 2 ) with \u03b1 1 < 0, 0 \u2264 \u03b1 2 \u2264 1, then the set of infection-free equilibrium states is also infinite and connected.", [["infection", "DISEASE", 774, 783], ["1If \u03a0", "PROTEIN", 669, 674], ["the vaccination rate", "TEST", 20, 40], ["D", "PROBLEM", 251, 252], ["the vaccination rate v", "TEST", 260, 282], ["\u2192", "TEST", 325, 326], ["different vaccination rates v", "TEST", 479, 508], ["the susceptible individuals", "PROBLEM", 602, 629], ["\u03b1", "TEST", 736, 737], ["infection", "PROBLEM", 774, 783], ["minimal", "OBSERVATION_MODIFIER", 64, 71], ["equilibria", "OBSERVATION", 386, 396], ["infected", "OBSERVATION", 544, 552], ["infection", "OBSERVATION", 774, 783], ["free equilibrium", "OBSERVATION", 784, 800]]], ["Further, in this case, a solution which starts from small infected population and converges to an infection-free equilibrium is characterized by higher vaccination rate at the end than at the beginning.", [["infection", "DISEASE", 98, 107], ["a solution", "TREATMENT", 23, 33], ["small infected population", "PROBLEM", 52, 77], ["an infection", "PROBLEM", 95, 107], ["small", "OBSERVATION_MODIFIER", 52, 57], ["infected", "OBSERVATION_MODIFIER", 58, 66], ["population", "OBSERVATION", 67, 77], ["infection", "OBSERVATION", 98, 107], ["free equilibrium", "OBSERVATION", 108, 124]]], ["Slightly abusing the notation, we will sometimes also refer to the two-dimensional curve (I(t), S(t)) as to a trajectory, omitting the component (8) in the state space of the Preisach operator.Proposition 1 Ifthen the infection-free equilibrium (25) is the global attractor of system (3), (13) .", [["infection", "DISEASE", 218, 227], ["the infection", "PROBLEM", 214, 227], ["infection", "OBSERVATION", 218, 227], ["free", "OBSERVATION_MODIFIER", 228, 232]]], ["If the opposite inequality (26) holds, then any trajectory of system (3), (13) , which has at most finite number of intersections with the nullcline\u0130 = 0 (the line S = S * = \u03b4/\u03b2), converges to an endemic equilibrium.Proposition 1 IfProof If \u03b4/\u03b2 \u2265 1, then the first equation of (3) implies that\u0130 < 0 in D. Therefore, on any given trajectory of (3), (13), the vaccination rate is defined by v(t) =v(I(t)) (cf. (17)), where the functionv(I) is a continuous descending branch of the Preisach operator; this branch depends on the initial state \u03bd 0 = \u03bd 0 \u03b1 .", [["\u03b4", "CELL_LINE", 174, 175], ["\u03b2", "CELL_LINE", 176, 177], ["Preisach operator", "PROTEIN", 479, 496], ["\u03bd 0 \u03b1", "PROTEIN", 545, 550], ["the nullcline\u0130", "TEST", 135, 149], ["the line S", "TEST", 155, 165], ["an endemic equilibrium", "PROBLEM", 193, 215], ["the vaccination rate", "TEST", 354, 374], ["endemic equilibrium", "OBSERVATION", 196, 215], ["descending", "ANATOMY_MODIFIER", 454, 464], ["branch", "ANATOMY_MODIFIER", 465, 471], ["branch", "ANATOMY_MODIFIER", 503, 509]]], ["Thus, a trajectory of (3), (13) is simultaneously a trajectory of the ordinary differential system\u0130 = \u03b2IS \u2212 \u03b4I, S = \u2212\u03b2IS \u2212\u1e7d(I)S \u2212 \u00b5S + \u00b5 (30) with\u1e7d(\u00b7) =v(\u00b7) depending on \u03bd 0 = \u03bd 0 \u03b1 .", [["\u03b4I", "PROTEIN", 108, 110], ["S", "TEST", 126, 127], ["\u00b5S", "TEST", 130, 132], ["with\u1e7d", "TEST", 142, 147], ["\u00b7", "TEST", 148, 149], ["v", "TEST", 152, 153], ["\u00b7", "TEST", 154, 155], ["depending", "TEST", 157, 166], ["\u03bd", "TEST", 170, 171]]], ["Since\u0130 < 0, each trajectory of (30) converges to the infection-free equilibrium (I * , S * ) for any branch\u1e7d(\u00b7) =v(\u00b7), and the result follows.Proposition 1 IfIf 1 > \u03b4/\u03b2 and (29) holds, then the second equation of (3) implies\u1e60 < 0 for S \u2265 \u03b4/\u03b2 = S * in D. Hence, all trajectories of (3), (13) enter the domain {(I, S) \u2208 D : S < S * } and remain there for all sufficiently large t.", [["infection", "DISEASE", 53, 62], ["the infection", "PROBLEM", 49, 62], ["Proposition", "TEST", 142, 153], ["Hence", "TEST", 254, 259], ["all trajectories", "TEST", 261, 277], ["the domain", "TEST", 297, 307], ["I", "TEST", 310, 311], ["S", "TEST", 313, 314], ["infection", "OBSERVATION", 53, 62]]], ["Therefore, the same argument as we used in the case \u03b4/\u03b2 \u2265 1 above shows that all the trajectories of system (3), (13) converge to the infection-free equilibrium (25).Proposition 1 IfFinally, assume that (26) holds, and suppose that a trajectory of system (3), (13) has at most finite number of intersections with the line S = S * where\u0130 = 0.", [["infection", "DISEASE", 134, 143], ["the infection", "PROBLEM", 130, 143], ["infection", "OBSERVATION", 134, 143]]], ["Then, after the last intersection, the I-component of the trajectory either strictly decreases or strictly increases with t.", [["decreases", "OBSERVATION_MODIFIER", 85, 94]]], ["In either case, the monotonicity of I(t) implies that the trajectory of the (3), (13) (after its last intersection with the line S = S * ) is simultaneously a trajectory of the ordinary differential system (30) where\u1e7d(\u00b7) is either a descending or an ascending branch of the Preisach operator.", [["I(t)", "PROTEIN", 36, 40], ["descending", "ANATOMY_MODIFIER", 233, 243], ["ascending", "ANATOMY_MODIFIER", 250, 259], ["branch", "ANATOMY_MODIFIER", 260, 266]]], ["Due to the fact that any branch\u1e7d(I) increases, relation (26) implies that system (30) has a unique endemic equilibrium (I * , S * ) given byProposition 1 IfFurthermore, system (30) has a global Lyapunov function (Korobeinikov et al. 2002 , Korobeinikov et al. 2004 )Proposition 1 IfThis implies convergence to the endemic equilibrium point.Poincar\u00e9-Bendixson type alternativeProposition 1 does not cover those trajectories that have infinitely many intersections with the nullcline S = S * in the case when relation (26) holds.Poincar\u00e9-Bendixson type alternativeTheorem 1 Let (26) hold.", [["any branch\u1e7d(I) increases", "PROBLEM", 21, 45], ["a global Lyapunov function", "PROBLEM", 185, 211], ["Lyapunov function", "OBSERVATION", 194, 211]]], ["Any trajectory of system (3), (13) (starting from any initial values from the region I > 0, S > 0, S + I \u2264 1 and any admissible initial state of the Preisach operator) converges either to an endemic equilibrium or to a simple periodic orbit.Poincar\u00e9-Bendixson type alternativeProof Consider a trajectory (I(t), S(t)) which does not converge to an equilibrium point.", [["the region I", "TEST", 74, 86], ["S", "TEST", 92, 93], ["an endemic equilibrium", "PROBLEM", 188, 210], ["endemic", "OBSERVATION", 191, 198], ["orbit", "ANATOMY", 235, 240]]], ["Due to Proposition 1, it has infinitely many intersections with the line S = S * at points I(t k ) = I k , k = 1, 2, ... with t k < t k+1 (where we can assume without loss of generality that I 1 > I 2 ).", [["I 2", "PROTEIN", 197, 200], ["the line S", "TEST", 64, 74], ["k", "TEST", 95, 96], ["I k", "TEST", 101, 104], ["k", "TEST", 107, 108], ["t k", "TEST", 126, 129], ["k", "TEST", 134, 135], ["loss of generality", "PROBLEM", 167, 185]]], ["If for some k we have I k < I k +2 < I k +1 , then let us compare the arc \u0393 k +2 of the trajectory (I(t), S(t)) connecting the points (I k +2 , S * ) and (I k +3 , S * ) with its arc \u0393 k connecting the points (I k , S * ) and (I k +1 , S * ).", [["some k", "TEST", 7, 13], ["k", "TEST", 24, 25], ["k", "TEST", 30, 31], ["I k", "TEST", 37, 40], ["the arc", "TEST", 66, 73], ["I k", "TEST", 135, 138], ["I k", "TEST", 155, 158], ["its arc", "TEST", 175, 182], ["I k", "TEST", 210, 213], ["I k", "TEST", 227, 230]]], ["Note that on each arc \u0393 k the vaccination rate follows a particular branch of the Preisach operator, which we will denote asv k (cf. (17)).Poincar\u00e9-Bendixson type alternativeBoth arcs \u0393 k +2 and \u0393 k lie above the nullcline S = S * , both go from left to right (hence I k +3 > I k +2 ), and \u0393 k starts to the left of \u0393 k +2 .", [["Preisach operator", "DNA", 82, 99], ["\u0393 k", "DNA", 290, 293], ["the vaccination rate", "TREATMENT", 26, 46], ["\u0393 k lie", "TEST", 195, 202], ["the nullcline S", "TEST", 209, 224], ["k", "TEST", 269, 270], ["k", "TEST", 278, 279], ["k", "TEST", 292, 293], ["left", "ANATOMY_MODIFIER", 246, 250], ["right", "ANATOMY_MODIFIER", 254, 259], ["left", "ANATOMY_MODIFIER", 308, 312]]], ["Since for the internal points of these arcs,Poincar\u00e9-Bendixson type alternativeandv k +2 (I) >v k (I), we see that \u0393 k and \u0393 k +2 cannot intersect except at the end point, hence I k < I k +2 < I k +3 \u2264 I k +1 as required.", [["these arcs", "TEST", 33, 43], ["Poincar\u00e9", "TEST", 44, 52], ["k", "TEST", 117, 118], ["k", "TEST", 125, 126], ["I k", "TEST", 178, 181], ["k", "TEST", 186, 187], ["I k", "TEST", 193, 196], ["I k +1", "TEST", 202, 208]]], ["Further, if I k +3 = I k +1 , then due to forward uniqueness the trajectory becomes periodic starting from the moment t = t k +1 , i.e. I k +2j+1 = I k +1 , I k +2j+2 = I k +2 for all j = 1, 2, . . .", [["k", "TEST", 14, 15], ["k", "TEST", 23, 24], ["periodic", "PROBLEM", 84, 92], ["k", "TEST", 124, 125], ["k", "TEST", 138, 139], ["k", "TEST", 150, 151], ["I k", "TEST", 157, 160], ["I k", "TEST", 169, 172]]], ["Similarly, relations I k +1 > I k +3 > I k +2 imply I k +1 > I k +3 > I k +4 \u2265 I k +2 , and if I k +4 = I k +2 , then the trajectory becomes periodic after the moment t = t k +2 .Poincar\u00e9-Bendixson type alternativeCombining the above two results, we see that if either I k < I k +2 < I k +1 or I k +1 > I k +3 > I k +2 for some k , and the trajectory does not become periodic, thenPoincar\u00e9-Bendixson type alternativeTherefore, the trajectory converges to a periodic orbit oscillating between the points (I , S * ) and (I , S * ) with I = lim j\u2192\u221e I k +2j and I = lim j\u2192\u221e I k +2j+1 (or an equilibrium if the two limits coincide).Poincar\u00e9-Bendixson type alternativeThe only remaining alternative to this scenario is to have either \u00b7 \u00b7 \u00b7 > I 5 > I 3 > I 1 > I 2 > I 4 > I 6 > \u00b7 \u00b7 \u00b7 or \u00b7 \u00b7 \u00b7 < I 5 < I 3 < I 1 < I 2 < I 4 < I 6 < \u00b7 \u00b7 \u00b7 for all I k .", [["\u00b7 \u00b7 \u00b7 > I 5 > I 3 > I 1 > I 2 > I 4 > I 6 > \u00b7 \u00b7 \u00b7 or \u00b7 \u00b7 \u00b7 < I 5 < I 3 < I 1 < I 2 < I 4 < I", "CHEMICAL", 728, 820], ["\u00b7 \u00b7 \u00b7", "SIMPLE_CHEMICAL", 772, 777], ["\u00b7 \u00b7 \u00b7", "SIMPLE_CHEMICAL", 781, 786], ["I k", "PROTEIN", 546, 549], ["I k", "PROTEIN", 570, 573], ["+2j+1", "PROTEIN", 574, 579], ["I 4", "PROTEIN", 760, 763], ["I 6", "PROTEIN", 766, 769], ["I 1", "PROTEIN", 801, 804], ["I 4", "PROTEIN", 813, 816], ["I 6", "PROTEIN", 819, 822], ["\u00b7", "PROTEIN", 827, 828], ["I k", "PROTEIN", 839, 842], ["k", "TEST", 23, 24], ["k", "TEST", 32, 33], ["I k", "TEST", 39, 42], ["k", "TEST", 54, 55], ["k", "TEST", 63, 64], ["I k", "TEST", 70, 73], ["I k", "TEST", 79, 82], ["I k", "TEST", 95, 98], ["I k", "TEST", 104, 107], ["the trajectory", "TEST", 118, 132], ["the moment t", "TEST", 156, 168], ["k", "TEST", 173, 174], ["Poincar\u00e9", "TEST", 179, 187], ["k", "TEST", 271, 272], ["k", "TEST", 277, 278], ["k", "TEST", 286, 287], ["k", "TEST", 296, 297], ["k", "TEST", 305, 306], ["I k", "TEST", 312, 315], ["some k", "TEST", 323, 329], ["a periodic orbit oscillating", "TEST", 455, 483], ["lim j\u2192\u221e I k", "TEST", 562, 573], ["an equilibrium", "TEST", 584, 598], ["\u00b7", "TEST", 728, 729], ["I", "TEST", 813, 814], ["I", "TEST", 819, 820]]], ["Indeed, on each arc \u0393 k which lies below the line S = S * , the component I(t) of the solution decreases, and the vaccination rate is given by v(t) =v k (I(t)) for some descending branchv k (\u00b7) of the Preisach operator.", [["arc \u0393 k", "DNA", 16, 23], ["the vaccination rate", "TREATMENT", 110, 130], ["descending", "ANATOMY_MODIFIER", 169, 179]]], ["Therefore, the Lyapunov function V k (I, S) given by (31), (32) with v(\u00b7) =v k (\u00b7) decreases along the segment \u0393 k of the trajectory, hence the value of V k (\u00b7, \u00b7) at the left end of \u0393 k is less than at the right end.", [["left end", "ANATOMY", 171, 179], ["the Lyapunov function", "TEST", 11, 32], ["k", "TEST", 35, 36], ["v(\u00b7) =v k (\u00b7) decreases", "PROBLEM", 69, 92], ["the value", "TEST", 140, 149], ["V k", "TEST", 153, 156], ["segment", "ANATOMY_MODIFIER", 103, 110], ["left", "ANATOMY_MODIFIER", 171, 175], ["less", "OBSERVATION_MODIFIER", 190, 194], ["right", "ANATOMY_MODIFIER", 207, 212]]], ["But the functions V k (\u00b7, S * ) : (0, 1] \u2192 R are uniformly bounded for I \u2208 [\u03b4 * , 1], \u03b4 * > 0, and satisfy V k (I, S * ) \u2265 \u2212I * k ln(I/I * k ), where I * k is the solution of (31) for\u1e7d(\u00b7) =v k (\u00b7).", [["R", "GENE_OR_GENE_PRODUCT", 43, 44], ["I", "PROTEIN", 133, 134], ["I * k", "PROTEIN", 150, 155], ["the functions V k", "TEST", 4, 21], ["satisfy", "TEST", 99, 106], ["\u2265", "TEST", 121, 122], ["I", "TEST", 124, 125], ["k ln", "TEST", 128, 132], ["I/I", "TEST", 133, 136], ["k", "TEST", 139, 140], ["k", "TEST", 154, 155], ["the solution", "TEST", 159, 171]]], ["Relation (26) ensures that inf I * k \u2265 \u03b5 0 > 0, hence inf k V k (I, S * ) \u2192 \u221e as I \u2192 0+, and consequently the fact that the set of values of V k (\u00b7, \u00b7) at the right ends of the arcs \u0393 k is bounded implies that the left ends satisfy inf I k \u2265 \u03b5 > 0.", [["right ends", "ANATOMY", 159, 169], ["Relation", "TEST", 0, 8], ["k", "TEST", 35, 36], ["\u2265", "TEST", 37, 38], ["\u03b5", "TEST", 39, 40], ["hence", "TEST", 48, 53], ["k", "TEST", 62, 63], ["\u2192", "TEST", 74, 75], ["\u221e", "TEST", 76, 77], ["\u2192", "TEST", 83, 84], ["values", "TEST", 131, 137], ["V k", "TEST", 141, 144], ["the arcs", "TEST", 173, 181], ["\u03b5", "TEST", 242, 243], ["right", "ANATOMY_MODIFIER", 159, 164], ["left", "ANATOMY_MODIFIER", 214, 218]]], ["4.2 Sufficient conditions for global stability of the set of endemic equilibrium states.Poincar\u00e9-Bendixson type alternativeIn the rest of the paper, we derive sufficient conditions which ensure the global convergence to endemic equilibrium states.", [["global", "OBSERVATION_MODIFIER", 30, 36], ["stability", "OBSERVATION_MODIFIER", 37, 46], ["endemic", "OBSERVATION_MODIFIER", 61, 68], ["equilibrium states", "OBSERVATION", 69, 87]]], ["We make the following assumption:Poincar\u00e9-Bendixson type alternative(A) Each input-output loop of the Preisach operator corresponding to a simple periodic input is convex.", [["Preisach operator", "DNA", 102, 119], ["Poincar\u00e9-Bendixson type alternative(A) Each input-output loop of the Preisach operator", "TREATMENT", 33, 119]]], ["In other words, the functionv(\u00b7) in (17) is convex and the functionv(\u00b7) in (17) is concave.Poincar\u00e9-Bendixson type alternativeWe need to show that \u03ba < 0, i.e. V SS (V I ) 2 + V II (V S ) 2 > 0, which for the function (32) is equivalent to Due to Theorem 1, it suffices to show that system (3), (13) has no simple periodic solutions if the quantity L defined by (22) is sufficiently small.", [["Bendixson type alternativeWe", "TREATMENT", 100, 128], ["V II (V S )", "TEST", 175, 186], ["simple periodic solutions", "TREATMENT", 306, 331], ["small", "OBSERVATION_MODIFIER", 382, 387]]], ["An explicit estimate for L will be established in the proof.DiscussionTo explore how the heterogeneity of the response of the susceptible population to the advent of an epidemic can affect dynamics of system (3), we consider the aggregate vaccination rate (13) with the Gaussian densityDiscussionwhere the normalizing parameter A = A(\u03b1 m1 , \u03b1 m2 , \u03c3) ensures that the integral of q over the domain (24) equals 1.", [["\u03c3", "CELL_LINE", 348, 349], ["the aggregate vaccination rate", "TEST", 225, 255]]], ["The limit \u03c3 \u2192 0 corresponds to the perfectly homogeneous response (10), i.e. the vaccination rate switches from the value v nat = 0 to the value v int = 1 at the switching threshold I = \u03b1 m2 and switches backwards at the threshold I = \u03b1 m1 .", [["\u03b1 m1", "PROTEIN", 235, 239], ["the vaccination rate", "TEST", 77, 97], ["the value v nat", "TEST", 112, 127], ["the value v", "TEST", 135, 146], ["homogeneous", "OBSERVATION_MODIFIER", 45, 56]]], ["Increasing the variance \u03c3 2 of the (truncated) Gaussian distribution corresponds to increasing the heterogeneity of the response within the susceptible population.", [["increasing", "OBSERVATION_MODIFIER", 84, 94], ["heterogeneity", "OBSERVATION_MODIFIER", 99, 112], ["susceptible", "OBSERVATION_MODIFIER", 140, 151], ["population", "OBSERVATION_MODIFIER", 152, 162]]], ["Figure 4 presents an example of the convergence to a periodic cyclic behavior for small \u03c3 > 0.", [["a periodic cyclic behavior", "PROBLEM", 51, 77], ["small \u03c3", "PROBLEM", 82, 89]]], ["Further, Figure 4 shows that as \u03c3 increases, the periodic behavior is replaced with the convergence to an endemic equilibrium.", [["\u03c3", "GENE_OR_GENE_PRODUCT", 32, 33], ["\u03c3", "PROTEIN", 32, 33], ["an endemic equilibrium", "PROBLEM", 103, 125], ["increases", "OBSERVATION_MODIFIER", 34, 43]]], ["Indeed, Theorem 2 ensures the global stability of the set of endemic equilibrium states when the quantity (22) becomes sufficiently small.DiscussionThe trajectory corresponding to the more heterogeneous response (\u03c3 = 0.01) in Figure 4 converges to an endemic equilibrium state with the densities I * = 0.00063, S * = 0.056 of the infected and susceptible populations, respectively.", [["the infected and susceptible populations", "PROBLEM", 326, 366], ["global", "OBSERVATION_MODIFIER", 30, 36], ["stability", "OBSERVATION_MODIFIER", 37, 46], ["endemic", "OBSERVATION_MODIFIER", 61, 68], ["equilibrium", "OBSERVATION", 69, 80], ["small", "OBSERVATION_MODIFIER", 132, 137], ["heterogeneous", "OBSERVATION_MODIFIER", 189, 202], ["response", "OBSERVATION_MODIFIER", 203, 211], ["endemic", "OBSERVATION_MODIFIER", 251, 258], ["infected", "OBSERVATION", 330, 338], ["susceptible", "OBSERVATION_MODIFIER", 343, 354], ["populations", "OBSERVATION_MODIFIER", 355, 366]]], ["The vaccination rate at this equilibrium is v * = 0.0041 (week \u22121 ).", [["The vaccination rate", "TEST", 0, 20]]], ["The trajectory corresponding to the more homogeneous response (\u03c3 = 0.0009), which converges to the periodic orbit, exhibits a lower initial peak of the infected population during the transient than the trajectory of the heterogeneous system.", [["a lower initial peak of the infected population", "PROBLEM", 124, 171], ["more", "OBSERVATION_MODIFIER", 36, 40], ["homogeneous", "OBSERVATION_MODIFIER", 41, 52], ["response", "OBSERVATION_MODIFIER", 53, 61], ["periodic", "ANATOMY_MODIFIER", 99, 107], ["orbit", "ANATOMY", 108, 113], ["lower", "OBSERVATION_MODIFIER", 126, 131], ["initial", "OBSERVATION_MODIFIER", 132, 139], ["peak", "OBSERVATION_MODIFIER", 140, 144], ["infected", "OBSERVATION_MODIFIER", 152, 160], ["population", "OBSERVATION_MODIFIER", 161, 171], ["transient", "OBSERVATION_MODIFIER", 183, 192], ["heterogeneous", "OBSERVATION", 220, 233]]], ["The average density of the susceptible population for the periodic trajectory,S = 0.057, is close to S * .", [["average", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION_MODIFIER", 12, 19], ["susceptible", "OBSERVATION_MODIFIER", 27, 38], ["population", "OBSERVATION_MODIFIER", 39, 49]]], ["The density of the infected population along the periodic trajectory is much higher than I * at its peaks, but the average density\u012a = 0.00016 is significantly lower than I * .", [["the infected population", "PROBLEM", 15, 38], ["the average density\u012a", "TEST", 111, 131], ["density", "OBSERVATION_MODIFIER", 4, 11], ["infected", "OBSERVATION_MODIFIER", 19, 27], ["population", "OBSERVATION_MODIFIER", 28, 38], ["periodic", "OBSERVATION_MODIFIER", 49, 57], ["trajectory", "OBSERVATION_MODIFIER", 58, 68], ["much", "OBSERVATION_MODIFIER", 72, 76], ["higher", "OBSERVATION_MODIFIER", 77, 83]]], ["This agrees with the fact that the average vaccination ratev = 0.023 (week \u22121 ) is significantly higher than v * .Proof of Theorem 2The following inequalities will be systematically used:Proof of Theorem 2We prove the theorem by contradiction.", [["the average vaccination ratev", "TEST", 31, 60]]], ["Let us assume that there exists a simple periodic solution (I(t), S(t)), for which I(t) increases from I 1 to I 2 and then decreases from I 2 to I 1 on a period with I 1 < I 2 .", [["I 1", "PROTEIN", 145, 148]]], ["Let us denote byv(I) andv(I) the two branches of the Preisach operator corresponding to the increasing I and decreasing I of this solution, respectively, hence relations (17) -(20) hold.", [["Preisach operator", "PROTEIN", 53, 70], ["this solution", "TREATMENT", 125, 138], ["branches", "ANATOMY_MODIFIER", 37, 45], ["increasing", "OBSERVATION_MODIFIER", 92, 102]]], ["Then system (3), (13) has an endemic equilibrium (\u012a * , S * ) defined by equation (31) with\u1e7d(\u00b7) =v(\u00b7) and an endemic equilibrium (\u00ce * , S * ) defined by equation (31) with\u1e7d(\u00b7) =v(\u00b7).", [["an endemic equilibrium", "TEST", 26, 48], ["an endemic equilibrium", "TEST", 106, 128]]], ["Further, since (I 1 , S * ) and (I 2 , S * ) are the turning points of the periodic solution,Proof of Theorem 2On the other hand, according to (31),Proof of Theorem 2Combining these four relations with (18) and recalling thatv andv are increasing functions, we see thatProof of Theorem 2Recall the definition of the functionsV (I, S) andV (I, S), see Lemma 1.", [["Lemma 1", "PROTEIN", 351, 358], ["the periodic solution", "TREATMENT", 71, 92]]], ["We now consider the following trivial identityProof of Theorem 2and estimate the differences participating in it to establish a lower bound for L.Proof of Theorem 2Since the part\u0393 of the periodic trajectory lies outside the level setV (I, S) \u2264 V (I 2 , S * ) and the line segment S = S * + h,\u012a * \u2264 I \u2264 I b belongs to this set, we have S \u2265 S * + h for (I, S) \u2208\u0393 ,\u012a * \u2264 I \u2264 I b .", [["I b", "PROTEIN", 372, 375], ["the line segment S", "TEST", 263, 281], ["this set", "TEST", 317, 325], ["S", "TEST", 335, 336], ["I", "TEST", 352, 353], ["S", "TEST", 355, 356], ["\u2208", "TEST", 358, 359], ["\u0393", "TEST", 359, 360]]], ["Therefore, on the interval [\u012a * , I b ], relation (40) impliesProof of Theorem 2We integrate this inequality along the trajectory over the interval I \u2208 [\u012a * , I b ] and using the monotonicity ofV which follows from (41), we obtainProof of Theorem 2Using inequality (36) and relation (43), we estimate the right hand side of (44) as follows:Proof of Theorem 2Therefore,VProof of Theorem 2In order to estimate S M \u2212 S * , we evaluate the functionV at the point (I 2 , S * ) using (32) and substitute the result into (42) to obtainProof of Theorem 2We estimate the left hand side of (46) from above usingProof of Theorem 2Further, we find a lower bound of the right hand side of (46) using estimate (37):Proof of Theorem 2Combining the last two inequalities with (46), we obtainProof of Theorem 2Substituting this relation into (45), we finally arrive atProof of Theorem 2where the last inequality holds due to I b \u2264 I 2 \u2264 1, S M \u2264 1 and S * = \u03b4/\u03b2.5.2Estimation ofV (I 1 , S * ) \u2212V (I 2 , S * ).", [["right hand", "ANATOMY", 305, 315], ["left hand", "ANATOMY", 562, 571], ["right hand", "ANATOMY", 657, 667], ["\u03b2", "PROTEIN", 943, 944], ["the monotonicity ofV", "TEST", 175, 195], ["\u03b4", "TEST", 941, 942], ["\u03b2", "TEST", 943, 944], [".5.2Estimation", "TEST", 944, 958], ["ofV", "TEST", 959, 962], ["V (I", "TEST", 977, 981], ["right", "ANATOMY_MODIFIER", 305, 310], ["left", "ANATOMY_MODIFIER", 562, 566], ["lower", "ANATOMY_MODIFIER", 638, 643], ["right", "ANATOMY_MODIFIER", 657, 662]]], ["We slightly modify the above argument.", [["the above argument", "TREATMENT", 19, 37], ["above argument", "OBSERVATION", 23, 37]]], ["The relation5.2which is similar to (40), implies dV dI > 0,5.2Hence,\u0393 lies outside the level setV (I, S) \u2264V (I 1 , S * ).", [["dV dI", "TEST", 49, 54]]], ["The bottom point (with the smallest S) of the level lineV (I, S) =V (I 1 , S * ) is defined by \u2202V /\u2202I = 0, therefore I =\u00ce * at this point.", [["\u2202V", "PROTEIN", 95, 97], ["\u2202V", "TEST", 95, 97], ["bottom", "OBSERVATION_MODIFIER", 4, 10]]], ["I 2 \u2212\u012a * \u2265 0,\u00ce * \u2212 I 1 \u2265 0, I 2 \u2212\u012a * +\u00ce * \u2212 I 1 \u2265 1 \u2212 L \u03b2 (I 2 \u2212 I 1 ), (60)5.2where L/\u03b2 < 1 according to (23) .", [["I", "TEST", 0, 1], ["\u2265", "TEST", 9, 10], ["I", "TEST", 19, 20], ["I", "TEST", 44, 45], ["\u2265", "TEST", 48, 49], ["L \u03b2", "TEST", 54, 57], ["\u2212 I", "TEST", 63, 66], ["L/\u03b2", "TEST", 85, 88]]], ["Let us find the minimum value F min of the function F (x, y) = Ax 2 + By 2 under the constraints x, y \u2265 0 and x + y \u2265 (1 \u2212 L/\u03b2)(I 2 \u2212 I 1 ).", [["Let us", "TEST", 0, 6]]], ["Clearly, the minimum value is achieved for x + y = (1 \u2212 L/\u03b2)(I 2 \u2212 I 1 ) and equals5.2Hence, due to (60), the left hand side of (59) satisfies5.2Recalling the definition of A and B, this is equivalent to5.25.4 Estimates of I 1 , S m .5.2Denote v max := 0\u2264\u03b11 \u00b5(1 \u2212 S * ), then5.2Combining the two cases,5.2where a + = a for a > 0 and a + = 0 for a \u2264 0.5.2Finally, we obtain a lower bound for S m .", [["left hand", "ANATOMY", 110, 119], ["the minimum value", "TEST", 9, 26], ["v max", "TEST", 244, 249], ["left", "ANATOMY_MODIFIER", 110, 114]]], ["From (54) and (58) it follows that \u2212S * ln S m S * \u2264 S * \u2212 S m + I 1 \u2212\u00ce * \u2212\u00ce * ln5.2Therefore,5.2\u03b2(S * ) 2 ln I 1 I * and using (67) we arrive at S m \u2265 S * exp \u22121 + \u00b5(1 \u2212 S * ) \u03b2(S * ) 2 ln \u03c1 1 .5.2Thus, we have shown that the existence of a simple periodic orbit implies estimates (61), (67) and (68), which establish a lower bound L \u2265 L 0 > 0 on the quantity (22) .", [["S m", "TEST", 59, 62], ["Therefore", "TEST", 84, 93], ["ln I", "TEST", 107, 111], ["using", "TEST", 122, 127], ["exp \u2212", "TEST", 156, 161], ["S *", "TEST", 171, 174], ["\u03b2", "TEST", 177, 178], ["S *", "TEST", 179, 182], ["ln \u03c1", "TEST", 187, 191], ["a simple periodic orbit", "PROBLEM", 240, 263], ["orbit", "ANATOMY", 258, 263], ["lower", "ANATOMY_MODIFIER", 321, 326]]], ["This completes the proof.ConclusionsWe considered an SIR model with vaccination, where we assumed that the vaccination rate changes in response to dynamics of the epidemic.", [["vaccination", "TREATMENT", 68, 79], ["the vaccination rate changes", "PROBLEM", 103, 131], ["the epidemic", "PROBLEM", 159, 171]]], ["This operator relationship between the vaccination rate and the number of active cases accounts for the heterogeneity of the response among the susceptible individuals.ConclusionsIf the basic reproduction number satisfies R 0 > 1, then the infection-free equilibrium is globally stable.", [["infection", "DISEASE", 240, 249], ["the vaccination rate", "TEST", 35, 55], ["the infection", "PROBLEM", 236, 249], ["active", "OBSERVATION_MODIFIER", 74, 80], ["infection", "OBSERVATION", 240, 249], ["globally", "OBSERVATION_MODIFIER", 270, 278], ["stable", "OBSERVATION_MODIFIER", 279, 285]]], ["On the other hand, if R 0 > 1, then the system has a connected infinite set of endemic equilibrium states.", [["endemic equilibrium states", "PROBLEM", 79, 105], ["endemic equilibrium", "OBSERVATION", 79, 98]]], ["In this case, we showed that each trajectory converges either to an endemic equilibrium or to a periodic orbit.", [["an endemic equilibrium", "PROBLEM", 65, 87], ["endemic equilibrium", "OBSERVATION", 68, 87], ["orbit", "ANATOMY", 105, 110]]], ["This is in agreement with Chladn\u00e1 et al. (2020) where a simpler system with the homogeneous response modeled by a single twostate two-threshold switch was considered.", [["a single twostate two-threshold switch", "TREATMENT", 112, 150]]], ["Further, we showed that the set of endemic equilibrium states is the global attractor if a certain parameter of the Preisach operator, which is associated with the width of the hysteresis loops relative to their length, is sufficiently small.", [["Preisach operator", "DNA", 116, 133], ["endemic", "OBSERVATION_MODIFIER", 35, 42], ["width", "OBSERVATION_MODIFIER", 164, 169], ["hysteresis", "OBSERVATION", 177, 187], ["length", "OBSERVATION_MODIFIER", 212, 218], ["sufficiently", "OBSERVATION_MODIFIER", 223, 235], ["small", "OBSERVATION_MODIFIER", 236, 241]]], ["This parameter decreases with increasing heterogeneity of the adaptive response among the susceptible population.", [["decreases", "OBSERVATION_MODIFIER", 15, 24], ["increasing", "OBSERVATION_MODIFIER", 30, 40], ["heterogeneity", "OBSERVATION_MODIFIER", 41, 54], ["susceptible", "OBSERVATION_MODIFIER", 90, 101], ["population", "OBSERVATION", 102, 112]]], ["Based on these results, one can conclude that the heterogeneity of the response promotes the convergence to an endemic equilibrium state, while the homogeneous response may result in recurrent periodic outbreaks of the epidemic.", [["an endemic equilibrium state", "PROBLEM", 108, 136], ["recurrent periodic outbreaks of the epidemic", "PROBLEM", 183, 227], ["recurrent", "OBSERVATION_MODIFIER", 183, 192], ["periodic", "OBSERVATION_MODIFIER", 193, 201], ["outbreaks", "OBSERVATION_MODIFIER", 202, 211], ["epidemic", "OBSERVATION_MODIFIER", 219, 227]]]], "PMC6431389": []}